2011 ASH Program Book - American Society of Hypertension

American Society of Hypertension, Inc. 

2011 Annual Scientific Meeting 

and Exposition 

Program Book 

Hilton New York 

Saturday, May 21, 2011 – Tuesday, May 24, 2011

8More than 

References: 1. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium 

antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery 

disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 

2003;290(21):2805-2816. 2. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention 

of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required 

versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes 

Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 

2005;366(9489):895-906. 3. Black HR, Elliott WJ, Grandits G, et al; CONVINCE Research Group. Principal 

results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 

2003;289(16):2073-2082. 4. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular 

morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a 

randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. 

Novartis Pharmaceuticals Corporation 

East Hanover, New Jersey 07936 

©2011 Novartis

Visit booth 

#1100 

to find out more 

out of 

10 

patients may need more than 

1 agent to get to BP goal 1-4 

Printed in USA 4/11 DIO-1052602

About the American Society of 

Hypertension, Inc. 

The American Society of Hypertension, Inc., (ASH) is the largest 

organization of hypertension researchers and health care providers 

in the United States committed to eliminating hypertension and its 

consequences. ASH has a domestic and international membership of 

basic science and clinical investigators, physicians, physician assistants, 

nurse practitioners and pharmacists, as well as other individuals 

with a scientific interest in hypertension. 

The Society was founded in 1985 in order to provide a forum for the 

exchange of information among basic scientists, clinical investigators 

and others involved in the study or management of high blood pressure. 

The specific focus of the Society is to translate current research 

findings in hypertension into effective treatment strategies, in order 

to better address the needs of hypertensive patients. The primary mission 

of the Society is to improve the care of patients with hypertension 

and associated disorders by: 

• Enhancing the education and treatment of patients with hypertension 

• Educating health care professionals regarding hypertension and 

current prevention and treatment strategies 

• Assisting health care professionals in addressing the challenges of 

the modern-day care of patients with hypertension 

• Advocating public policy that ensures patient access to high 

quality hypertension care and supports increased hypertension 

research 

• Facilitating communication and collaboration among providers, 

investigators, policymakers, and patients in areas relating to hypertension 

and vascular health 

• Promoting the career development of researchers in hypertension 

and associated disorders, including research in the pathobiology, 

prevention, diagnosis, treatment, and psychosocial aspects of 

hypertension 

The American Society of Hypertension, Inc. is an accredited provider 

of Continuing Medical Education (CME) by the Accreditation Council 

for Continuing Medical Education (ACCME) to sponsor continuing 

medical education for physicians. 

For more information contact the American Society of Hypertension, 

Inc. at: 


148 Madison Avenue 

Fifth Floor 

New York, NY 10016 

Telephone: 212-696-9099 

Fax: 212-696-0711 

E-mail: ash@ash-us.org 

Website: www.ash-us.org

Past Presidents of the American 

Society of Hypertension, Inc. 

John H. Laragh, MD 

First President 

Edward G. Biglieri, MD President 1988 – 1990 

Jay N. Cohn, MD President 1990 – 1992 

Louis Tobian, MD President 1992 – 1994 

Barry M. Brenner, MD President 1994 – 1995 

Lawrence R. Krakoff, MD President 1995 – 1996 

Michael H. Alderman, MD President 1996 – 1998 

Michael A. Weber, MD President 1998 – 2000 

Theodore W. Kurtz, MD President 2000 – 2002 

Haralambos Gavras, MD President 2002 – 2004 

Thomas D. Giles, MD President 2004 – 2006 

Jean E. Sealey, DSC President May 19, 2006 

Suzanne Oparil, MD President 2006 – 2008 

Henry R. Black, MD President 2008 – 2010

Table of Contents 

General Information.................................................................... 9 

Continuing Education................................................................ 9 

Hilton New York Floor Layout................................................ 10 

Corporate Members.................................................................... 16 

Meeting Sponsors........................................................................ 17 

ASH Leadership.............................................................................. 18 

2011 Program Committee....................................................... 19 

Robert Tigerstedt Award Lecture........................................ 20 

Young Scholar Award Lectures............................................ 22 

Marvin Moser Clinical Hypertension 

Award Lecture................................................................................. 24 

2011 Abstract Reviewers.......................................................... 26 

Poster Category Presentation by Day .............................. 30 

ASH Faculty....................................................................................... 32 

Program at a Glance.................................................................... 35 

Hypertension Highlights 2011, May 21........................... 40 

ASH Program, May 21................................................................. 41 

Primary Care Clinician Program, May 22......................... 49 




ASH Program Posters, May 21............................................... 86 



ASH Program Late-Breaking Posters, May 23.............. 144 

Faculty Disclosure Listing......................................................... 145 

ASH Exhibitor Floor Plan........................................................... 154 

ASH Innovations Theater.......................................................... 157 

ASH Exhibitors ................................................................................ 158 

Author Index.................................................................................... 168 

Hilton New York Floor Plans................................................... 181 

5

Program Color Key 

The pages of this Program Book are color-coded to match the 

Program at a Glance (pages 35–36) and serve as a quick, identifiable 

reference of the type of educational activity or event taking place. 

Scientific Sessions* 

1 Pathobiology Track 2 Translational Track 3 Therapy Track 

Hypertension Highlights 2011 

Special Event 

Meet the Professor Sessions 

Hypertension for the Primary Care Clinician 

Debates 

Poster Sessions 

Satellite Symposia 

Hypertension Resource Pavilion 

The ASH Twenth-Sixth Annual Scientific Meeting is 

organized around three (3) concurrent themes: 

• Pathobiology of Hypertension 

• Translational Issues in Hypertension 

• Therapy of Hypertension 

Sessions in each of the three (3) themes (or tracks) are labeled 

throughout the Program Book to be easily identifiable. 

Future Meeting Dates 

Saturday, May 19, 2012 to Tuesday, May 22, 2012 

Hilton New York, New York, NY 

Wednesday, May 15, 2013 to Saturday, May 18, 2013 

San Francisco Marriott, San Francisco, CA

Letter from the President 

and Program Committee Chair 

Dear Colleague, 

On behalf of the Board of Directors of the 


(ASH), we are pleased to welcome you to 

the Twenty-Sixth Annual Scientific Meeting 

and Exposition of ASH. The theme of 

this year’s Scientific Meeting is Adolescent 

Obesity and Cardiovascular Risk Reduction: 

The Expanding Epidemic. 

The 2011 Annual Scientific meeting topics 

are organized around three (3) concurrent 

George L. Bakris, MD, FASH 

themes: 

— Pathobiology of Hypertension 

— Translational Issues in Hypertension 

— Therapy of Hypertension 

The Scientific Sessions feature several innovative 

components designed to enhance the 

translation of basic and applied research 

into effective hypertension prevention and 

treatment strategies. 

• Hypertension Highlights 2011 – 

Saturday, May 21, 2011 

Hypertension Highlights is a full-day William B. White, MD, FASH 

program dedicated to educating clinicians 

and scientists about some of the most interesting, controversial 

and evolving topics in the field. It is an ideal update for 

Hypertension Specialists and those wishing to become specialists 

in the field. 

• Plenary Session I – Sunday, May 22, 2011 

The Keynote speaker for the opening session will be F. Xavier 

Pi-Sunyer, MD, MPH, Professor of Medicine, Chief of Endocrinology, 

Diabetes, and Nutrition, Director of the New York Obesity 

Research Center, St. Luke’s/Roosevelt Hospital Center, New York, 

New York. Dr. Pi-Sunyer will speak on “Blood Pressure in Obesity.” 

Following Dr. Pi-Sunyer’s lecture will be Dr. Rae-Ellen Kavey 

presenting a lecture on “Cardiovascular Risk and Risk Reduction 

in Children and Adolescents,” Dr. Sadaf Farooqi, PhD, presenting a 

lecture on “Mechanisms from Studies of Human Obesity” and Dr. 

Joseph Flynn addressing the topic of “Evaluation and Treatment of 

Hypertension in Childhood.” 

• Plenary Session II – Monday, May 23, 2011 

This session will include the Awards Session as well as state-of-theart 

topics. Dr. Oscar Carretero will present the Robert Tigerstedt 

Award Lecture on “Acetyl-Ser-Asp-Lys-Pro, an Endogenous Tetrapeptide: 

Role in Target Organ Damage in Hypertension, and Autoimmune 

Myocarditis.” Young Scholar Awards will be presented to 

Drs. Michael Ryan and Alessandro Cataliotti. Dr. Murray Epstein 

will receive the Marvin Moser Clinical Hypertension Award. 

7

Letter continued 

Following the Awards Session, Dr. Abraham Aviv will present a 

lecture on the “Leukocyte Telomere Length Genetics and Cardiovascular 

Disease” and Dr. Joseph Hill will discuss “Development of 

Cardiac Hypertrophy.” 

• Young Investigator-in-Training Abstract Competition 


Trainees submitting the highest ranking abstracts to the meeting 

will present their work orally in a special session and compete for 

cash prizes. This highlighted session is consistent with ASH’s goal 

to foster and facilitate the training of young and new investigators 

in hypertension. 

• Hypertension for the Primary Care Clinician – 

Sunday, May 22, 2011 

This program will address commonplace questions that face clinicians 

in day-to-day care of hypertension including peri-operative 

hypertension management, clinical partners in ambulatory care 

management of hypertension and the resistant hypertensive 

patient. 

• Debates – Saturday, May 21 – Sunday, May 22, 2011 

This year there are five debates on controversial topics of relevance 

to Hypertension Specialists. 

• Joint Society Symposia 

Interactions with other societies, both national and international, 

focused on the topic of hypertension and cardiovascular and 

kidney disease risk as it relates to obesity will be covered. This year 

we have a record number of joint society sessions that include: 

AHA Council for High Blood Pressure Research (HBPR), the 

Association for Research into Arterial Structure and Physiology 

(ARTERY), the China Social Worker’s Association Vascular Protection 

Committee, the European Society of Hypertension (ESH), 

Hypertension Canada, the International Pediatric Hypertension 

Association (IPHA), the International Society on Hypertension 

in Blacks (ISHIB), the Inter-American Society of Hypertension 

(IASH), the National Lipid Association/American Society 

for Preventive Cardiology (NLA/ASPC), the National Kidney 

Foundation (NKF) and the Preventive Cardiovascular Nurses 

Association (PCNA). 

The Society will also sponsor a small number of industry-supported 

Satellite Symposia which will introduce novel approaches to antihypertensive 

therapy. The Pavilion will host many informative scientific, 

technical, periodical and book exhibits designed to support you in 

your mission of providing the latest in care for your hypertensive 

patients. 

We look forward to seeing you in New York. 

Sincerely, 


President, 2010 – 2012 

William B. White, MD, FASH 

Chair, 2011 Scientific Program 

Committee 

8

General Information 

This program book has been underwritten by Novartis 

Pharmaceuticals Corporation. 

Education 

Program Objectives 

In keeping with the purpose of the American Society of Hypertension, 

Inc. (ASH), the Twenty-Sixth Annual Scientific Meeting is designed to 

encourage and promote the development, advancement, and exchange 

of fair and balanced and evidence-based information regarding the 

research, diagnosis and treatment of hypertension and related cardiovascular 

diseases, with the goal of improved patient care and health. 

The sessions will: 

• Present and examine new findings on the physiology, pathophysiology, 

epidemiology, diagnosis, and management of hypertension 

and related conditions. 

• Review current state-of-the-art advances in managing particular 

groups of patients. 

• Evaluate specific treatment modalities and pharmacological 

agents. 

Target Audience 

Physicians, scientists, pharmacists, physician assistants, nurses and 

other health care professionals with an interest in the mechanisms or 

management of hypertension and related diseases will benefit from 

attending Scientific Sessions, Satellite Symposia, Embedded Symposia, 

Meet the Professor Sessions, Case Discussions, Poster Sessions and 

the Scientific Exposition. 

Continuing Education Credit 

The American Society of Hypertension, Inc. is accredited by the 

Accreditation Council for Continuing Medical Education to provide 

continuing medical education for physicians. The American Society of 

Hypertension, Inc. designates this educational activity for a maximum 

of 30 AMA PRA Category 1 Credits. Each physician should claim 

credit commensurate with the extent of their participation in the 

activity. 

Conflict of Interest Disclosure 

The American Society of Hypertension, Inc. strives to ensure balance, 

independence, objectivity, and scientific rigor in all of its educational 

programs. All faculty members participating in this program have 

been required to disclose any real or apparent conflict(s) of interest 

that may have a direct bearing on the subject matter of the session in 

which they are participating. This includes relationships in place at 

the time of the meeting or in the twelve (12) months preceding the 

meeting, with pharmaceutical companies, biomedical device manufacturers, 

or other corporations whose products or services are related 

to the subject matter of the presentation topic. 

The intent of the policy is to identify openly any conflict of interest so 

that the listeners may form their own judgments about the presentations 

with the full disclosure of the facts. All Conflict of Interest Disclosure 

Statements are available to meeting attendees in the program 

book on pages 145–153 and at the ASH Information/Membership 

Booth located at the entrance of the Hypertension Resource Pavilion 

on the third Floor. 

9

General Information continued 

Disclosures not available at the time the program book was printed 

are included as a separate listing in the registrant bags. 

Dagger (†) denotes that the abstract presenting author has related 

disclosure information. Please reference the full Disclosure Index at 

the ASH Information /Membership Booth, located at the entrance 

of the Hypertension Resource Pavilion on the third Floor and in the 

Author Index of The Journal of Clinical Hypertension 2011 Abstract 

Supplement. 

Hilton New York Floor Layout 

For detailed floor plans of Exhibition and Poster Areas, see pages 154 & 155. 

For detailed floor plans of Hilton New York, see pages 181 – 183. 

10


Meeting Venue/Headquarters Hotel 

Hilton NY 

1335 Avenue of the Americas 


Phone: 1-212-586-7000 

Fax: 1-212-315-1374 

Meeting Registration 

Registration for the Meeting will be held on the 

Third Floor Promenade. 

Registration Desk Hours 

Groups 

Friday, May 20 

Individuals 


Saturday, May 21 

Sunday, May 22 

Monday, May 23 

Tuesday, May 24 

4:00 PM to 6:00 PM 

6:00 PM to 9:00 PM 

7:00 AM to 7:00 PM 

7:00 AM to 6:00 PM 

5:30 AM to 5:00 PM 

7:00 AM to 9:30 AM 

ASH Information/Membership Booth 

The ASH Information/Membership booth will be located at the 

entrance of the Hypertension Resource Pavilion on the Third Floor. 

Information/Membership Booth Hours 


Saturday, May 21 

Sunday, May 22 

Monday, May 23 

Tuesday, May 24 

4:00 PM to 9:00 PM 

8:30 AM to 5:00 PM 

8:30 AM to 5:00 PM 

8:30 AM to 5:00 PM 

8:30 AM to 12:00 PM 

Program Information 


Hypertension Highlights is a full-day program dedicated to educating 

clinicians and scientists about some of the most interesting, 

controversial and evolving topics in the field. It is an ideal update for 

Hypertension Specialists and those wishing to become specialists in 

the field. 


8:30 AM to 3:00 PM 

ASH Plenary Sessions 

Plenary Sessions feature engaging lectures by keynote speakers. The 

topics are of broad general interest. 


1:15 PM to 3:00 PM 

Monday, May 23, 2011 

1:30 PM to 4:00 PM 

11


ASH Scientific Sessions 

The Scientific Sessions will address basic and clinical science issues 

over a wide range of topics. 


4:30 PM to 6:00 PM 


3:30 PM to 5:15 PM 


8:00 AM to 10:00 AM 

10:30 AM to 12:00 PM 

Tuesday, May 24, 2011 

8:15 AM to 9:30 AM 

10:00 AM to 11:30 AM 


The Hypertension for the Primary Care Clinician program will address 

commonplace questions that face clinicians in day-to-day care 

of hypertension. 


8:00 AM to 12:30 PM 

Joint Sessions 

Special Sessions jointly sponsored by Society-related organizations 

will enrich the knowledge base and foster new interactions between 

attendees. 


4:30 PM to 6:00 PM 


9:00 AM to 10:30 AM 

3:30 PM to 5:15 PM 


8:30 AM to 10:00 AM 

10:30 AM to 12:00 PM 


Distinguished faculty will provide valuable instructions on (1) writing 

a grant; (2) developing an abstract and lecture and (3) understanding 

statistics in clinical research. 

Attendees will be admitted on a first-come, first-served basis. 


11:00 AM to 12:00 PM 

Clinical Debates 

Clinical Debates will provide for lively discussion on controversial 

topics. 



11:00 AM to 12:00 PM 

11:45 AM to 12:15 PM 

4:30 PM to 5:00 PM 

Abstract Presentations 

Authors will showcase their research in oral or poster format. 


6:00 PM to 7:00 PM 


5:30 PM to 6:30 PM 


4:30 PM to 5:30 PM 

12



The latest information regarding new concepts, treatments, devices 

and techniques will be addressed in Satellite Symposia supported by 

educational grants. 


6:00 AM to 7:30 AM 

ASH Hypertension Resource Pavilion - Technical Exhibits 

Technical Exhibits will be located in the Hypertension Resource 

Pavilion at the Hilton NY. ASH will host a welcome reception, 

lunches, and high teas in the exhibit hall. 


4:30 PM to 7:30 PM 

Opening Reception 

6:00 PM to 7:30 PM 


High Tea 

10:00 AM to 1:00 PM 

and 3:30 PM to 6:30 PM 

5:30 PM to 6:30 PM 


High Tea 

10:00 AM to 1:30 PM 

and 4:00 PM to 5:30 PM 

4:30 PM to 5:30 PM 

Innovations Theater – Rhinelander Gallery 


6:30 PM to 7:30 PM 


12:00 PM to 1:00 PM 

5:30 PM to 6:30 PM 

2011 ASH Hypertension Community Outreach 

ASH is proud to present its 4th Annual Hypertension Community 

Outreach Initiative in conjunction with the Twenty-Sixth Annual 

Scientific Meeting & Exposition. In 2008, ASH began the 

Hypertension Community Outreach Initiative in New Orleans with 

great success. We continued the Outreach Initiative in San Francisco 

in 2009 and in New York once again, in 2010. 

In 2011, the Outreach Initiative will provide hypertension screening 

and education targeting local New York underinsured and uninsured 

population segments. ASH will educate the residents of the New York 

City, Long Island and New Jersey about hypertension and provide 

them with products and tools to take home. 

Visit the ASH Hypertension Community Outreach Booth #1600 in 

the Pavilion, learn more about the Outreach program and check your 

blood pressure. 

Multimedia CD-ROM of Scientific Meeting 

Audio recordings on CD-ROM including select speaker presentations 

in PDF format of the Scientific Sessions and Satellite Symposium will 

be for sale through AVMG in the Second Flood Promenade. You may 

also download the individual sessions in MP3 format to your computer 

post-conference. Visit our e-commerce store at www.ash-us.org. 

13


ASH Policy Regarding Videotaping, Photography and 

Audio Taping 

No individual is permitted to film, videotape, photograph and/or 

audiotape meeting symposia, scientific sessions, posters or exhibits 

without prior written approval from the American Society of 

Hypertension, Inc. 

ASH Information/Membership Booth 

The On-Site ASH Information/Membership Booth will be located 

at the entrance of the Hypertension Resource Pavilion on the Third 

Floor. 

ASH Staff Members 

Executive Office 

Torry Mark Sansone, Executive Director 

Mary Trifault, Executive Associate 

Scientific Meetings & Professional Affairs 

Melissa Levine, Associate Executive Director 

Ashley Buron, Program Coordinator 

Meeting and Exhibit Services, Hypertension Community Outreach Services 

Gilda C. Caputo Hansen, Director 

Education Services 

Kathleen Sheridan, Director of Education 

Nicole Rabin, Associate Manager, Continuing Education (CE) 

Services 

Olivia Carr, Program Manager, Educational Services 

Membership & Marketing Services 

Angel Loayza, Manager 

Barbara E. Escobar, Associate Manager 

Financial Services 

Kevin Lee, Manager 

Kereyne A. Bishop, Associate Accounting Manager 

Journal of the American Society of Hypertension (JASH) 

Ashley Buron, Managing Editor 

14

ASH EDUCATION AND RESEARCH 

FOUNDATION announces its 

ASH EDUCATION AND RESEARCH 

FOUNDATION announces its 

[New Logo] 

[New Logo] 

Inaugural ASH Foundation 

5K & 10K Run/Walk 

Inaugural ASH Foundation 

5K & 10K Run/Walk 

Registration: 

Registration: 

Monday, May 23 rd , 2011 

NYC Central Park 

7:00 AM 

Monday, May 23 rd , 2011 

NYC Central Park 

7:00 AM 

Daiichi Sankyo, Inc. 

Booth # 1200 

Hypertension Resource 

Pavilion 


Booth # 1200 

Hypertension Resource 

Pavilion 

Running Shirt, Water bottle, and Course Maps 

will be provided upon registration. 

Please consider supporting the Foundation with a 

registration donation. 

Running Shirt, Water bottle, and Course Maps 

will be provided upon registration. 

Please consider supporting the Foundation with a 

registration donation. 

The Foundation thanks Daiichi Sankyo, Inc. for 

their generous supporting donation.

2011 ASH Corporate Members 

Boehringer Ingelheim Pharmaceuticals, Inc. 


Forest Laboratories, Inc. 

Merck & Co., Inc. 


Pfizer Inc 

Takeda Pharmaceuticals North America, Inc. 

16

ASH Sponsors 

The American Society of Hypertension, Inc. wishes 

to acknowledge the following Corporate Sponsors 

for their generous support of the ASH Twenty-Sixth 

Annual Scientific Meeting. 

2011 Annual Scientific Meeting 

Sponsors 



SERVIER 


2011 Hypertension Community 

Outreach 

The American Society of Hypertension, Inc. wishes 

to acknowledge and thank our Community Partners 

for their generous support of this program. 

American Kidney Fund 

Association of Black Cardiologists, Spirit of the Heart 

AVMG, Inc. 

Boomer Esiason Foundation 

Forest Pharmacueticals, Inc. 

Foundation of National Lipid Association 

Hilton NY 

HoMedics, Inc. 

Institute for Health Equity at Nassau University Medical Center 

Metropolitan Exposition, Inc. 

MR CHAMMPS at St. Joseph’s Regional Medical Center 


Omron Healthcare, Inc. 

PepsiCo, Inc. 

Society for Cardiovascular Angiography and Interventions (SCAI) 

17

ASH Leadership 

2010-2011 Board of Directors 

Officers 

President: George L. Bakris, MD, FASH 

President-Elect: William B. White, MD, FASH 

Vice President: Sandra J. Taler, MD, FASH 

Secretary: John D. Bisognano, MD, PhD, FASH 

Treasurer: Franz H. Messerli, MD, FASH 

Immediate Past President: Henry R. Black, MD, FASH 

Directors-At-Large 

Keith C. Ferdinand, MD, FASH 

Alan H. Gradman, MD, FASH 

Daniel T. Lackland, DrPH, FASH 

Robert A. Phillips, MD, PhD, FASH 

Addison A. Taylor, MD, PhD, FASH 

Mattew R. Weir, MD, FASH 

Ex Officio Non-Voting Members 

Thomas D. Giles, MD, FASH, Chair, ASH Specialists Program Inc. 

Michael A. Weber, MD, FASH, Editor-In-Chief, 

The Journal of Clinical Hypertension (JCH) 

Myron H. Weinberger, MD, Editor-In-Chief, 

Journal of the American Society of Hypertension (JASH) 

Torry Mark Sansone, Executive Director 

18

2011 Scientific Program 

Committee 

George L. Bakris, MD, FASH, President 

William B. White, MD, FASH, Chair 

Pathobiology of Hypertension 

David G. Harrison, MD, Co-Chair 

Nancy J. Brown, MD 

Michael W. Brands, PhD 

Joey P. Granger, PhD 

Allyn L. Mark, MD 

Susanne B. Nicholas, MD, PhD, MPH 

J. Howard Pratt, MD 

Translational Issues in Hypertension 

Brent M. Egan, MD, FASH, Co-Chair 

Donald L. Batisky, MD 

John D. Bisognano, MD, PhD, FASH 

Stephen R. Daniels, MD, PhD, FASH 

Daniel Duprez, MD, PhD, FASH 


Joel Handler, MD 

Nancy Houston Miller, RN, BSN 

Therapy of Hypertension 

Robert A. Phillips, MD, PhD, FASH, Co-Chair 

Jan N. Basile, MD, FASH* 

Michael J. Bloch, MD, FASH* 

Lynne T. Braun, PhD, CNP 

Barry L. Carter, PharmD 

Joseph A. Diamond, MD, FASH 

F. Wilford Germino, MD, FASH* 

David S. Kountz, MD 

Louis Kuritzky, MD* 

Gbenga Ogedegbe, MD, MPH, MS, FASH* 

Aldo J. Peixoto, MD, FASH 

C. Venkata S. Ram, MD, FASH 

Scott D. Solomon, MD 

*Indicates Primary Care 

19

Special Lecture 

Monday, May 23, 2011, 1:30 PM – 4:00 PM • East Ballroom • Third Floor 

Robert Tigerstedt Award Lecture 

Oscar A. Carretero, MD, FASH 

Oscar A. Carretero, MD was born in 

Mendoza, Argentina and received his 

degree from the School of Medicine at the 

University of Cuyo, Mendoza, Argentina. 

Dr. Carretero has contributed greatly to 

our understanding of the role of vasoactive 

hormones in the regulation of blood 

pressure and renal function, as well as the 

pathogenesis of hypertension and target 

organ damage (TOD). His research has 

resulted in over 360 publications. His 

fundamental contributions began with 

his initial hypothesis in 1972 that renal 

kinins may be involved in the regulation 

of sodium and water excretion, acting as natriuretic and diuretic hormones. 

His work has contributed uniquely to the understanding of the 

role of the renal kallikrein-kinin system, ranging from the development 

of methods to measure the components of the system and its localization 

to demonstrating that the renal kallikrein-kinin system is natriuretic and 

diuretic not only in high mineralocorticoid situations but also in the basal 

state. This work culminated with the demonstration that animals lacking 

the main kinin receptor (B2) develop hypertension when they are fed a 

high sodium diet. As a pioneer in the field of kinin research, where his 

contributions have been fundamental, numerous, and of high quality, 

we now understand that kinins act as paracrine hormones, regulating 

organ blood flow and renal function, and also participate on the chronic 

cardiovascular protective effect of angiotensin-converting enzyme (ACE) 

and angiotensin resector blockers. He and his colleagues demonstrated 

that kallikrein in the kidney is produced mainly in the connecting tubule 

(CNT) and in collaboration with Luciano Barajas they demonstrated that 

the CNT returns to the glomerulus and makes contact with the afferent 

arteriole. Recently he demonstrated that there is a crosstalk between the 

CNT and the afferent arteriole, showing that when sodium is increased 

in the perfusate of the CNT, the afferent arteriole dilates. They call this 

cross talk between the CNT and the afferent arteriole connecting tubuloglomerular 

feedback. This seminal contribution explains why during 

a sodium load, renal blood flow increases. 

Recently he has made another seminal contribution by demonstrating 

that the endogenous tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro (Ac-SDKP); 

that is destroyed mainly by ACE; has anti-inflammatory and anti-fibrotic 

effects, and also contributes to the cardiovascular and renal protective effect 

of ACE inhibitors. Furthermore, he discovered that the enzyme prolyl 

oligopeptidase is involved in the release of Ac-SDKP from the protein 

thymosin β-4. He has shown that inhibition of this enzyme promotes 

vascular and renal fibrosis. He and his group have demonstrated that 

this peptide inhibits fibrosis by a) decreasing inflammation, b) fibroblast 

proliferation and collagen synthesis, c) TGF expression and d) its TGF 

signaling (Smad phosphorylation). 

20 

continued…

Special Lecture continued 

In addition, Dr. Carretero has trained numerous investigators in the 

field of hypertension. Among his distinguished and well-known students 

are Alberto Nasjletti, Professor of Pharmacology at the Medical College 

of New York; A Guillermo Scicli, Professor of Medicine Henry Ford 

Health Sciences, Wayne State University; and Sadayoshi Ito, Chairman 

and Professor of Medicine, Tohoku University; Luis Juncos, Division 

Director, Nephrology, University of Mississippi. These are among many 

who have become important investigators in the field of cardiovascular 

or renal physiology and medicine. 

Dr. Carretero is an active invited international lecturer, and has received 

many awards including a Lifetime Achievement Award from the Inter- 

American Society of Hypertension and the Novartis award from the 

Council of High Blood Pressure Research, American Heart Association. 

He also received a Dr. Honoris Causa from University of Cordoba and a 

Professor Honoris Causa from the University of Mendoza. He has been 

Chairman, Council for High Blood Pressure Research of the AHA, and 

President of the Inter-American Society of Hypertension. He also serves 

in various NIH study sections and committees and serves on the editorial 

boards of several scientific journals. 

21

Young Scholar Award* 


Alessandro Cataliotti, MD, PhD 

Alessandro Cataliotti, MD, PhD, is an 

associate consultant in the Division of 

Cardiovascular Diseases and Internal 

Medicine at Mayo Clinic Rochester. He 

holds the academic rank of associate 

professor of medicine. 

Dr. Cataliotti obtained his medical degree 

with the highest score cum laude from 

the University of Catania, Italy where he 

also pursued residency and fellowship 

in internal medicine, as well as a PhD 

program in cardiovascular science. Dr. 

Cataliotti began a research fellowship at 

Mayo Clinic under the supervision of Dr. Burnett in 1998. Throughout 

his research career, Dr. Cataliotti has been the recipient of numerous 

awards, including competitive travel awards from the American Society 

of Hypertension in 2000 and 2003; Heart Failure Society of America in 

1999, 2000, 2001 and 2003; European Society of Hypertension in 2001; 

and International Society of Hypertension in 2002; and many more in 

the following years. Of note, Dr. Cataliotti received a two-year grant 

from Bristol-Myers Squibb in 1999 in support for his research here at 

Mayo Clinic. Dr. Cataliotti was also a recipient of a Beginning Grant in 

Aid from the American Heart Association in 2003-2004. From 2005 to 

2009, he was awarded a Ministry of Education, University and Research of 

Italy (MIUR), Rientro dei Cervelli Project. Underscoring Dr. Cataliotti’s 

outstanding research achievements and again recognition by his scientific 

peers was the awarding of one of twelve 2006 Doris Duke Clinical Scientist 

Development Grants. He has been funded by the National Institutes of 

Health and currently is the principal investigator of two RO1s. 

Dr. Cataliotti’s research has focused on humoral integration of the heart 

and kidney in heart failure and hypertension with a special emphasis 

upon the natriuretic peptide system. He has published over 70 publications 

in leading peer-reviewed journals, including the Circulation, 

Lancet, Proceedings of The National Academy of Science, American 

Journal of Physiology, Kidney International, Journal of American Society 

of Nephrology, American Journal of Kidney Disease, Peptide, Journal of 

Hypertension, Regulatory Peptides, European Journal of Heart Failure, 

Hypertension, Circulation Research, American Journal of Hypertension 

and the Mayo Clinic Proceedings. 

Dr. Cataliotti has been active in the discovery of novel drug delivery 

strategies for cardiac peptides in cardiovascular disease and in hypertension. 

He was the first to report feasibility of oral delivery of human 

B-type natriuretic peptide in experimental hypertension, and has 

pioneered the cardiac gene delivery strategy for natriuretic peptides in 

hypertensive heart disease. 

*Supported by an educational grant from SERVIER. 

22

Young Scholar Award* 


Michael J. Ryan, PhD 

Dr. Ryan is an Associate Professor of 

Physiology & Biophysics at the University 

of Mississippi Medical Center in Jackson, 

MS. He earned his doctorate from the 

State University of New York at Buffalo 

in 1999 and received his post-doctoral 

training at the University of Iowa from 

1999-2004. In 2004, he was recruited as 

an Assistant Professor of Physiology & 

Biophysics at the University of Mississippi 

Medical Center where he rose to his current 

rank of Associate Professor in 2009. 

Dr. Ryan’s research focuses on the 

mechanistic role that chronic inflammation has in the development of 

hypertension. In order to examine this link, he studies an animal model 

that develops the chronic autoimmune inflammatory disorder systemic 

lupus erythematosus (SLE). Hypertension is prevalent and cardiovascular 

disease is a leading cause of death in individuals with SLE. Dr. Ryan is 

specifically interested in the effect of immune and inflammatory mediators 

on renal function, renal injury and vascular physiology as it pertains to 

the development of hypertension. His work has been continuously funded 

by the American Heart Association and National Institutes of Health. 

Dr. Ryan currently sits on the editorial board of Hypertension, the American 

Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 

the Journal of Hypertension and Frontiers in Vascular Physiology. 

He is an active member of the American Heart Association peer review 

system serving as a co-chair of the Vascular Biology & Blood Pressure 

II peer review committee. Dr. Ryan is a Fellow of the American Heart 

Association and serves on the Leadership Committee of the Council 

for High Blood Pressure as well as on the Greater Southeast Affiliate 

Research Committee. Ryan is also an active member of the American 

Physiological Society. He has served on the Porter Physiology Development 

Committee and currently serves on the Education Committee of 

the American Physiological Society where he actively contributes to the 

educational missions of the society. 


23

Special Lecture 


Marvin Moser Clinical Hypertension Award Lecture 

Murray Epstein, MD 

Dr. Murray Epstein is Professor of Medicine 

at the University of Miami, School 

of Medicine. He was a recipient of the 

1990 Distinguished Scientist Award of the 

National Kidney Foundation. He served 

as a member of the National High Blood 

Pressure Education Program Coordinating 

Committee and is a contributor to the 6th 

Report of the Joint National Committee. 

Dr. Epstein is listed in Who’s Who in 

America (59th, 60th and 61st edition) and 

Who’s Who in Medicine. 

Dr. Epstein has authored over 400 journal 

articles and book chapters. Many of these have related to 1) the pathogenesis 

and management of hypertension, 2) renal function in diseases 

characterized by abnormal volume regulation, and 3) the role of the 

renin angiotensin aldosterone system. He has also written extensively 

on head out water immersion, a unique clinical investigational model 

that he has defined and applied to the study of a wide range of disease 

states. The unique attributes of this clinical investigative model include 

a prompt redistribution of circulating blood volume with a consequent 

relative central hypervolemia, in the absence of concomitant changes in 

plasma composition. Dr. Epstein has successfully applied the immersion 

model as a clinical investigative tool to characterize the determinants 

of deranged volume homeostasis and renin-aldosterone, eicosanoid, 

kallikrein, vasopressin and ANF responsiveness in diverse edematous 

disorders including advanced liver diseases, chronic renal failure and 

hypertension. He has also utilized the immersion model to define the 

relative roles of volume and the renin-angiotensin axis as determinants 

of aldosterone responsiveness in anephric humans. 

Dr. Epstein has also defined the effects of calcium antagonists on renal 

hemodynamics and renal function At the preclinical level Dr. Epstein, 

in collaboration with his co-investigator Dr. Rodger Loutzenhiser, developed 

and used the isolated perfused hydronephrotic kidney model to 

visualize the renal microvasculature and define the effect of interventions 

with calcium antagonists and a wide array of vasoconstrictors including 

angiotensin II and endothelin on the afferent and efferent arterioles. He 

extended these studies to the clinical arena in order to define the effect of 

calcium antagonists on renal hemodynamics and as prophylactic agents 

to obviate acute renal failure in diverse clinical settings. Most recently 

Dr. Epstein has focused his clinical and investigative attention on the 

role of aldosterone as a pivotal determinant of cardiovascular and renal 

injury, and the use of aldosterone blockade to reverse these adverse 

effects. Currently his major investigative focus is on mineralocorticoid 

receptor blockade as an intervention to abrogate progressive kidney disease, 

and as an intervention to confer cardiovascular and renal benefits 

in patients with chronic kidney disease, and in ESRD patients who are 

being treated by hemodialysis. 

24 

continued…

Special Lecture continued 

A member of several editorial boards, Dr. Epstein also serves as a 

reviewer for numerous prominent journals and for study sections for 

granting agencies. 

Dr. Epstein has served as the editor of 4 editions of THE KIDNEY IN 

LIVER DISEASE (Hanley & Belfus, Philadelphia, 1996), the premier 

book in the field, which surveys the wide spectrum of renal functional 

abnormalities in liver disease. Dr. Epstein has also co authored HYPER- 

TENSION: PRACTICAL MANAGEMENT (1988), which has subsequently 

been published in Spanish and Portuguese editions. He has also edited 

CALCIUM ANTAGONISTS AND THE KIDNEY (Hanley & Belfus, 1990), 

the first comprehensive book to survey the diverse effects of calcium 

antagonists on renal function, and the clinical applicability of these findings, 

including renal protection. Most recently, Dr. Epstein has edited 

3 editions of CALCIUM ANTAGONISTS IN CLINICAL MEDICINE 

(Hanley and Belfus, 1992, 1997, and 2002), the first comprehensive book 

to survey the effects of calcium antagonists on both cardiovascular and 

renal function. In addition, this book considers the effects of calcium 

antagonists on other organ systems including the management of gastrointestinal 

disorders, and disorders of the cerebral circulation. 

Dr. Epstein has also co-edited ANGIOTENSIN II RECEPTOR ANTAGO- 

NISTS (Hanley & Belfus 2001), the first comprehensive book to survey 

the effects of AT1 receptor antagonists on both cardiovascular and renal 

function. In addition, this book considers the effects of these novel agents 

in elucidating the profound physiological effects of angiotensin II. 

Dr. Epstein, who is a 1963 graduate of Columbia University College of 

Physicians and Surgeons, did his postgraduate medical training at University 

Hospital in Madison, Wisconsin and at the Cleveland MetroHealth 

Medical Center of Western Reserve University from 1966 to 1968, he 

was a Research Fellow in Nephrology in the Kidney Laboratory of Peter 

Bent Brigham Hospital in Boston, under Professor John P. Merrill. Dr. 

Epstein was also an Established Investigator of the Howard Hughes 

Medical Institute. He is ABIM-certified in internal medicine and nephrology, 

and is a Fellow of both the American College of Physicians and the 

American Society of Nephrology. Dr Epstein has also been designated 

a Hypertension Specialist by the American Society of Hypertension. 

25

2011 Abstract Reviewers 

Lawrence J. Appel, MD, MPH, 

FASH 

Baltimore, MD 

Steven A. Atlas, MD, FASH 

Bronx, NY 


Chicago, IL 

Jan N. Basile, MD, FASH 

Charleston, SC 


Atlanta, GA 

Dan R. Berlowitz, MD, MPH 

Bedford, MA 

John D. Bisognano, MD, PhD, 


Rochester, NY 

Henry R. Black, MD, FASH 

New York, NY 

Michael J. Bloch, MD, FASH 

Reno, NV 


Augusta, GA 


Chicago, IL 

Robert D. Brook, MD, FASH 

Ann Arbor, MI 

Angela L. Brown, MD 

St. Louis, MO 

David A. Calhoun, MD 

Birmingham, AL 

Oscar A. Carretero, MD, FASH 

Detroit, MI 


Iowa City, IA 

John R. Cockcroft, MD 

Cardiff, United Kingdom 

Stephen R. Daniels, MD, PhD, 


Aurora, CO 

Prakash C. Deedwania, MD, 


Fresno, CA 

Joseph A. Diamond, MD, FASH 

New Hyde Park, NY 

Daniel Duprez, MD, PhD, 


Minneapolis, MN 

Brent M. Egan, MD, FASH 


Gilbert M. Eisner, MD, FASH 

Washington, DC 

William J. Elliott, MD, PhD, 


Yakima, WA 

Michael Ernst, PharmD 

Iowa City, IA 

Bonita Falkner, MD, FASH 

Philadelphia, PA 

Pamela J. Fall, MD, FASH 

Augusta, GA 

Daniel I. Feig, MD, PhD 

Houston, TX 

John M. Flack, MD, MPH 

Detroit, MI 

Joseph T. Flynn, MD, FASH 

Seattle, WA 

Philip B. Gorelick, MD, MPH 

Lincoln, IL 


Pittsburgh, PA 


Jackson, MS 

Richard H. Grimm, Jr., MD, PhD 


John E. Hall, PhD 

Jackson, MS 


Anaheim, CA 

Willa A. Hsueh, MD 

Houston, TX 

David J. Hyman, MD, MPH 

Houston, TX 

Kenneth A. Jamerson, MD, FASH 

Ann Arbor, MI 

Richard J. Johnson, MD 

Denver, CO 

John B. Kostis, MD, FASH 

New Brunswick, NJ 


Neptune, NJ 

Louis Kuritzky, MD 

Gainesville, FL 

Theodore W. Kurtz, MD 

San Francisco, CA 

Daniel T. Lackland, DrPH, FASH 


Lewis Landsberg, MD 

Chicago, IL 

26

2011 Abstract Reviewers continued 

Friedrich C. Luft, MD 

Berlin, Germany 

Giuseppe Mancia, MD 

Milan, Italy 

Samuel J. Mann, MD 

New York, NY 


Iowa City, IA 

Nancy Houston Miller, RN, 

BSN 

Palo Alto, CA 

Gary Mitchell, MD 

Norwood, MA 

Michael A. Moore, MD, FASH 

Winston Salem, NC 

L. Gabriel Navar, PhD 

New Orleans, LA 

Shawna D. Nesbitt, MD, MS, 


Dallas, TX 

Susanne B. Nicholas, MD, PhD, 

MPH 

Los Angeles, CA 

Daniel T. O’Connor, MD 

San Diego, CA 

Gbenga Ogedegbe, MD, MPH, 

MS, FASH 

New York, NY 

Suzanne Oparil, MD, FASH 


Vasilios Papademetriou, MD, 




West Haven, CT 

Robert A. Phillips, MD, PhD, 


Worcester, MA 

Bertram Pitt, MD 

Ann Arbor, MI 


Indianapolis, IN 

L. Michael Prisant, MD, FASH 

Augusta, GA 

Clive Rosendorff, MD, PhD, 


Bronx, NY 

Gary E. Sander, MD, PhD, 


Metairie, LA 

Ernesto L. Schiffrin, MD, PhD 

Montreal, Canada 

Alan B. Schwartz, MD, FASH 


Scott D. Solomon, MD 

Boston, MA 

James R. Sowers, MD, FASH 

Columbia, MO 

Jan A. Staessen, MD, PhD 

Leuven, Belgium 

Sandra J. Taler, MD, FASH 

Rochester, MN 

Addison A. Taylor, MD, PhD, 


Houston, TX 

Sheldon W. Tobe, MD, FASH 

Toronto, Canada 

Peter P. Toth, MD, PhD 

Sterling, IL 

Rhian M. Touyz, MD, PhD 

Ottawa, Canada 

Raymond R. Townsend, MD 


Jason G. Umans, MD, PhD 

Bethesda, MD 

Alan B. Weder, MD 

Ann Arbor, MI 

Myron H. Weinberger, MD 


Howard Weintraub, MD 

New York, NY 

Matthew R. Weir, MD, FASH 

Baltimore, MD 


Farmington, CT 

Peter W. F. Wilson, MD 

Atlanta, GA 

Nathan D. Wong, PhD, MPH 

Irvine, CA 

Jackson T. Wright, Jr., MD, 

PhD, FASH 

Cleveland, OH 

Steven A. Yarows, MD, FASH 

Chelsea, MI 

27

More than half of 

hypertensive patients need 

3 or more 

agents 

to help them get to BP GOAL 1-4 

References: 1. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium antagonist vs 

a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International 

Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816. 2. Wright 

JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of 

blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from 

the AASK trial. JAMA. 2002;288(19):2421-2431. 3. Cushman WC, Ford CE, Cutler JA, et al; ALLHAT Collaborative 

Research Group. Success and predictors of blood pressure control in diverse North American settings: the 

Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393- 

404. 4. Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or 

hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428. 5. Flack JM, 

Calhoun DA, Satlin L, Barbier M, Hilkat R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/ 

valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. 

J Hum Hypertens. 2009;23(7):479-489. 6. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure 

in blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 

2010;56(5):780-800. 



©2011 Novartis

Looking for 

antihypertensive 

EFFICACY 

in African American 

patients 5,6, * 

Visit booth 

#1100 

to find out more 

* Patients with stage 2/severe hypertension, including African American patients with moderate-to-severe 

hypertension. Stage 2 hypertension is defined as ≥160/100 mm Hg. 

Printed in USA 4/11 EXR-1052006

Poster Category Presentation 

Posters will be displayed in the Second Floor Promenade. 


Posters on Display: 4:30 PM – 7:30 PM • Poster Viewing: 6:00 PM – 7:00 PM 

Adolescent Hypertension and Obesity.............................. (PO-1 – PO-5) 

Antiatherosclerotic Drugs................................................... (PO-6 – PO-7) 

Cardiac Structure and Function/Imaging....................... (PO-8 – PO-10) 

Comprehensive Multi-Level Interventions for 

Hypertension Management in High-Risk Groups......(PO-11 – PO-30) 

Endothelial Function.......................................................(PO-31 – PO-45) 

Epidemiology/Special Populations................................(PO-46 – PO-78) 

Immune Mechanisms in Hypertension........................(PO-79 – PO-82) 

Metabolic Syndrome (Diabetes/Glycemic Control; 

Dysglycemic Drugs; Insulin Resistance).....................(PO-83 – PO-102) 

New Insights into the Role of Uric Acid 

in Hypertension............................................................(PO-103 – PO-104) 

Pediatric Hypertension...............................................(PO-105 – PO-111) 

Risk Factors (Lipids)....................................................(PO-112 – PO-115) 

Stroke.............................................................................(PO-117 – PO-119) 

Vascular Injury/Inflammation and Remodeling......(PO-120 – PO-123) 


Posters on Display: 10:00 AM – 6:30 PM • Poster Viewing: 5:30 PM – 6:30 PM 

Featured Posters 

Blood Pressure Measurement/Monitoring......................(FP-1 – FP-4) 

Adolescent Hypertension..................................................(FP-5 – FP-8) 

Aldosterone and Anti-Aldosterone Agents..............(PO-124 – PO-130) 

Antihypertensive Drugs and Pharmacology............(PO-131 – PO-157) 

Clinical Trials................................................................(PO-158 – PO-184) 

Coronary Artery Disease............................................(PO-185 – PO-191) 

Genetics/Gene Therapy/Proteomics..........................(PO-192 – PO-198) 

Heart Failure/Hypertrophy 

(Diastolic Dysfunction)...............................................(PO-199 – PO-216) 

Hypertension in Patients with Chronic 

Kidney Disease.............................................................(PO-217 – PO-226) 

Kidney and Hypertension...........................................(PO-227 – PO-242) 

Off-Target Cardiovascular Effects of 

Non-Cardiovascular Drugs........................................(PO-243 – PO-244) 

Dagger (†) denotes that the presenting author has related disclosure 

information. 

30

Poster Category Presentation 




Cardiac Structure and Function.................................... (FP-9 – FP-13) 

Arterial Structure and Compliance...........................(PO-245 – PO-259) 

Blood Pressure Measurement/Monitoring............(PO-260 – PO-305A) 

Cellular Mechanisms (Cell Biology; 

Cell Membrane Transport/Ion Channels; 

Coagulation/Thrombosis; Growth Factors).............(PO-306 – PO-308) 

Lipid Metabolism...........................................................................(PO-309) 

Neural Hormonal Mechanisms (Renin; Neural Control; Vasoactive 

Autacoids).....................................................................(PO-310 – PO-312) 

Non – Pharmacological Therapy (Alternative 

Medicine; Diet; Physical Activity).............................(PO-313 – PO-322) 

Nutrition and Cardiovascular Prevention................(PO-323 – PO-330) 

Obesity...........................................................................(PO-331 – PO-339) 

Patient – Provider-Healthcare System Issues...........(PO-340 – PO-355) 

Preclinical Models/Experimental Hypertension.....(PO-357 – PO-358) 

Pregnancy......................................................................(PO-359 – PO-361) 

Salt-Sensitive Mechanisms of Hypertension............(PO-362 – PO-364) 

Secondary Hypertension.............................................(PO-365 – PO-367) 

Late-Breaking Posters.........................................(LB-PO-01 – LB-PO-03) 


information. 

31

2011 ASH Faculty 

Rajiv Agarwal, MD 


Lawrence J. Appel, MD, MPH, 


Baltimore, MD 

Nancy Artinian, PhD, RN 

Detroit, MI 

Phyllis August, MD, MPH 

New York, NY 

Abraham Aviv, MD 

Newark, NJ 


Chicago, IL 

Jan N. Basile, MD, FASH 



Atlanta, GA 

John D. Bisognano, MD, PhD, 


Rochester, NY 

Henry R. Black, MD, FASH 

New York, NY 

Michael J. Bloch, MD, FASH 

Reno, NV 

William E. Boden, MD 

Buffalo, NY 


Augusta, GA 


Chicago, IL 

Emmanuel Bravo, MD 

Cleveland, OH 


St. Louis, MO 


Nashville, TN 

David A. Bushinsky, MD 

Rochester, NY 

Norman R. C. Campbell, MD 

Calgary, Canada 

Oscar A. Carretero, MD 

Detroit, MI 


Iowa City, IA 


Rochester, MN 


Cardiff, United Kingdom 

Jay N. Cohn, MD 


Steven D. Crowley, PhD 

Durham, NC 

William C. Cushman, MD, 


Memphis, TN 

Stephen R. Daniels, MD, PhD, 


Aurora, CO 

Michael H. Davidson, MD 

Chicago, IL 

Daniel Duprez, MD, PhD, 



Lance D. Dworkin, MD 

Providence, RI 

Brent M. Egan, MD, FASH 


Paula T. Einhorn, MD, MS 

Bethesda, MD 

William J. Elliott, MD, PhD, 


Yakima, WA 


Miami, FL 

Murray D. Esler, MBBS, PhD 

Melbourne, Australia 

Bonita Falkner, MD, FASH 


Sadaf Farooqi, PhD 

Cambridge, United Kingdom 


Houston, TX 

Ross Feldman, MD 

London, Canada 


Atlanta, GA 


Detroit, MI 

Joseph T. Flynn, MD, FASH 

Seattle, WA 

Stanley S. Franklin, MD, FASH 


William H. Frishman, MD 

Valhalla, NY 

James B. Froehlich, MD, MPH 

Ann Arbor, MI 

Leonard M. Fromer, MD 


Jeffrey L. Garvin, PhD 

Detroit, MI 

32

2011 ASH Faculty continued 

Haralambos Gavras, MD 

Boston, MA 

F. Wilford Germino, MD, FASH 

Orland Park, IL 

Ali G. Gharavi, MD 

New York, NY 

Thomas D. Giles, MD, FASH 


Alan S. Go, MD 

Oakland, CA 


Pittsburgh, PA 


Jackson, MS 

Richard H. Grimm, Jr., MD, 

PhD 


Yuan Guo, MD, MS 

Beijing, China 


Jackson, MS 


Anaheim, CA 

David Harder, MD, PhD 

Milwaukee, WI 

Raymond C. Harris, MD 

Nashville, TN 

David G. Harrison, MD 

Atlanta, GA 

Joseph A. Hill, MD, PhD 

Dallas, TX 

Norman K. Hollenberg, MD, 

PhD 

Boston, MA 

Suzanne Hughes, RN, MSN 

Akron, OH 

Joseph L. Izzo, Jr., MD, FASH 

Buffalo, NY 

Edgar A. Jaimes, MD 


Kenneth A. Jamerson, MD, 


Ann Arbor, MI 

Julie A. Johnson, PharmD 



Denver, CO 

Pedro A. Jose, MD 


Luis Juncos, MD 

Córdoba, Argentina 

Rae-Ellen W. Kavey, MD, MPH 

Rochester, NY 

Donald E. Kohan, MD, PhD 

Salt Lake City, UT 


Neptune, NJ 

Lawrence R. Krakoff, MD 

New York, NY 

Henry Krum, MBBS, PhD 

Melbourne, Australia 




San Francisco, CA 

Robert F. Kushner, MD 

Chicago, IL 

Daniel T. Lackland, DrPH, 



Edward G. Lakatta, MD 

Baltimore, MD 

Babbette LaMarca, PhD 

Jackson, MS 

Marc B. Lande, MD, MPH 

Rochester, NY 

Daniel Levy, MD 

Framingham, MA 

Nita A. Limdi, PharmD, PhD, 

MSPH 


Tianhu Liu, MD 

Chengdu, China 

Charles J. Lowenstein, MD 

Rochester, NY 

Jianfang Luo, MD 

Guangzhou, China 

James M. Luther, MD 

Nashville, TN 

Guiseppe Mancia, MD 

Milan, Italy 


New York, NY 

Athanasios J. Manolis, MD, 

PhD 

Athens, Greece 


Iowa City, IA 

Barry J. Materson, MD, MBA, 


Miami, FL 

33


David L. Mattson, PhD 

Milwaukee, WI 

Richard J. McManus, MD 

Birmingham, United Kingdom 

John Merenich, MD 

Denver, CO 

Franz H. Messerli, MD, FASH 

New York, NY 

Nancy Houston Miller, RN, 

BSN 

Palo Alto, CA 

Mark E. Molitch, MD 

Chicago, IL 

Krzysztof Narkiewicz, MD, 

PhD 

Gdánsk, Poland 



Shawna D. Nesbitt, MD, MS, 


Dallas, TX 

Joel M. Neutel, MD, FASH 

Tustin, CA 

Susanne B. Nicholas, MD, PhD, 

MPH 


Eoin O’Brien, MD 

Dublin, Ireland 

Gbenga Ogedegbe, MD, MPH, 

MS, FASH 

New York, NY 

Suzanne Oparil, MD, FASH 


Julio A. Panza, MD 


Vasilios Papademetriou, MD, 



Gianfranco Parati, MD 

Milan, Italy 


West Haven, CT 

Robert A. Phillips, MD, PhD, 


Worcester, MA 

Thomas A. Pearson, MD, PhD, 

MPH 

Rochester, NY 

F. Xavier Pi-Sunyer, MD, MPH 

New York, NY 


Ann Arbor, MI 

Velvie A. Pogue, MD 

New York, NY 

David M. Pollock, PhD 

Augusta, GA 



Henry A. Punzi, MD 

Carrollton, TX 

Leopoldo Raij, MD, FASH 

Miami, FL 

C. Venkata S. Ram, MD, FASH 

Dallas, TX 

James Rippe, MD 

Shrewsbury, MA 

Talma Rosenthal, MD 

Tel Aviv, Israel 

Peter M. Rothwell, MD 

Oxford, United Kingdom 

Luis M. Ruilope, MD 

Madrid, Spain 


Jackson, MS 

Elijah Saunders, MD, FASH 

Baltimore, MD 


Montreal, Canada 

Roland E. Schmieder, MD 

Erlangen, Germany 

Antoinette Schoenthaler, EdD 

New York, NY 

Domenic A. Sica, MD 

Richmond, VA 

Sidney Smith, Jr., MD 

Chapel Hill, NC 

Matthew Sorrentino, MD 

Chicago, IL 

Thomas A. Sos, MD 

New York, NY 

James R. Sowers, MD, FASH 

Columbia, MO 

Lesley A. Stevens, MD, MS 

Boston, MA 

Allan D. Struthers, MD 

Dundee, United Kingdom 

Laura P. Svetkey, MD 

Durham, NC 

Sandra J. Taler, MD, FASH 

Rochester, MN 

Ting Tao, MD 

Shanghai, China 

34

2011 American Society of Hypertension Annual Meeting & Expostion – Program at a Glance 

Day – Date – Time Pathobiology Translational Therapy Special Sessions Joint Sessions Debates/Meet the Professor Innovations Theater Satellite Symposia 


8:30 AM to 3:00 PM 

Saturday, May 21, 2011 Pavilion Hours – Open 4:30 PM to 7:30 PM Posters on Display – 4:30 PM to 7:30 PM; Poster Viewing – 6:00 PM to 7:00 PM 

Americas Hall, 3rd Floor 

Hypertension 

Highlights 2011 

East Ballroom, 3rd Floor 


3:15 PM to 4:15 PM 

Membership Meeting 

ASH Members Only 


4:30 PM to 6:00 PM 

Trianon Rendezvous, 3rd Floor 

Young Investigator 

Competition Award 

Joint Session – American 

Heart Association’s Council for 

High Blood Pressure Research 


6:30 PM to 7:30 PM 


8:00 AM to 12:30 PM 


Genomics and Hypertension 

Beekman Parlor, 2nd Floor 

Joint Session – Preventive 

Cardiovascular Nurses 

Association 

Sutton South, 2nd Floor 

Joint Session – Association for 

Research into Atterial Structure 

and Physiology and North 

American Artery 

Regent Parlor, 2nd Floor 

Joint Session – National Lipid 

Association/American Society 

of Preventive Cardiology 

Sutton Center, 2nd Floor 

Saturday, May 21, 2011 6:00 PM to 7:30 PM Opening Reception – Hypertension Resource Pavilion 


Sunday, May 22, 2011 10:00 AM to 1:00 PM Hypertension Resource Pavilion Opens – 11:30 AM to 1:00 PM Brunch 


Hypertension for the 

Primary Care Clinician 2011 

Sutton North, 2nd Floor 

Innovations Theater 

Rhinelander Gallery, 2nd Floor 


9:30 AM to 11:00 AM 

Joint Session – International 

Pediatric Hypertension 

Association 


Joint Session – China Social 

Worker’s Association Vascular 

Protection Committee 


Joint Session – 

Hypertension Canada 



11:00 AM to 12:00 PM 


Inter-American Society of 



Meet the Professor – 

How to Write a 12 Page Grant 



Understanding Statistics in 

Clinical Research 



How to Develop an Abstract/ 

Lecture 


Debate – 

Is it Blood Pressure Variablility 

or Average Daily Blood 

Pressure that Best Predicts 

Stroke 


Debate – 

Surgical Intervention for Renal 

Artery Stenosis is Indicated 



12:00 PM to 1:00 PM 

West Ballroom, 3rd Floor 




1:15 PM to 3:00 PM 

Plenary Session I 



3:30 PM to 5:15 PM 

Aldosterone 

Mercury Ballroom, 3rd Floor 

Hypertension in Patients 

With Chronic Kidney 

Disease 


Comprehensive Multi- 

Level Interventions for 

Hypertension Management 

in High-Risk Groups 


Control of Hypertension is 

Leaving the Office: The Role 

of Home Blood Pressure and 

Telemedicine 

Trianon Ballroom, 3rd Floor 


International Society of 

Hypertension in Blacks 


Sunday, May 22, 2011 5:30 PM to 6:30 PM High Tea and Poster Viewing 



5:30 PM to 6:30 PM 



Monday, May 23, 2011 10:00 AM to 1:30 PM Hypertension Resource Pavilion Opens – Lunch in Pavilion 12:00 PM to 1:15 PM 



6:00 AM to 7:30 AM 

Symposia 



8:00 AM to 10:00 AM 

Off-Target Cardiovascular 

Effects of Non- 

Cardiovascular Drugs 

New Insights into the Role 

of Uric Acid in Hypertension 

Devices and Surgical 

Ablation for Refractory 



National Kidney Foundation 






10:30 AM to 12:00 PM 

Immune Mechanisms in 


Management of Elevated 

Blood Pressure in the 

Hospital Setting 

Management of 

Hypertension in Diabetics 

and Chronic Kidney Disease 

Hyperkalemia Management 

in High Risk Patients: New 

Evidence-Based Approaches 


European Society of 








11:45 AM to 12:15 PM 

Debate 

Are Elevated Potassium Levels 

Really a Concern 



1:30 PM to 4:00 PM 


4:30 PM to 5:00 PM 


8:15 AM to 9:30 AM 


10:00 AM to 11:30 AM 

Salt-Sensitive Mechanisms 

of Hypertension 

Plenary Session II 

Monday, May 23, 2011 4:00 PM to 5:30 PM Hypertension Resource Pavilion Opens – High Tea and Poster Viewing 4:30 PM to 5:30 PM 


Integrated Cardiovascular 

Disease Guidelines and 

Implementation 

Nutrition and 

Cardiovascular Prevention 


Late-Breaking Clinical Trials 


Debate 

The Dominant Contributor 

to Systemic Hypertension is: 

Sympathetic Nervous System 

not the RAAS; or Activation 

of the Intrarenal RAAS not 

the SNS 


Debate 

Hypertension is a Disorder of 

the Kidney 




Beekman Parlor, 2nd Floor


2011 Annual Scientific Meeting and Exposition 

2011 Program 

at a Glance 

Hilton New York 

Saturday, May 21, 2011 – Tuesday, May 24, 2011


Addison A. Taylor, MD, PhD, 


Houston, TX 

Jens Titze, MD 

Erlangen, Germany 

Sheldon W. Tobe, MD, FASH 

Toronto, Canada 

Robert D. Toto, MD 

Dallas, TX 


Ottawa, Canada 



Joseph A. Vassalotti, MD 

New York, NY 

Ronald G. Victor, MD 


Hongyu Wang, MD, PhD 

Beijing, China 

R. Clinton Webb, PhD 

Augusta, GA 

David J. Webb, MD 

Edinburgh, United Kingdom 

Michael A. Weber, MD, FASH 

New York, NY 


Ann Arbor, MI 



Matthew R. Weir, MD, FASH 

Baltimore, MD 

Adam Whaley-Connell, DO, 


Columbia, MO 

Andrew Whelton, MD 

Baltimore, MD 


Farmington, CT 

Ian B. Wilkinson, MD 

Cambridge, United Kingdom 

Bryan Williams, MD 

Leicester, United Kingdom 

Gordon H. Williams, MD 

Boston, MA 


Atlanta, GA 

Nathan D. Wong, PhD, MPH 

Irvine, CA 

Martin S. Zand, MD 

Rochester, NY 

37

Program Color Key 

The pages of this Program Book are color-coded to match the 

Program at a Glance (pages 35–36) and serve as a quick, identifiable 

reference of the type of educational activity or event taking place. 

Scientific Sessions* 



Special Event 



Debates 

Poster Sessions 


Hypertension Resource Pavilion 

The ASH Twenth-Sixth Annual Scientific Meeting is 

organized around three (3) concurrent themes: 

• Pathobiology of Hypertension 

• Translational Issues in Hypertension 

• Therapy of Hypertension 

Sessions in each of the three (3) themes (or tracks) are labeled 

throughout the Program Book to be easily identifiable.

2011 

American Society 


Program

MAY 21 

Saturday Morning 


8:00 AM – 3:00 PM • East Ballroom • Third Floor 

Part I: 

Co-Chairs: Henry R. Black, MD, FASH, New York, NY and 

Michael A. Weber, MD, FASH, New York, NY 

8:00 AM Breakfast 

8:30 AM Cardiovascular Effects of Anti-Diabetic Drugs 

Nancy J. Brown, MD, Nashville, TN 

9:00 AM Role of the Kidney in Angiotensin II Hypertension 

Steven D. Crowley, PhD, Durham, NC 

9:30 AM Neurohormonal Assessment in the Diagnosis and 

Management of Hypertension 

Ronald G. Victor, MD, Los Angeles, CA 

10:00 AM Break 

Part II: 

10:30 AM Panel Discussion: Hypertension and Obesity in 

Adolescence: Epidemiology, Nutritional Aspects, 

Evaluation and Management 

Moderator: Bonita Falkner, MD, FASH, Philadelphia, 

PA 

Panel Discussion Participants: 

Donald L. Batisky, MD, Atlanta, GA 

Joseph T. Flynn, MD, FASH, Seattle, WA and 

Robert F. Kushner, MD, Chicago, IL 

11:15 AM Partnership with the Patient to Improve Blood 

Pressure Control and the Role of the Hypertension 

Specialist in the “Medical Home” 

Moderator: Elijah Saunders, MD, FASH, Baltimore, 

MD 

Joel Handler, MD, Anaheim, CA and 

Nancy Houston Miller, RN, BSN, Palo Alto, CA 

12:15 PM Lunch 

Part III: 

1:00 PM Panel Discussion: Resistant Hypertension: 

Pathophysiology, Evaluation, and New/Old 

Treatment Considerations 

Moderator: C. Venkata S. Ram, MD, FASH, Dallas, TX 


Michael W. Brands, PhD, Augusta, GA 

John D. Bisognano, MD, PhD, FASH, Rochester, NY 

Domenic A. Sica, MD, Richmond, VA and 

Gordon H. Williams, MD, Boston, MA 

2:15 PM Complementary and Alternative Therapies in 


Moderator: Robert A. Phillips, MD, PhD, FASH, 

Worcester, MA 


Brent M. Egan, MD, FASH, Charleston, SC and 

Matthew Sorrentino, MD, Chicago, IL 

40

Saturday Afternoon MAY 21 

ASH Membership Meeting 

3:15 PM – 4:15 PM • Trianon Rendezvous • Third Floor 

ASH Annual Membership Meeting 

41

MAY 21 

Sessions 

Saturday Afternoon 

4:30 PM – 6:00 PM • Beekman Parlor • Second Floor 

Genomics and Hypertension 

Co-Chairs: Theodore W. Kurtz, MD, San Francisco, CA and 

Alan B. Weder, MD, Ann Arbor, MI 

4:30 PM Pharmacogenetics and Cardiovascular Disease 

Nita A. Limdi, PharmD, PhD, MSPH, Birmingham, AL 

5:00 PM Genomics of Experimental Hypertension: 

Translation to Humans 


5:30 PM Antihypertensive Drug Pharmacogenomics 

Julie A. Johnson, PharmD, Gainesville, FL 

42


Sessions 

4:30 PM – 6:00 PM • Sutton North • Second Floor 

Advancements in the Pathophysiology of 

Hypertension: Some Novel Concepts 

Held in Partnership with the American Heart Association’s Council 

for High Blood Pressure Research (HBPR) 

Co-Chairs: Phyllis August, MD, MPH, New York, NY and 

Rhian M. Touyz, MD, PhD, Ottawa, Canada 

4:30 PM Overview 


4:40 PM Pathophysiology of Hypertension in Preeclampsia: 

Novel Concepts 

Joey P. Granger, PhD, Jackson, MS 

5:06 PM Vascular Function, Hypertension and Erectile 

Dysfunction: Novel Mechanisms 

R. Clinton Webb, PhD, Augusta, GA 

5:32 PM Obesity-Related Hypertension: Basic Concepts and 

Clinical Implications 

John E. Hall, PhD, Jackson, MS 

43

MAY 21 

Sessions 


4:30 PM – 6:00 PM • Sutton Center • Second Floor 

Cardiovascular Risk Prevention 

Held in Partnership with the American Society of Preventive 

Cardiology (ASPC) and the National Lipid Association (NLA) 

Co-Chairs: George L. Bakris, MD, FASH, Chicago, IL and 

Peter W. F. Wilson, MD, Atlanta, GA 

4:30 PM Welcoming Remarks 


4:40 PM Prevention Strategy and National Healthcare 

Thomas A. Pearson, MD, PhD, MPH, Rochester, NY 

5:00 PM National Health Forum Initiatives: Dollars and 

Cents 

Keith C. Ferdinand, MD, FASH, Atlanta, GA 

5:20 PM Aggressive Medical Management versus 

Intervention: An Uphill Road to Policy Change 

William E. Boden, MD, Buffalo, NY 

5:40 PM Leadership Panel Discussion 

George L. Bakris, MD, FASH, Chicago, IL, Michael H. 

Davidson, MD, Chicago, IL and Nathan D. Wong, PhD, 

MPH, Irvine, CA 

Questions and Answers 

44


Sessions 

4:30 PM – 6:00 PM • Sutton South • Second Floor 

Advocating for Adherence to Better Control 


Held in Partnership with the Preventive Cardiovascular Nurses 

Association (PCNA) 

Co-Chairs: Nancy Artinian, PhD, RN, Detroit, MI and 

Barry L. Carter, PharmD, Iowa City, IA 

4:30 PM Enhancing Adherence in Ethically-Diverse 

Populations 

Gbenga Ogedegbe, MD, MPH, MS, FASH, New York, 

NY and Antoinette Schoenthaler, EdD, New York, NY 

4:52 PM From Adherence to Advocacy: The Need to Reduce 

Sodium 

Suzanne Hughes, RN, MSN, Akron, OH 

5:14 PM Adherence and Persistence with Medications: 

The ASH Position 

Nancy Houston Miller, RN, BSN, Palo Alto, CA 

5:36 PM Practical Tips to Assess and Promote Adherence in 

Clinical Practice 

Lynne T. Braun, PhD, CNP, Chicago, IL 

45

MAY 21 

Sessions 


4:30 PM – 6:00 PM • Regent Parlor • Second Floor 

Arterial Stiffness: A Paradigm Shift in 

Understanding the Increased Cardiovascular Risk 

Associated with Aging and Chronic Disease 

Held in Partnership with the Association for Research into Arterial 

Structure and Physiology (ARTERY) and North American Artery 

(NAA) 

Co-Chairs: John R. Cockcroft, MD, Cardiff, United Kingdom and 

Stanley S. Franklin, MD, FASH, Los Angeles, CA 

4:30 PM Chronic Obstructive Pulmonary Disease Arterial 

Stiffness and Cardiovascular Disease 


4:52 PM Vasculitides Arterial Stiffness and Cardiovascular 

Disease 

Ian B. Wilkinson, MD, Cambridge, United Kingdom 

5:14 PM Is Vascular Aging Inevitable 

Edward G. Lakatta, MD, Baltimore, MD 

5:36 PM Pulse Wave Analysis in Subjects with Chronic 

Kidney Disease 

Raymond R. Townsend, MD, Philadelphia, PA 

46


Sessions 


Young Investigator-in-Training Abstract 

Competition 

Moderator: 

Judges: 

Addison A. Taylor, MD, PhD, FASH, Houston, TX 

Stephen R. Daniels, MD, PhD, FASH, Aurora, CO, 

Thomas D. Giles, MD, FASH, New Orleans, LA, 

Lawrence R. Krakoff, MD, New York, NY, 

Susanne B. Nicholas, MD, PhD, MPH, Los Angeles, CA, 

and Myron H. Weinberger, MD, Indianapolis, IN 

4:30 PM OR-1: Waist Hip Ratio vs Body Mass Index as 

Predictors of Endothelial Dysfunction 

Arantxa Rodriguez, Rosa Fabregate, Martin Fabregate, 

Susana Tello, Angelica Fernandez, Asuncion Guerri, 

Nuria De la Torre, Jose Saban‐Ruiz. Ramon y Cajal 

Hospital, Madrid, ES. 

4:42 PM OR-2: M-Atrial Natriuretic Peptide, a Novel Anti- 

Hypertensive Therapeutic Peptide, Is Markedly 

Resistant to In Vitro Degradation 

Paul M. McKie, Alessandro Cataliotti, Tomoko Ichiki, 

S. Jeson Sangaralingham, Valentina Cannone, John C. 

Burnett, Jr. Mayo Clinic, Rochester, MN, US. 

4:54 PM OR-3: Outcomes with Atenolol or Other β-Blockers: 

Network and Bayesian Meta-Analyses of Clinical 

Trials in Hypertension 

W. Kurtis Childers†, 1 William J. Elliott, 1 Sanjib Basu, 2 

Peter M. Meyer. 2 1 Pacific Northwest University of 

Health Sciences, Yakima, WA, US; 2 RUSH Medical 

College, Chicago, IL, US. 

5:06 PM OR-4: Role of Renal DJ-1 in the Regulation of 

Oxidative Stress 

Santiago Cuevas Gonzalez, Yanrong Zhang, Yu Yang, 

Laureano D. Asico, Pedro A. Jose, Ines Armando. 

Children’s National Medical Center, George 

Washington University, Washington, DC, US. 

5:18 PM OR-5: Adiposity, Metabolic and Dietary Risk Factors 

Associated with Prehypertension in Black and White 

Adolescent Males: A Cross-Sectional Study 

Samip J. Parikh, Haidong Zhu, Norman K. Pollock, 

Inger Stallmann-Jorgensen, Gutin Bernard, Yanbin 

Dong. Medical College of Georgia, Augusta, GA, US. 

47

MAY 21 

Posters 

Saturday Evening 


















Stroke.............................................................................(PO-117 – PO-119) 



information. 

48

Sunday Morning MAY 22 

Sessions 

8:00 AM – 12:30 PM • West Ballroom • Third Floor 

Hypertension for the Primary Care Clinician 2011 

7:30 AM Breakfast 

8:00 AM to 9:00 AM 

The Management of the Hypertensive Patient 

Before and After Surgery 

Co-Chairs: Jan N. Basile, MD, FASH, Charleston, SC and 

F. Wilford Germino, MD, FASH, Orland Park, IL 

8:00 AM Case Presentation 

F. Wilford Germino, MD, FASH 

8:10 AM Pre-operative Evaluation of the Patient with 


James B. Froehlich, MD, MPH, Ann Arbor, MI 

8:35 AM Peri-operative Management of the Hospitalized 

Patient with Hypertension 


9:00 AM to 10:00 AM 

A Systems Approach to Optimize Blood Pressure 

Control 

Co-Chairs: Paula T. Einhorn, MD, MS, Bethesda, MD and Gbenga 

Ogedegbe, MD, MPH, MS, FASH, New York, NY 

9:00 AM Exporting Lifestyle Modification into Your Practice 

Laura P. Svetkey, MD, Durham, NC 

9:20 AM Electronic Medical Records and the Hypertension 

Initiative in the Carolinas 

Brent M. Egan, MD, FASH, Charleston, SC 

9:40 AM A Team Based Approach to Blood Pressure Control 

Barry L. Carter, PharmD, Iowa City, IA 

10:00 AM Break 

10:15 AM to 11:15 AM 

Evaluation of Resistant Hypertension 

Co-Chairs: Louis Kuritzky, MD, Gainesville, FL and 

Samuel J. Mann, MD, New York, NY 

10:15 AM Out of Office Monitoring to Rule Out Resistant 


Angela L. Brown, MD, St. Louis, MO 

continued… 

49

MAY 22 

Sunday morning 

Sessions continued 

10:30 AM Outpatient Evaluation for Secondary Causes of 

Resistant Hypertension 

Emmanuel Bravo, MD, Cleveland, OH 

10:55 AM Treatment of Resistant Hypertension: 

Tricks of the Trade 

William J. Elliott, MD, PhD, FASH, Yakima, WA 

11:15 AM Panel Discussion: 

How Has the Management of Hypertension in 

Primary Care Changed Since JNC 7 

Chair: Michael J. Bloch, MD, FASH, Reno, NV 


George L. Bakris, MD, FASH, Chicago, IL, 

Jan N. Basile, MD, FASH, Charleston, SC, 

Angela L. Brown, MD, St. Louis, MO and 

Leonard M. Fromer, MD, Los Angeles, CA 

This Live activity, Hypertension for the Primary Care Clinician 2011, 

has been reviewed and is acceptable for up to 4.25 Prescriptive credits by 

the American Academy of Family Physicians. Physicians should claim 

only the credit commensurate with the extent of their participation in 

the activity. 

50


Sessions 

9:00 AM – 10:30 AM • Sutton North • Second Floor 

The Role of Neurohumoral and Vasoactive 

Substances in Hypertension 

Held in Partnership with the International Pediatric Hypertension 

Association (IPHA) 

Co-Chairs: Donald L. Batisky, MD, Atlanta, GA and 

Jay N. Cohn, MD, Minneapolis, MN 

9:00 AM Effects of Endothelin Blockade on Blood Pressure: 

Pro and Con 

David M. Pollock, PhD, Augusta, GA 

9:30 AM The Interplay of Race/Ethnicity, Inflammation 

and Elevated Blood Pressure in Children and 

Adolescents 

Marc B. Lande, MD, MPH, Rochester, NY 

10:00 AM Dopamine, the Kidney and Hypertension 

Pedro A. Jose, MD, Washington, DC 

51

MAY 22 

Sessions 

Sunday Morning 

9:00 AM – 10:30 AM • Regent Parlor • Second Floor 

Renin-Angiotensin System in Hypertension: 

Regulation and Consequences 

Held in Partnership with the Inter-American Society of Hypertension 

(IASH) 

Co-Chairs: Haralambos Gavras, MD, Boston, MA and 

L. Gabriel Navar, PhD, New Orleans, LA 

9:00 AM Introduction: The Intratubular RAS in Hypertension 


9:22 AM Role of the Transcription Factor ETS-1 as Mediator 

of Angiotensin II Induced End-Organ Injury 

Edgar A. Jaimes, MD, Birmingham, AL 

9:44 AM Hypertension, Insulin Resistance and Oxidative 

Stress 

Leopoldo Raij, MD, FASH, Miami, FL 

10:06 AM Therapeutic Efficacy of New Renin Inhibitors 

Luis Juncos, MD, Córdoba, Argentina 

52


Sessions 

9:00 AM – 10:40 AM • Sutton Center • Second Floor 

The 3rd American Society of Hypertension/China 

Social Worker’s Association Vascular Protection 

Committee Session on Early Vascular Disease 

Detection and Management: Experience from China 

Co-Chairs: Suzanne Oparil, MD, FASH, Birmingham, AL and 

Hongyu Wang, MD, PhD, Beijing, China 

9:00 AM Chinese Guidelines for Early Vascular Disease 

Detection 2011: Experience from China 


9:20 AM Role of Cardiometabolic Syndrome and Related 

Vascular Disease in Chinese Elderly 

Ting Tao, MD, Shanghai, China 

9:40 AM Epidemiology of Hypertension and Peripheral 

Vascular Disease in China 

Jianfang Luo, MD, Guangzhou, China 

10:00 AM Carotid IMT Examination for Atherosclerosis 

Screening in Diabetes 

Yuan Guo, MD, MS, Beijing, China 

10:20 AM Arterial Stiffness Parameters Integrated for Vascular 

Health Evaluation in Hypertensive Patients 

Tianhu Liu, MD, Chengdu, China 

53

MAY 22 

Sessions 


9:00 AM – 10:30 AM • Sutton South • Second Floor 

Overcoming Clinical Inertia: Changing Practice 

Paradigms on Both Sides of the 49th Parallel 

Held in Partnership with Hypertension Canada 

Co-Chairs: Ross Feldman, MD, London, Canada and 

Alan H. Gradman, MD, FASH, Pittsburgh, PA 

9:00 AM Introduction: Definitions and Scope of the Issue 

Joel M. Neutel, MD, FASH, Tustin, CA 

9:10 AM Clinic Focused Educational Interventions to 

Improve Blood Pressure Control: Using the Heart 

and Stroke Hypertension Clinic Model as the 

Paradigm 

Sheldon W. Tobe, MD, FASH, Toronto, Canada 

9:35 AM Simplifying Treatment Algorithms as a Means of 

Reducing Clinical Inertia 


10:00 AM US Approaches for Guidelines Implementation 

William C. Cushman, MD, FASH, Memphis, TN 

10:10 AM Implementation and Impact of the Canadian 

Hypertension Education Program 

Norman R.C. Campbell, MD, Calgary, Canada 

10:20 AM Questions and Answers 

54


Posters 




















information. 

55

MAY 22 

Debates 


11:00 AM – 12:00 PM 

Sutton South • Second Floor 

Debate: Is it Blood Pressure Variability or Average 

Daily Blood Pressure that Best Predicts Stroke 

Moderator: William B. White, MD, FASH, Farmington, CT 

11:00 AM Blood Pressure Variability 

Peter M. Rothwell, MD, Oxford, United Kingdom 

11:20 AM Average Daily Blood Pressure 

Eoin O’Brien, MD, Dublin, Ireland 

11:40 AM Rebuttal 


Regent Parlor • Second Floor 

Debate: Surgical Intervention for Renal Artery 

Stenosis is Indicated 

Moderator: Bryan Williams, MD, Leicester, United Kingdom 

11:00 AM Yes: Thomas A. Sos, MD, New York, NY 

11:20 AM No: Lance D. Dworkin, MD, Providence, RI 



56


Special Sessions 

11:00 AM – 12:00 PM 


Beekman Parlor • Second Floor 

How to Write a 12 Page Grant 

David Harder, MD, PhD, Milwaukee, WI 

Sutton North • Second Floor 

Understanding Statistics in Clinical Research 

Richard H. Grimm, Jr., MD, PhD, Minneapolis, MN 

Sutton Center • Second Floor 

How to Develop an Abstract/Lecture 

David G. Harrison, MD, Atlanta, GA 

57

MAY 22 


Sunday Afternoon 

1:15 PM – 3:00 PM • East Ballroom • Third Floor 



William B. White, MD, FASH, Farmington, CT 

1:15 PM President’s Opening Address 

1:30 PM Keynote Lecture: Blood Pressure in Obesity 

F. Xavier Pi‐Sunyer, MD, MPH, New York, NY 

2:00 PM Cardiovascular Risk and Risk Reduction in Children 

and Adolescents 

Rae‐Ellen W. Kavey, MD, MPH, Rochester, NY 

2:20 PM Mechanisms from Studies of Human Obesity 

Sadaf Farooqi, PhD, Cambridge, United Kingdom 

2:40 PM Evaluation and Treatment of Hypertension in 

Childhood 

Joseph T. Flynn, MD, FASH, Seattle, WA 

58

Sunday Afternoon MAY 22 

Sessions 

3:30 PM – 5:15 PM • Mercury Ballroom • Third Floor 

1 Aldosterone 

Co-Chairs: J. Howard Pratt, MD, Indianapolis, IN and 

Gordon H. Williams, MD, Boston, MA 

3:30 PM Non-Renal Effects of Aldosterone 

James M. Luther, MD, Nashville, TN 

3:50 PM Interactions Between Aldosterone and 

Nitric Oxide 

Charles J. Lowenstein, MD, Rochester, NY 

4:10 PM Role of Aldosterone and Mineralocorticoid Receptor 

Activation in Obesity Related Hypertension 

John E. Hall, PhD, Jackson, MS 

Original Communications 

4:30 PM OR-6: Spironolactone Reverses Chlorthalidone- 

Induced Sympathetic Activation in Hypertensive 

Patients 

Prafull Raheja, Debbie Arbique, Zhijun Wang, Wanpen 

Vongpatanasin. UT Southwestern Medical Center, 

Dallas, TX, US. 

4:45 PM OR-7: Plasma Aldosterone Levels Affect Calcium 

Metabolism in Patients with Essential Hypertension 

Gian Luca Colussi, Cristiana Catena, GianLuca Colussi, 

Leonardo A. Sechi. University of Udine, Udine, IT. 

5:00 PM OR-8: Inappropriately Intense Salt Restriction, 

Which Causes Elevation of Plasma Aldosterone 

Level, Might Augment Myocardial Fibrosis in 

Animal Model of Renal Tubular Injury 

Tatsuhiko Mori, 1 Kenichi Hasegawa, 2 Hirohisa 

Matsuda, 1 Yasuo Matsumura, 2 Nobukazu Ishizaka. 1 

1 Osaka Medical College, Takatsuki, JP; 2 Osaka 

University of Pharmaceutical Sciences, Takatsuki, JP. 


59

MAY 22 

Special Sessions 



2 Hypertension in Patients with Chronic Kidney 

Disease 

Co-Chairs: Rajiv Agarwal, MD, Indianapolis, IN and 

Aldo J. Peixoto, MD, FASH, West Haven, CT 

3:30 PM Clinical Epidemiology of Hypertension and Chronic 

Kidney Disease 


3:50 PM Hypertension in Advanced Kidney Disease 

Luis M. Ruilope, MD, Madrid, Spain 

4:10 PM Hypertension in Renal Transplant Patients 

Martin S. Zand, MD, Rochester, NY 


4:30 PM OR-9: Administration-Time-Dependent Effects of 

Angiotensin Receptor Blockers in Hypertensive 

Patients with Chronic Kidney Disease 

Ramon C. Hermida, Diana E. Ayala, Artemio Mojon, 

Maria J. Fontao, Luisa Chayan, Jose R. Fernandez. 

University of Vigo, Vigo, ES. 

4:45 PM OR-10: Carvedilol for the Treatment of Intradialytic 

Hypertension: The Mechanisms and Treatment of 

Intradialytic Hypertension (MATCH) Study 

Jula K. Inrig, Peter Van Buren, Catherine Kim, Robert 

Toto. UT Southwestern, Dallas, TX, US. 

5:00 PM OR-11: Cardiovascular Risk Assessment – Addition 

of CKD and Race to the Framingham Equation 

Paul E. Drawz, 1,2 Sarah Baraniuk, 3 Barry R. Davis, 3 

Mahboob Rahman. 2,4 1 MetroHealth Medical Center, 

Cleveland, OH, US; 2 Case Western Reserve University, 

Cleveland, OH, US; 3 University of Texas School of 

Public Health, Houston, TX, US; 4 University Hospitals 

Case Medical Center, Cleveland, OH, US. 


60


Sessions 

3:30 PM – 5:15 PM • West Ballroom • Third Floor 

3 Comprehensive Multi-Level Interventions for 

Hypertension Management in High-Risk Groups 

Co-Chairs: Daniel Levy, MD, Framingham, MA and 

Robert A. Phillips, MD, PhD, FASH, Worcester, MA 

3:30 PM Hypertension in Minorities: A New York State 

Clinical Guidance Statement 

Joseph L. Izzo, Jr., MD, FASH, Buffalo, NY 

3:50 PM Clinical Trial Interventions: Where Have We Gone 

Right or Wrong 

Bryan Williams, MD, Leicester, United Kingdom 

4:10 PM Integrated and Alternate Approaches to Treatment 

William J. Elliott, MD, PhD, FASH, Yakima, WA 


4:30 PM OR-12: Influence of Inflammatory and 

Prothrombotic Factors in Left Ventricular Structure 

and Function in Essential Hypertensive Patients 

Gregory Vyssoulis, 1 Eva Karpanou, 2 Stella Maria 

Kyvelou, 1 I. Barbetseas, 1 C. Stefanadis. 1 1 1st Cardiology 

Clinic Athens University Hippokration Hospital, GR; 

2 1st Cardiology Clinic Onassis Cardiosurgery Center, 

GR. 

4:45 PM OR-13: The Kaiser Permanente Northern California 

Hypertension Project 2001-2009: How an Integrated 

Care Delivery System Increased Blood Pressure 

Control Rates from 44% to 80% in 8 Years 

Marc G. Jaffe, Joseph D. Young. The Permanente 

Medical Group, Oakland, CA, US. 

5:00 PM OR-14: Intensive Blood Pressure Control Does Not 

Increase Falls and Fractures in Patients with Type 2 

Diabetes:The ACCORD Trial 

Karen Margolis, 1 Lisa Palermo, 2 Eric Vittinghoff, 2 Hal 

Atkinson, 3 Gregory Evans, 3 Bruce Hamilton, 4 Robert 

Josse, 5 Patrick O’Connor, 1 Debra Simmons, 6 Margaret 

Tiktin, 7 Ann Schwartz. 2 1 HealthPartners Research 

Foundation, US; 2 U of CA-SF, US; 3 Wake Forest SOM, 

US; 4 Baltimore VAMC, US; 5 University of Toronto, 

CA; 6 Central Arkansas Veterans Healthcare System, 

US; 7 Case Western Research University, US. 


61

MAY 22 

Sessions 



New Perspectives in ISHIB Consensus Statement: 

Is Clinical Judgment Medically Appropriate 

Held in Partnership with the International Society on Hypertension 

in Blacks (ISHIB) 

Co-Chairs: Kenneth A. Jamerson, MD, FASH, Ann Arbor, MI and 

Daniel T. Lackland, DrPH, FASH, Charleston, SC 

3:30 PM Is There a Role for Opinion in Guidelines or 

Consensus Reports A Perspective 

Keith C. Ferdinand, MD, FASH, Atlanta, GA 

3:45 PM Highlights of the New Consensus Statement 

Shawna D. Nesbitt, MD, MS, FASH, Dallas, TX 

Debate 

4:00 PM Supporting Perspective 

John M. Flack MD, MPH, Detroit, MI 

4:20 PM Opposing Perspective 

William C. Cushman, MD, FASH, Memphis, TN 

4:40 PM Rebuttal 

62


Sessions 

3:30 PM – 5:00 PM • Trianon Ballroom • Third Floor 

Control of Hypertension is Leaving the Office: 

The Role of Home Blood Pressure and Telemedicine 

Co-Chairs: Lawrence R. Krakoff, MD, New York, NY and 


3:30 PM Home Blood Pressure and Cardiovascular Risk 

Gianfranco Parati, MD, Milan, Italy 

3:52 PM Using Home Blood Pressure in Clinical Practice 

Gbenga Ogedegbe, MD, MPH, MS, FASH, New York, 

NY 

4:14 PM Home Blood Pressure and Telemetry to Improve 

Hypertension Control 

Richard J. McManus, MD, Birmingham, United 

Kingdom 

4:36 PM The Future of Telemedicine in the Management of 



Supported by an educational grant from Omron Healthcare, Inc. 

63

MAY 23 

Satellite Symposium 

6:00 AM – 7:30 AM • Trianon Ballroom • Third Floor 

Monday morning 

The Role of Beta-Blockers in Hypertension: 

A Healthy Debate 

Chairman: Jan N. Basile, MD, FASH, Charleston, SC 

Learning Objectives: 

• Describe the differences and similarities 

among agents within the beta-blocker class of 

antihypertensive agents 

• Summarize the results of key clinical trials 

investigating beta blockade in African American, 

Hispanic, and Asian patient populations 

• List reasons why beta-blockers should or should 

not be used as first line or second step therapy for 

hypertension 

Program Agenda: 

6:00 AM Welcome 

Overview of Program Learning Objectives 

Audience Response System (ARS) 

Jan N. Basile, MD, FASH, Chairman 

6:05 AM The Class Effect With Beta-Blockers: Does One Size 

Fit All 

Addison A. Taylor, MD, PhD, FASH, 

Houston, TX 

6:25 AM Beta-Blockers and Ethnicity: What Do We Really 

Know 

Henry A. Punzi, MD, Dallas, TX 

6:45 AM Debate: Beta-Blockers Are Appropriate for First 

Line or Second Step Therapy in Patients With 


AGREE: William H. Frishman, MD, 

Valhalla, NY 

DISAGREE: Franz H. Messerli, MD, FASH, 

New York, NY 

7:15 AM Faculty Panel Discussion With Questions From the 

Audience 

Jan N. Basile, MD, FASH, Moderator 

7:30 AM Review of Program Learning Objectives and Closing 

Remarks 

Jan N. Basile, MD, FASH, Moderator 

A Breakfast will be held at 5:30 AM in the 

Trianon Ballroom. 

Supported by an educational grant from Forest Laboratories, Inc. 

64

Monday Morning MAY 23 

Sessions 

8:00 AM – 10:05 AM • Mercury Ballroom • Third Floor 

1 Off-Target Cardiovascular Effects of Non- 

Cardiovascular Drugs 

Co-Chairs: Franz H. Messerli, MD, FASH, New York, NY and 

Suzanne Oparil, MD, FASH, Birmingham, AL 

8:00 AM Anti-VEGF and Other Chemotherapeutic Agents 

Rhian M. Touyz, MD, PhD, Ottawa, Canada 

8:20 AM Non-Steroidal Anti-Inflammatory Drugs 

Raymond C. Harris, MD, Nashville, TN 

8:40 AM PDE5 Inhibitors and Organic Nitrates 

David J. Webb, MD, Edinburgh, United Kingdom 

9:00 AM PPAR Agents 

Julio A. Panza, MD, Washington, DC 


9:20 AM OR-15: Effects on Ambulatory Blood Pressure of 

Adding Low-Dose Aspirin at Bedtime in Subjects 

with Treated Hypertension 

Ramon C. Hermida, University of Vigo, Vigo, ES. 

9:35 AM OR-16: Cardio-Metabolic Effects of Acute and 

Sub-Acute Exposures to Ambient Levels of Fine 

Particulate Matter Air Pollution 

Robert D. Brook, 1 Robert L. Bard, 1 J. Timothy 

Dvonch, 1 Masako Morishita, 1 Niko Kaciroti, 1 Sanjay 

Rajagopalan. 2 1 University of Michigan, US; 2 Ohio State 

University, US. 

9:50 AM OR-17: Impact of Nonsteroidal Anti-Inflammatory 

Drugs on Nocturnal Blood Pressure 

W. B. White†, 1 L. Lavange, 2 A. Marquis. 2 1 University of 

Connecticut School of Medicine, Farmington, CT, US; 

2 University of North Carolina at Chapel Hill, Chapel 

Hill, NC, US. 


65

MAY 23 

Sessions 


8:00 AM – 10:00 AM • East Ballroom • Third Floor 

2 New Insights into the Role of Uric Acid in 


Co-Chairs: Richard J. Johnson, MD, Denver, CO and 

Andrew Whelton, MD, Baltimore, MD 

8:00 AM Fructose-Obesity-Uric Acid Link 


8:25 AM Oxidative Stress and Impact of Uric Acid 

Allan D. Struthers, MD, Dundee, United Kingdom 

8:40 AM Urate-Lowering and Blood Pressure Response 

Daniel I. Feig, MD, PhD, Houston, TX 


9:00 AM OR-18: Associations of Uric Acid with Asymmetric 

Dimethylarginine, L-arginine and Arterial Stiffening 

in Hypertension 

K. Dimitriadis, C. Tsioufis, A. Aggelis, S. Kyvelou, 

E. Stefanadi, L. Lioni, D. Flessas, C. Stefanadis. 

Hippokration Hospital, Athens, GR. 

9:15 AM OR-19: Epoxyeicosatrienoic Acid Agonist Attenuates 

Adipogenesis Derived from Mesenchymal Stem Cells 

Via Heme Oxygenase-PPARg Pathways 

DongHyun Kim, 1 Luca Vanella, 1 Nitin Puri, 1 Michal L. 

Schwartzman, 2 John R. Falck, 3 Komal Sodhi, 1 Nader G. 

Abraham. 1 1 University of Toledo College of Medicine, 

Toledo, OH, US; 2 New York Medical College, Valhalla, 

NY, US; 3 University of Texas Southwestern Medical 

Center, Dallas, TX, US. 

9:30 AM OR-20: Effect of Allopurinol on Blood Pressure: 

A Systematic Review 

Vikram Agarwal, 1 Nidhi Hans, 2 Franz Messerli. 1 1 St. 

Luke’s-Roosevelt Hospital Center, NY, US; 2 Harvard 

School of Public Health, MA, US. 


66


Sessions 

8:00 AM – 10:00 AM • West Ballroom • Third Floor 

3 Devices and Surgical Ablation for Refractory 


Co-Chairs: Domenic A. Sica, MD, Richmond, VA and 

Ronald G. Victor, MD, Los Angeles, CA 

8:00 AM How to Evaluate and Choose the Appropriate 

Patient 

Henry Krum, MBBS, PhD, Melbourne, Australia 

8:20 AM Renal Nerve Ablation 

Roland E. Schmieder, MD, Erlangen, Germany 

8:40 AM Carotid Baroreceptor Manipulation 



9:00 AM OR-21: True Resistant Hypertension: Optimal Cut- 

Off Ambulatory Blood Pressure Level for Diagnosis 

and Effect of Spironolactone 

Jose A. Garcia‐Donaire, Julian Segura, Cesar Cerezo, 

Luis M. Ruilope. Hospital 12 de Octubre, Madrid, ES. 

9:15 AM OR-22: Individualized Programming Demonstrates 

Feasibility of Unilateral Approach to Delivery of 

Baroreflex Activation Therapy® 

Domenic Sica†, 1 John Bisognano, 2 Mitra Nadim, 3 Luis 

Sanchez, 4 George Bakris. 5 1 Virginia Commonwealth 

University, Richmond, VA, US; 2 University of 

Rochester, Rochester, NY, US; 3 University of Southern 

California, Los Angeles, CA, US; 4 Washington 

University, St. Louis, MO, US; 5 University of Chicago, 

Chicago, IL, US. 

9:30 AM OR-23: The Efficacy of Adding the Direct Renin 

Inhibitor Aliskiren on the Patients with Resistant 

Hypertension (55% Had Chronic Kidney Disease) 

– Subgroup Analysis on Different Levels of Plasma 

Renin Activity 

Fumitoshi Satoh, Ryo Morimoto, Masataka Kudo, 

Yoshitugu Iwakura, Yoshikiyo Ono, Sadayoshi Ito. 

Tohoku University Hospital, Sendai, JP 

9:45 AM OR-24: Exploring the Prevalence of Resistant 

Hypertension in a Large Ethnically Diverse 

Hypertensive Population 

Simran Bhandari, In Lu Liu, Jiaxiao Shi, Federico 

Calara, Scott Rasgon, John Sim. Kaiser Permanente 

Los Angeles Medical Center, Los Angeles, CA, US. 


67

MAY 23 

Sessions 


8:30 AM – 10:00 AM • Trianon Rendezvous • Third Floor 

The Kidney Early Evaluation Program (KEEP): 

A New Longitudinal Dimension for a New Decade 

Held in Partnership with the National Kidney Foundation (NKF) 


Joseph A. Vassalotti, MD, New York, NY 

8:30 AM KEEP: CKD Screening Program Overview 


8:52 AM KEEP: Longitudinal Preliminary Results 


9:14 AM KEEP: Experience with the CKD-EPI Equation 

Lesley A. Stevens, MD, MS Boston, MA 

9:36 AM Where Do We Stand on Blood Pressure Control 

in KEEP 

Adam Whaley‐Connell, DO, FASH, Columbia, MO 

68

Monday Morning Afternoon MAY 21 23 

Posters 












Neural Hormonal Mechanisms (Renin; Neural Control; Vasoactive 

Autacoids).....................................................................(PO-310 – PO-312) 




Obesity...........................................................................(PO-331 – PO-339) 








information. 

69

MAY 23 

Sessions 


10:05 AM – 11:35 AM • Trianon Ballroom • Third Floor 

Hyperkalemia Management in High Risk Patients: 

New Evidence-Based Approaches 

Co-Chairs: Murray Epstein, MD, Miami, FL and 

Luis M. Ruilope, MD, Madrid, Spain 

10:05 AM The Spectrum of Cardiovascular Risk Associated 

with Potassium Abnormalities 

Domenic A. Sica, MD, Richmond, VA 

10:35 AM Use of RAAS Inhibitors for Cardio-Renal Risk 

Reduction and Potassium Management 


11:05 AM Conventional versus Novel Approaches to the 

Management of Hyperkalemia 

David A. Bushinsky, MD, Rochester, NY 

Supported by an educational grant from Relypsa, Inc. 

70


Debate 

11:45 AM – 12:15 PM • Trianon Ballroom • Third Floor 

Debate: Are Elevated Potassium Levels Really a 

Concern 

Moderator: Barry J. Materson, MD, MBA, FASH, Miami, FL 

11:35 AM Yes: Vasilios Papademetriou, MD, FASH, 


11:45 AM No: Bertram Pitt, MD, Ann Arbor, MI 


71

MAY 23 

Sessions 


10:30 AM – 12:00 PM • Mercury Ballroom • Third Floor 

1 Immune Mechanisms in Hypertension 

Co-Chairs: Michael W. Brands, PhD, Augusta, GA and 


10:30 AM The Role of Inflammatory Cytokines in Pregnancy- 

Induced Hypertension 

Babbette LaMarca, PhD, Jackson, MS 

10:52 AM T-Regulatory Cells in Hypertension 

Ernesto L. Schiffrin, MD, PhD, Montreal, Canada 

11:14 AM Novel Mechanisms of Renal Injury in Hypertension 

David L. Mattson, PhD, Milwaukee, WI 

11:36 AM Adaptive Immune Response in Hypertension 



72


Sessions 

10:30 AM – 12:00 PM • East Ballroom • Third Floor 

2 Management of Elevated Blood Pressure in the 

Hospital Setting 

Co-Chairs: William J. Elliott, MD, PhD, FASH, Yakima, WA and 

Sandra J. Taler, MD, FASH, Rochester, MN 

10:30 AM Hypertension in the Emergency Department 

C. Venkata S. Ram, MD, FASH, Dallas, TX 

10:52 AM Hypertension in the Inpatient Unit 

Alan B. Weder, MD, Ann Arbor, MI 

11:14 AM Hypertension in the Peri-operative Period 

Daniel Duprez, MD, PhD, FASH, Minneapolis, MN 

11:36 AM Hypertension in the Dialysis Unit 

Aldo J. Peixoto, MD, FASH, West Haven, CT 


73

MAY 23 

Sessions 


10:30 AM – 12:00 PM • West Ballroom • Third Floor 

3 Management of Hypertension in Diabetics and 

Chronic Kidney Disease 

Co-Chairs: James R. Sowers, MD, FASH, Columbia, MO and 

Bryan Williams, MD, Leicester, United Kingdom 

10:30 AM Is There an Optimal Blood Pressure Goal in the 

Patient with Type-2 Diabetes 

Matthew R. Weir, MD, FASH, Baltimore, MD 

10:52 AM Prevention of Renal Disease in the Hypertensive, 

Type-2 Diabetic 

Robert D. Toto, MD, Dallas, TX 

11:14 AM Prevention of Renal Disease in the African- 

American Patient with Hypertension 

Velvie A. Pogue, MD, New York, NY 

11:36 AM Management of Metabolic Co-Morbidities in the 

Hypertensive Patient 

Mark E. Molitch, MD, Chicago, IL 


74


Sessions 

10:30 AM – 12:00 PM • Trianon Rendezvous • Third Floor 

Blood Pressure Variability and Treatment Goals 

Held in Partnership with the European Society of Hypertension 

(ESH) 


Krzysztof Narkiewicz, MD, PhD, Gdánsk, Poland 

10:30 AM Short and Long-Term Blood Pressure Variability 

Giuseppe Mancia, MD, Milan, Italy 

10:52 AM J-Curve Revisited 

Athanasios J. Manolis, MD, PhD, Athens, Greece 

11:14 AM Target Blood Pressure in Nephropatic Patients 


11:36 AM Ambulatory and Home Blood Pressure Targets 


75

MAY 23 

Plenary Session II 

Monday Afternoon 


Award Presentations 

Co-Chairs: 

George L. Bakris, MD, FASH, Chicago, IL and 

Norman K. Hollenberg, MD, PhD, Boston, MA 

1:30 PM Robert Tigerstedt Award Lecture 

Acetyl-Ser-Asp-Lys-Pro, an Endogenous 

Tetrapeptide: Role in Target Organ Damage in 

Hypertension, and Autoimmune Myocarditis 

Oscar A. Carretero, MD, FASH, Detroit, MI 

2:00 PM Young Scholar Award Lecture* 

Novel Mechanisms Linking Chronic Inflammation 

and Hypertension in Systemic Lupus Erythematosus 

Michael J. Ryan, PhD, Jackson, MS 

2:20 PM Young Scholar Award Lecture* 

State Rescued with Innovative BNP Based 

Technologies 

Alessandro Cataliotti, MD, PhD, Rochester, MN 

2:40 PM Marvin Moser Clinical Award Lecture 

Water Immersion: A Model of Volume Expansion 

for Assessing Renin-Aldosterone Responsiveness 

and Renal Sodium Handling in Humans 

Murray Epstein, MD, Miami, FL 

State-of-the-Art Lectures 



3:00 PM Leukocyte Telomere Length Genetics and 

Cardiovascular Disease 

Abraham Aviv, MD, Newark, NJ 

3:30 PM Development of Cardiac Hypertrophy 

Joseph A. Hill, MD, PhD, Dallas, TX 


76

Monday Afternoon MAY 23 

Debates 

4:30 PM – 5:00 PM 

Beekman Parlor • Second Floor 

Debate: The Dominant Contributor to Systemic 

Hypertension is 

Moderator: Murray Epstein, MD, Miami, FL 

4:30 PM Sympathetic Nervous System not the RAAS 

Murray D. Esler, MBBS, PhD, Melbourne, Australia 

4:40 PM Activation of the Intrarenal RAAS not the SNS 

L. Gabriel Navar, PhD, New Orleans, LA 


Sutton North • Second Floor 

Debate: Hypertension is a Disorder of the Kidney 

Moderator: Jens Titze, MD, Erlangen, Germany 

4:30 PM Yes: Joey P. Granger, PhD, Jackson, MS 

4:40 PM No: Allyn L. Mark, MD, Iowa City, IA 


77

MAY 24 

Sessions 

Tuesday Morning 

8:15 AM – 9:30 AM • West Ballroom • Third Floor 

Late-Breaking Clinical Trials 



8:15 AM LB-OR-01: Evaluation of Cardiovascular Effects in 

Three Double-Blind, Placebo-Controlled Clinical 

Trials with Controlled-Release Phentermine/ 

Topiramate 

Suzanne Oparil†, 1 Wesley Day, 2 Charles Bowden. 2 

1 University of Alabama, Birmingham, AL, US; 2 Vivus, 

Mountain View, CA, US. 

8:30 AM LB-OR-02: Longterm (3 – 5 Months) Spaceflight 

Promotes a Sustained Decrease in Blood Pressure 

and Systemic Vascular Resistance in Astronauts 

Peter Norsk, 1 Ali Asmar, 1 Niels Juel Christensen. 2 

1 University of Copenhagen, Copenhagen, DK; 2 Herlev 

University Hospital, Herlev, DK. 

8:45 AM LB-OR-03: Azilsartan Medoxomil Plus 

Chlorthalidone Reduces BP More Effectively 

Than Olmesartan Plus HCTZ in Stage 2 Systolic 


William C. Cushman†, 1 George Bakris, 2 William B. 

White, 3 Michael Weber, 4 Domenic Sica, 5 Andrew 

Roberts, 6 Eric Lloyd, 6 Stuart Kupfer. 6 1 University of 

TN College of Medicine, US; 2 U of Chicago Pritzker 

School of Medicine, US; 3 U of CT School of Medicine, 

US; 4 New York, NY, US; 5 VA Commonwealth U Health 

System, US; 6 Takeda Global Research & Development, 

US. 

9:00 AM LB-OR-04: Common Blood Pressure Genetic 

Variants and Their Relations to Hypertension, 

Target-Organ Damage, and Cardiovascular Disease 

Risk: The International Collaboration for Blood 

Pressure Genome-Wide Association Studies (ICBP) 

Georg Ehret, 1 Patricia Munroe, 4 Christopher Newton- 

Cheh, 5 Kenneth Rice, 3 Cornelia van Duin, 6 Aravinda 

Chakravarti, 1 Daniel Levy, 2 Mark Caulfield, 4 Toby 

Johnson. 4 1 Johns Hopkins, Baltimore, MD, US; 

2 NHLBI, Framingham, MA, US; 3 University of 

Washington, Seattle, WA, US; 4 London School of 

Medicine, London, GB; 5 Broad Institute, Cambridge, 

MA, US; 6 The Rotterdam Study, Rotterdam, NL. 

continued… 

78

Tuesday Morning MAY 24 

Sessions continued 

9:15 AM LB-OR-05: Sixteen Novel Loci Influence Blood 

Pressure in Diverse Populations 

Georg B. Ehret, 1 Patricia B. Munroe, 2 Kenneth M. 

Rice, 3 Murielle Bochud, 4 Andrew D. Johnson, 5 

Daniel I. Chasman, 6 Albert V. Smith, 7 Bruce M. 

Pstay, 3 Goncalo R. Abecasis, 8 Aravinda Chakravarti, 1 

Paul Elliott, 9 Cornelia M. van Duijn, 10 Christopher 

Newton Cheh, 11 Daniel Levy, 5 Mark J. Caulfield, 2 

Toby Johnson. 2 1 Johns Hopkins University School of 

Medicine, US; 2 Queen Mary University of London, 

GB; 3 University of Washington, Seattle, US; 4 University 

of Lausanne, CH; 5 National Heart Lung, and Blood 

Institute, Bethesda, US; 6 Brigham and Women’s 

Hospital, Boston, US; 7 University of Iceland, Reykajvik, 

IS; 8 University of Michigan School of Public Health, 

Ann Arbor, US; 9 Imperial College, GB; 10 Erasmus 

Medical Center, NL; 11 Massachusetts General Hospital, 

US. 

79

MAY 24 

Sessions 


10:00 AM – 11:30 AM • Sutton North • Second Floor 

1 Salt-Sensitive Mechanisms of Hypertension 

Co-Chairs: Allyn L. Mark, MD, Iowa City, IA and 

Jens Titze, MD, Erlangen, Germany 

10:00 AM Renal Sodium Handling, Endothelin, and 

Genetic Models 

Donald E. Kohan, MD, PhD, Salt Lake City, UT 

10:30 AM Significance of Non-Osmotic Sodium 


11:00 AM Nitric Oxide, Superoxide and Renal Sodium 

Handling 

Jeffrey L. Garvin, PhD, Detroit, MI 


80

Tuesday Morning MAY 24 

Sessions 

10:00 AM – 11:30 AM • Sutton Center • Second Floor 

2 Integrated Cardiovascular Disease Guidelines 

and Implementation 

Co-Chairs: Henry R. Black, MD, FASH, New York, NY and 

Sidney Smith, Jr., MD, Chapel Hill, NC 

10:00 AM Rationale for the NHLBI Integrated Cardiovascular 

Risk Reduction Guidelines 

Sidney Smith, Jr., MD 

10:30 AM Implementation of the Integrated Cardiovascular 

Risk Reduction Guidelines 

John Merenich, MD, Denver, CO 

11:00 AM Results of the Integrated Cardiovascular Risk 

Reduction Guidelines Implementation in Northern 

California 

Alan S. Go, MD, Oakland, CA 


81

MAY 24 

Sessions 


10:00 AM – 11:30 AM • Beekman Parlor • Second Floor 

3 Nutrition and Cardiovascular Prevention 

Co-Chairs: Lawrence J. Appel, MD, MPH, FASH, Baltimore, MD 

and David S. Kountz, MD, Neptune, NJ 

10:00 AM High Fructose Corn Syrup, Sucrose and Fructose: 

What Do We Really Know 

James Rippe, MD, Shrewsbury, MA 

10:30 AM Cations and Blood Pressure Control 

Lawrence J. Appel, MD, MPH, FASH 

11:00 AM Low Protein and Renal Protection 

Robert D. Toto, MD, Dallas, TX 


82

Hypertension Awareness Campaign for Your Patients 

ARE YOU 1 IN 3 

GET THE FACTS. KNOW YOUR RISKS. 

Help spread the word by visiting 1in3people.com. 

As per the American Heart Association, 1 in 3 US adults has high blood pressure. 1 

1. Roger VL, Go AS, Lloyd-Jones DM, et al; for the American Heart Association Statistics Committee and Stroke 

Statistics Subcommittee. Heart disease and stroke statistics—2011 update: a report from the American 

Heart Association. Circulation. 2011;123;e18-e209. 



© 2011 Novartis Printed in USA 4/11 CVF-1058015 Printed on Recycled Paper

2011 

American Society 


Program 

Posters

MAY 21 

Posters 



















Stroke.............................................................................(PO-117 – PO-119) 



information. 

86


Posters 

4:30 PM – 7:30 PM • Second Floor Promenade 

Adolescent hypertension and obesity 

PO-1: 

PO-2: 

PO-3: 

PO-5: 

Common Carotid Artery Intima-Media Thickness 

in Patients with Abdominal Obesity and Essential 


Evgeny V. Shlyakhto, 1 Olga D. Belyaeva, 2 Olga O. 

Bolshakova, 1 Aelita V. Berezina, 2 Olga O. Berkovich, 2 

Elena I. Baranova. 2 1 Almazov Federal Heart, Blood 

and Endocrinology Centre, Saint-Petersburg, RU; 

2 Saint-Petersburg State Medical University, Saint- 

Petersburg, RU. 

Prevalence of Hypertension in Pediatric Oncology 

Survivors 

Kathy K. Y. Lee‐Son, 1 Sheila L. Pritchard, 2 Douglas 

G. Matsell, 1 Josephine X. Chow, 1 Janis M. Dionne. 1 

1 BC Children’s Hospital, Vancouver, BC, CA; 2 BC 

Children’s Hospital, Vancouver, BC, CA. 

Blood Pressure Variability in White Coat 

Hypertensive Adolescents 

Egle R. Silva, Jose J. Villasmil, Greily A. Bermudez, 

Mayela J. Bracho, Carlos E. Esis, Gustavo E. Calmon, 

Alicex C. Gonzalez. Instituto de Enfermedades 

Cardiovasculares, Universidad del Zulia, Maracaibo, 

VE. 

Pharmacologic Management of Primary 

Hypertension in Adolescents 

Esther Yoon, Lisa Cohn, Albert Rocchini, David 

Kershaw, Gary Freed, Frank Ascione, Sarah Clark. 

University of Michigan, US. 

Antiatherosclerotic Drugs 

PO-6: 

PO-7: 

Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A 

Reductase Inhibitors on Blood Pressure 

Vikram V. Agarwal, Alexandros Briasoulis, Franz H. 

Messerli. St. Luke’s-Roosevelt Hospital, Columbia 

University College of Physicians and Surgeons, New 

York, NY, US. 

Statin Effect on the Blood Pressure in Young and 

Elderly Adults: Meta-Analysis 

Camila Hartmann, Manuela S. Baldo, Talita R. 

Strano, Tariane F. Foiato, Emilton Lima, Jr.. Pontifícia 

Universidade Católica do Paraná, Curitiba, PR, BR. 

Cardiac Structure and Function/Imaging 

PO-8: 

Effect of Telmisartan on Paroxymal Atrial 

Fibrillation in Hypertensive Patients with Different 

Left Atrial Size 

Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi, 

Gianluigi Marasi, Pierangelo Lazzari. University of 

Pavia, Pavia, IT. 

87

MAY 21 

Posters 


PO-9: 

PO-10: 

Effect of Aliskiren on QT Dispersion in Diabetic and 

Non Diabetic Hypertensive Patients 

Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi, 

Gianluigi Marasi, Pierangelo Lazzari. University of 

Pavia, IT. 

Impact of Antihypertensive Therapy on 

Dyssynchrony in Patients with Never-Treated 


Beom‐June Kwon, Sung‐Won Jang, Kyu‐Young Choi, 

Dong‐Bin Kim, Eun‐Joo Cho, Ho‐Joong Youn, Tae‐Ho 

Rho, Jae‐Hyung Kim. The Catholic University of 

Korea, Seoul, KR. 

Comprehensive multi-level interventions 

for hypertension management in highrisk 

groups 

PO-11: 

PO-12: 

PO-13: 

PO-14: 

PO-15: 

Refractory Hypertension Characterized by 

Heightened Sympathetic Tone 

Maria Czarina Acelajado, 1 Roberto Pisoni, 2 Tanja 

Dudenbostel, 3 Suzanne Oparil, 3 David A. Calhoun. 3 

1 Philippine General Hospital, Manila, PH; 2 Medical 

University of South Carolina, Charleston, SC, US; 

3 University of Alabama at Birmingham, Birmingham, 

AL, US. 

Prehypertension has Increased Peripheral Resistance 

in Patients with Obesity 

Ricardo M. Cabrera Sole, 1 Caridad Turpin Lucas, 1 Erik 

Luepke, 2 Santiago Garcia Ruiz, 1 Santos J. Martinez. 1 

1 University General Hospital of Albacete, Albacete, ES; 

2 University General Hospital “La Paz”, Madrid, ES. 

Some Fixed Combinations are Better Reducing 

Central Blood Pressure and Hypertensive Time than 

Others 

Ricardo M. Cabrera Sole, 1 Caridad Turpin Lucas, 1 

Santiago Garcia Ruiz, 1 Ana Galdamez Nuñez, 2 Erik 

Luepke, 3 Manuel Aguilera Saldaña. 1 1 University 

General Hospital of Albacete, Albacete, ES; 2 Health 

Center of Villacerrada, Albacete, ES; 3 University 

General Hospital “La Paz”, Madrid, ES. 

Prevalence of Orthostatic Hypotension among Very 

Elderly Persons with Hypertension 

Elaine Ku, 1 Yee Lu, 1 Edward Schneider, 1 Rick Smith, 2 

Vito M. Campese. 1 1 USC/Keck School of Medicine, Los 

Angeles, CA, US; 2 Los Angeles Jewish Home for the 

Aging, Reseda, CA, US. 

Effects of Renal Stenting on Renal and Cardiac 

Outcomes in Patients with Resistant Hypertension 

Cristiana Catena, GianLuca Colussi, Frine Capobianco, 

Stefania Fedrizzi, Leonardo A. Sechi. University of 

Udine, Udine, IT. 

88


Posters 

PO-16: 

PO-17: 

PO-18: 

PO-19: 

PO-20: 

PO-21: 

PO-22: 

Evaluation of a Treatment Algorithm Using 

Combination Therapy for the Management 

of Patients with Hypertension and 

Hypercholesterolemia (STITCH2) 

G. K. Dresser†, S. A. E. Nelson, J. L. Mahon, G. Y. Zou, 

M. K. Vandervoort, C. J. Wong, B. G. Feagan, R. D. 

Feldman. Robarts Research Institute, London, CA. 

Sex Differences Impact the Hemodynamics of 

Untreated Essential Hypertensive Subjects 

Carlos M. Ferrario, 1,2 Ronald D. Smith. 1 1 Consortium 

Southeastern Hypertension Control, Winston Salem, 

NC, US; 2 Wake Forest University School of Medicine, 

Winston Salem, NC, US. 

Improving Global Vascular Risk Management Using 

the COSEHC Cardiovascular Risk Assessment Tool 

Carlos M. Ferrario†, 1,2 Michael A. Moore, 1 Debra 

Simmons, 1,2 Chris Colby, 3 Alex Exuzides, 3 Sumeet 

Panjabi. 4 1 Consortium for Southeastern Hypertension 

Control, Winston Salem, NC, US; 2 Wake Forest 

University School of Medicine, Winston Salem, NC, 

US; 3 ICON Clinical Research, San Francisco, CA, US; 

4 Daiichi Sankyo, Inc., Parsippany, NJ, US. 

A COSEHC Sponsored Quality Improvement 

Initiative Enriches Chronic Disease Practice and 

Performance of North Carolina Diabetic Patients 

Mazen Hamad, 1 Brian Forrest, 2 Michael Moore, 2 

Debra Simmons, 2 JaNae Joyner. 2 1 Cary Healthcare 

Associates, Cary, NC, US; 2 The Consortium for 

Southeastern Hypertension Control (COSEHC), 

Winston Salem, NC, US. 

Cardiovascular Care Disparities in a South Carolina 

Primary Care Site Participating in the COSEHC 

Customized Model of Intervention and Care 

(COSMIC) Project 

JaNae Joyner, 1 Brian Forrest, 1 Kristina Yu‐Isenberg, 2 

Debra Simmons, 1 Daniel Lackland. 1 1 The Consortium 

for Southeastern Hypertension Control (COSEHC), 

Winston Salem, NC, US; 2 Novartis Pharmaceuticals 

Corporation, US. 

Adherence to Comprehensive Interventions for 

Management of Uncontrolled Hypertension 

Tessa J. Kerby, Stephen E. Asche, Michael V. Maciosek, 

JoAnn M. SperlHillen, Simrandeep K. Tiawana, 

Patrick J. O’Connor, Karen L. Margolis. HealthPartners 

Research Foundation, Minneapolis, MN, US. 

Blood Pressure Control in Spanish Speaking 

Patients with Type II Diabetes Mellitus Using a 

Group Visit Model 

Mateo Levine Ledezma, Marie F. Martinez, Scott A. 

Rasgon. Kaiser Permanente, Los Angeles, CA, US. 

89

MAY 21 

Posters 


PO-23: 

PO-25: 

PO-26: 

PO-27: 

PO-28: 

PO-29: 

PO-30: 

A Multi-Level Intervention to Control Hypertension 

in African Americans 

Gbenga Ogedegbe, 1 Jonathan Tobin, 2 Joseph Schwartz, 3 

Thomas Pickering. 3 1 NYU School of Medicine, NY, 

NY, US; 2 Clinical Directors Network, NY, NY, US; 

3 Columbia University, NY, NY, US. 

Physical Characteristics of Salt in the Treatment and 

Prevention of Hypertension 

Maithri Reddy, 1 Podduturu S. Reddy, 2 Sushma Reddy. 1 

1 Endocrinology & Diabetes Center, Fort Gratiot, MI, 

US; 2 St.Clair Pulmonary & Critical Care, Port Huron, 

MI, US. 

Relation between Cardiovascular Risk Score, 

Asymptomatic Peripheral Disease and Left 

Ventricular Hypertrophy 

Juan José Tamarit‐García, 1 Belén Roig‐Espert, 2 Vicente 

Navarro‐Ibáñez. 2 1 Dr. Peset Universitary Hospital, 

Valencia, ES; 2 Manises Hospital, Manises, Valencia, ES. 

A Computer-Mediated Intervention and DASH Diet, 

WHEELS-I Program, Sustains Improved Blood 

Pressure over 8 Weeks in Women from Diverse 

Ethnic Backgrounds 

Margaret Scisney‐Matlock, 1 Susan Steigerwalt, 2 

Kenneth Jamerson, 1 Stephanie Lucas, 3 Susan Pressler, 1 

Amanda Sen, 1 Elizabeth Brough. 1 1 University of 

Michigan, Ann Arbor, MI, US; 2 St. John Health 

System, Detroit, MI, US; 3 Center Preventative 

Medicine, St Clair Shores, MI, US. 

Relationships between Aggressive Systolic BP Goals, 

Nocturnal BP Dipping, and Carotid Atherosclerosis 

in Type 2 Diabetes: The SANDS Study 

Angela Silverman, 3 Mihriye Mete, 3 Jerome L. Fleg, 2 

Marie Russell, 1 Robert E. Ratner, 3 Mary J. Roman, 4 

Mario Stylianou, 2 Jason G. Umans, 3 Matthew R. 

Weir, 5 Barbara V. Howard. 3 1 Phoenix Indian Medical 

Center, US; 2 National Heart, Lung, and Blood Institute, 

US; 3 MedStar Health Research Institute, US; 4 Weill 

Medical College of Cornell University, US; 5 University 

of Maryland School of Medicine, US. 

Improved Hypertension Control Rates through a 

Multidisciplinary Regional Approach 

Ann M. Wells, Stephanie C. Schneider, Jennifer Bajaj, 

Susan Schreiner, Beverly Kroner. Kaiser Permanente 

Colorado, Denver, CO, US. 

Clinical Pharmacist-Physician Team Approach in 

Treating Resistant Hypertension Cases 

Sandra A. Yoo, Joel Handler, Alec V. Does. Kaiser 

Permanente, Anaheim, CA, US. 

90


Posters 

Endothelial Function 

PO-31: 

PO-32: 

PO-33: 

PO-34: 

PO-35: 

PO-37: 

PO-38: 

PO-39: 

A Novel ANP-Like Peptide, ANP1-28RR, Revealed 

by a Single Nucleotide Polymorphism of the ANP 

Gene, rs5065 Codes for a Peptide with Increased 

Permeability Properties In Vitro 

Valentina Cannone, Brenda K. Huntley, Guido 

Boerrigter, Alessandro Cataliotti, Denise M. Heublein, 

John C. Burnett. Mayo Clinic, Rochester, MN, US. 

Exaggerated Exercise Blood Pressure Response 

is Associated with Arterial Stiffness, Asymmetric 

Dimethylarginine and Osteoprotegerin in Essential 


K. Dimitriadis, C. Tsioufis, A. Aggelis, A. Michaelides, 

S. Aslam, C. Wilcox, V. Papademetriou, C. Stefanadis. 


Endothelial Impact of Blood Pressure above the 

Goals in Hypertensive Patients 

Jose Saban‐Ruiz, Martin Fabregate, Rosa Fabregate, 

Olivia Sanchez, Susana Tello, Angelica Fernandez, 

Nuria De la Torre, Arantxa Rodriguez. Ramon y Cajal 


Plasma Sodium but Not Sodium to Potassium Ratio 

Could be a Simple and Low-Cost Technique to 

Predict Vascular Inflammation. Correlation with 

Resistin Levels 

Martin Fabregate, Rosa Fabregate, Nuria De la Torre, 

Cristina Martinez, Arantxa Rodriguez, Ana Alonso, 

Carlos Moreno, Jose Saban‐Ruiz. Ramon y Cajal 


Time for Action. Correlation between Plasma Renin 

Activity and Biomarkers. A Mandatory Study as 

Result of a Recent Heart Outcomes Prevention 

Evaluation Analysis 

Jose Saban‐Ruiz, Martin Fabregate, Rosa Fabregate, 

Elena Tutor, Elena Castresana, Nuria De la Torre, 

Juanjo Villafruela, Susana Tello, Arantxa Rodriguez. 

Ramon y Cajal Hospital, Madrid, ES. 

Variability of Flow Mediated Dilation Technique: A 

Multicentre Italian Study 

Francesco Faita, Lorenzo Ghiadoni, Vincenzo 

Gemignani, Elisabetta Bianchini, Almerina Biggi, 

Giuseppe Ambrosio, Gaetano A. Lanza, Maria Lorenza 

Muiesan, Francesco Cosentino, Stefano Taddei. 

Working Group on Endothelium of the Italian Society 

of Hypertension, IT. 

Endothelial Dysfunction in Hypertensive Patients 

with Metabolic Syndrome 

Olga Gonzalez‐Albarran, Sara Calvo, Marta Carrasco, 

Marta Cano, Berniza Calderon, Ana Maria Matei. 

Hospital Ramón y Cajal, Madrid, ES. 

Normative Brachial Artery Diameter Dilatation 

Following Reactive Hyperemia 

Martha A. Kaeser, Daniel W. Haun, Norman W. 

Kettner. Logan College of Chiropractic, Chesterfield, 

MO, US. 

91

MAY 21 

Posters 


PO-40: 

PO-41: 

PO-42: 

PO-43: 

PO-44: 

PO-45: 

Severity of Obstructive Sleep Apnea and 

Atherosclerosis: Multiple Associations in the Setting 


A. Kasiakogias, C. Tsioufis, C. Thomopoulos, I. 

Andrikou, M. Almiroudi, I. Mpafakis, K. Kintis, C. 

Stefanadis. Hippokration Hospital, Athens, GR. 

Modulation of Vascular Function and Oxidative 

Stress in Type II Diabetes Mellitus: Effects of Alpha- 

Lipoic Acid 

Bobby V. Khan†, 1 Tahir Haque, 1 Desikan Rajagopal, 1 

Nadya Merchant, 1 Barry Connell, 2 Tarek M. Saleh. 2 

1 Atlanta Vascular Research Foundation, Atlanta, 

GA, US; 2 University of Prince Edward Island, 

Charlottetown, PE, CA. 

Atherogenic Index of the Plasma as Marker of 

Oxidative Stress and Endothelial Dysfunction 

Rosa Fabregate, Arantxa Rodriguez, Martin Fabregate, 

Elena Marin, Andres Reyes, Cristina Martinez, Susana 

Tello, Nuria De la Torre, Jose Saban‐Ruiz. Ramon y 

Cajal Hospital, Madrid, ES. 

The Effect of Angiotensin Converting Enzyme 

Inhibitors and Angiotensin-II Receptor Antagonists 

on the Endothelial Dysfunction in Patients 

with Chronic Pulmonary Heart with Arterial 


Nestor M. Seredyuk, Igor P. Vakalyuk, Vitaliy N. 

Seredyuk, Sergiy V. Fedorov. Ivano-Frankivsk National 

Medical University, Ivano-Frankivsk, UA. 

Associations of Renal Flow Reserve with Endothelial 

Dysfunction in Essential Hypertensives 

C. Tsioufis, D. Tsiachris, I. Tatsis, K. Dimitriadis, D. 

Syrseloudis, I. Kallikazaros, V. Papademetriou, C. 


Increased Endothelin-1 Vasoconstrictor Tone with 

Prehypertension 

Brian R. Weil, 1 Michael L. Mestek, 1 Jared J. Greiner, 1 

Brian L. Stauffer, 2 Christopher A. DeSouza. 1 

1 University of Colorado at Boulder, Boulder, CO, 

US; 2 University of Colorado Denver and the Health 

Sciences Center, Aurora, CO, US. 

Epidemiology/Special Populations 

PO-46: 

Management of Hypertensive Patients in France 

as a Function of Gender and Cardiovascular Risk: 

PARITE Study 

Simon Tabassome, 1 Claire Mounier‐Vehier, 2 

Dominique Guedj, 3 Assya Achouba, 4 Emmanuel 

Ghannad, 5 Stéphane Quéré, 4 Maxime Guenoun. 6 

1 CHU Saint-Antoine, Paris, FR; 2 Cardiologic Hospital, 

Lille, FR; 3 Cardiologist, Paris, FR; 4 Novartis Pharma 

SAS, Paris, FR; 5 Cardiologist, Gif sur Yvette, FR; 

6 Cardiologist, Marseille, FR. 

92


Posters 

PO-47: 

PO-48: 

PO-49: 

PO-50: 

PO-51: 

PO-52: 

PO-53: 

PO-54: 

The Relationship of Resistant Hypertension and 

Treatment Outcomes with Total Compliance and 

Brain Natriuretic Peptide in an African American 

Hypertensive Cohort 

Omid Bakhtar, Brian A. Ference, Phillip D. Levy, 

Samar A. Nasser, Lowell Hedquist, John M. Flack. 

Division of Translational Research and Clinical 

Epidemiology, Wayne State University, Detroit Medical 

Center, Detroit, MI, US. 

Which Ambulatory Blood Pressure Monitoring 

Parameters Predict Mortality in Elderly Subjects 

Iddo Z. Ben‐Dov, 1 Michael Bursztyn. 2 1 The Rockefeller 

University, New York, NY, US; 2 Hadassah – Hebrew 

University Medical Center, Jerusalem, IL. 

Birth Weight, Stimulus Response and Hemodynamic 

Variability Implicates Ethnic Contrasts of 

Autonomic Control of Heart Rate and Blood 

Pressure and an Effect on CV Disease 

Wei Chen, Pronabesh DasMahapatra, Camilo 

Fernandez, Gerald S. Berenson. Tulane University 

Health Sciences Center, New Orleans, LA, US. 

Changes in Levels of Serum Cholesterol and 

Development of Hypertension in the Brisighella 

Heart Study 

Claudio Borghi, Ada Dormi, Sergio d’Addato, Arrigo 

Cicero, Luca Laghi, Eugenio Roberto Cosentino, 

Maddalena Veronesi. St. Orsola-Malpighi Hospital, 

Bologna, IT. 

Alcohol Consumption and the Risk of Hypertension: 

A Systematic Review and Meta-Analysis 

Alex Briasoulis, Vikram Agarwal, Manpreet S. 

Sabharwal, George Syros, Girish N. Nadkarni, Franz 

H. Messerli. St. Luke’s-Roosevelt Hospital Center, 

Columbia University College of Physicians and 

Surgeons, New York, NY, US. 

Trends in Albuminuria under RAS Suppression and 

Relationship with Cardiovascular Disease 

Cesar Cerezo, 1 Julian Segura, 1 Jose R. Banegas, 2 Juan 

J. de la Cruz, 2 Ton J. Rabelink, 3 Luis M. Ruilope. 1 

1 Hospital 12 de Octubre, Madrid, ES; 2 Universidad 

Autónoma, Madrid, ES; 3 Leiden University Medical 

Center, Leiden, NL. 

Large Change in the Opinon on Antihypertensive 

Drug Treatment among General Practioners in 

Sweden between 2002 and 2009 

John K. F. Dahlström, Mats Persson, Bo Carlberg, 

Lars‐Hjalmar Lindholm. Family Medicine, Umeå, SE. 

Novel Method for Assessing the Prevalence of 

Hypertension and Cardiovascular Disease Risk in 

a Community Screening Program in a South East 

Region of US 

Mahfouz El Shahawy, 1 Miglena Entcheva, 1 Susan 

Gaida, 1 Joshua Grant. 2 1 Sarasota Memorial Hospital, 

Sarasota, FL, US; 2 Lake Erie College of Osteopathic 

Medicine, US. 

93

MAY 21 

Posters 


PO-55: 

PO-56: 

PO-57: 

PO-58: 

PO-59: 

PO-60: 

PO-61: 

Pre-Hypertension: Is it a Disease 

Mahfouz El Shahawy, 1 Miglena Entcheva, 1 Susan 

Gaida, 1 Joshua Grant. 2 1 Sarasota Memorial Hospital, 

Sarasota, FL, US; 2 Lake Erie College of Osteopathic 

Medicine, US. 

Exercise Capacity Predicts Progression from Pre- 

Hypertension to Hypertension in African American 

Men 

Charles Faselis, 1,2 Raya Kheirbek, 1 Michael Doumas, 1,2 

Ross Fletcher, 1 Vasilios Papademetriou, 1,3 Peter 

Kokkinos. 1,2,3 1 Veterans Affairs Medical Center, 

Washington, DC, US; 2 George Washington University, 

Washington, DC, US; 3 Georgetown University, 

Washington, DC, US. 

Biracial (Black-White) Divergence and Correlates 

of Augmentation Index among Younger Adults: The 

Bogalusa Heart Study 

Camilo Fernandez, Pronabesh DasMahapatra, Wei 

Chen, Sathanur R. Srinivasan, Gerald S. Berenson. 

Tulane University Health Sciences Center, New 

Orleans, LA, US. 

Use of Electronic Health Records to Evaluate 

Hypertension Pharmacoepidemiology in a Primary 

Care Practice Network 

Christopher Hebert†, Rustam Kudyakov, Yahya Daoud, 

Dunlei Cheng, Andrew Masica. Baylor Health Care 

System, Dallas, TX, US. 

Cardiovascular Risk Factors Prevalence in Greek 

Hypertensives Stratified by Gender and Age 

Gregory Vyssoulis, 1 Eva Karpanou, 2 Stella Maria 

Kyvelou, 1 M. Liakos, 1 C. Stefanadis. 1 1 1st Cardiology 

Clinic Athens University Hippokration Hospital, GR; 

2 1st Cardiology Clinic Onassis Cardiosurgery Center, 

GR. 

ABO and Rhesus Blood Groups and Cardiovascular 

Risk in Essential Hypertensive Patients 

Stella Maria Kyvelou, 1 Gregory Vyssoulis, 1 Eva 

Karpanou, 2 T. Gialernios, 1 C. Stefanadis. 1 1 1st 

Cardology Clinic Athens University Hippokration 

Hospital, GR; 2 1st Cardiology Clinic Onassis 

Cardiosurgery Center, GR. 

Efficacy, Safety and Tolerability of Valsartan/ 

Hydrochlorothiazide Single Pill Combination in 

Asian Patients with Essential Hypertension: An 

Observational Study 

Wen‐Ter Lai†, 1 Jeong‐Euy Park, 2 Neelesh Dongre, 3 

Jackson Wang. 3 1 Kaohsiung Medical University 

Hospital, Kaohsiung, TW; 2 Samsung Medical Center, 

Irwon-dong, Gangnam-gu, Seoul, KR; 3 Novartis 

Pharma AG, Basel, CH. 

94


Posters 

PO-62: 

PO-63: 

PO-64: 

PO-65: 

PO-66: 

PO-67: 

PO-68: 

PO-69: 

PO-70: 

Trends in Serum Lipids, Hypertension, Physician 

Advice and Compliance among Reproductive- 

Aged Women: United States National Health and 

Nutrition Examination Survey 1999-2008 

Tabassum H. Laz, Mahbubur Rahman, Abbey B. 

Berenson. University of Texas Medical Branch, 

Galveston, TX, US. 

Excessive Blood Pressure Elevation during Exercise 

Correlates with Low Fitness among Normotensive 

Firefighters 

Adi Leiba, 1,2 Dorothee M. Baur, 1,3 Stefanos N. Kales. 1,3 

1 Harvard School of Public Health, Boston, MA, US; 

2 Sheba Medical Center, Tel Hashomer, IL; 3 Cambridge 

Health Alliance, Cambridge, MA, US. 

Smoking and Hypertension: Do They Follow the 

Same Trend 

Aurelio Leone. City Hospital, Massa, Ms, IT. 

Arterial Hypertension and Liver Cirrhosis: The 

Experience of a Single Liver Unit 

Simona Leoni, Serena Flori, Barbara Stagni, Ilaria 

Serio, Luigi Bolondi. Malpighi Hospital, Division of 

Internal Medicine Prof. Bolondi, Bologna, IT. 

Blood Pressure Control and Age: The Experience of 

a Single Centre 

Serena Flori, Simona Leoni, Barbara Stagni, Ilaria 

Serio, Luigi Bolondi. Malpighi Hospital, Division of 

Internal Medicine, Bologna, IT. 

The Effect of Coffee on Blood Pressure and 

Cardiovascular Disease among Hypertensive 

Individuals: Meta-Analysis 

Arthur E. Mesas, Luz Leon‐Muñoz, Fernando 

Rodriguez‐Artalejo, Esther Lopez‐Garcia. Autonoma 

University of Madrid, Madrid, ES. 

Mechanisms Underlying Increased Aortic BP in 

Black Versus White Young Adults: The ENIGMA 

Study 

Carmel M. McEniery, 1 Andrew T. Garrett, 2 Nigel 

Baber, 2 John R. Cockcroft, 3 Ian B. Wilkinson. 1 

1 University of Cambridge, Cambridge, GB; 2 University 

of Hertfordshire, GB; 3 Cardiff University, GB. 

Diabetes Type 2 and Other Cardiovascular Risk 

Factors in an Adult Mediterranean Population 

Javier Nieto, 1 Patricio Giralt, 2 Maria Jose Ballesteros, 1 

G. Gutierrez, 3 Carmen Mora, 1 Agustin Carreño. 1 

1 Hospital General, Ciudad Real, ES; 2 Fundacion 

Sociosanitaria, Ciudad Real, Castilla La Mancha, ES; 

3 Consejería de Salud, Toledo, ES. 

Serum Uric Acid is an Independent Risk Factor for 

Cardiovascular Diseases Mortality in Hypertensive 

Patients 

Mitsuru Ohishi, Yasushi Takeya, Miyuki Onishi, Yuji 

Tatara, Kei Kamide, Hiromi Rakugi. Osaka University, 

Suita, Osaka, JP. 

95

MAY 21 

Posters 


PO-71: 

PO-72: 

PO-73: 

PO-74: 

PO-75: 

PO-76: 

PO-77: 

Blood Pressure Control and All Cause Mortality in 

Old and Very Old Patients with Hypertension 

Vasilios Papademetriou, Richard Amdur, Charles 

Faselis, Michael Doumas, Costas Tsioufis, Peter 

Kokkinos, Ross D. Fletcher. Veterans Administration 

and Georgetown University Medical Centers 

Washington DC, Washington, DC, US. 

Ambulatory Blood Pressure Monitoring Profile in 

Untreated African Blacks and Causasians Untreated 

Hypertensive Patients Matched for Age and Gender 

Albertino Damasceno, 1 C. Mavimbe, 1 Loide Barbosa, 2 

Jose A. Silva, 2 Domingos Diogo, 1 T. Madede, 1 Jorge 

Polonia. 2 1 Universidade Eduardo Mondlane, Maputo, 

MZ; 2 Hospital Pedro Hispano, Matosinhos, PT. 

Regional Differences in Hypertensive 

Cardiovascular Remodeling between Fishing and 

Farming Communities in Japan 

Koji Sakata, 1 Yuichiro Yano, 2 Takuro Imamura, 1 Kazuo 

Kitamura, 1 Kazuomi Kario. 2 1 University of Miyazaki, 

JP; 2 Jichi Medical University School of Medicine, JP. 

Relevance of Atrial Fibrillation in a Large Cohort of 

Hypertensive Patients 

Julian Segura, 1 Vanesa Moñivas, 1,2 Jose A. Garcia- 

Donaire, 1 Cesar Cerezo, 1 Luis M. Ruilope. 1 1 Hospital 

12 de Octubre, Madrid, ES; 2 Hospital Puerta de Hierro, 

Madrid, ES. 

Periodontal Disease Severity and Albumin Excretion 

in Hypertensive Patients: A Positive Association 

Beyond Systemic Inflammation 

C. Tsioufis, A. Kasiakogias, C. Thomopoulos, N. 

Soldatos, A. Kordalis, M. Almiroudi, K. Kintis, C. 


Efficacy of Amlodipine/Olmesartan Medoxomil with 

or without Hydrochlorothiazide in Elderly Patients 

Uncontrolled by Monotherapy 

Matthew R. Weir†, 1 Henry A. Punzi, 2 Ali Shojaee, 3 

William F. Waverczak, 3 Jen‐Fue Maa. 3 1 University 

of Maryland School of Medicine, US; 2 Trinity 

Hypertension & Metabolic Research Institute, US; 

3 Daiichi Sankyo, Inc., US. 

Blood Pressure Therapy and Risk of CVD: 

Framingham Heart Study Experience 

Peter W. F. Wilson†, 1 Michael Pencina, 2 Ralph B. 

D’Agostino, 2 Asya Lyass, 2 R. S. Vasan, 2 Philip A. Wolf, 2 

Daniel Levy. 3 1 Emory University, Atlanta, GA, US; 

2 Boston University, Boston, MA, US; 3 Framingham 

Heart Study, Framingham, MA, US. 

96


Posters 

Immune mechanisms in hypertension 

PO-79: 

PO-80: 

PO-81: 

PO-82: 

Renal Specific Silencing of Dopamine D 2 Receptors 

in Mice Increases Blood Pressure and Pro- 

Inflammatory Factors 

Ines Armando, Santiago Cuevas, Yanrong Zhang, 

Laureano Asico, Crisanto Escano, Pedro A. Jose. 

Children’s National Medical Center, Washington, DC, 

US. 

Macrophages Regulate Pressor Responses to 

Endothelin-1 

E. L. Owen, N. Dhaun, M. Bailey, D. J. Webb, D. C. 

Kluth. University of Edinburgh, GB. 

BMI Influences the Association of an IL-6 

Polymorphism on Increased Insulin Resistance in a 

Hypertensive Population 

P. Underwood, 1 B. Chamarthi, 1 J. Williams, 1 B. Sun, 1 

P. Hopkins, 2 G. Adler, 1 G. Williams. 1 1 Brigham and 

Women’s Hospital, US; 2 University of Utah, US. 

Correlation between Endothelial Dysfunction and 

Inflammatory Markers at the Chronic Heart Failure 

with Arterial Hypertension 

Roman I. Yatsyshyn, Natalya G. Yatsyshyn. Medical 

University, Ivano-Frankivsk, UA. 

Metabolic Syndrome (Diabetes/Glycemic 

Control; Dysglycemic Drugs; Insulin 

Resistance) 

PO-83: 

PO-84: 

PO-85: 

Screening for Diabetes in a Developing Country 

Olutayo Christopher Alebiosu, 1 Olawale Ogunsemi, 2 

Olatunde Odusan, 2 Oluranti Familoni. 2 1 College of 

Health Sciences, Osun State University, Osogbo, Osun, 

NG; 2 Olabisi Onabanjo University, Sagamu Campus, 

Ogun State, NG. 

Metabolic Profile and Framingham Heart Scores 

among Hypertensives in Turkey from 2003 to 2007 

Mustafa Arici, 1 Ulver Derici, 2 Cetin Turgan, 1 Yunus 

Erdem, 1 Sukru Sindel, 2 Bulent Altun, 1 Bulent Erbay, 3 

Oktay Karatan, 3 Enver Hasanoglu, 2 Sali Caglar. 4 

1 Hacettepe University Faculty of Medicine, Ankara, 

TR; 2 Gazi University Faculty of Medicine, Ankara, TR; 

3 Ankara University Faculty of Medicine, Ankara, TR; 

4 Turkish Society of Hypertension and Renal Diseases, 

Ankara, TR. 

Gender-Independent Elevation of Fasting Glucose 

with the Progressive Decrease in Sleep-Time 

Relative Blood Pressure Decline: The Hygia Project 

Diana E. Ayala, 1 Juan J. Crespo, 2 Ana Moya, 3 Pedro A. 

Callejas, 2 Peregrina Eiroa, 2 Alfonso Otero, 4 Artemio 

Mojon, 1 Jose R. Fernandez, 1 Ramon C. Hermida, 1 

Investigadores Proyecto Hygia. 1 1 University of Vigo, 

Vigo, ES; 2 Gerencia de Atención Primaria, Vigo, ES; 

3 Gerencia de Atención Primaria, Pontevedra, ES; 

4 Complejo Hospitalario Universitario, Orense, ES. 

97

MAY 21 

Posters 


PO-86: 

PO-87: 

PO-88: 

PO-89: 

PO-90: 

PO-91: 

PO-92: 

First-Line Aliskiren/HCTZ Lowers BP in Older 

Patients with Stage 2 Hypertension and Metabolic 

Syndrome or Diabetes 

Jan Basile†, 1 Simon Babazadeh, 2 Michael Lillestol, 3 

Thomas Severin, 4 Cheraz Cherif Papst, 4 Richard 

Weitzman. 5 1 Ralph H Johnson VA Medical Center, 

Medical University of South Carolina, Charleston, 

SC, US; 2 Crest Clinical Trials Inc, Santa Ana, CA, US; 

3 Lillestol Research LLC, Fargo, ND, US; 4 Novartis 

Pharma AG, Basel, CH; 5 Novartis Pharmaceuticals 

Corporation, East Hanover, NJ, US. 

Effects of Time of Day of Hypertension Treatment 

on the Ambulatory Blood Pressure Pattern of 

Patients with Diabetes: The Hygia Project 

Juan J. Crespo, 1 Manuel Dominguez‐Sardiña, 1 

Maria T. Rios, 1 Ana Moya, 2 Sonia M. Gomara, 2 Luis 

Meijide, 2 Artemio Mojon, 3 Diana E. Ayala, 3 Ramon C. 

Hermida, 3 Investigadores Proyecto Hygia. 3 1 Gerencia 

de Atención Primaria, Vigo, ES; 2 Gerencia de Atención 

Primaria, Pontevedra, ES; 3 University of Vigo, Vigo, 

ES. 

Overweight and High Blood Pressure as the 

Cardiometabolic Risk Factors Most Frequently 

Related to Nonalcoholic Fatty Liver Disease 

Susana Tello, Angelica Fernandez, Asuncion Guerri, 

Rosa Fabregate, Martin Fabregate, Jose Campoy, Arturo 

Ugalde, Jose Saban‐Ruiz. Ramon y Cajal Hospital, 

Madrid, ES. 

Myeloperoxidase, Leptin and Retinol Binding 

Protein 4, as Biomarkers of Osteopenia and 

Atherosclerosis, Two Sister-Diseases 

Rosa Fabregate, Olivia Sanchez, Elena Marin, Andres 

Reyes, Cristina Martinez, Susana Tello, Martin 

Fabregate, Arantxa Rodriguez, Jose Saban‐Ruiz. 


Unlike Sex, HDL-Cholesterol, Body Mass Index, 

Homocysteine and Smoking, Blood Pressure is Not a 

Determinant Factor of Plasma Leptin Levels 

Martin Fabregate, Olivia Sanchez, Rosa Fabregate, Olga 

Fernandez, Jose Manuel Del Rey, Susana Tello, Nuria 

De la Torre, Elena Tutor, Ana Alonso, Jose Saban‐Ruiz. 


Salt Sensitive Type 2 Diabetics Have Greater 

Metabolic Improvements on a Paleolithic-Type Diet 

Compared to an ADA Diet 

Lynda A. Frassetto, Olga Schmidlin, Anthony 

Sebastian, Umesh Masharani. UCSF, San Francisco, 

CA, US. 

Impact of Gender in Cardiovascular Control in 

Hypertensive Patients with Metabolic Syndrome. 

OPENMET Survey 

Olga Gonzalez, 1 Alberto Galgo, 2 Carlos Alvarez. 3 

1 Hospital Ramón y Cajal, Madrid, ES; 2 Primary Care 

Center, Madrid, ES; 3 Pfizer Laboratory, Madrid, ES. 

98


Posters 

PO-93: 

PO-94: 

PO-95: 

PO-96: 

PO-97: 

PO-98: 

PO-99: 

Microalbuminuria in Women with Prior Gestational 

Diabetes 

Olga Gonzalez Albarran, Marta Carrasco, Marta Cano, 

Berniza Calderón, Ana Maria Matei. Hospital Ramón y 

Cajal, Madrid, ES. 

Elevation of Blood Suger Changes Glomerular and 

Tubular Function in Normotesive Subjects 

Shigeo Kakinoki, 1 Tetsuya Fujimoto, 2 Maiko Machida, 2 

Shigeru Takechi, 3 Kouichi Kanda, 4 Takeshi Kobayashi, 5 

Akikazu Nomura. 2 1 Otaru kyoukai Hospital, Otaru, 

Hokkaido, JP; 2 Hokkaido College of Pharmacy, 

Otaru, Hokkaido, JP; 3 Date Red Cross Hospital, Date, 

Hokkaido, JP; 4 Sapporo Kosei General Hospital, 

Sapporo, Hokkaido, JP; 5 Hokkaido Social Insurance 

Health Care and Research Center, Sapporo, Hokkaido, 

JP. 

Effects of Simvastatin and Rosiglitazone 

Combination in Patients with the Metabolic 

Syndrome (The SIROCO Study) 

Ivana Lazich†, Pantelis A. Sarafidis, Raymond Oliva, 

Basil Burney, George Bakris. University of Chicago 

Pritzker School of Medicine, Chicago, IL, US. 

Pulse Wave Analysis in Type 2 Diabetic Hypertensive 

Patients 

Ari L. Lieber, 1 Michel E. Safar, 1 Julie Peroz, 1 Gerard 

Slama, 1 Bernard I. Levy, 2 Jacques Blacher. 1 1 Hotel-Dieu 

Hospital, Paris, FR; 2 Hopital Lariboisiere, Paris, FR. 

Circadian Blood Pressure Pattern and Prevalence 

of Nocturnal Hypertension in Subjects with and 

without Type 2 Diabetes: The Hygia Project 

Maria C. Castiñeira, 1 Ana Moya, 2 Jesus Perez de Lis, 3 

Lorenzo Pousa, 3 Jose L. Salgado, 3 Susana Hernaiz, 3 

Artemio Mojon, 4 Jose R. Fernandez, 4 Ramon C. 

Hermida, 4 Investigadores Proyecto Hygia. 4 1 Gerencia 

de Atención Primaria, Lugo, ES; 2 Gerencia de Atención 

Primaria, Pontevedra, ES; 3 Gerencia de Atención 

Primaria, Vigo, ES; 4 University of Vigo, Vigo, ES. 

Influence of Sleep-Time Blood Pressure for the 

Proper Identification of Isolated Office and Masked 

Hypertension among Patients with Type 2 Diabetes: 

The Hygia Project 

Ana Moya, 1 Elvira Sineiro, 1 Maria C. Castiñeira, 2 

Sonia M. Gomara, 1 Artemio Mojon, 3 Maria J. Fontao, 3 

Sonia Lorenzo, 3 Diana E. Ayala, 3 Ramon C. Hermida, 3 

Investigadores Proyecto Hygia. 3 1 Gerencia de Atención 

Primaria, Pontevedra, ES; 2 Gerencia de Atención 

Primaria, Lugo, ES; 3 University of Vigo, Vigo, ES. 

Suboptimal Control of Arterial Hypertension in 

Patients with Type 2 Diabetes Mellitus 

Maria Sarigianni, Eleni Mpekiari, Apostolos Tsapas, 

Konstantinos Paletas. Medical School, Aristotle 

University of Thessaloniki, Thessaloniki, GR. 

99

MAY 21 

Posters 


PO-100: 

PO-101: 

PO-102: 

Prevalence of Metabolic Syndrome According to 

Different Definitions in a Mediterranean Cohort of 

Hypertensives 

John A. Papadakis, 1 Eirini Lioudaki, 1,2 George E. 

Vrentzos, 1 Helen Mavrogeni, 1 Maria‐Helen Zeniodi, 1 

Emmanuel S. Ganotakis, 1 Dimitri P. Mikhailidis. 2 

1 University Hospital of Heraklion, Heraklion, GR; 

2 Royal Free Hospital campus, University College 

London (UCL) Medical School, London, GB. 

Telmisartan Prophylactic Treatment Induces Tissue- 

Specific Gene Modulation Favoring Normal Glucose 

Homeostasis in CRDH Rats 

Firas Younis, 1 Yoram Oron, 1 Rona Limor, 2 Naftali 

Stern, 2 Talma Rosenthal. 1 1 Tel Aviv Univeristy, Tel Aviv, 

Ramat Aviv, IL; 2 Tel Aviv-Sourasky Medical Center, Tel 

Aviv, IL. 

Hyperuricemia and the Pathogenesis of 

Hypertension and Insulin Resistance in Murine 

Model of the Metabolic Syndrome 

William Baldwin, 1 Steven McRae, 1 George Marek, 1 

David Wymer, 1 Varinderpal Pannu, 1 Chris Baylis, 2 

Richard J. Johnson, 1,2 Yuri Y. Sautin. 1 1 University of 

Florida, Gainesville, FL, US; 2 University of Florida, 

Gainesville, FL, US; 3 University of Colorado, Denver, 

CO, US. 

New insights into the role of uric acid in 

hypertension 

PO-103: 

PO-104: 

Relation of Uric Acid with Blood Pressure and 

Health Related Quality of Life One Year Post 

Myocardial Infarction 

Antonios Ioannidis, Dimitrios Tsounis. Hellenic Open 

University, GR. 

Hypertension in Hyperuricemic Gout Subjects 

Receiving Febuxostat or Allopurinol 

Andrew Whelton†, 1,2 Patricia MacDonald, 3 Barbara 

Hunt, 3 Lhanoo Gunawardhana. 3 1 Universal Clinical 

Research Center, Inc, Hunt Valley, MD, US; 2 Johns 

Hopkins University School of Medicine, Baltimore, 

MD, US; 3 Takeda Global Research & Development 

Center, Inc, Deerfield, IL, US. 

Pediatric Hypertension 

PO-105: 

Systolic and Diastolic Blood Pressures among Sickle 

Cell Patients 

Guillermo A. De Angulo, 1 Robert J. Adams, 1 Yim 

Eunsil, 1 Janet L. Kwiatkowski, 2 Ana C. Xavier, 1 Ellen 

Debenham, 1 Jessica A. Peterson, 1 Daniel T. Lackland. 1 

1 Medical University of South Carolina, Charleston, 

SC, US; 2 The Children’s Hospital of Philadelphia, 

Philadelphia, PA, US. 

100


Posters 

PO-106: 

PO-107: 

PO-108: 

PO-109: 

PO-110: 

PO-111: 

Antihypertensive Drug Use in Children: Are the 

Drugs Labeled and Indicated 

Joseph Flynn†, 1 W. Pete Welch, 2 Wenya Yang, 2 Drew 

Braucht, 2 Perdita Taylor‐Zapata, 3 Anne Zajicek. 3 

1 Seattle Children’s Hospital, Seattle, WA, US; 2 The 

Lewin Group, Inc., Falls Church, VA, US; 3 Eunice 

Kennedy Shriver National Institute of Child Health 

and Human Development, Bethesda, MD, US. 

Clinical and Demographic Characteristics of 

Children with Hypertension: New Multicenter Data 

Joseph Flynn†, 1 Ying Zhang, 2 Susan Solar‐Yohay, 2 

Victor Shi. 2 1 Seattle Children’s Hospital, Seattle, WA, 

US; 2 Novartis Pharma AG, East Hanover, NJ, US. 

Cardiovascular Risk Factors in Obese Children and 

Adolescents 

Isabel Torro, 1,2 Julio Alvarez, 1,2 Francisco Aguilar, 1,2 

Jose Alcon, 1,2 Empar Lurbe. 1,2 1 Hospital General 

Universitario, University of Valencia, Valencia, ES; 

2 Health Institute Carlos III, Madrid, ES. 

Left Ventricular Geometry in Children with Primary 

Hypertension: Prevalence and Predictors 

Cozumel S. Pruette, 1 Barbara A. Fivush, 1 Joseph T. 

Flynn, 2 Tammy M. Brady. 1 1 Johns Hopkins University, 

Baltimore, MD, US; 2 Seattle Children’s Hospital, 

Seattle, WA, US. 

Serum Uric Acid in U.S. Adolescents: Distribution 

and Relationship to Demographic Characteristics 

and Cardiovascular Risk Factors 

Ibrahim F. Shatat, 1 Rany T. Abdallah, 2 David J. Sas, 1 

Susan M. Hailpern. 3 1 Medical University of South 

Carolina Children’s Hospital, Charleston, SC, US; 

2 Medical University of South Carolina, Charleston, SC, 

US; 3 Independent Consultant, Katonah, NY, US. 

Clinic and Ambulatory Blood Pressure 

Measurements and Patterns in Asymptomatic 

Children with Sickle Cell Disease 

Ibrahim F. Shatat, 1 Ram V. Kalpatthi, 2 Amanda E. 

Blue, 1 Katelyn Graeme, 1 Mary A. Johnson, 1 John K. 

Orak, 1 Sharron M. Jackson. 1 1 Medical University of 

South Carolina Children’s Hospital, Charleston, SC, 

US; 2 Children’s Mercy Hospital, Kansas City, MO, US. 

Risk Factors (Lipids) 

PO-112: 

Evaluating the Effects of Hypercholesterolemia 

on Vascular Risk Profile of Treated Hypertensive 

Patients. Results of a Cross-Sectional National Study 

Pedro Aranda, Manuel Gorostidi, Julian Segura, 

Alex de la Sierra, Jose Juan de la Cruz, Jose 

Carlos Fernandez, Luis Maria Ruilope. Cardiorisk 

Investigators Group, Madrid, ES. 

101

MAY 21 

Posters 


PO-113: 

PO-114: 

PO-115: 

Negative Influence of Hypercholesterolemia on 

Blood Pressure Control. Results of a Spanish 

National Survey with ABPM 

Pedro Aranda, Jose Carlos Fernandez, Manuel 

Gorostidi, Julian Segura, Alejandro de la Sierra, Jose 

Juan de la Cruz, Luis Maria Ruilope. Cardiorisk 

Investigators Group, Madrid, ES. 

Association of Weight Misperception with Abnormal 

Lipid Levels and Hypertension among Overweight 

and Obese Reproductive-Age Women 

Mahbubur Rahman, Tabassum H. Laz, Abbey B. 

Berenson. University of Texas Medical Branch, 

Galveston, TX, US. 

Influence of Metabolic Syndrome Components in 

Atherosclerotic Disease and Intima Media Thickness 

of Carotid Artery Assessed by Gray Scale Method 

Priscilla Lopes Sarmento, Frida Liane Plavnik, Sérgio 

Aron Ajzen. Federal University of Sao Paulo, Sao 

Paulo, SP, BR. 

Stroke 

PO-117: Hypertension and Other Co-Morbid Conditions are 

Not Determinants of Treatment in Acute Ischemic 

Stroke 

Jordan A. Magarik, Robert J. Adams, Christine A. 

Holmstedt, Edward C. Jauch, Andrea D. Boan, Aquilla 

S. Turk, Daniel T. Lackland. Medical University of 

South Carolina, Charleston, SC, US. 

PO-118: Profile of Incidental Thyroid Nodules in 2996 

Patients Undergoing Carotid Ultrasound 

Saxena Naveen, 1 Srivastava Vinita, 1 William Bridges, 2 

Ricardo Abaunza, 1 Chanda Craft, 1 Nomita Joshi, 1 

Govind Rughani. 1 1 Internal Medicine and Cardiology 

Center, Greenville, SC, US; 2 Clemson University, 

Clemson, SC, US. 

PO-119: Additional Impact of Morning Haemostatic Factors 

and Blood Pressure Surgeon Stroke in Older 

Japanese Hypertensives 

Yuichiro Yano, Satoshi Hoshide, Kazuyuki Shimada, 

Kazuomi Kario. Jichi Medical University School of 

Medicine, Tochigi, JP. 

Vascular Injury/Inflammation and 

Remodeling 

PO-120: 

Non-Dipping Status is Accompanied by 

Hypoadiponectinemia and Increased Aortic 

Stiffness in Essential Hypertension 

I. Andrikou, C. Tsioufis, D. Syrseloudis, A. Kordalis, 

M. Almiroudi, I. Mpafakis, K. Kintis, T. Papaioannou, 

D. Aragiannis, C. Stefanadis. Hippokration Hospital, 

Athens, GR. 

102


Posters 

PO-121: 

PO-122: 

PO-123: 

Association of Retinal Microvascular Caliber with 

Blood Pressure Levels 

Raz Gibstein, 1 Yosi Rosman, 2 Ehud Rechtman, 1 Nira 

Koren‐Morag, 2 Yehonatan Sharabi, 2 Shlomo Segev, 2 

Ehud Assia, 1 Ehud Grossman. 2 1 Meir Hospital, IL; 2 The 

Chaim Sheba Medical Center, Tel Hashomer, Affiliated 

to Sackler School of Medicine, IL. 

Inhibiting the Renin-Angiotensin System with 

Aliskiren and/or Valsartan Protects Against 

C-Reactive Protein Mediated Vascular Injury 

Response 

Fadi G. Hage†, Caleb Pierce, Wei Zhang, Dongqi 

Xing, Yiu‐Fai Chen, Mark A. McCrory, Suzanne 

Oparil, Alexander J. Szalai. University of Alabama at 

Birmingham, Birmingham, AL, US. 

High Osteopontin N-Terminal/C-Terminal 

Fragment Ratio is Associated with Carotid Plaque 

Inflammation 

Talya Wolak, 1 Netta Sion‐Vrdy, 1 George Grennberg, 1 

Gabriel Szendro, 1 Assaf Rudich, 2 Ori Nov, 2 Victor 

Novack, 1 Esther Paran. 1 1 Soroka University Medical 

Center, Bear Sheva, IL; 2 Faculty of Health Sciences, 

Ben-Gurion University of the Negev Israel, Bear Sheva, 

IL. 

103

MAY 22 

Posters 





















information. 

104


Posters 

10:00 AM – 6:30 PM • Second Floor Promenade 

Featured Posters – Blood Pressure 

Measurement/Monitoring 

Moderators: 

FP-1: 

FP-2: 

FP-3: 

FP-4: 

Suzanne Oparil, MD, Birmingham, AL and 

Talma Rosenthal, MD, Tel Aviv, Israel 

Ambulatory Blood Pressure Monitoring and 

Cardiovascular Events in High-Risk Patients 

Alejandro de la Sierra†, 1 Julian Segura, 2 Jose R. 

Banegas, 2 Manuel Gorostidi, 2 Felipe Madruga, 2 Xavier 

Clar, 2 Teresa Gijon, 2 Luis M. Ruilope. 2 1 Hospital 

Mutua Terrassa, Terrassa, ES; 2 Spanish Society of 

Hypertension, Madrid, ES. 

A Perfect Replacement for the Mercury 

Sphygmomanometer: The Case of the Hybrid Blood 

Pressure Monitor 

George S. Stergiou, Nikos Karpettas, Anastasios Kollias, 

Antonis Destounis, Dimitris Tzamouranis. University 

of Athens, Athens, GR. 

Improvement in Blood Pressure Control among 

Hypertensive Patients Treated in the Department of 

Veterans Affairs 

Ross D. Fletcher, Vasilios Papademetriou, Richard 

Amdur, Chris McManus, Ronald Jones, Charles 

Faselis. Veterans Affairs and Georgetown University, 


Clinical Characteristics of Patients with 

Uncontrolled and Apparent Treatment Resistant 

Hypertension: NHANES 1988-2008 

Brent Egan, 1 Yumin Zhao, 1 R. Neal Axon, 1 R. Neal 

Axon, 2 Keith Ferdinand. 3 1 Medical University of 

S.C., Charleston, SC, US; 2 Ralph H. Johnson, VAMC, 

Charleston, SC, US; 3 Emory University, Atlanta, GA, 

US. 

105

MAY 22 

Posters 



Featured Posters – Adolescent 


Moderators: 

FP-5: 

FP-6: 

FP-7: 

FP-8: 

Daniel I. Feig, MD, PhD, Houston, TX and 

Joseph T. Flynn, MD, Seattle, WA 

Which BP Measurement Method Best Predicts 

Target Organ Damage in Youth 

Elaine M. Urbina, 1,2 Philip R. Khoury, 1 Connie E. 

McCoy, 1 Stephen R. Daniels, 3 Lawrence M. Dolan, 1,2 

Thomas R. Kimball. 1,2 1 Cincinnati Children’s Hospital 

Medical Center, Cincinnati, OH, US; 2 University 

of Cincinnati, Cincinnati, OH, US; 3 University of 

Colorado, Aurora, CO, US. 

Effects of the DASH Diet on Flow Mediated 

Dilation in Adolescents with Pre-Hypertension and 


Sarah C. Couch, 1 Linda Levin, 2 Amanda Thopy, 1 Brian 

E. Saelens, 3 Mark Mitsnefes, 4 Stephen R. Daniels, 5 

Elaine M. Urbina. 4 1 University of Cincinnati Medical 

Center, Cincinnati, OH, US; 2 University of Cincinnati, 

Cincinnati, OH, US; 3 Children’s Hospital and 

Regional Medical Center, Seattle, WA, US; 4 Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 

US; 5 University of Colorado School of Medicine, 

Denver, CO, US. 

Determinants of Arterial Stiffness in Children and 

Adolescents 

George S. Stergiou, Anastasios Kollias, Periklis Giovas, 

Leonidas Roussias. University of Athens, Athens, GR. 

Prevalence of Overweight and Elevated Blood 

Pressure in a Large Cohort of Children and 

Adolescents (Age 3-17 Years) at an Initial Clinic 

Examination 

Kenneth F. Adams, 1 Karen L. Margolis, 1 David 

J. Magid, 2 Joan C. Lo, 3 Alan R. Sinaiko, 4 Elyse 

O. Kharbanda, 1 Nancy E. Sherwood, 1 Matt F. 

Daley, 2 Emily D. Parker, 1 Patrick J. O’Connor. 1 

1 HealthPartners Research Foundation, Minneapolis, 

MN, US; 2 Kaiser Permanente Colorado, Denver, CO, 

US; 3 Kaiser Permanente Northern California, Oakland, 

CA, US; 4 University of MN, Minneapolis, MN, US. 

106


Posters 


Aldosterone and anti-aldosterone 

agents 

PO-124: 

PO-125: 

PO-126: 

PO-127: 

PO-128: 

PO-129: 

Aldosterone Metrics and Their Ability to 

Discriminate between Incident Resistant 

Hypertension during Follow-Up in a Hypertensive 

Cohort 

Jennifer D. Dochee, Berhane Seyoum, Phillip Levy, 

Brain Ference, Shiling Zhang, Lowell Hedquist, John 

Flack. Wayne State University, Detroit, MI, US. 

Aldosterone-Induced Rise in Blood Pressure in 

Normotensive Rats is Due to a Decrease in PGE 2 

Levels 

Danita Eatman, Aisha Rollins-Hairston, Deborah Lyn, 

Mohamed A. Bayorh. Morehouse School of Medicine, 

Atlanta, GA, US. 

Delayed Diagnosis of Primary Aldosteronism- 

Help from the Web: A Yahoo Support Group for 

Patients Struggling with Diagnosis and Long-Term 

Management 

Clarence E. Grim. High Blood Pressure Consulting, 

Milwaukee, US. 

Dose Titration of the Oral Potassium Binder- 

RLY5016 to Maintain Normal Serum Potassium in 

Heart Failure and Chronic Kidney Disease Patients 

on Aldosterone Antagonists 

Bertram Pitt†, 1 David Bushinsky, 2 Sherin Halfon, 3 

Dalane Kitzman, 4 Mitja Lainscak, 5 Vandana Mathur, 3 

Yuri Stasiv, 3 I.‐Zu Huang. 3 1 U. of Michigan, US; 2 U. of 

Rochester, US; 3 Relypsa, US; 4 Wake Forest U., US; 5 U. 

Clinic Golnik, SI. 

Hyperkalemia with Aldosterone Antagonist 

Monotherapy in Essential Hypertension. A Meta- 

Analysis 

Jorge Romero, 1 Harikrishna Makani, 1 Jonathan 

Kahan, 1 Omar Wever‐Pinzon, 2 Clinton Colaco, 1 Franz 

H. Messerli. 1 1 St Luke’s Roosevelt Medical Center/ 


Surgeons, New York, NY, US; 2 The University of Utah- 

Health Sciences Center, US. 

Body Mass Index Correlates with Plasma 

Aldosterone in Overweight/Obese Hypertensive 

Patients Despite Drug Therapy 

Riccardo Sarzani, Federico Guerra, Lucia Mancinelli, 

Alessia Buglioni, Eliana Franchi, Paolo Dessì‐Fulgheri. 

University Politecnica delle Marche, Ancona, IT. 

107

MAY 22 

Posters 


PO-130: 

Aldosterone to Renin Ratio as a Predictor of 

Mortality and Cardiovascular Outcomes 

John J. Sim†, 1 Simran K. Bhandari, 1 Jiaxiao M. Shi, 2 

Federico B. Calara, 4 Scott A. Rasgon, 1 Kamyar 

Kalantar‐Zadeh. 3 1 Kaiser Permanente Los Angeles 

Medical Center, Los Angeles, CA, US; 2 Kaiser 

Permanente Southern California, US; 3 Harbor UCLA 

Medical Center, US; 4 Novartis Corporation, US. 

Antihypertensive Drugs and 

Pharmacology 

PO-131: 

PO-132: 

PO-133: 

PO-134: 

PO-135: 

PO-136: 

Both Morning and Evening Dosing of Nebivolol 

Reduces Trough to Morning Blood Pressure Surge in 


Maria Czarina Acelajado, 1 Roberto Pisoni, 3 Tanja 

Dudenbostel, 2 David A. Calhoun, 2 Stephen P. Glasser. 2 

1 Philippine General Hospital, Manila, PH; 2 University 

of Alabama at Birmingham, Birmingham, AL, US; 

3 Medical University of South Carolina, Charleston, SC, 

US. 

Administration-Time-Dependent Effects on 

Ambulatory Blood Pressure of Hydrochlorothiazide 

as Added Therapy in Hypertensive Subjects 

Uncontrolled with Valsartan 

Diana E. Ayala, Ramon C. Hermida, Artemio Mojon, 

Jose R. Fernandez. University of Vigo, Vigo, ES. 

Irbesartan/Amlodipine Fixed Combination 

in Patients Uncontrolled on Amlodipine 5 mg 

(I-COMBINE Study) 

Guillaume Bobrie. European George Pompidou 

Hospital, Paris, FR. 

Irbesartan/Amlodipine Fixed Combination in 

Patients Uncontrolled on Irbesartan 150 mg (I-ADD 

Study) 

Guillaume Bobrie. European George Pompidou 

Hospital, Paris, FR. 

Poly(3-Hydroxybutyrate) Nanoparticles Loaded with 

Paclitaxel Cause Prolonged Antiproliferative Action 

Anton P. Bonartsev, 1 Sergey A. Yakovlev, 2 Elena 

A. Filatova, 2 Galina M. Soboleva, 1 Tatiana K. 

Mahina, 2 Vera L. Myshkina, 2 Garina A. Bonartseva. 2 

1 M.V.Lomonosov Moscow State University, Moscow, 

RU; 2 Russian Academy of Sciences, Moscow, RU. 

The Efficacy and Safety of Angiotensin Receptor 

Blocker and Calcium Channel Blocker Combination 

in Hypertension 

Bulent Boyaci, 1 Mehmet Berktas, 2 Pinar Kizilirmak. 2 

1 Gazi University Faculty of Medicine, Ankara, TR; 

2 Novartis Pharma, Istanbul, TR. 

108


Posters 

PO-137: 

PO-138: 

PO-139: 

PO-140: 

PO-141: 

Better Control of Central Pressures and Total 

Hypertensive Time in Patients with Hypertension 

Receiving Telmisartan as Monotheraphy. Prospective 

Study 

Ricardo M. Cabrera Sole, 1 Caridad Turpin Lucas, 1 

Santiago Garcia Ruiz, 1 Rafael Fernandez, 2 Erik 

Luepke. 3 1 University General Hospital of Albacete, 

Albacete, ES; 2 Health Center of Villarrobledo, 

Albacete, ES; 3 University General Hospital “La Paz”, 

Madrid, ES. 

Intravenous Hydralazine for Blood Pressure 

Management in the Hospitalized Patient 

Patrick T. Campbell, William L. Baker, Bendel D. 

Steven, William B. White. University of Connecticut 

School of Medicine, Farmington, CT, US. 

Long-Term Efficacy and Safety of Combination 

Olmesartan Medoxomil/Amlodipine 

Besylate+Hydrochlorothiazide in Study Participants 

with Hypertension Based on Age: The TRINITY 

Study 

Steven G. Chrysant†, 1 Dean J. Kereiakes, 2 Suzanne 

Oparil, 3 Joseph Izzo, 4 Thomas Littlejohn, 5 Michael 

Melino, 6 James Lee, 6 Victor Fernandez, 6 Reinilde 

Heyrman. 6 1 Oklahoma Cardiovascular and 

Hypertension Center and University of Oklahoma 

College of Medicine, US; 2 The Christ Hospital Heart 

and Vascular Center and The Carl and Edyth Lindner 

Center for Research and Education at the Christ 

Hospital, US; 3 University of Alabama at Birmingham, 

US; 4 State University of New York at Buffalo, US; 

5 Piedmont Medical Research Associates, US; 6 Daiichi 

Sankyo, Inc, US. 



Besylate+Hydrochlorothiazide—The TRINITY 

Study: A Subgroup Analysis by Study Participant 

Race 

Steven G. Chrysant†, 1 Dean J. Kereiakes, 2 Joseph Izzo, 3 

Thomas Littlejohn, 4 Suzanne Oparil, 5 Michael Melino, 6 

James Lee, 6 Victor Fernandez, 6 Reinilde Heyrman. 6 

1 Oklahoma Cardiovascular and Hypertension Center 

and University of Oklahoma College of Medicine, US; 

2 The Christ Hospital Heart and Vascular Center and 

The Carl and Edyth Lindner Center for Research and 

Education at the Christ Hospital, US; 3 State University 

of New York at Buffalo, US; 4 Piedmont Medical 

Research Associates, US; 5 University of Alabama at 

Birmingham, US; 6 Daiichi Sankyo, Inc, US. 

Comparison of Valsartan/Amlodipine Added to 

Diuretic with Losartan Added to Diuretic on BP 

Load in Hypertension 

Daniel Duprez†, 1 Keith Ferdinand, 2 Das Purkayastha, 3 

Rita Samuel, 3 Richard F. Wright. 4 1 University of 

Minnesota, Minneapolis, MN, US; 2 Emory University, 

Atlanta, GA, US; 3 Novartis Pharmaceuticals 

Corporation, East Hanover, NJ, US; 4 Pacific Heart 

Insitute, Santa Monica, CA, US. 

109

MAY 22 

Posters 


PO-142: 

PO-143: 

PO-144: 

PO-145: 

PO-146: 

PO-147: 

PO-148: 

The Impact of Initial Treatment of Hypertension 

on Control in the First Year: Comparison of Initial 

Monotherapy, Free-Dose Combination and Fixed- 

Dose Combinations 

Brent Egan†, 1 Stephanie Shaftman, 1 Dipankar 

Bandyopadhyay, 1 C. Wagner, 1 Daniel Lackland, 1 

Kristina Yu‐Isenberg. 2 1 Medical University of South 

Carolina, SC, US; 2 Novartis Pharmaceuticals, NJ, US. 

A Bedtime Dose of ARB Reduces Urinary Albumin 

Excretion Via the Improvement of Baroreflex 

Sensitivity – The J-TOP Study 

Kazuo Eguchi, Motohiro Shimizu, Satoshi Hoshide, 

Kazuyuki Shimada, Shizukiyo Ishikawa, Kazuomi 

Kario. Jichi Medical University School of Medicine, 

Shimotsuke, Tochigi-ken, JP. 

Response to Aliskiren in Patients with Non- 

Controlled Blood Pressure Seems to be Irrespective 

of Previous Therapy and Plasma Renin Activity 

Angelica Fernandez, Susana Tello, Asuncion Guerri, 

Olivia Sanchez, Rosa Fabregate, Martin Fabregate, 

Arantxa Rodriguez, Jose Saban‐Ruiz. Ramon y Cajal 


Impact of Initial Combination Therapy vs. 

Monotherapy on Major Cardiovascular Events: A 

Matched Cohort Study 

Alan H. Gradman†, 1 Hélène Parisé, 2 Marie‐Hélène 

Lafeuille, 2 Heather Falvey, 3 Patrick Lefebvre, 2 Mei 

Sheng Duh. 2 1 Temple University School of Medicine 

(Clinical Campus), Pittsburgh, PA, US; 2 Analysis 

Group, Inc., Boston, MA, US; 3 Novartis Pharma AG, 

Basel, CH. 

Relationship between Sleep-Time Blood Pressure 

Control and Reduction of Urinary Albumin 

Excretion after Timed-Treatment with Olmesartan 

in Essential Hypertension 

Ramon C. Hermida, Diana E. Ayala, Maria J. Fontao, 

Artemio Mojon, Jose R. Fernandez. University of Vigo, 

Vigo, ES. 

Nebivolol and Hydrochlorothiazide in African- 

Americans with Hypertension: Effects on Diastolic 

and Endothelial Function 

Bobby V. Khan†, Nadya Merchant, Tahir Haque, Syed 

T. Rahman, Sujan Bhaheetharan, Keith C. Ferdinand. 

Emory University School of Medicine, Atlanta, GA, 

US. 

Peripheral Edema Associated with Calcium 

Antagonists 

Harikrishna Makani, Jorge Romero, Nay Htyte, 

Ronaldo Sevilla Berrios, Arpit Shah, Waddy Gonzalez, 

Franz H. Messerli. St. Luke’s Roosevelt Hospital 

and Columbia University College of Physicians and 


110


Posters 

PO-149: 

PO-150: 

PO-152: 

PO-153: 

PO-154: 

PO-155: 

Efficacy of a Simplified Mechanistic Algorithm 

for Management of Resistant Hypertension: A 

Retrospective Study 

Neal S. Parikh, Samuel J. Mann†. NY Presbyterian 

Hospital – Weill Cornell Med Ctr, New York, NY, US. 



Besylate+Hydrochlorothiazide—The TRINITY 

Study: Subgroup Analyses Based on Study 

Participant Diabetes Status and BMI 

Suzanne Oparil†, 1 Joseph Izzo, 2 Steven G. Chrysant, 3 

Dean J. Kereiakes, 4 Thomas Littlejohn, 5 Michael 

Melino, 6 James Lee, 6 Victor Fernandez, 6 Reinilde 

Heyrman. 6 1 University of Alabama at Birmingham, 

US; 2 State University of New York at Buffalo, US; 

3 Oklahoma Cardiovascular and Hypertension Center 

& University of Oklahoma College of Medicine, US; 

4 The Christ Hospital Heart and Vascular Center & 

The Carl and Edyth Lindner Center for Research 

and Education, US; 5 Piedmont Medical Research 

Associates, US; 6 Daiichi Sankyo, Inc, US. 

Differential Cardioprotective Effects of Carvedilol 

and Valsartan under Different Cardiac Loading 

Conditions 

Minesh Rajpal†, Shaila Karan, Sirisha Srikakarlapudi, 

Peter J. Osmond, Joseph L. Izzo. SUNY at Buffalo, NY, 

US. 

Effects of Time of Hypertension Treatment on the 

Circadian Blood Pressure Pattern of Subjects with 

Resistant Hypertension: The Hygia Project 

Maria T. Rios, 1 Manuel Dominguez‐Sardiña, 1 Lorenzo 

Pousa, 1 Jesus Perez de Lis, 1 Alfonso Otero, 2 Maria 

J. Fontao, 3 Jose R. Fernandez, 3 Diana E. Ayala, 3 

Ramon C. Hermida, 3 Investigadores Proyecto Hygia. 3 

1 Gerencia de Atención Primaria, Vigo, ES; 2 Complejo 

Hospitalario Universitario, Orense, ES; 3 University of 

Vigo, Vigo, ES. 

Plasma Renin-Guided Treatment in Young 

Untreated Hypertension: A Randomized 

Comparative Pilot Study 

Il‐Suk Sohn, 1 Chang‐Bum Park, 1 Eun‐Sun Jin, 1 

Chong‐Jin Kim, 1 Jin‐Man Cho. 2 1 Kyung Hee 

University Gangdong Hospital, Seoul, KR; 2 Aab 

Cardiovascular Research Institute, Rochester, NY, US. 

Angiotensin Converting Enzyme Inhibitors or 

Angiotensin Receptor Blockers as First-Line 

Treatment in Patients with Uncomplicated 


Konstantinos Tziomalos, Maria Baltatzi, Athinodoros 

Pavlidis, Konstantinos Koulousios, Vasiliki Dourliou, 

Anastasios Hatzopoulos, Vaia Bougatsa, Lambrini 

Kirkineska, Christos Savopoulos, Apostolos I. 

Hatzitolios. Medical School, Aristotle University of 

Thessaloniki, AHEPA Hospital, Thessaloniki, GR. 

111

MAY 22 

Posters 


PO-156: 

PO-157: 

Amlodipine/Valsartan Single Pill Combination 

Treatment of Arterial Hypertension in a Real Life 

Practice in Russia 

Irina E. Chazova, 1 Yuri A. Karpov, 1 Alexey V. 

Vigdorchik†, 2 Antonina Y. Zazulina. 2 1 Russian 

Cardiology Scientific-Industrial Complex, Moscow, 

RU; 2 Novartis Pharma LLC, Moscow, RU. 

Real Life Safety and Effectiveness of Amlodipine/ 

Valsartan Single Pill Combination in the Treatment 


Irina E. Chazova, 1 Neelesh Dongre, 2 Alexey V. 

Vigdorchik†. 3 1 Russian Cardiology Scientific-Industrial 

Complex, Moscow, RU; 2 Novartis Pharma AG, Basel, 

CH; 3 Novartis Pharma LLC, Moscow, RU. 

Clinical Trials 

PO-158: 

PO-159: 

PO-160: 

PO-161: 

PO-162: 

The Influence of Antihypertensive Therapy on Blood 

Pressure Variability: The X-CELLENT Study 

Yi Zhang, 1,2 Davide Agnoletti, 1 Michel E. Safar, 1 

Jacques Blacher. 1 1 Paris Descartes University, Paris, 

FR; 2 Jiaotong University School of Medicine, Shanghai, 

CN. 

A Double-Dummy Comparison of De Novo 

Combination vs Sequential Add-On Therapy: 

‘ACCELERATE’ 

Morris Brown, 1,2 Gordon McInnes, 1,3 Cheraz Cherif 

Papst, 4 Jack Zhang, 4 Thomas MacDonald. 1,5 1 British 

Hypertension Society, GB; 2 University of Cambridge, 

GB; 3 University of Glasgow, GB; 4 Novartis Pharma 

AG, CH; 5 University of Dundee, GB. 

Amlodipine Plus Telmisartan or Amiloride for 

Hypertensive Patients: Focus on Effects on Metabolic 

Profiles 

Hong Yuan, Jingjing Cai, Zhijun Huang. The Center of 

Clinical Pharmacology of the Third Xiangya Hospital, 

Central South University, Changsha, CN. 

Amlodipine Plus Telmisartan or Amiloride for 

Hypertension in Moderate and High-Risk Patients: 

A 24-Week Observation 

Jingjing Cai, Zhijun Huang, Rong Cui, Hong Yuan. The 

Center of Clinical Pharmacology of the Third Xiangya 

Hospital, Central South University, Changsha, CN. 

Efficacy and Safety of Azilsartan Medoxomil/ 

Chlorthalidone vs Olmesartan/HCTZ Combinations 

in Stage 2 Systolic HTN 

William C. Cushman†, 1 Domenic Sica, 2 George L. 

Bakris, 3 Michael A. Weber, 4 William B. White, 5 

Charlie Cao, 6 Andrew Roberts, 6 Stuart Kupfer. 6 1 U 

of TN College of Medicine, Memphis, TN, US; 2 VA 

Commonwealth U Health System, Richmond, VA, 

US; 3 U of Chicago Pritzker School of Medicine, 

Chicago, IL, US; 4 New York, NY, US; 5 U of CT School 

of Medicine, Farmington, CT, US; 6 Takeda Global 

Research & Development, Deerfield, IL, US. 

112


Posters 

PO-163: Effect of Aliskiren and Antihypertensive Drugs on 

Diastolic Function in Hypertensives with Diastolic 

Dysfunction: A Randomised Study 

Maria Leonarda De Rosa. University of Naples 

Federico II, Naples, IT. 

PO-164: Effects of Add-On Nebivolol on Blood Pressure and 

Glucose Parameters in Hypertensive Patients with 

Prediabetes 

P. Deedwania†, 1 D. G. Cheung, 2 J. Shea, 3 W. Chen, 3 J. J. 

Whalen. 3 1 UCSF, US; 2 Long Beach Center for Clinical 

Research, US; 3 Forest Research Institute, US. 

PO-165: Incident Diabetes with Antihypertensive Drugs: 

Updated Network and Bayesian Meta-Analyses of 

Clinical Trial Data 

William J. Elliott†, 1 Sanjib Basu, 2 Peter M. Meyer. 2 

1 Pacific Northwest University of Health Sciences, 

Yakima, WA, US; 2 RUSH Medical College, Chicago, 

IL, US. 

PO-166: Efficacy and Safety of Combination DRI/CCB (± 

Diuretic) in US Minority Patients with Stage 2 

Hypertension and Obesity 

Keith C. Ferdinand†, 1 Richard Weitzman, 2 Das 

Purkayastha, 2 Kanaka Sridharan, 2 Edgar A. Jaimes. 3 

1 Emory University, Atlanta, GA, US; 2 Novartis 

Pharmaceuticals Corporation, East Hanover, NJ, 

US; 3 The University of Alabama at Birmingham, 

Birmingham, AL, US. 

PO-167: Efficacy of Combination Aliskiren/Amlodipine with 

and without Diuretic on Ambulatory Blood Pressure 

in Minorities with Hypertension 




Pharmaceuticals Corp, East Hanover, NJ, US; 3 The 

University of Alabama at Birmingham, Birmingham, 

AL, US. 

PO-168: Role of Plasma Renin Activity on BP Response to 

Aliskiren-Based Therapy in Stage 2 Hypertensive 

African Americans 







PO-169: Efficacy and Safety of Combination DRI/CCB 

(±Diuretic) Therapy in African Americans with 

Stage 2 Hypertension 







113

MAY 22 

Posters 


PO-170: 

PO-171: 

PO-172: 

PO-173: 

PO-174: 

PO-175: 

PO-176: 

PO-177: 

PO-178: 

Combination Aliskiren/Amlodipine with and 

without Diuretic in Minorities with Hypertension 

and Metabolic Syndrome or Diabetes 




Pharmaceuticals Corp, East Hanover, NJ, US; 3 Univ of 

Alabama at Birmingham, Birmingham, AL, US. 

Efficacy and Safety of Olmesartan Medoxomil 

Versus Losartan Potassium in Subjects with Stage 1 

or 2 Hypertension 

John M. Flack†, 1 Alan Graff, 2 Wei Li, 3 Kathleen J. 

Chavanu, 3 Robert Dubiel. 3 1 Wayne State University 

School of Medicine, US; 2 Private Practice, US; 3 Daiichi 

Sankyo, Inc., US. 

Decreasing Sleep-Time Blood Pressure Determined 

by Ambulatory Monitoring Reduces Cardiovascular 

Risk in Resistant Hypertension 

Ramon C. Hermida, 1 Diana E. Ayala, 1 Artemio 

Mojon, 1 Luisa Chayan, 2 Maria J. Dominguez, 3 Maria 

J. Fontao, 1 Ignacio Alonso, 1 Jose R. Fernandez. 1 

1 University of Vigo, Vigo, ES; 2 Urgencias Sanitarias 

061 Galicia, Santiago, ES; 3 Policlinica La Rosaleda, 

Santiago, ES. 

Influence of Circadian Time of Blood Pressure- 

Lowering Treatment on Cardiovascular Risk in 




Administration-Time Differential Benefit on 

Cardiovascular Risk Reduction of the Various 

Classes of Hypertension Medications 



Influence of Number of Hypertension Medications 

and Circadian Time of Treatment on Cardiovascular 

Morbidity and Mortality 



Doppler Measurement of Ankle Brachial Index is 

Still the Standard in Screening of Peripheral Arterial 

Disease 

Laura Rantamaula, Juha Varis, Ilkka M. Kantola. Turku 

University Hospital, Turku, FI. 

Comparative Effects of Carvedilol and Valsartan on 

Cardiac Workload 

Shaila Karan†, Sirisha Srikakarlapudi, Minesh Rajpal, 

Peter J. Osmond, Joseph L. Izzo, Jr. SUNY at Buffalo, 

Buffalo, NY, US. 

Olmesartan + CCB vs Olmesartan + Diuretic as 

Combination Therapy for Elderly Hypertensive 

Patients 

Johji Kato, Naoto Yokota, Toshihiro Kita, Tanenao Eto, 

Kazuo Kitamura. University of Miyazaki, Miyazaki 

City, Miyazaki, JP. 

114


Posters 

PO-179: 

PO-180: 

PO-181: 

PO-182: 

PO-183: 

PO-184: 

Efficacy and Safety of Olmesartan Medoxomil 

Versus Losartan Potassium in Antihypertensive 

Naïve/Non-Naïve Subjects 

Henry A. Punzi†, 1 Andrew Lewin, 2 Wei Li, 3 Kathleen J. 

Chavanu, 3 Robert Dubiel. 3 1 Trinity Hypertension and 

Metabolic Research Institute, US; 2 National Research 

Institute, US; 3 Daiichi Sankyo, Inc., US. 

Computer-Mediated System, WHEELS-I, Provides 

Evidence of Feasibility for Momentary Assessment 

of DASH Diet Adherence over 8 Weeks 

Margaret Scisney‐Matlock, 1 Susan Steigerwalt, 2 

Kenneth Jamerson, 1 Amanda Sen, 1 Susan Pressler, 1 

Elizabeth Brough. 1 1 University of Michigan, Ann 

Arbor, MI, US; 2 St. John Health System, Detroit, US. 

Carvedilol Reduces Aortic Wave Reflection and 

Improves Left Ventricular/Vascular Coupling 

Compared to Atenolol: The CENTRAL Study 

Niren K. Shah†, 1 Benjamin J. Epstein, 1,2 Wilmer W. 

Nichols, 2 Steven M. Smith, 2 Julie A. Johnson. 2 1 East 

Coast Institute for Research, Jacksonville, FL, US; 

2 University of Florida, Gainesville, FL, US. 

Fixed-Dose Combination of Azilsartan Medoxomil/ 

CLD Provides Superior BP Reduction to 

Monotherapies in Stage 2 HTN 

D. Sica†, 1 G. L. Bakris, 2 W. B. White, 3 M. A. Weber, 4 

W. C. Cushman, 5 A. Roberts, 6 C. Cao, 6 S. Kupfer. 6 1 VA 

Commonwealth U Health System, Richmond, VA, US; 

2 U of Chicago Pritzker School of Medicine, Chicago, 

IL, US; 3 U of CT School of Medicine, Farmington, 

CT, US; 4 New York, NY, US; 5 U of TN College of 

Medicine, Memphis, TN, US; 6 Takeda Global Research 

& Development, Deerfield, IL, US. 

Efficacy of an Amlodipine/Olmesartan Medoxomil 

Algorithm in Patients Uncontrolled on Prior ACE 

Inhibitor Monotherapy 

Matthew R. Weir†, 1 Alan Graff, 2 Ali Shojaee, 3 William 

F. Waverczak, 3 Jen‐Fue Maa. 3 1 University of Maryland 

School of Medicine, US; 2 Private Practice, US; 3 Daiichi 

Sankyo, Inc., US. 

Pilot Randomized Controlled Trial of Intensive 

Blood Pressure Control in Hemodialysis Dialysis 

Patients: The BID Trial 

Philip Zager, 1 Dana Miskulin, 2 Jennifer Gassman. 3 

1 University of New Mexico Health Sciences Center, 

Albuquerque, NM, US; 2 Tufts Medical Center, Boston, 

MA, US; 3 Cleveland Clinic Research Foundation, 

Cleveland, OH, US. 

Coronary Artery Disease 

PO-185: 

Blood Pressure and Heart Related Quality of Life 

One Year Post Myocardial Infarction 

Antonios Ioannidis, Dimitrios Tsounis. Hellenic Open 

University, GR. 

115

MAY 22 

Posters 


PO-186: 

PO-187: 

PO-188: 

PO-189: 

PO-190: 

PO-191: 

False-Positive Stress Testing Results in 

Hypertensives with No Coronary Artery Disease 

Fei Lu, 1 Gabriele Fragasso, 2 Chunzeng Lu, 1 Vitantonio 

Di Bello, 1 Roberto Pedrinelli, 1 Mario Marzilli, 1 Alberto 

Balbarini. 1 1 University of Pisa, IT; 2 Scientific Institute 

of H San Raffaele, IT. 

Inadequate Blood Pressure Control in Hypertensives 

Referred for Cardiac Stress Testing 

Tarek M. Mousa, Harmony Leighton, Seema Patel, 

Todd Kerwin. New York Hospital Medical Center of 

Queens/Cornell University Weill Medical College, 

Flushing, NY, US. 

Relationship between Exercise Intolerance and 

Plasma Natriuretic Peptide Level in Hypertensives 

with Postinfarction Cardiosclerosis 

Mariya A. Orynchak, Iryna I. Vakalyuk, Igor P. 

Vakalyuk. Ivano-Frankivsk National Medical 

University, Ivano-Frankivsk, UA. 

Influence of a History of Hypertension with Clinical 

Presentation and Prognosis after Admission 

with Non ST Segment Elevation Acute Coronary 

Syndrome 

Joaquin Rueda Soriano, Miguel Angel Arnau Vives, 

Ana Osa Saez, Esther Zorio Grima, Luis Martínez 

Dolz, Luis Almenar, Miguel Palencia Pérez, Antonio 

Salvador Sanz. Hospital La Fe, Valencia, ES. 

Characteristics of Hypertensive Response during 

Exercise Echocardiography in Hypertensive Patients 

with No History of Coronary Artery Disease 

Il‐Suk Sohn, Chang‐Bum Park, Eun‐Sun Jin, Jin‐Man 

Cho, Chong‐Jin Kim, Jong‐Hoa Bae. Kyung Hee 

University School of Medicine, Seoul, KR. 

The Ankle-Brachial Index as a Predictor of Coronary 

Artery Disease 

Svetlana Kostic, Dragan Mijalkovic, Ivan Tasic. 

Institute for Therapy and Rehabilitation “Niska Banja”, 

Niska Banja, RS. 

Genetics/Gene Therapy/Proteomics 

PO-192: 

PO-193: 

Cardiac BNP Gene Delivery Prevents Hypertensive 

Heart Disease in Spontaneous Hypertensive Rats 

Alessandro Cataliotti, 1 Fernando L. Martin, 1 Jason M. 

Tonne, 2 Diego Bellavia, 1 John C. Burnett, 1 Yasuhiro 

Ikeda. 2 1 Mayo Clinic, Rochester, MN, US; 2 Mayo 

Clinic, Rochester, MN, US. 

DNA Variants in NOS3 are Associated with 

Improved Small Artery Elasticity and Decreased 

Systolic Blood Pressure 

Daniel Duprez, 1 Natalia Florea, 1 Sara Saul, 1 Ryan 

Palaciao, 1 Steven Rich, 2 Jay N. Cohn, 1 Jennifer Hall. 1 

1 University of Minnesota, Minneapolis, MN, US; 

2 University of Virginia, Charlottesville, VA, US. 

116


Posters 

PO-194: 

PO-195: 

PO-196: 

PO-198: 

SNP-SNP Interactions among Hypertension Related 

Genes 

Masahiko Eto, 1 Takanori Aonuma, 1 Masanobu 

Okayama, 2 Maki Kumada, 2 Ritei Uehara, 2 Yoshikazu 

Nakamura, 2 Eiji Kajii. 2 1 Wakuya Medical and Welfare 

Center, Wakuya, Miyagi, JP; 2 Jichi Medical University, 

Shimotsuke, Tochigi, JP. 

Blood Pressure, Endothelial Dysfunction, Lipid 

Profile and CYP3A5 Gene Polymorphism in Uzbek 


Amayak Kevorkov, Marietta Eliseyeva. Republican 

Specialized Center of Cardiology, Tashkent, UZ. 

Mitochondrial Polymorphisms are Associated 

with Blood Pressure and Metabolic Traits in the 

Framingham Heart Study 

Chunyu Liu, 1,2 Qiong Yang, 3 Shih‐Jen Hwang, 1,2 

Fengzhu Sun, 4 Caroline S. Fox, 1 Ramachandran S. 

Vasan, 1,5 Faina Schwartz, 5 Daniel Levy. 1,2 1 National 

Heart, Lung, and Blood Institute’s Framingham Heart 

Study, Framingham, MA, US; 2 NHLBI, Bethesda, 

MD, US; 3 Boston University School of Public Health, 

Boston, MA, US; 4 University of Southern California, 

Los Angeles, CA, US; 5 Boston University School of 

Medicine, Boston, MA, US. 

Targeted Disruption of Npr1 Gene Upregulates 

Renin-Angiotensin System and Cardiac 

Hypertrophy in Null Mutant Mice 

Kailash N. Pandey. Tulane University Health Sciences 

School of Medicine, New Orleans, LA, US. 

Heart Failure/Hypertrophy (Diastolic 

Dysfunction) 

PO-199: 

PO-200: 

PO-201: 

A Meta-Analysis of the Effect of Anti-Hypertensive 

Treatment on Echocardiogram Parameters in Heart 

Failure Patients with Preserved Ejection Fraction 

Alex Briasoulis, 1 Vikram Agarwal, 1 Manpreet S. 

Sabharwal, 1 Girish N. Nadkarni, 1 Franz H. Messerli. 2 

1 St. Luke’s-Roosevelt Hospital Center, Columbia 

University College of Physicians and Surgeons, New 

York, NY, US; 2 St. Luke’s-Roosevelt Hospital Center, 



Effects of Renin-Angiotensin System Blockade on 

Mortality and Rehospitalization in Heart Failure 

with Preserved Ejection Fraction 

Vikram V. Agarwal, 1 Alexandros Briasoulis, 1 Girish 

Nadkarni, 1 Manpreet S. Sabharwal, 1 Nidhi Hans, 2 

Franz H. Messerli. 1 1 St. Luke’s-Roosevelt Hospital 

Center, New York, NY, US; 2 Harvard School of Public 

Health, Boston, MA, US. 

Socioeconomic Status and Costs in Heart Failure 

Billy G. Chacko, Tej K. Atluri, Syed U. Naqvi, Hamza 

Rana, Pavel J. Levy, Kimberley J. Hansen. Wake Forest 

University Baptist Medical Center, Winston Salem, 

NC, US. 

117

MAY 22 

Posters 


PO-202: Can High Dose of Valsartan Improve Ventricular- 

Vascular Coupling in Heart Failure 

Wook‐Jin Chung†, 1 Hye‐Sun Seo, 2 Sung‐Hee Shin, 3 

Young‐Sup Byun, 4 Sung‐Kee Ryu, 5 Wook‐Bum Pyun, 6 

Se‐Joong Rim. 7 1 Gachon University Gil Hospital, 

Gachon University School of Medicine, Incheon, 

KR; 2 Inha University Hospital, KR; 3 Soonchunhyang 

University School of Medicine, KR; 4 Sanggye Paik 

Hospital, Inje University College of Medicine, KR; 

5 Eulji General Hospital, Eulji University School of 

Medicine, KR; 6 Ewha Womans University, School of 

Medicine, KR; 7 Gangnam Severance Hospital, Yonsei 

University College of Medicine, KR. 

PO-203: Can N-Terminal pro-B Type Natriuretic Peptide 

Predict LV Diastolic Dysfunction in Hypertensive 

Heart Disease 

Wook‐Jin Chung, 1 Sung‐Hee Shin, 2 Hye‐Sun Seo, 3 

Young‐Sup Byun, 4 Sung‐Kee Ryu, 5 Wook‐Bum 

Pyun, 6 Se‐Joong Rim. 7 1 Gachon University Gil 

Hospital, Gachon University School of Medicine, 

Incheon, KR; 2 Inha University Hospital, Incheon, 

KR; 3 Soonchunhyang University School of Medicine, 

Bucheon, KR; 4 Sanggye Paik Hospital, Inje University 

College of Medicine, KR; 5 Eulji General Hospital, Eulji 

University School of Medicine, KR; 6 Ewha Womans 

University, School of Medicine, KR; 7 Gangnam 

Severance Hospital, Yonsei University College of 

Medicine, KR. 

PO-204: PPARg Agonist Inhibits, and PPARg Antagonist 

Exacerbates, Pressure Overload-Induced Cardiac 

Fibrosis and Dysfunction 

Kaizheng Gong, Yiu‐Fai Chen, Peng Li, Wei Zhang, 

Fadi Hage, Namasivayam Ambalavanan, Suzanne 

Oparil, Dongqi Xing. University of Alabama at 


PO-205: Left Ventricular Mass Index is Associated with 

Cognitive Impairment Independently of Blood 

Pressure in the Elderly 

Manabu Hayakawa, 1,2 Yuichiro Yano, 2,3 Kazuo 

Kuroki, 1 Kazuyuki Shimada, 3 Kazuomi Kario. 3 

1 Kushima Shimin Hospital, Miyazaki, JP; 2 University 

of Miyazaki, Miyazaki, JP; 3 Jichi Medical University 

School of Medicine, Tochigi, JP. 

PO-206: Heart Failure Hospitalization in Tennessee (2006- 

2008): Race, Age, and Gender Analyses 

Baqar Husaini†, 1 Van Cain, 1 Pamela Hull, 1 Zahid 

Samad, 1 H. Okafor, 2 Robert Levine, 2 U. Sampson. 3 

1 Tennessee State University, US; 2 Meharry Medical 

College, Nashville, TN, US; 3 Vanderbilt University, 

Nashville, TN, US. 

118


Posters 

PO-207: 

PO-208: 

PO-209: 

PO-210: 

PO-211: 

PO-212: 

Reverse Association of Early Relaxation Tissue 

Doppler Waves with Left Ventricle Mass in 

Hypertensive Non Diabetic Patients 

Athanasios N. Kartalis, Nikolaos E. Smyrnioudis, 

Stefanos H. Garoufalis, Georgios N. Benetos, 

Panagiotis M. Moschouris, Panagiotis D. Sgourakis, 

Nikolaos V. Papagiannis, Ioannis V. Georgiadis, 

Georgios E. Georgiopoulos. General Hopsital of Chios 

Island, Chios, GR. 

Association of Geometric Patterns of the Left 

Ventricle with Microalbuminuria in Hypertensive 

Non-Diabetic Patients 

Athanasios N. Kartalis, Nikolaos E. Smyrnioudis, 

Stefanos H. Garoufalis, Georgios N. Benetos, 

Panagiotis M. Moschouris, Panagiotis D. Sgourakis, 

Nikolaos V. Papagiannis, Georgios E. Georgiopoulos. 

General Hopsital of Chios Island, Chios, GR. 

Relation of Ventricular Geometry to Brain 

Natriuretic Peptide Levels, EF and NYHA Class in 

Heart Failure 

Sanjay Kumar, 1 Amit Nautiyal, 2 Jason Lazar. 1 1 SUNY 

Downstate Medical Center, Brooklyn, NY, US; 

2 University of Wisconsin, Madison, WI, US. 

The Influence of Telmisartan on Plasma Potassium 

Levels in Hypertensives with Insulin Resistance and 

Heart Failure 

Mariya A. Orynchak, Oleg M. Sheremeta, Nestor 

M. Seredyuk, Nadiya V. Skrypnyk. Ivano-Frankivsk 

National Medical University, Ivano-Frankivsk, UA. 

The Types of Left Ventricular Diastolic Dysfunction 

and Plasma NT-pro BNP Levels in Patients with 

Metabolic Syndrome 

Mariya A. Orynchak, Iryna I. Vakalyuk, Iryna O. 

Gaman. Ivano-Frankivsk National Medical University, 

Ivano-Frankivsk, UA. 

Postoperatiave B-Type Natriuretic Peptide Level 

Associates with Prolonged Hospitalization after 

Non-Cardiac Surgery in Patients with Hypertension 

Wook Bum Pyun, 1 Jae Hong Park, 2 Sang‐Hak Lee, 3 

Wook‐Jin Chung, 4 Young‐Sup Byun, 5 Sung‐Kee Ryu, 6 

Se‐Joong Rim, 7 Gil Ja Shin. 1 1 Mokdong Hospital, 

School of Medicine, Ewha Womans University, Seoul, 

KR; 2 Kangnam General Hospital, Yongin, KR; 3 Yonsei 

Cardiovascular Center, Yonsei University College 

of Medicine, Seoul, KR; 4 Heart Center, Gachon 

University Gil Medical Center, Incheon, KR; 5 Sanggye 

Paik Hospital, Inje University College of Medicine, 

Seoul, KR; 6 Eulji General Hospital, Eulji University 

School of Medicine, Seoul, KR; 7 Gangnam Severance 

Hospital, Yonsei University College of Medicine, Seoul, 

KR. 

119

MAY 22 

Posters 


PO-213: 

PO-214: 

PO-215: 

PO-216: 

Treatment Blocking the Renin-Angiotensin System 

and Two-Year Mortality in Very Old Patients with 

Heart Failure and Preserved Ventricular Ejection 

Fraction 

Carlos Rodriguez‐Pascual, 1 Emilio Paredes‐Galan, 3 

Arturo Vilches‐Moraga, 1 Ana Isabel Ferrero- 

Martinez, 1 Marta Torrente‐Carballido, 1 Fernando 

Rodríguez‐Artalejo. 2 1 Hospital Meixoeiro, Vigo, 

Pontevedra, ES; 2 Universidad Autonoma, Madrid, ES; 

3 Hospital Meixoeiro, Vigo, Pontevedra, ES. 

Left Ventricular Hypertrophy in Overweight/Obese 

Hypertensives with Metabolic Syndrome Depends 

on Body Mass Index 

Federico Guerra, Lucia Mancinelli, Luca Angelini, 

Marco Fortunati, Paolo Dessì-Fulgheri, Riccardo 

Sarzani. University Politecnica delle Marche, Ancona, 

IT. 

The Association of Left Ventricular Hypertrophy 

with Exercise Induced Intraventricular Asynchrony 

Hye‐Sun Seo, 1 Young‐Sup Byun, 2 Sung‐Kee Ryu, 3 

Wook‐Bum Pyun, 4 Se‐Joong Rim, 5 Wook‐Jin Chung, 6 

Sung‐Hee Shin. 7 1 Soonchunhyang University Hospital, 

Bucheon, KR; 2 Sanggye Paik Hospital, Inje University 

College of Medicine, Seoul, KR; 3 Eulji General 

Hospital, Eulji University School of Medicine, Seoul, 

KR; 4 Ewha Womans University Hospital, Seoul, KR; 

5 Gangnam Severance Hospital, Yonsei University 

College of Medicine, Seoul, KR; 6 Gachon University 

Gil Hospital, Gachon University School of Medicine, 

Incheon, KR; 7 Inha University Hospital, Incheon, KR. 

Gender Specific Prognostic Differences in Regard 

to the Regression of Hypertensive Left Ventricular 

Hypertrophy (12 Years Follow-Up Study) 

Ivan Tasic, 1 Svetlana Kostic, 1 Dragan Djordjevic, 1 

Gordana Lazarevic, 2 Dragan Lovic. 3 1 Institute for 

Therapy and Rehabilitation “Niska Banja”, Niska Banja, 

RS; 2 Clinic of Cardiology, Nis, RS; 3 Clinic for Internal 

Disease InterMedica-Dr Lovic, Nis, RS. 

Hypertension in patients with chronic 

kidney disease 

PO-217: 

PREdictors of Adequate Control of Hypertension 

among Chronic Kidney Disease Patients (PREACH- 

CKD) 

Ma Czarlota M. Acelajado‐Valdenor, Angelo Dave C. 

Javier, Maria Czarina M. Acelajado. Philippine General 

Hospital, Manila, PH. 

120


Posters 

PO-218: 

PO-219: 

PO-220: 

PO-221: 

PO-222: 

PO-223: 

Prevalence, Awareness, Treatment and Control of 

Hypertension in Chronic Kidney Disease 

Bulent Altun, 1 Gultekin Suleymanlar, 2 Cengiz Utas, 3 

Turgay Arinsoy, 4 Kenan Ates, 5 Tevfik Ecder, 6 Taner 

Camsari, 7 Kamil Serdengecti. 8 1 Hacettepe University 

Faculty of Medicine, Ankara, TR; 2 Akdeniz University 

Medical School, Antalya, TR; 3 Erciyes University 

Faculty of Medicine, Kayseri, TR; 4 Gazi University 

Faculty of Medicine, Ankara, TR; 5 Ankara University 

Faculty of Medicine, Ankara, TR; 6 Istanbul University 

Istanbul Faculty of Medicine, Istanbul, TR; 7 Dokuz 

Eylul University Faculty of Medicine, Izmir, TR; 

8 Istanbul University Cerrahpasa Faculty of Medicine, 

Istanbul, TR. 

Selective Endothelin-A Receptor Antagonism 

Reduces Proteinuria, Blood Pressure and Arterial 

Stiffness in Chronic Proteinuric Kidney Disease 

N. Dhaun, I. MacIntyre, J. Goddard, D. J. Webb. 

University of Edinburgh, GB. 

Discordant Estimation of the Prevalence of Masked 

Hypertension According to Daytime or Nighttime 

Blood Pressure in Subjects with Chronic Kidney 

Disease. The Hygia Project 

Ramon C. Hermida, 1 Alfonso Otero, 2 Luis Piñeiro, 3 

Diana E. Ayala, 1 Ana Moya, 4 Elvira Sineiro, 4 Maria 

J. Fontao, 1 Artemio Mojon, 1 Jose R. Fernandez, 1 

Investigadores Proyecto Hygia. 1 1 University of Vigo, 

Vigo, ES; 2 Complejo Hospitalario Universitario, 

Orense, ES; 3 Complejo Hospitalario Universitario, 

Pontevedra, ES; 4 Gerencia de Atención Primaria, 

Pontevedra, ES. 

Alteration of the Circadian Blood Pressure Pattern 

in Subjects with Chronic Kidney Disease: The Hygia 

Project 

Alfonso Otero, 1 Manuel Dominguez‐Sardiña, 2 Maria 

C. Castiñeira, 3 Juan J. Crespo, 2 Amelia Ferreras, 2 

Artemio Mojon, 4 Diana E. Ayala, 4 Jose R. Fernandez, 4 


1 Complejo Hospitalario Universitario, Orense, ES; 

2 Gerencia de Atención Primaria, Vigo, ES; 3 Gerencia 

de Atención Primaria, Pontevedra, ES; 4 University of 


Usefulness of the Resistive Index in Renal Doppler 

Ultrasonography as an Indicator of Vascular 

Damage in Patients with Risks of Atherosclerosis 

Tatsuo Kawai, Kei Kamide, Miyuki Onishi, Hiroko 

Yamamoto‐Hanasaki, Yoshichika Baba, Kazuhiro 

Hongyo, Izumi Shimaoka, Yuji Tatara, Yasushi Takeya, 

Mitsuru Ohishi, Hiromi Rakugi. Osaka University 

Graduate School of Medicine, Suita, Osaka, JP. 

Intradialytic Hypertension is Not Associated with 

Increased Blood Pressure Variability 

Catherine Kim, Peter N. Van Buren, Robert Toto, Jula 

K. Inrig. University of Texas at Southwestern, Dallas, 

TX, US. 

121

MAY 22 

Posters 


PO-224: 

PO-225: 

PO-226: 

Effect of Vitamin D Supplementation on Blood 

Pressure among HD Patients Undergoing Dialysis 

Bharadwaj Cheruvu, 1 Yap Jason, 1,2 Saklayen 

Mohammad. 1,2 1 Veterans Medical Center, Dayton, OH, 

US; 2 Wright State University, Dayton, OH, US. 

Heme Oxygenase Induction Prevents Endothelial 

Dysfunction and Renal Damage in ec-SOD KO Mice 

Nitin Puri, 1 Tomoko Kawakami, 1 Luca Vanella, 1 Lars 

Bellner, 2 Rita Rezzani, 3 Toru Takahashi, 4 Kiyoshi 

Morita, 4 Nader G. Abraham. 1 1 University of Toledo, 

Toledo, OH, US; 2 New York Medical College, Valhalla, 

NY, US; 3 University of Brescia, IT; 4 Okayama 

University Medical School, Okayama, JP. 

Mean Hemodialysis-Unit Systolic BP is Similar in 

Patients with and without Frequent Intradialytic 


Peter N. Van Buren, Catherine Kim, Robert D. Toto, 

Jula K. Inrig. University of Texas Southwestern 

Medical Center, Dallas, TX, US. 

Kidney and Hypertension 

PO-227: 

PO-228: 

PO-229: 

PO-230: 

PO-231: 

Nighttime Hemodynamics and Arterial Stiffness 

Exert a Powerful Additive Predictive Effect on the 

Occurrence of Microalbuminuria in Hypertension: 

A 6-year Follow-Up Study 

E. Andrikou, C. Tsioufis, C. Thomopoulos, A. Kordalis, 

I. Andrikou, M. Giakoumis, L. Lioni, M. Almiroudi, I. 

Eleftheriadou, C. Stefanadis. Hippokration Hospital, 

Athens, GR. 

Learning Nephrology through Mobile Devices: The 

Nephrology On-Demand Mobile Experience 

Tejas Desai, 1 Maria Ferris. 2 1 East Carolina University 

Brody School of Medicine, US; 2 The University of 

North Carolina at Chapel Hill, US. 

Characteristics of Hypertensive Patients Using 

Either Aliskiren or Other Antihypertensive 

Medications 

Debra F. Eisenberg†, 1 Jinhee Park, 2 Christy Fang, 1 

Jean Lian, 2 Andrea DeVries. 1 1 HealthCore, Inc., 

Wilmington, DE, US; 2 Novartis Pharmaceuticals, East 

Hanover, NJ, US. 

The Dopamine D1-Like Receptors Interact with the 

a 1A Adrenergic Receptor in Human Renal Epithelial 

Tubule Cells 

Riley C. Ennis, Van Anthony M. Villar, Julie A. Jurgens, 

John E. Jones, Pedro A. Jose. Children National 

Medical Center, Washington, DC, US. 

Uncoupled NOS is a Major Source of Renal 

Superoxide in Angiotensin II-Induced Hypertension 

Maria C. Gongora, Li Li, Wei Chen, Kin Lung Siu, 

David G. Harrison. Emory University, Atlanta, GA, 

US. 

122


Posters 

PO-232: 

PO-233: 

PO-234: 

PO-235: 

PO-236: 

PO-237: 

PO-238: 

Loss of SNX5 Impairs Dopamine D 1 Receptor 

Endocytosis and Recycling and Aggravates the 

Blood Pressure in SHR 

Van Anthony M. Villar, 1,2 Ines Armando, 1,2 Lauren 

C. Frazer, 2 Kristen M. Russo, 2 Patricia M. Notario, 2 

Hewang Li, 1,2 Hironobo Sanada, 3 Yingjin Luo, 2 Lauren 

Comisky, 2 Holly Ann Russell, 2 Yu Yang, 1 Pedro A. 

Jose, 1,2 John E. Jones. 1,2 1 Children’s National Medical 

Center, Washington, DC, US; 2 Georgetown University 

School of Medicine, Washington, DC, US; 3 Fukushima 

Medical University School of Medicine, Fukushima, JP. 

Ambulatory Blood Pressure Measurement in 

Patients with Chronic Kidney Disease: Outcomes 

and Correlation with Clinic BP and BpTRU 

Ashok L. Kirpalani, Aditya S. Bhabhe, Dilip A. 

Kirpalani, Hardik K. Shah. Bombay Hospital Institute 

of Medical Sciences, Mumbai, Maharashtra, IN. 

Perinatal Dietary Protein and NaCl on Offspring’s 

Ambulatory Blood Pressure and Renal Injury 

Jong Y. Lee, Silvia H. Azar. Univ of MN School of 

Medicine, Minneapolis, MN, US. 

Effects of a Direct Renin Inhibitor on RRI in 


Francesco Natale, Chiara Cirillo, Chiara Granato, 

Claudia Concilio, Alessandro Siciliano, Luigi Aronne, 

Maria Credendino, Emanuela Lo Priore, Alessandro 

Ranieri, Maria Giovanna Russo, Raffaele Calabrò. 

Second University of Naples, Monaldi Hospital, 

Naples, IT. 

Uncontrolled Hypertension in CKD Patients is 

Associated with Higher Heart Rate 

Alexander Kagan, 1,2,3 Hedy Feibel, 3 Ishay Shoval, 3 

Jayson Rapoport. 1,2 1 Kaplan Medical Center, Rehovot, 

IL; 2 Hebrew University, Jerusalem, IL; 3 ”Meuhedet” 

Sick Fund, IL. 

Analysis of Left Ventricular Function and of 

Coronary Circulation in Relationship to Renal 

Function 

César S. Rosa, 1,2 Bruno B. Pelazza, 1,2 Sebastião R. 

Filho. 1 1 Federal University of Uberlândia, Uberlândia, 

Minas Gerais, BR; 2 Heart Institute of Triangulo 

Mineiro, Uberlândia, Minas Gerais, BR. 

Discrepancies in Hypertension Control Rates 

Evaluated by Means of Office BP and Ambulatory 

BP Monitoring in Hypertensive Patients with and 

without Chronic Kidney Disease 

Manuel Gorostidi, 1 Julian Segura, 2 Alejandro de la 

Sierra, 3 Juan J. de la Cruz, 4 Jose R. Banegas, 4 Luis M. 

Ruilope. 2 1 Hospital Central de Asturias, Oviedo, ES; 

2 Hospital 12 de Octubre, Madrid, ES; 3 Hospital Mutua 

Terrasa, Universidad de Barcelona, Barcelona, ES; 

4 Universidad Autónoma, Madrid, ES. 

123

MAY 22 

Posters 


PO-239: 

PO-240: 

PO-241: 

PO-242: 

Impaired Coronary Microcirculation is Associated 

with Increased Urine Albumin Excretion in 

Untreated Hypertensives 

D. Tsiachris, C. Tsioufis, K. Dimitriadis, D. Rousos, 

I. Tatsis, A. Kordalis, A. Kefala, C. Stefanadis. 


Associations of Renal Hemodynamics with Target 

Organ Damage in Untreated Hypertensives. An 

Invasive Approach 

C. Tsioufis, D. Tsiachris, K. Dimitriadis, D. Rousos, I. 

Tatsis, D. Syrseloudis, G. Latsios, V. Papademetriou, C. 


Albuminuria is Related to Circulating Soluble 

Receptor for Advanced Glycation End Products 

and Biomarkers of Endothelial Function in 


C. Tsioufis, K. Dimitriadis, A. Aggelis, M. Poulakis, A. 

Kefala, A. Kasiakogias, A. Miliou, M. Almiroudi, C. 


Chronic Kidney Disease Education in the 

Community Health Center Setting Improves 

Prescription Filling Rates for Antihypertensive 

Medications 

Paul Bolin, Cindy Christiano, Melanie Hames, 

Tejas Desai, Hsiao Lai, Karen Parker, Rachel Ward, 

Courtland Winborne, Lacy Dean. East Carolina 

University Brody School of Medicine, US. 

Off-target cardiovascular effects of 

non-cardiovascular drugs 

PO-243: 

PO-244: 

Sitagliptin is Associated with Increased Blood 

Pressure in Rats 

Dov Gavish, 1,3 Eyal Leibovitz, 1,3 Yonatan Shrabi, 2,3 

Ehud Grosman, 2,3 Dror Harats. 2,3 1 Wolfson Hospital, 

Holon, IL; 2 Sheba Medical Center, Ramat Gan, IL; 3 Tel 

Aviv Univeristy, Tel Aviv, IL. 

Blood Pressure Evaluation in Oncology and CNS 

Indications: Implementation of ABPM and Home 

BP Telemonitoring 

Jeffrey Heilbraun. Scientific Affairs, Rockville, MD, US. 

124


Posters 












Neutral Hormonal Mechanisms (Renin; Neutral Control; Vasoactive 

Autacoids.......................................................................(PO-310 – PO-312) 




Obesity...........................................................................(PO-331 – PO-339) 








information. 

125

MAY 21 23 

Posters 


Morning 


Featured Posters – Cardiac Structure 

and Function 

Moderators: 

FP-9: 

FP-10: 

FP-11: 

FP-12: 

FP-13: 

John D. Bisognano, MD, PhD, Rochester, NY and 

Robert A. Phillips, MD, PhD, Worcester, MA 

Parallel Deterioration of Albuminuria, Arterial 

Stiffness and Left Ventricular Mass in Essential 

Hypertension: Integrating Target Organ Damage 

E. Andrikou, C. Tsioufis, K. Dimitriadis, D. Flessas, K. 

Kintis, I. Mpafakis, M. Almiroudi, G. Chlapoutakis, M. 

Poulakis, M. Giakoumis, C. Stefanadis. Hippokration 

Hospital, Athens, GR. 

The Prognostic Value of Left Ventricular 

Hypertrophy in the Very Elderly: The PROTEGER 

Study 

Yi Zhang, 1,2 Davide Agnoletti, 1 Julie Peroz, 1 Ari 

Lieber, 1 Pierre Iaria, 1 Athanase D. Protogerou, 3 Michel 

E. Safar, 1 Jacques Blacher. 1 1 Paris Descartes University, 

Paris, FR; 2 Jiaotong University School of Medicine, 

Shanghai, CN; 3 University of Athens, Athens, GR. 

Cornell Product Left Ventricular Hypertrophy 

in Electrocardiogram and Mortality in a General 

Population 

Joji Ishikawa, 1 Shizukiyo Ishikawa, 2 Kazunori Kayaba, 3 

Kazuomi Kario. 1 1 Jichi Medical University School 

of Medicine, Tochigi, JP; 2 Jichi Medical University, 

Tochigi, JP; 3 Saitama Prefectural University, Saitama, 

JP. 

Identification of Myocardial Viability in 

Hypertensive Patients Receiving Beta-Blockers by 

Dobutamine Echocardiography 

Fei Lu, Vitantonio Di Bello, Chunzeng Lu, Mario 

Marzilli, Alberto Balbarini. University of Pisa, IT. 

Targeted Delivery of Endothelial Cells 

Overexpressing IL8RA and IL8RB Receptors 

Promotes Structural and Functional Recovery of 

the Left Ventricle in Rats Following Myocardial 

Infarction 

Peng Li, Dongqi Xing, Kaizheng Gong, Fadi Hage, 

Onyedika John IIonze, Suzanne Oparil, Yiu‐Fai Chen. 

UAB, Birmingham, AL, US. 

126


Posters 


Arterial Structure and Compliance 

PO-245: 

PO-246: 

PO-247: 

PO-248: 

PO-249: 

PO-250: 

PO-251: 

PO-252: 

Vascular Injury in Hypertensive Patients. are Men 

and Women Equal PARITE Study 

Claire Mounier‐Vehier, 1 Simon Tabassome, 2 

Dominique Guedj, 3 Assya Achouba, 4 Emmanuel 

Ghannad, 5 Stéphane Quéré, 4 Maxime Guenoun. 6 

1 Cardiologic Hospital, Lille, FR; 2 CHU Saint-Antoine, 

Paris, FR; 3 Cardiologist, Paris, FR; 4 Novartis Pharma 

SAS, Rueil-Malmaison, FR; 5 Cardiologist, Gif sur 

Yvette, FR; 6 Cardiologist, Marseille, FR. 

Peripheral Pulse Pressure Strongly Correlates with 

Central Systolic Blood Pressure in Adults: Bogalusa 

Heart Study 

Rebecca I. Clark, Camilo Fernandez, Gerald S. 

Berenson, Thomas D. Giles, Gary E. Sander. Tulane 

University Health and Sciences Center, New Orleans, 

LA, US. 

Addition of Eplerenone to RAAS Blockade in 

Patients with CKD and Proteinuria Correlates with 

Baseline Vascular Compliance 

Debbie L. Cohen†, Kevin A. Sterling, Raymond R. 

Townsend. University of Pennsylvania, Philadelphia, 

PA, US. 

Arterial Stiffness Evaluation in HIV Patients 

Antonio J. Delgado‐Leon, 1 Zenaida Castillo, 1 Jose M. 

Rojas, 1 Susana I. Celis, 2 Jennifer Moreno. 1 1 University 

of Carabobo, Valencia, Carabobo, VE; 2 Instituto 

Docente de Urologia, Valencia, Carabobo, VE. 

A New Vibrational Approach for Carotid Pulse Wave 

Velocity Assessment 

Francesco Faita, 1 Vincenzo Gemignani, 1 Elisabetta 

Bianchini, 1 Rosa Maria Bruno, 2 Lorenzo Ghiadoni. 2 

1 Institute of Clinical Physiology – National Research 

Council, Pisa, IT; 2 University of Pisa, Pisa, IT. 

Central-Peripheral Blood Pressure Differences are 

Greater in Hispanics and African-Americans 

Haroon Kamran, Louis Salciccioli, Rinkesh Patel, 

Mohamed Munshi, Stephen Littman, Jason Lazar. 

SUNY Downstate Medical Center, Brooklyn, NY, US. 

The Left Ventricular Septal – Aortic Angle 

Relationship with the Augmentation Index and 

Central Blood Pressures 

Mediha Ibrahim, Kinda Venner-Jones, Haroon 

Kamran, Louis Salciccioli, Carl Bastien, Jason Lazar. 

SUNY Downstate Medical Center, Brooklyn, NY, US. 

Differences in Post-Ischemic Reactive Hyperemia 

Tissue Oxygen Saturation between Normals and 

Hypertensive Subjects 

Revathy Thangaratnavel, Haroon Kamran, Louis 

Salciccioli, Wah Wah Htun, Ilir Maraj, Edinrin Rae 

Obasare, Jason Lazar. Downstate Medical Center, 

Brooklyn, NY, US. 

127

MAY 21 23 

Posters 


Morning 

PO-253: 

PO-254: 

PO-255: 

PO-256: 

PO-257: 

PO-258: 

PO-259: 

The Relationship between Impaired Lung Function 

and Cardiac Function in Older Individuals 

Barry J. McDonnell, 1 Iain Munnery, 2 Margaret M. 

Munnery, 2 Charlotte Bolton, 2 Carmel M. McEniery, 3 

Ian B. Wilkinson, 3 John R. Cockcroft. 2 1 University 

of Wales Institute, Cardiff, Cardiff, GB; 2 Cardiff 

University, Cardiff, GB; 3 University of Cambridge, 

Cambridge, GB. 

Hyperemia Induced Changes in Carotid-Radial 

Pulse Wave Velocity before and after Pre and Post 

Ischemic Conditioning 

Nwamaka Onuigbo, Haroon Kamran, Louis Salciccioli, 

Abhishek Sharma, Jason Lazar. SUNY Downstate 

Medical Center, Brooklyn, NY, US. 

The Predictive Value of Carotid Artery Features over 

Traditional Risk Factors and Endothelial Function 

Oana Sandu, 1 Iulian Nastac, 2 Jaime Uribarri. 1 1 MSSM, 

NY, US; 2 UPB, Bucharest, RO. 

Determinants of Central Reflected Pressure Waves 

Sirisha Srikakarlapudi, Minesh Rajpal, Shaila Karan, 

Peter J. Osmond, Joseph L. Izzo. SUNY at Buffalo, 

Buffalo, NY, US. 

Regular Exercise-Induced Upregulation of 

Circulating Endothelial Progenitor Cells Attenuates 

Age-Related Decline in Arterial Elasticity in Healthy 

Men 

Jun Tao, Zhen Yang. The First Affilaited Hospital. Sun 

Yat-Sen University, CN. 

Subendocardial Viability Ratio as an Index of 

Impaired Coronary Flow Reserve in Untreated 

Hypertensives 

D. Tsiachris, C. Tsioufis, K. Dimitriadis, D. Rousos, 

A. Kordalis, I. Anastasopoulos, D. Syrseloudis, C. 


Impaired Coronary Microcirculation is Not 

Accompanied by Adverse Vascular Remodeling in 

Untreated Hypertensives 

D. Tsiachris, C. Tsioufis, D. Rousos, C. Thomopoulos, 

A. Kasiakogias, A. Kordalis, G. Latsios, C. Stefanadis. 


Blood Pressure Measurement/Monitoring 

PO-260: 

Comparison of Central Hemodynamics between 

A_PULSE and Other Two Tonometry-Based Devices 

Yi Zhang, 1,2 Davide Agnoletti, 1 Julie Peroz, 1 Ari 

Lieber, 1 Michel E. Safar, 1 Paolo Salvi, 3,4 Jirar 

Topouchian, 1 Jacques Blacher. 1 1 Paris Descartes 

University, Paris, FR; 2 Jiaotong University School of 

Medicine, Shanghai, CN; 3 University of Nancy, Nancy, 

FR; 4 University of Bologna, Bologna, IT. 

128


Posters 

PO-261: 

PO-262: 

PO-263: 

PO-264: 

PO-265: 

PO-266: 

PO-267: 

Two Office Blood Pressure Readings Taken on 

Each of Two Visits are Not Enough for an Accurate 

Estimation and an Adequate Hypertension 

Diagnosis 

María M. Martínez, 1 María T. Díaz, 1 María T. Ríos, 1 

Rocío Del Tío, 1 Jesús Barros, 1 Victoria Mota, 1 Isabel 

Bueno, 1 Moncho Velhas, 1 Javier Pérez, 2 Ignacio 

Alonso. 2 1 Sergas (Health Department of Galicia), ES; 

2 University of Vigo, ES. 

Prevalence of Self-Monitoring Blood Pressure 

among Adults – Healthstyles, 2005 and 2008 

Carma Ayala, Xin Tong, Nora L. Keenan. CDC/ 

NCCDPHP/DHDSP, Atlanta, GA, US. 

Prognostic Value of Clinic and Ambulatory Blood 

Pressure Measurements in Resistant Hypertension 

Diana E. Ayala, 1 Ramon C. Hermida, 1 Artemio 

Mojon, 1 Luisa Chayan, 2 Maria J. Dominguez, 3 Maria 

J. Fontao, 1 Ignacio Alonso, 1 Jose R. Fernandez. 1 

1 University of Vigo, Vigo, ES; 2 Urgencias Sanitarias 

061 Galicia, Santiago, ES; 3 Policlinica La Rosaleda, 

Santiago, ES. 

Can Personal Exposures to Higher Nighttime 

and Early Morning Temperatures Increase Blood 

Pressure 

Robert D. Brook, 1 Hwashin H. Shin, 2 Robert L. Bard, 1 

Richard T. Burnett, 2 Alan Vette, 3 Carry Croghan, 3 

Ron Williams. 3 1 University of Michigan, US; 2 Health 

Canada, CA; 3 USEPA, US. 

24-h Ambulatory Blood Pressure and 

Cardiovascular Events in Elderly Hypertensive 

Patients Followed-Up for Seven Years 

Jose Mesquita Bastos, 1 Susana Bertoquini, 2 Jorge 

Polonia. 3 1 Universidade de Aveiro, Aveiro, PT; 

2 Faculdade Psicologia e Ciências da Educação, PT; 

3 Faculdade de Medicina do Porto, PT. 

Total Peripheral Resistance and its Relationship with 

Hypertension in Patients with Severe Sleep Apnea 

Ricardo M. Cabrera Sole, 1 Ramon Coloma, 1 Caridad 

Turpin Lucas, 1 Ana Galdamez Nuñez, 2 Erik Luepke, 3 

Juan Cañas, 4 Manuel Aguilera Saldaña. 1 1 University 

General Hospital of Albacete, Albacete, ES; 2 Health 

Center of Villacerrada, Albacete, ES; 3 University 

General Hospital “La Paz”, Madrid, ES; 4 Health Center 

No. 3, Albacete, ES. 

Patients with Hypertensive Crisis Have Higher Risk 

Following First Month after the Crisis Compared 

with Hypertensive Patients at Similar Blood 

Pressure 

Ricardo M. Cabrera Sole, 1 Caridad Turpin Lucas, 1 Ana 

Galdamez Nuñez, 2 Juan Cañas, 3 Manuel Aguilera 

Saldaña. 1 1 University General Hospital of Albacete, 

Albacete, ES; 2 Health Center of Villacerrada, Albacete, 

ES; 3 Health Center No. 3, Albacete, ES. 

129

MAY 21 23 

Posters 


Morning 

PO-268: 

PO-269: 

PO-270: 

PO-271: 

PO-272: 

PO-273: 

PO-274: 

PO-275: 

PO-276: 

Correlation between Left Ventricular Mass and 

Ambulatory or Clinic Blood Pressure in Very Elderly 

Subjects 

S. Carugo, 1 A. Esposito, 1 D. Solari, 1 M. Maisaidi, 1 

G. Mancia. 2 1 ASP IMMeS e PAT, University of Milan, 

Milan, IT; 2 University Milano-Bicocca, S. Gerardo 

Hospital, Monza, IT. 

Clinical and Ambulatory Blood Pressure Values in 

Centenaries 

S. Carugo, 1 A. Esposito, 1 D. Solari, 1 M. Maisaidi, 1 

G. Mancia. 2 1 ASP IMMeS e PAT, University of Milan, 

Milan, IT; 2 University Milano-Bicocca, S. Gerardo 

Hospital, Monza, IT. 

Usefulness of Automated Office Blood Pressure 

Measurement by BpTRU for the Diagnosis of 


Giuseppe Crippa, 1 Antonino Cassi, 1 Matteo Bosi, 2 

Maria Luisa Fares. 1 1 Guglielmo da Saliceto Hospital, 

Piacenza, IT; 2 Universita’ Cattolica, Piacenza, IT. 

Effects of Aliskiren- and Ramipril-Based Treatment 

on Central Aortic Blood Pressure in Systolic 


Daniel Duprez†, 1 Fabio Baschiera, 2 Alan Charney, 3 

InYoung Baek, 2 Patrick Brunel. 2 1 University of 

Minnesota, Minneapolis, MN, US; 2 Novartis Pharma 

AG, Basel, CH; 3 Novartis Pharmaceutical Corporation, 

East Hanover, NJ, US. 

Apparent Treatment Resistant Hypertension in a 

Community-Based Practice Network 

Brent Egan†, Yumin Zhao, W. Adam Brzezinski, 

Benjamin Clyburn, Jan Basile, Daniel Lackland. 

Medical University of South Carolina, Charleston, SC, 

US. 

Progression from Pre-Hypertension to Hypertension 

is Accelerated in African Americans 

Anbesaw Selassie, C. Shaun Wagner, Brent Egan†. 

Medical University of South Carolina, Charleston, US. 

Clinical Characteristics of Patients with 

Uncontrolled and Apparent Treatment Resistant 

Hypertension: NHANES 2005-2008 

Brent Egan†, 1 Yumin Zhao, 1 R. Neal Axon, 1 Keith 

Ferdinand. 2 1 Medical University of South Carolina, 

Charleston, SC, US; 2 Emory University, Atlanta, GA, 

US. 

Impacting Population Cardiovascular Health 

through a Community-Based Practice Network: 

Update on An-ASH-Supportive Collaborative 

Brent Egan†, Marilyn Laken, Daniel Lackland. Medical 

University of S.C., Charleston, SC, US. 

Estimation of Central Cardiovascular Parameters 

from Brachial Cuff Pressure Waveform 

Kenji Fujii, 1 Tatsuya Kobayashi, 1 Toshihiko Ogura, 1 

Hirofumi Tomiyama, 2 Akira Yamashina. 2 1 Omron 

Healthcare Co., Ltd, JP; 2 Tokyo Medical University, JP. 

130


Posters 

PO-277: 

PO-278: 

PO-279: 

PO-280: 

PO-281: 

PO-282: 

PO-283: 

Blood Pressure Measurement-Device and 

Calibration Patterns in Home Health Care 

F. W. Germino, 1,2 Megan M. Germino. 3 1 Orland 

Primary Care Specialists, Orland Park, IL, US; 2 Rush 

School of Medicine, Chicago, IL, US; 3 Rush University, 

Chicago, IL, US. 

ABPM in Octogenarians 

Eduardo Podjarny, 1 Jacques Bernheim, 1,2 Eliezer 

Golan. 1,2 1 Meir Medical Center, Kfar-Saba, IL; 2 Tel- 

Aviv University, Tel-Aviv, IL. 

Impact of Initial Antihypertensive Treatment with 

a Single-Pill Combination on Blood Pressure Goal 

Attainment: A Matched Cohort Study 

Alan H. Gradman†, 1 Hélène Parisé, 2 Marie‐Hélène 

Lafeuille, 2 Heather Falvey, 3 Patrick Lefebvre, 2 Mei 

Sheng Duh. 2 1 Temple University School of Medicine 

(Clinical Campus), Pittsburgh, PA, US; 2 Analysis 

Group, Inc., Boston, MA, US; 3 Novartis Pharma AG, 

Basel, CH. 

Influence of Dipping Classification on Fasting 

Glucose in Subjects with and without Elevated 

Ambulatory Blood Pressure: The Hygia Project 

Manuel Dominguez‐Sardiña, 1 Pedro A. Callejas, 1 

Peregrina Eiroa, 1 Juan J. Crespo, 1 Jose L. Salgado, 1 

Alfonso Otero, 2 Maria J. Fontao, 3 Sonia Lorenzo, 3 


1 Gerencia de Atención Primaria, Vigo, ES; 2 Complejo 

Hospitalario Universitario, Orense, ES; 3 University of 


Influence of Duration of Ambulatory Blood Pressure 

Monitoring (48 vs. 24 Hours) on Cardiovascular 

Risk Assessment 

Ramon C. Hermida, Diana E. Ayala, Maria J. Fontao, 

Artemio Mojon, Jose R. Fernandez. University of Vigo, 

Vigo, ES. 

Reproducibility of Nocturnal Blood Pressure 

Dipping is Influenced by Day-to-Day Changes in 

Sleep Quality 

Alan L. Hinderliter, 1 Faye S. Routledge, 2 James A. 

Blumenthal, 2 William K. Wohlgemuth, 3 Andrew 

Sherwood. 2 1 University of North Carolina School 

of Medicine, Chapel Hill, NC, US; 2 Duke University 

Medical Center, Durham, NC, US; 3 University of 

Miami School of Medicine, Miami, FL, US. 

Using Telephonic Outreach to Improve Blood 

Pressure Control 

Timothy Ho, 1 Joel Handler, 1 Michael Kanter, 2 Kristi 

Reynolds, 3 Ruthie Goldberg, 2 Joe Kimura. 1 1 Kaiser 

Permanente Medical Center, Anaheim, CA, US; 

2 Southern California Permanente Medical Group, 

Pasadena, CA, US; 3 Kaiser Permanente Southern 

California, Pasadena, CA, US. 

131

MAY 21 23 

Posters 


Morning 

PO-284: 

PO-285: 

PO-287: 

PO-288: 

PO-289: 

PO-290: 

PO-291: 

Relationship between the Reduction of Left 

Ventricular Mass Index and the Changes in Sleep 

Blood Pressure with Sodium Restriction and/or 

Diuretic Treatment 

Joji Ishikawa, Kazuo Eguchi, Satoshi Hoshide, 

Kazuyuki Shimada, Kazuomi Kario. Jichi Medical 

University School of Medicine, Tochigi, JP. 

BpTRU – A Useful Alternative to 24 Hour 

Ambulatory Blood Pressure Monitoring in 

Evaluation and Management of Hypertension in 

India 

Dilip A. Kirpalani, Hardik K. Shah, Aditya S. Bhabhe, 

Ashok L. Kirpalani. Bombay Hospital Institute of 

Medical Sciences, Mumbai, Maharashtra, IN. 

Effects of Traffic-Related Particles on Blood Pressure 

and DNA Methylation 

Denise P. Lamoureux, Edgar A. Diaz, Yeonseung 

Chung, Mark S. Long, Joy Lawrence, Vasileios 

Papapostolou, Phuong‐son Nguyen, John J. Godleski. 

Harvard School of Public Health, US. 

Ambulatory Blood Pressure in the Biological Time 

Structures 

Mary S. Lee, 1 John S. Lee, 2 Jong Y. Lee, 3 Franz 

Halberg. 4 1 Northwestern Univ. School of Medicine, 

Chicago, IL, US; 2 Univ of Minnesota School of 

Medicine, Minneapolis, MN, US. 


Hypertensive Smokers: Evidence of Impaired Night- 

Response 

Linda Landini, 1 Aurelio Leone. 2 1 University of Pisa, 

Pisa, Pi, IT; 2 City Hospital, Massa, Ms, IT. 

Oscillometric and Auscultatory Blood Pressure 

Measurements before and after Acute Exercise and 

Rest in the Elderly 

Leandra Gonçalves Lima, Iara Felício Anunciato, 

Fernanda Jatte, Júlio Cesar Moriguti, Eduardo Ferriolli, 

Nereida K. Costa Lima. Ribeirao Preto Medical School 

Sao Paulo University, Ribeirao Preto, SP, BR. 

Home Blood Pressure Monitoring Requires 

Feedback to Patients to Improve Treatment of 


Alexander G. Logan, 1 Warren McIsaac, 2 Jane Irvine, 3 

Andras Tisler, 4 Denice Feig, 5 Joseph Cafazzo. 6 1 Mount 

Sinai Hospital, Toronto, ON, CA; 2 Mount Sinai 

Hospital, Toronto, ON, CA; 3 York University, Toronto, 

ON, CA; 4 Semmelweis University, Budapest, HU; 

5 Mount Sinai Hospital, Toronto, ON, CA; 6 Toronto 

General Hospital, Toronto, ON, CA. 

132


Posters 

PO-292: 

PO-293: 

PO-294: 

PO-295: 

PO-297: 

PO-298: 

PO-299: 

Blood Pressure in Firefighters 

Steven M. Moffatt†, 1,4 Suchita Garg, 2 Michael J. 

Epstein, 2 Nandini Hadker, 2 Lora Lex, 1,4 Feride Frech- 

Tamas. 3 1 Indianapolis Fire Department, Indianapolis, 

IN, US; 2 United BioSource Corporation, Lexington, 

MA, US; 3 Novartis Pharmaceuticals, East Hanover, NJ, 

US; 4 Public Safety Medical, Indianapolis, IN, US. 

Long-Term Effects of Telemetric Blood Pressure 

Monitoring in Adequately Treated Patients with 

Arterial Hypertension 

Claas L. Neumann, Eike M. Rieken, Jan‐Marc Schmidt 

Thrun, Egbert G. Schulz. Nephrologisches Zentrum 

Göttingen, Göttingen, Niedersachsen, DE. 

Relationship between Central and Peripheral Blood 

Pressure in Type 2 Diabetic and Prediabetic Patients 

Anna Oliveras, 1,3 Julián Segura, 3 Carmen Suárez, 3 

Manuel Gómez, 3 Luis García‐Ortiz, 3 Nieves Martell, 3 

María Abad, 3 Luis Vigil, 3 David Ferrero, 3 Juan J. de 

la Cruz, 2 Luis M. Ruilope, 3 Alejandro de la Sierra. 3 

1 Hosp.del Mar. Parc Salut Mar, Barcelona, ES; 

2 Autonomous University of Madrid, ES; 3 On Behalf of 

the PRESCEN Study, ES. 

Clinical Characteristics, Blood Pressure Control, 

and Antihypertensive Treatment Patterns among 

Elderly Patients with Hypertension 

Sujata P. Sarda, 1 Si‐Tien Wang, 1 Priyanka 

Ramamurthy, 1 Robert Wei, 1 Jinhee Park†, 2 L. M. 

Andrews, 2 Feride Frech‐Tamas, 2 Mei Sheng Duh. 1 

1 Analysis Group, Inc., Boston, MA, US; 2 Novartis 

Pharmaceuticals Corporation, East Hanover, NJ, US. 

Antihypertensive Effectiveness of Combination 

Lercanedipine with Diltiazemi in Patients with Mild 

to Moderate Arterial Hypertension 

Oksana L. Rekovets, Yuriy M. Sirenko, Anna S. 

Dobrokhod, Galina F. Primak, Alla S. Vaschilko, 

Evhenia A. Pavlyuk. Institute of Cardiology, Kyiv, UA. 

Higher Night-Time Blood Pressure and Cardiac 

Damage in 1176 Patients: Effects of BMI and Drug 

Therapy 

Riccardo Sarzani, Federico Guerra, Massimiliano 

Fedecostante, Paolo Barbatelli, Elena Giannini, Letizia 

Lancioni, Emma Espinosa, Paolo Dessì‐Fulgheri. 


Seasonality of 24 H, Daytime and Night-Time Blood 

Pressure: Summer Does Not Always Mean Lower 

Federico Guerra, Massimiliano Fedecostante, Letizia 

Lancioni, Elena Giannini, Paolo Barbatelli, Emma 

Espinosa, Paolo Dessì‐Fulgheri, Riccardo Sarzani. 


133

MAY 21 23 

Posters 


Morning 

PO-300: 

PO-301: 

PO-302: 

PO-303: 

PO-304: 

PO-305: 

PO-305A: 

Improvement in Hypertension Control after a 2-Year 

Participation in a Web-Based Program on High BP 

Management 

Julian Segura, 1 Manuel Gorostidi, 2 Alejandro de la 

Sierra, 3 Jose R. Banegas, 4 Juan J. de la Cruz, 4 Luis 

M. Ruilope. 1 1 Hospital 12 de Octubre, Madrid, ES; 

2 Hospital Central de Asturias, Oviedo, ES; 3 Hospital 

Mutua Terrasa, Universidad de Barcelona, Barcelona, 

ES; 4 Universidad Autónoma, Madrid, ES. 


Prehypertension 

Gabor Simonyi, Mihaly Medvegy. Flor Ferenc Hospital 

of County Pest, Kistarcsa, HU. 

Diagnostic Accuracy of Home Versus Ambulatory 

Blood Pressure Monitoring 

George S. Stergiou, Efthimia G. Nasothimiou, Dimitrios 

Tzamouranis, Vagia Rarra, Leonidas G. Roussias. 

University of Athens, Athens, GR. 

Patients’ Preference for Out-of-Office Blood 

Pressure Evaluation Method: Ambulatory or Home 

Monitoring 

Efthimia G. Nasothimiou, Nikolaos Karpettas, 

Antonios Destounis, George S. Stergiou. University of 

Athens, Athens, GR. 

Preditive Value of Ambulatory Blood Pressure for 

Cardiovascular Events in Hypertensive Patients after 

a First Event 

Tiago Teixeira, 1 José Nuno Figueiredo, 1 Jose Mesquita 

Bastos, 1 Jose Nobre Santos, 1 Jorge Polonia. 2 1 Hospital 

Infante D.Pedro, EPE, Aveiro, PT; 2 Faculdade de 

Medicina do Porto, PT. 

Methods for Fast and Accurate Normalization of 

Real-World Prescription Data: A Report from the 

O’QUIN Hypertension Initiative 

C. Shaun Wagner, Brent Egan. Medical University of 

South Carolina, Charleston, SC, US. 

High Blood Pressure Treatment among Black and 

White Stroke Patients 

Andrea D. Boan, David L. Bachman, Robert J. Adams, 

Brent M. Egan, Joyce S. Nicholas, Andrew B. Lawson, 

Daniel T. Lackland. Medical University of South 

Carolina, Charleston, SC, US. 



Coagulation/Thrombosis; Growth 

Factors; Ion Channels) 

PO-306: 

Pharmacological Inhibition of PI3Kg Reduces Blood 

Pressure by a Vasorelaxant Akt/LTCC Mechanism 

Daniela Carnevale, 1 Giada Mascio, 1 Giuseppe Cifelli, 1 

Carmine Vecchione, 1 Giuseppe Lembo. 1,2 1 IRCCS 

Neuromed, Pozzilli, IT; 2 ”Sapienza” University of 

Rome, Rome, IT. 

134


Posters 

PO-307: 

PO-308: 

Hypertension Induces b-Amyloid Deposition and 

Cognitive Impairment by Activating RAGE in Brain 

Endothelium 

Daniela Carnevale, 1 Giada Mascio, 1 Giuseppe Cifelli, 1 

Shi Du Yan, 3 Giuseppe Lembo. 1,2 1 IRCCS Neuromed, 

Pozzilli, IT; 2 ”Sapienza” University of Rome, Rome, IT; 

3 Columbia University, New York, US. 

Downmodulation of Peroxiredoxin-3 Expression in 

Cardiac Fibroblasts by Angiotensin II 

Paul J. Lijnen, Jos F. van Pelt. University of Leuvan 

(KULeuven), Leuven, BE. 

Lipid Metabolism 

PO-309: 

Does the Association between Lipid Profile and 

Obesity Indices Vary through Decades in Essential 


Stella Maria Kyvelou, 1 Gregory Vyssoulis, 1 Eva 

Karpanou, 2 I. Skoumas, 1 C. Stefanadis. 1 1 1st 

Cardiology Clinic Athens University Hippokration 

Hospital Athens Greece, GR; 2 1st Cardiology Clinic 

Onassis Cardiosurgery Center Athens, GR. 

Neural hormonal Mechanisms (Renin; 

Neural Control; Vasoactive Autacoids) 

PO-310: 

PO-311: 

PO-312: 

Long Term Follow-Up of Patients with Postural 

Orthostatic Tachycardia Syndrome 

Joao Freitas, 1,2 Alexandra Sousa, 1 Ana Lebreiro, 1 Maria 

Julia Maciel, 1,2 Francisco Rocha Goncalves. 2 1 Hospital 

de Sao Joao -E.P.E., Porto, PT; 2 Unoversidade do Porto, 

Porto, PT. 

Resistant Hypertension and Intravascular Volume 

Expansion 

Guilherme Augusto Mariano Pego, João Bernardo Pego, 

Maria Fátima Leitão, Helia Martins, Nadia Moreira, 

Luis Augusto Providência. University Hospital of 

Coimbra, PT. 

Expression of the Renin-Angiotensin System in a 

Human Placental Cell Line 

Nan Pan, 1 Wayne L. Frome, 1 Richard A. Dart, 1 Duane 

A. Tewksbury, 1 Jiangming Luo. 2 1 Marshfield Clinic 

Research Foundation, Marshfield, WI, US; 2 Marshfield 

Clinic, Marshfield, WI, US. 

135

MAY 21 23 

Posters 


Morning 

Non-Pharmacological Therapy 

(Alternative Medicine; Diet; Physical 

Activity) 

PO-313: 

PO-314: 

PO-315: 

PO-316: 

PO-317: 

PO-318: 

PO-319: 

The HARMONY Study: Hypertension Analysis of 

Stress Reduction Using Mindfulness Meditation and 

Yoga 

Kimberly C. Blom, 1 Brian Baker, 2 Jane Irvine, 4 Susan 

Abbey, 2 Beth Abramson, 3 Martin Myers, 1 Nancy 

Perkins, 1 Sheldon W. Tobe. 1 1 Sunnybrook Health 

Sciences Centre, Toronto, ON, CA; 2 University Health 

Network, Toronto, ON, CA; 3 St. Michael’s Hospital, 

Toronto, ON, CA; 4 York University, Toronto, ON, CA. 

Impact of Smoking Cessation on Nocturnal Blood 

Pressure 

Patrick T. Campbell, Carla J. Rash, Sheila M. Alessi, 

Nancy M. Petry, William B. White. University of 

Connecticut, Farmington, CT, US. 

Leisure Physical Activity and Emergent 

Cardiovascular Risk Factors in Hypertensive 

Patients 

Cristiana Catena, GianLuca Colussi, Andrea Russo, 

Gabriele Brosolo, Leonardo A. Sechi. University of 

Udine, IT. 

Aerobic Exercise Training Improves Renal Function 

in African Americans 

Keith M. Diaz, 1 Deborah L. Feairheller, 1 Kathleen 

M. Sturgeon, 1 Praveen Veerabhadrappa, 1 Sheara 

Williamson, 1 Jan Kretzschmar, 1 Michael D. Brown. 1 

1 Temple University, Philadelphia, PA, US; 2 Temple 

University, Philadelphia, PA, US. 

Actions to Control Hypertension among Adults with 


Jing Fang, Nora L. Keenan. CDC, Atlanta, GA, US. 

Exercise Capacity is Inversely Related to Mortality 

Risk in Hypertensive Individuals with Sleep Apnea 

Peter Kokkinos, 1,2,3 Shikha Khosla, 1 Marshal Balish, 1 

Raya Kheirbek, 1 Helen Sheriff, 1 Eric Nylen, 1,3 

Charles Faselis. 1,3 1 Veterans Affairs Medical Center, 

Washington, DC, US; 2 Georgetown University 

School of Medicine, Washington, DC, US; 3 George 

Washington University School of Medicine, 


Heart Rate Recovery, Fitness and Mortality Risk in 

Hypertensive Individuals 

Peter Kokkinos, 1,2,3 Charles Faselis, 1,3 Michael 

Doumas, 1,3 Ross Fletcher, 1,2 Andreas Pittaras, 1 

Athanasios Manolis, 1 Rhea Kheirbek, 1 Vasilios 

Papademetriou. 1,2 1 Veterans Affairs Medical Center, 

Washington, DC, US; 2 Georgetown University 

School of Medicine, Washington, DC, US; 3 George 

Washington University, Washington, DC, US. 

136


Posters 

PO-321: 

PO-322: 

The Cost-Effectiveness of Interventions Designed to 

Reduce Sodium Intake 

Guijing Wang, Darwin Labarthe. Centers for Disease 

Control and Prevention, Atlanta, GA, US. 

Seasonal Effects of Blood Pressure in 

Postmenopausal Women 

Adrian D. Wood, 1 Frank Thies, 1 William D. Fraser, 2 

Lorna Aucott, 1 Karen R. Secombes, 1 William G. 

Simpson, 3 David M. Reid, 1 Helen M. Macdonald. 1 

1 University of Aberdeen, Aberdeen, GB; 2 University of 

Liverpool, Liverpool, GB; 3 Aberdeen Royal Infirmary, 

Aberdeen, GB. 

Nutrition and Cardiovascular 

Prevention 

PO-323: 

PO-324: 

PO-325: 

PO-325A: 

PO-326: 

Antihypertensive Effect of Dietary Integration with 

Grana Padano Cheese in Hypertensive Patients 

Giuseppe Crippa, 1 Matteo Bosi, 2 Cassi Antonino, 1 

Lucia Fiorentini, 2 Filippo Rossi. 2 1 Guglielmo da 

Saliceto Hospital, Piacenza, IT; 2 Universita’ Cattolica 

del Sacro Cuore, Piacenza, IT. 

Abnormal Circadian Blood Pressure Variability in 

Healthy Adults: A Function of Weight Gain, Increase 

in Waist Circumference and Insulin Resistance 

Alok K. Gupta, 1 Germaine G. Cornelissen‐Guillaume, 2 

William D. Johnson, 1 Frank L. Greenway, 1 Darcy 

Johannsen, 1 Eric Ravussin. 1 1 Pennington Biomedical 

Research Center, Louisiana State University System, 

Baton Rouge, LA, US; 2 University of Minnesota, 

Minneapolis, MN, US. 

Endothelial Dysfunction in Healthy Adults: 

A Function of Weight Gain, Increase in Waist 

Circumference and Insulin Resistance 

Alok K. Gupta, William D. Johnson, Darcy Johannsen, 

Eric Ravussin. Pennington Biomedical Research 

Center, Louisiana State University System, Baton 

Rouge, LA, US. 

Dysglycemia Induces Abnormal Circadian 

Variability of Blood Pressure 

Alok K. Gupta, 1 Kathirvel Gopalakrishnan, 2 Sivarajan 

Kumarasamy, 2 William D. Johnson, 1 Bina Joe. 2 

1 Pennington Biomedical Research Center, Louisiana 

State University System, Baton Rouge, LA, US; 

2 University of Toledo College of Medicine, Toledo, 

OH, US. 

Relationship between Salt Intake and Central 

Aortic Hemodynamics in a Cohort of Untreated 


Jorge J. Polonia, Jose A. Silva, Susana P. Bertoquini, 

Barbosa Loide. Faculdade Medicina Porto, Matosinhos 

Porto, PT. 

137

MAY 21 23 

Posters 


Morning 

PO-327: 

PO-328: 

PO-329: 

PO-330: 

Effect of Lifestyle Modification in Menopausal 

Women with Obesity, Hypertension, Autonomic and 

Endothelial Dysfunction 

Rosa M. Santos, 1 Joao Freitas, 1 Agostinho Monteiro, 3 

Espiga Macedo, 3 Eduardo Tejera, 2 Irene Rebelo. 2 

1 Hospital S Joao, Porto, PT; 2 Faculty Pharmacy, Porto, 

PT; 3 Faculty Medicine, Porto, PT. 

At Risk Older Latino Men and Women: Blood 

Pressure, Body Mass Index and DASH Accordance 

Beth A. Staffileno, 1 Christy Tangney, 1 David X. 

Marquez, 2 Louis Fogg, 1 Eduardo E. Bustamante, 2 

Martha Clare Morris, 1 Ruby Hoyem, 1 Alexis 

Manning, 1 JoEllen Wilbur. 1 1 Rush University Medical 

Center, Chicago, IL, US; 2 University of Illinois at 

Chicago, Chicago, IL, US. 

Medical Avatar Can Select Patients with 

Cardiovascular Risk Factors 

Jerzy T. Tyszkiewicz, Bartosz Symonides, Zbigniew 

Gaciong. Medical University of Warsaw, Warsaw, PL. 

Aerobic Exercise Training Improves Endothelial 

Function in Pre-Hypertensive African Americans 

Sheara T. Williamson, Deborah L. Feairheller, Kathleen 

M. Sturgeon, Praveen Veerabhadrappa, Michael 

D. Brown, Jan Kretzschmar. Temple University, 

Philadelphia, PA, US. 

Obesity 

PO-331: 

PO-332: 

PO-334: 

PO-335: 

The Effect of BMI on the Systemic Catecholamine 

and Haemodynamic Response to Increased 

Sympathetic Activity in Young Adults: A Pilot Study 

James M. Coulson†, John R. Cockcroft. Cardiff 

University, Cardiff, Wales, GB. 

Aldosterone Release is Positively Correlated with 

Increasing Body Weight in Patients with Resistant 


Tanja Dudenbostel, Maria Czarina Acelajado, Roberto 

Pisoni, Suzanne Oparil, David A. Calhoun. Vascular 

Biology and Hypertension, University of Alabama at 


Beta2-Adrenoceptor Polymorphisms (Arg16Gly) 

Accompanying High Plasma Norepinephrine is 

Related to Cardiovascular and Renal Complications 

in Obese Subjects 

Kazuko Masuo, 1 Hiromi Rakugi, 2 Toshio Ogihara, 2 

Murray D. Esler, 1 Gavin W. Lambert. 1 1 Baker IDI 

Heart & Diabetes Institute, Melbourne, VIC, AU; 

2 Osaka University Graduate School of Medicine, Suita, 

Osaka, JP. 

Efficacy of an Amlodipine/Olmesartan Medoxomil 

Algorithm on BP Control in Obese Patients 

Uncontrolled by Monotherapy 

Joel M. Neutel†, 1 Willa Hsueh, 2 Ali Shojaee, 3 William F. 

Waverczak, 3 Jen‐Fue Maa. 3 1 Orange County Research 

Center, US; 2 The Methodist Hospital Research 

Institute, US; 3 Daiichi Sankyo, Inc., US. 

138


Posters 

PO-336: 

PO-337: 

PO-338: 

PO-339: 

Resolution of Hypertension after Adjustable Gastric 

Banding – 1 Year Interim Results of the LAP-BAND 

AP® EXperience (APEX) Study 

John Dixon, 1 Michael Oefelein, 2 Ted Okerson†. 2 

1 Monash University, Melbourne, AU; 2 Allergan, Inc, 

Irvine, CA, US. 

Initial Aliskiren/HCTZ Combination Therapy 

Lowers BP in Obese Patients with Stage 2 

Hypertension and Type 2 Diabetes 

Raymond R. Townsend, 1 Alan Forker, 2 Thomas 

Severin, 3 Cheraz Cherif Papst, 3 Anthony Yadao. 4 

1 University of Pennsylvania Medical Center, 

Philadelphia, PA, US; 2 St Luke’s Lipid and Diabetes 

Research Center, Kansas City, MO, US; 3 Novartis 



Aliskiren/HCTZ Inhibits RAAS Activity in Obese 

and Non-Obese Patients with Stage 2 Hypertension 

and Type 2 Diabetes 

Raymond R. Townsend, 1 Alan Forker, 2 Thomas 

Severin, 3 Cheraz Cherif Papst, 3 Anthony Yadao. 4 

1 University of Pennsylvania Medical Center, 

Philadelphia, PA, US; 2 St Luke’s Lipid and Diabetes 

Research Center, Kansas City, MO, US; 3 Novartis 



Aliskiren/Amlodipine Combination Lowers BP in 

Obese and Non-Obese Patients with Moderate-to- 

Severe Hypertension 

Rudiger C. Braun‐Dullaeus, 1 Sergey B. Shustov, 2 

Carmen Alvarez, 3 Gregorio G. Rogelio, 4 Cheraz Cherif 

Papst, 5 Jack Zhang†. 6 1 Otto-von-Guericke University, 

Magdeburg, DE; 2 State Educational Institution of 

High Professional Education, St Petersburg, RU; 3 ABS 

Centelles, Barcelona, ES; 4 St Luke’s Medical Center, 

Quezon, PH; 5 Novartis Pharma AG, Basel, CH; 

6 Novartis Pharmaceuticals Corporation, East Hanover, 

NJ, US. 

Patient-Provider-Healthcare System 

Issues 

PO-340: 

PO-341: 

Clinical Inertia in Hypertension: Identifying 

Barriers to Improve Quality 

Bryan Batson, 1 JaNae Joyner, 2 Philip Mellen, 1 William 

Smith. 1 1 Hattiesburg Clinic, Hattiesburg, PA, US; 2 The 

Consortium for Southeastern Hypertension Control 

(COSEHC), Winston-Salem, NC, US. 

Renal Artery Stent Management: A Survey of Local 

Practice Patterns 

Frank K. Boateng, Daniel L. Landry, Barbara A. Greco. 

Baystate Medical Center, Springfield, MA, US. 

139

MAY 21 23 

Posters 


Morning 

PO-342: 

PO-343: 

PO-344: 

PO-345: 

PO-346: 

PO-347: 

Impact of Switching from Valsartan to a Lower- 

Tiered Angiotensin Receptor Blocker on Subsequent 

Treatment Patterns 

E. K. Buysman†, 1 L. M. Andrews, 2 T. J. Bancroft, 1 H. 

B. Dastani, 2 J. Zhang, 2 M. L. Monsalvo. 3 1 i3 Innovus, 

Eden Prairie, MN, US; 2 Novartis Pharmaceuticals 

Corporation, East Hanover, NJ, US; 3 i3 Research, 

Buenos Aires, AR. 

Hypertension Specialists’ Current and Potential 

Impact on Resistant Hypertension in the Medicare 

Population 

William J. Elliott†, 1 Brent M. Egan, 2 Thomas D. Giles, 3 

George L. Bakris, 4 Torry Mark Sansone. 5 1 Pacific 

Northwest University of Health Sciences, Yakima, WA, 

US; 2 Medical University of South Carolina, Charleston, 

SC, US; 3 Tulane University School of Medicine, New 

Orleans, LA, US; 4 The University of Chicago, Chicago, 

IL, US; 5 The American Society of Hypertension, New 

York, NY, US. 

Mitigating Risk – Cardiovascular Health Assessment 

for the Men/Ms of Paterson and Passaic County – 

MR CHAMMP 

Robert T. Faillace, Margaret Latrella, Carolyn Strimike, 

Deborah Terrone, James Pruden, Ken Morris, Kathleen 

Sauter. St. Joseph’s Healthcare System, Paterson, NJ, 

US. 

Quantification of Clinical Inertia during GP’s 

Management of Uncontrolled Hypertensive Patients 

– Clepsydre Study 

Xavier Girerd, 1 Béatrice Fiquet, 2 Stéphane Quéré, 2 

Alain Francillon. 2 1 Pitié-Salpétrière Hospital, Paris, FR; 

2 Novartis Pharma SAS, Rueil-Malmaison, FR. 

Time to Talk CARDIO Communication Tool Use 

Improves Cardiovascular Disease Management 

Behaviors and Satisfaction 

Brian Forrest, 1 Stephanie Brinson, 1 Susan Harris 

Bavisotto, 1 JaNae Joyner. 2 1 Access Healthcare, 

Apex, NC, US; 2 The Consortium for Southeastern 

Hypertension Control (COSEHC), Winston Salem, 

NC, US. 

Automated Outreach for Antihypertensive 

Medication Refill Reminders 

Kelley R. Green, 1 Joel Handler, 2 Southida S. 

Vansomphone, 3 Claire Mesirov, 4 Kristi Reynolds. 4 

1 Kaiser Permanente Southern California Permanente 

Medical Group, Pasadena, CA, US; 2 Kaiser Permanente 

Medical Center, Anaheim, CA, US; 3 Kaiser 

Permanente, Downey, CA, US; 4 Kaiser Permanente 

Southern California, Pasadena, CA, US. 

140


Posters 

PO-348: 

PO-350: 

PO-351: 

PO-352: 

PO-353: 

PO-354: 

PO-355: 

Impact of Non-Medical Switching between Different 

Angiotensin Receptor Blockers on Blood Pressure 

and Medical Resource Utilization 

Khalid M. Kamal†, 1 Christopher Zacker, 2 Louis 

Civitarese. 3 1 Duquesne University Mylan School 

of Pharmacy, Pittsburgh, PA, US; 2 Novartis 

Pharmaceuticals Corporation, Emmaus, NJ, US; 

3 Preferred Primary Care Physicians, Pittsburgh, PA, 

US. 

Simple Drug Preference Questions are Predictive of 

Antihypertensive Response: A STITCH2 Substudy 

Sigrid A. Nelson, 1 George K. Dresser, 2,3 Jeffrey L. 

Mahon, 1,2,3 Brian G. Feagan, 1,2,3 Guang Y. Zou, 1,3 

Margaret K. Vandervoort, 1 Cindy J. Wong, 1 Ross D. 

Feldman. 1,2,3 1 Robarts Research Institute, CA; 2 London 

Health Sciences Centre, CA; 3 University of Western 

Ontario, CA. 

Increased Clinical Outcomes at One Year Follow-Up 

Found in a Diabetic Patient-Centered Medical Home 

Pilot Program 

Jennifer O’Donnell, 1 Cyndi Shull, 2 Amber Winkler, 1 

JaNae Joyner, 3 Laura Long. 2 1 Palmetto Primary Care 

Physicians, US; 2 Blue Cross and Blue Shield of South 

Carolina, US; 3 The Consortium for Southeastern 

Hypertension Control, Winston-Salem, NC, US. 

Single Pill vs Free-Equivalent Combination 

Therapies for Hypertension: Meta-Analysis of 

Adherence and Costs 

Beth Sherrill, 1 Michael Halpern, 2 Sumeet Panjabi†, 3 

Shahnaz Khan, 1 Jie Zhang. 1 1 RTI Health Solutions, 

Research Triangle Park, NC, US; 2 RTI International, 

Washington, DC, US; 3 Daiichi Sankyo, Inc, Parsippany, 

NJ, US. 

Differences and Similarities in Explanatory Models 

of Hypertension in the U.S., Tanzania and Jamaica 

John Purakal, 1 Jean Williams‐Johnson, 2 Eric Williams, 2 

Ibtissam Ammary, 3 Senga Pemba, 4 Joseph Kambona, 4 

Robert Welch, 1 John Flack, 1 Phillip Levy. 1 1 Wayne 

State University School of Medicine, Detroit, MI, 

US; 2 University Hospital of the West Indies, JM; 

3 University of Michigan School of Public Health, 

Ann Arbor, MI, US; 4 Tanzanian Training Centre for 

International Health, TZ. 

Treat to Target using Interactive Voice Messaging 

to Enhance Primary Care Physican Management of 


Graham A. Scott. Kaiser Permanente Medical Center, 

Riverside, CA, US. 

Is Poor Blood Pressure Control in Patients 

Presenting for Elective Surgery Predictable 

Patrick E. Benedict, Sachin Kheterpal, Amy M. Shanks, 

Alan B. Weder. University of Michigan, Ann Arbor, 

MI, US. 

141

MAY 21 23 

Posters 


Morning 

Preclinical Models/Experimental 


PO-357: 

PO-358: 

Paraventricular Nucleus of the Hypothalamus 

Neurons Project to Parasympathetic Brainstem 

Neurons that Control Heart Rate 

David Mendelowitz, Ramon Pinol. George Washington 

University, Washington, DC, US. 

Effects of Sex on Sympathetic Neural and 

Hemodynamic Responses to Head-Up Tilt in 

Hypertensive Seniors 

Yoshiyuki Okada, 1,2 M. Melyn Galbreath, 1,2 Shigeki 

Shibata, 1,2 Sara S. Jarvis, 1,2 Tiffany B. VanGundy, 1 

Rhonda L. Meier, 1 Wanpen Vongpatanasin, 2 Benjamin 

D. Levine, 1,2 Qi Fu. 1,2 1 Institute for Exercise and 

Environmental Medicine, Texas Health Presbyterian 

Hospital, Dallas, TX, US; 2 The UT Southwestern 

Medical Center at Dallas, Dallas, TX, US. 

Pregnancy 

PO-359: Autoantibodies to the Angiotensin II Type 1 

Receptor in Preeclampsia 

Maciej Adamczyk, R. Jeffrey Brashear, Stephen C. Hsu, 

Phillip G. Mattingly. Abbott Laboratories, Abbott Park, 

IL, US. 

PO-360: The Correlation between the Serum Testosterone 

Level and Insulin Sensitivity in Pre-Eclampsia – 

Eclampsia Syndrome 

M. Yousri K. Amin, Ibrahim L. Abdellatifi, Yousri 

A. Mohyeldin, Abdelmoneim A. Fawzy, Akram A. 

Deghedi, Mohamed A. Harb. Alexandria University, 

Alexandria, EG. 

PO-361: Effects of High Altitude and Ancestry on Uterine 

Artery Shear Stress and Blood Pressure in Normal 

Pregnant vs. Preeclamptic Women 

Ronald Magness, 1 Ira Bernstein, 2 Stacy Zamadio. 3 

1 University of Wisconsin - Madison, Madison, WI, 

US; 2 University of Vermont, Vermont, US; 3 New Jersey 

Medical School, New Jersey, US. 

Salt-Sensitive Mechanisms of 


PO-362: 

PO-363: 

Silencing of PKG1 Gene Sensitizes Vascular Smooth 

Muscle Cells to Marinobufagenin: Impact on Aging, 

Fibrosis, and Salt-Sensitivity 

Olga V. Fedorova, 1 Victoria Y. Shilova, 1 Joseph I. 

Shapiro, 2 Edward G. Lakatta, 1 Alexei Y. Bagrov. 1 

1 Intramural Research Program, National Institute on 

Aging, NIH, Baltimore, MD, US; 2 College of Medicine, 

University of Toledo, Toledo, OH, US. 

Heritability of Na/K Excretion during the Saline/ 

Lasix Protocol in African American Twins 

Clarence E. Grim, Robinson Miguel. High Blood 

Pressure Consulting, Milwaukee, WI, US. 

142


Posters 

PO-364: 

Gender Difference in the Relationship of 

Marinobufagein to Salt-Sensitivity of Blood Pressure 

Alexei Y. Bagrov, 1 Olga V. Fedorova, 1 Philippe Burri, 2 

Edward G. Lakatta, 1 Olle Melander. 2 1 National Institute 

on Aging, NIH, Baltimore, MD, US; 2 Lund University, 

Malmö, SE. 

Secondary Hypertension 

PO-365: 

PO-366: 

PO-367: 

Association of Renal Artery Stenosis with Acute 

Pulmonary Edema in Hypertensive Patients 

Roxana O. Darabont, 1 Alexandru Corlan, 2 Mircea 

Cinteza, 1 Dragos Vinereanu. 1 1 University of Medicine 

and Pharmacy ‘Carol Davila’, Bucharest, RO; 

2 University Emergency Hospital, Bucharest, RO. 

Big Endothelin-1 and Nitric Oxid Levels in 

Hypertensive Elderly with and without Obstructive 

Sleep Apnea 

Nereida K. C. Lima, Iara F. Anunciato, Romulo R. 

Lobo, Alan L. Eckeli, Regina M. R. Fernandes, Paulo 

R. B. Evora, Fernando Nobre, Waldiceu A. Verri- 

Junior, Julio C. Moriguti, Eduardo Ferriolli, Eduardo B. 

Coelho. Ribeirao Preto School of Medicine – Sao Paulo 

University, Ribeirao Preto, SP, BR. 

Pheochromocytoma and Coronary Artery Disease 

Galina N. Potapova, 1 L. M. Sergakova, 1 G. V. 

Ryabikina, 1 L. N. Lyutikova, 1 I. E. Chazova, 1 N. S. 

Kuznetsov, 2 E. G. Popov, 1 I. Y. Gavrilov. 1 1 Cardiology 

Research Complex, Moscow, RU; 2 Endocrinology 

Research Center, Moscow, RU. 

143

MAY 21 23 

Posters Late-Breaking Posters 


Morning 

LB-PO-01: 

LB-PO-02: 

LB-PO-03: 

ANP-cGMP-PKG Activation Inhibits TGF-b- 

Induced Smad3 Nuclear Translocation by Increasing 

Smad3 Binding to Cytosolic b2-Tubulin in Rat 

Pulmonary Arterial Smooth Muscle Cells 

Kaizheng Gong, 1,2 Dongqi Xing, 1 Peng Li, 1 

Namasivayam Ambalavanan, 3 Suzanne Oparil, 1 Yiu- 

Fai Chen. 1 1 University of Alabama at Birmingham, 

Birmingham, AL, US; 2 The Second Medical School of 

Yangzhou University, Yangzhou, CN; 3 University of 

Alabama at Birmingham, Birmingham, AL, US. 

Effect of Carvedilol CR, Lisinopril and Their 

Combination on Markers of Early Cardiovascular 

Disease in Subjects with High-Normal Blood 

Pressure: The DETECT Study 

Sara M. Saul, 1 Daniel A. Duprez, 1 Wei Zhong, 2 

Gregory A. Grandits, 2 Jay N. Cohn. 1 1 University of 

Minnesota Medical School, Minneapolis, MN, US; 

2 University of Minnesota School of Public Health, 

Minneapolis, MN, US. 

Consistency of Masked Hypertension in African 

Americans during Repeat Office Visits 

Praveen Veerabhadrappa, Keith M. Diaz, Sheara M. 

Williamson, Jan Kretzschmar, Deboarh L. Feairheller, 

Kathleen M. Sturgeon, Shannon B. Watkins, Michael 

D. Brown. Temple University, Philadephia, PA, US. 

144

Faculty Disclosure Listing 


Advisor/Consultant: Abbott, Merck, Daiichi-Sankyo, Reata, Amgen. 

Trustee/Board Member/Committee Member: Abbott. Speakers’ Bureau/Speaking/Teaching: 

Abbott, Merck. 

Lawrence J. Appel, MD, MPH 

I have no relationships to disclose. 

Donna K. Arnett, PhD, MSPH 


Nancy Artinian, RN, BSN 


Phyllis August, MD, MPH 

Advisor/Consultant: Otsuka. 

Abraham Aviv, MD 

Employment Income/Salary: University of Medicine and Dentistry, 

New Jersey Medical School. Grant/Research Support: National Institutes 

of Health. 

George L. Bakris, MD 

Advisor/Consultant: Takeda, Abbott, CVRx, Ardian, Walgreen’s, 

Johnson & Johnson, Merck. Trustee, Board Member, Committee 

Member: National Kidney Foundation. Grant/Research Support: 

Forest Labs, Novartis. Speaker’s Bureau/Speaking/Teaching: Forest 

Labs, Novartis. President, ASH Board of Directors. 

Jan N. Basile, MD 

Advisor/Consultant: Boehringer-Ingelheim, Forest Laboratories, 

Daiichi-Sankyo, Takeda. Speakers’ Bureau/Speaking/Teaching: 

Daiichi-Sankyo, Forest, Takeda. 



John D. Bisognano, MD, PhD 

Advisor/Consultant: CVRx. Grant/Research Support: CVRx. Secretary, 

ASH Board of Directors. 

Henry R. Black, MD 

Advisor/Consultant: Servier, Mitsubushi, Xoma, Ligand, Bristol-Myers 

Squibb, Biosante, Novartis. Grant/Research Support: AHRQ/HHS. 

Speakers’ Bureau/Speaking/Teaching: Daiichi-Sankyo, Boehringer- 

Ingelheim, MSD. Immediate Past President, ASH Board of Directors. 

Michael J. Bloch, MD 

Advisor/Consultant: Takeda. Grant/Research Support: Novartis. 

Speakers’ Bureau/Speaking/Teaching: AstraZeneca, Abbott, Boehringer-Ingelheim. 




Royalties (Including Trademarks or Patents): UpToDate, Inc. Grant/ 

Research Support: National Institutes of Health. Speakers’ Bureau/ 

Speaking/Teaching: American Heart Association, Spotlight Speaker. 

Other Relevant Financial Benefit or Relationship: National Lipid Association 

Web Presentation. 

Emmanuel Bravo, MD 


145

Faculty Disclosure Listing continued 


Advisor/Consultant: Takeda. Speakers’ Bureau/Speaking/Teaching: 

Novartis, Forest, Pfizer. 


Advisor/Consultant: Novartis, Merck. Grant/Research Support: Forest, 

Shire HGT. Ownership/Partnership or Principal of Non-Profit or 

for Profit Corporation: Protein Discovery. 

David A. Bushinksy, MD 

Employment Income/Salary: Univeristy of Rochester. Advisor/Consultant: 

Amgen, Genzyme, Relypsa, Cytochroma. Grant/Research 

Support: National Institutes of Health, Renal Research Institute. Ownership 

Interest (Stocks, Excluding Diversified Mutual Funds): Amgen, 

Relypsa. Speakers’ Bureau/Speaking/Teaching: Amgen, Genzyme. 

Norman R.C. Campbell, MD 

Other Relevant Financial Benefit or Relationship: Boehringer-Ingelheim. 

Oscar A. Carretero, MD 

Grant/Research Support: National Institutes of Health, Roche Pharmaceuticals. 




Grant/Research Support: National Institutes of Health. 


Advisor/Consultant: Forest, Novartis, Genzyme, GlaxoSmithKline. 

Grant/Research Support: GlaxoSmithKline. Speakers’ Bureau/Speaking/Teaching: 

Genzyme, Amgen. 

Jay N. Cohn, MD 


Steven D. Crowley, PhD 


William C. Cushman, MD 

Advisor/Consultant: Takeda, Novartis. 

Stephen R. Daniels, MD, PhD 


Michael H. Davidson, MD 

Advisor/Consultant: Abbott, Aegerion, Amgen, AstraZeneca, Atherotech, 

Daiichi-Sankyo, DTC MD, Esperion, GlaxoSmithKline, iMD 

(Intelligent Medical Decisions), Kinemed, LipoScience, Merck, Novo 

Nordisk, Roche, Sanofi-Aventis, Synarc, Takeda, Vindico Medical 

Education. Trustee/Board Member/Committee Member: DTC MD, 

Omthera, Professional Education, Inc. Medical Education Company, 

Sonogene. Grant/Research Support: Abbott, Daiichi-Sankyo, GlaxoSmithKline, 

Merck, Roche. 

Daniel Duprez, MD, PhD 

Advisor/Consultant: Novartis, Abbott, Pfizer, Merck. Grant/Research 

Support: Novartis, Roche, Merck. Speakers’ Bureau/Speaking/Teaching: 

Novartis, Pfizer, Merck, Boehringer-Ingelheim, Forest, Abbott. 

Lance D. Dworkin, MD 

Advisor/Consultant: Questcor. Grant/Research Support: Questcor, 

Pfizer, AstraZeneca. 

146


Brent M. Egan, MD 

Advisor/Consultant: NiCox. Grant/Research Support: Daiichi-Sankyo, 

Novartis, Takeda. 

Paula T. Einhorn, MD, MS 


William J. Elliott, MD, PhD 

Royalties (Including Trademarks or Patents): Elsevier, Inc. Grant/ 

Research Support: Forest Research Institute. Speakers’ Bureau/Speaking/Teaching: 

Forest Laboratories, Boehringer-Ingelheim, NiCox, 

Inc., American Society of Hypertension. 


Advisor/Consultant: Bristol-Myers Squibb, AstraZeneca. 

Murray D. Esler, MBBS, PhD 

Advisor/Consultant: ADRIAN Corporation, Chief Investigator International 

Trial. Speakers’ Bureau/Speaking/Teaching: Solvay Australia. 

Bonita Falkner, MD 

Advisor/Consultant: AstraZeneca, Pfizer, Merck. 

Sadaf Farooqi, PhD 





Advisor/Consultant: AstraZeneca, Boehringer-Ingelheim, Bristol- 

Myers Squibb, Merck, Forest Canada, Novartis, Pfizer, Sanofi-Aventis, 

Servier, Takeda. Trustee/Board Member/Committee Member: Servier, 

Takeda. 

Keith C. Ferdinand, MD 

Advisor/Consultant: AstraZeneca, Merck, Pfizer, Novartis, Takeda, 

Forest. Grant/Research Support: Daiichi-Sankyo. Speakers’ Bureau/ 

Speaking/Teaching: Novartis, AstraZeneca. Member, ASH Board of 

Directors. 


Advisor/Consultant: Novartis, Daiichi-Sankyo. Grant Research/ 

Support: Novartis. Speakers’ Bureau/Speaking/Teaching: Novartis, 

Daiichi-Sankyo, Boehringer-Ingelheim. 

Joseph T. Flynn, MD 

Advisor/Consultant: Pfizer, Novartis, PTC Therapeutics. 

Stanley S. Franklin, MD 


William H. Frishman, MD 

Ownership Interest (Stocks, Excluding Diversified Mutual Funds): 

Merck, Pfizer. Speakers’ Bureau/Speaking/Teaching: NCME (Bristol- 

Myers Squibb), Pfizer, Forest Laboratories, Boehringer-Ingelheim. 

James B. Froehlich, MD, MPH 

Advisor/Consultant: Merck, Sanofi-Aventis. Speakers’ Bureau/Speaking/Teaching: 

Merck, Schering-Plough. 

Leonard M. Fromer, MD 

Trustee/Board Member/Committee Member: TransferMed, LLC. 

Jeffrey L. Garvin, PhD 


147


Haralambos Gavras, MD 

Advisor/Consultant: Medivation, Merck. Speakers’ Bureau/Speaking/ 

Teaching: Novartis. 

F. Wilford Germino, MD 


Thomas D. Giles, MD 

Advisor/Consultant: Amylin, Forest, NiCox. Grant/Research Support: 

Forest. Speakers’ Bureau/Speaking/Teaching: Forest. Member, ASH 

Board of Directors. Chair, ASH Specialists Program Inc. 

Alan H. Gradman, MD 

Advisor/Consultant: Novartis, Forest, Takeda, Daiichi-Sankyo. Speakers’ 

Bureau/Speaking/Teaching: Novartis, Forest, Takeda. Member, 




Richard H. Grimm, MD, PhD 

Advisor/Consultant: Abbott. Grant/Research Support: Roche. Speakers’ 

Bureau/Speaking/Teaching: Merck. 

Yuan Guo, MD, MS 






David Harder, MD, PhD 


Raymond C. Harris, MD 




Joseph A. Hill, MD 


Norman K. Hollenberg, MD, PhD 

Advisor/Consultant: Novartis, Merck, Vitae Pharmaceuticals. Grant/ 

Research Support: Vitae Pharmaceuticals. 

Suzanne Hughes, MSN, RN 


Joseph L. Izzo, Jr., MD 

Advisor/Consultant: Pharmacists Mutural, Boehringer-Ingelheim, 

Novartis, Curry Rockfeller, Thornton Medical, Daiichi-Sankyo, SCS 

Healthcare, Takeda, Maritz Travel Co. Grant/Research Support: 

Novartis, Daiichi-Sankyo. Speakers’ Bureau/Speaking/Teaching: Novartis, 

Daiichi-Sankyo, SCS Healthcare, Maritz Travel Co. 

Edgar A. Jaimes, MD 

Advisor/Consultant: Novartis. 

148


Kenneth A. Jamerson, MD 

Advisor/Consultant: Boehringer-Ingelheim, Eli Lily, Daiichi-Sankyo, 

Novartis. Trustee/Board Member/Committee Member: American 

Society Of Hypertension, International Society of Hypertension 

in Blacks. Grant/Research Support: National Institutes of Health, 

National Institute of Diabetes and Digestive and Kidney Diseases, National 

Heart, Lung, and Blood Institute, Novartis. Speakers’ Bureau/ 

Speaking/Teaching: Daiichi-Sankyo. 

Julie A. Johnson, PharmD 

Advisor/Consultant: Medco. 


Grant/Research Support: National Institutes of Health. Other Relevant 

Financial Benefit or Relationship: Patent on the Use of Allopurinol to 

Treat Hypertension. 

Pedro A. Jose, MD 

Grant/Research Support: National Heart, Lung, and Blood Institute, 

National Institutes of Health, National Institute of Diabetes and 

Digestive and Kidney Diseases, BIAL. Ownership/Partnership or 

Principal of Non-Profit or for Profit Corporation: Hypogen, Inc. 

Luis I. Juncos, MD 


Rae‐Ellen W. Kavey, MD, MPH 


Donald E. Kohan, MD, PhD 

Advisor/Consultant: Abbott, Pfizer, Gilead, Bristol-Myers Squibb. 

Grant/Research Support: National Institutes of Health. VA, Gilead. 





Henry Krum, MBBS 

Grant/Research Support: Ardian. 


Advisor/Consultant: Boehringer-Ingelheim, Takeda. Speakers’ Bureau/Speaking/Teaching: 

Boehringer-Ingelheim, Takeda. 



Robert F. Kushner, MD 


Daniel T. Lackland, DrPH 

Speakers’ Bureau/Speaking/Teaching: Sanofi-Aventis, Boehringer- 

Ingelheim. Member, ASH Board of Directors. 

Edward G. Lakatta, MD 


Babbette LaMarca, PhD 

Grant/Research Support: American Heart Association, National 

Institutes of Health. 

Marc B. Lande, MD, MPH 


149


Daniel Levy, MD 

Member, ASH Board of Directors. 

Nita A. Lindi, PharmD, PhD, MSPH 


Tianh Liu, MD 

Employment Income/Salary: Pi County People’s Hospital. 

Charles J. Lowenstein, MD 


Jianfang Luo, MD 


James M. Luther, MD 


Giuseppe Mancia, MD 

Advisor/Consultant: Bayer, Boehringer-Ingelheim, MSD, Menaribni 

International, Novartis, Recordati, Sanofi-Aventis, Servier. Grant/ 

Research Support: Gilead, Servier. 


Grant/Research Support: Forest. Speaker’s Bureau/Speaking/Teaching: 

Forest. 

Athanasios J. Manolis, MD, PhD 

Advisor/Consultant: Menarini, Abbott. Speakers’ Bureau/Speaking/ 

Teaching: Menarini, Recordati. 



Barry J. Materson, MD, MBA 

Grant/Research Support: Forest, Takeda, Merck. 

David L. Mattson, PhD 


Richard J. McManus, MD 

Grant/Research Support: Omron Europe (potential). 

John Merenich, MD 


Franz H. Messerli, MD 

Advisor/Consultant: Novartis, Daiichi-Sankyo, Sanofi-Aventis, 

Takeda, Abbott. Grant/Research Support: Forest, Daiichi-Sankyo, 

Boehringer-Ingelheim. Treasurer, ASH Board of Directors. 

Nancy Houston Miller, RN, BSN 

Advisor/Consultant: Abbott, Gilead, Novartis. 

Mark E. Molitch, MD 

Advisor/Consultant: Novartis, Abbott. Grant/Research Support: Eli 

Lily. 

Krzysztof Narkiewicz, MD, PhD 

Speakers’ Bureau/Speaking/Teaching: Berlin Chernie Menarini, 

Boehringer-Ingelheim, Daiichi-Sankyo, Krka, Novartis, Servier. 

150



Advisor/Consultant: Forest, Novartis, Nicor, Merck & Co., Boehringer-Ingelheim. 

Trustee/Board Member/Committee Member: American 

Heart Association, American Society of Hypertension, InterAmerican 

Society of Hypertension. Grant/Research Support: National Heart, 

Lung and Blood Institute, NCRR, Merck, Forest. Ownership Interest 

(Stocks, Excluding Diversified Mutual Funds): Abbott, AstraZeneca, 

Baxter International, Merck & Co., Pfizer, Inc. Speakers’ Bureua/ 

Speaking/Teaching: Merck & Co., Forest Pharmaceuticals. 

Shawna D. Nesbitt, MD, MS 

Advisor/Consultant: Daiichi-Sankyo. Speakers’ Bureau/Speaking/ 

Teaching: Novartis, Gilead, Boehringer-Ingelheim. 

Joel M. Neutel, MD 

Speakers’ Bureau/Speaking/Teaching: Novartis, Forest, Bristol-Myers 

Squibb – Sanofi-Aventis, Takeda, Boehringer-Ingelheim, Daiichi- 

Sankyo. 

Susanne B. Nicholas, MD, PhD, MPH 


Eoin O’Brien, MD 


Gbenga Ogedegbe, MD, MPH, MS 


Suzanne Oparil, MD 

Advisor/Consultant: Boehringer-Ingelheim, Daiichi-Sankyo, Eli Lily, 

Forest, NiCox, Novartis, Omron. Grant/Research Support: Amgen, 

Inc., Merck & Co. Speakers’ Bureau/Speaking/Teaching: Daiichi- 

Sankyo, Novartis, Pfizer. 

Julio A. Panza, MD 


Vasilios Papademetriou, MD 


Thomas A. Pearson, MD, PhD, MPH 


Aldo J. Peixoto, MD 


Robert A. Phillips, MD, PhD 

Member, ASH Board of Directors. 

F. Xavier Pi‐Sunyer, MD, MPH 

Advisor/Consultant: Novo Nordisk, AstraZeneca. Grant/Research 

Support: Novo Nordisk. 


Advisor/Consultant: Relypsa. Ownership Interest (Stocks, Excluding 

Diversified Mutual Funds): Relypsa, BG-Medicine, Nile Therapeutics. 

Velvie A. Pogue, MD 

Employment Income/Salary: Columbia University Affiliation at the 

Harlem Hospital Center. Grant/Research Support: Amgen. 

David M. Pollock, PhD 

Advisor/Consultant: Abbott Laboratories. 

Howard J. Pratt, MD 


151


Henry A. Punzi, MD 

Advisor/Consultant: Daiichi-Sankyo, Boehringer-Ingelheim, Forest 

Pharamaceuticals. Grant/Research Support: Daiichi-Sankyo, Boehringer-Ingelheim, 

Forest Pharmaceuticals, Abbott. Speakers’ Bureau/ 

Speaking/Teaching: Daiichi-Sankyo, Boehringer-Ingelheim, Forest 

Pharmaceuticals, Abbott. 

Leopoldo Raij, MD 


C. Venkata S. Ram, MD 

Advisor/Consultant: Daiichi-Sankyo, Forest. Speakers’ Bureau/Speaking/Teaching: 

Peer Group Med Knowledge. 

James Rippe, MD 

Advisor/Consultant: ConAgra Foods, Corn Refiners Association. 

Grant/Research Support: ConAgra Foods, Corn Refiners Association. 

Talma Rosenthal, MD 

Royalties (Including Trademarks or Patents): Patent (2%) Allyl 

Mercaptocptopril), Weitzmann Institute. Trustee/Board Member/ 

Committee Member: Tel-Aviv University Sackler School of Medicine. 

Grant/Research Support: Boehringer-Ingelheim. Speakers’ Bureau/ 

Speaking/Teaching: Tel-Aviv University Sackler School of Medicine. 


Advisor/Consultant: AstraZeneca, Novartis, Bayer, Servier, Daiichi- 

Sankyo, Takeda, Pfizer, Otsuka. Menarini, Bayer. Speakers’ Bureau/ 

Speaking/Teaching: AstraZeneca, Novartis, Bayer, Servier, Daiichi- 

Sankyo, Takeda, Pfizer, Otsuka. Menarini, Bayer. 


Grant/Research Support: National Institutes of Health/ National 

Heart, Lung and Blood Institute. 

Elijah Saunders, MD 

Advisor/Consultant: Pfizer, Novartis, Forest, Bristol-Myers Squibb- 

Sanofi-Aventis, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli 

Lilly. Grant/Research Support: Pfizer, Novartis, Forest, Bristol-Myers 

Squibb-Sanofi-Aventis. Speakers’ Bureau/Speaking/Teaching: Pfizer, 

Novartis, Forest, Bristol-Myers Squibb-Sanofi-Aventis, Boehringer- 

Ingelheim, Bristol-Myers Squibb, Eli Lilly. 



Roland E. Schmieder, MD 

Grant/Research Support: Ardian. 

Antoinette Schoenthaler, EdD 

Advisor/Consultant: Harlem Hospital Stroke Center. 

Domenic A. Sica, MD 

Advisor/Consultant: Novartis, Takeda, Merck, Boehringer-Ingelheim, 

CVRx. Grant/Research Support: CVRx. Speakers’ Bureau/Speaking/ 

Teaching: Takeda. 

Matthew Sorrentino, MD 


Thomas A. Sos, MD 

Royalties (Including Trademarks or Patents): AngioDynamics, Cook 

Medical. 

152


James R. Sowers, MD 

Advisor/Consultant: Novartis Pharmaceuticals. Grant/Research Support: 

National Institutes of Health, VA Merit. 

Lesley A. Stevens, MD, MS 


Allan D. Struthers, MD 

Royalties (Including Trademarks or Patents): Filed a patent on the 

use of xanthine oxidate inhibitors in angina. 

Laura P. Svetkey, MD 


Sandra J. Taler, MD 

Vice President, ASH Board of Directors. 

Ting Tao, MD 


Addison A. Taylor, MD, PhD 

Employment Income/Salary: Baylor College of Medicine. Advisor/ 

Consultant: National Association of Managed Care Physicians. Grant/ 

Research Support: Bristol-Myers Squibb, Novartis, National Institues 

of Health. Speakers’ Bureau/Speaking/Teaching: Forest Pharmaceuticals, 

Novartis, The Methodist Hospital, University of Texas. Member, 




Sheldon W. Tobe, MD 

Advisor/Consultant: Pfizer, Bristol-Myers Squibb, Merck, Abbott. 

Grant/Research Support: Pfizer, Novartis, Amgen. Speakers’ Bureau/ 

Speaking/Teaching: Abbott, 

Bristol-Myers Squibb, Pfizer, Merck. 




Royalties (Including Trademarks or Patents): UptoDate. Advisor/Consultant: 

GlaxoSmithKline, Merck, Novartis. Grant/Research Support: 

National Institutes of Health. 



Ronald G. Victor, MD 

Advisor/Consultant: Merck Research Laboratories. Grant/Research 

Support: Pfizer, Forest Research Laboratories. 



R. Clinton Webb, PhD 


David J. Webb, MD 

Advisor/Consultant: Abbott, Pfizer. Grant/Research Support: Pfizer. 

Michael A. Weber, MD 

Advisor/Consultant: Bristol-Myers Squibb, Boehringer-Ingelheim, 

Takeda, Novartis, Daiichi-Sankyo. Trustee/Board Member/Committee 

Member: Center for Medicine in the Public Interest. Member, 

ASH Board of Directors. Editor-In-Chief, The Journal of Clinical 

Hypertension (JCH). 

153





Employment Income/Salary: American Society Of Hypertension 

(Editor-in-Chief, Journal of the American Society of Hypertension 

(JASH)). Member, ASH Board of Directors. 

Matthew R. Weir, MD 

Advisor/Consultant: Amgen, Daiichi-Sankyo. Member, ASH Board of 

Directors. 

Adam Whaley‐Connell, DO 


Andrew Whelton, MD 

Advisor/Consultant: Takeda. Speakers’ Bureau/Speaking/Teaching: 

Takeda. 

William B. White, MD 

Advisor/Consultant: Astellas, Forest, Novartis, Roche, Teva, Takeda. 

Grant/Research Support: Novartis. Other Relevant Financial Benefit 

or Relationship: Pfizer, Inc., DMC Consultant. President-Elect ASH 

Board of Directors. ASH Scientific Program Committee Chair. 

Ian B. Wilkinson, MD 

Advisor/Consultant: GlaxoSmithKline, MSD. Grant/Research Support: 

GlaxoSmithKline. 

Bryan Williams, MD 


Gordon H. Williams, MD 


Peter F. Wilson, MD 


Nathan D. Wong 

Advisor/Consultant: Abbott. Grant/Research Support: Merck, Bristol- 

Myers Squibb. 

Martin S. Zand, MD 


154

ASH Hypertension Resource Pavilion 

Hilton New York • Americas Hall I • Third Floor 


Americas Hall I 

(Third Floor) 

ASH Posters 

(Second Floor Promenade) 

ASH 

Outreach 


1600 

Takeda 

Pharmaceuticals 

North American Inc. 

1400 

1600 

ASH 

Outreach 

TO AMERICAS HALL II 

ESCALATOR 

UP 

Daiichi Sankyo Inc. 

1200 

Novartis 


1100 

Takeda 


North American Inc. 

Wiley-Blackwell 

1400 

1202 1204 

Mortara 

HoMedics 

1105 1107 

Daiichi David Sankyo Inc. ISHIB 

Lerner 

1200 

1102 1103 

Elsevier Inc. 

AtCor Medical, Inc. 

1106 


1202 1204 

1104 

Mortara 

HoMedics 

Elsevier Inc. 

Ajinomoto 

AtCor Medical, Inc. 

Omron Healthcare Novartis Forest Lippincott 1105 1107 A & D 

SunTech 

Medical 

Medical 

Novartis 

David ISHIB 

1106 

1000 Pharmaceuticals 1004 1006 1008 Lerner 1010 1014 

1100 

1102 1103 

1104 

Ajinomoto 

National 

Kidney 

1206 

Woman 

Heart 

1110 

National 

Kidney 

1206 

Woman 

Heart 

1110 

ENTRANCE 

Omron Healthcare Novartis Forest Lippincott A & D 

Medical 

SunTech 

Medical 

1000 1004 1006 1008 1010 1014 

TED FIRE ALARMS 

TED FIRE EXITS 

155

ASH Exposition Guide 

Hilton New York • Americas Hall I • Third Floor 

Hours: 

Saturday, May 21, 4:30 PM – 7:30 PM 

Sunday, May 22, 10:00 AM – 1:00 PM, 3:30 PM – 6:30 PM 

Monday, May 23, 10:00 AM – 1:30 PM, 4:00 PM – 5:30 PM 

ASH Hypertension Resource Pavilion 

America’s Hall I – Third Floor 

American Society of 

Hypertension Community 

Outreach 

Booth Number: 1600 

Controlling your blood pressure is a 

check away! 

Get your blood pressure checked 

today at our Outreach Booth!! 

In 2011, we are proud to continue 

with our Fourth Annual Hypertension 

Community Outreach Program in the 

Greater New York City area, Northern 

New Jersey, and Long Island, NY. 

View videos and photos of all of our 

past Outreach Programs from New 

Orleans (2008), San Francisco (2009), 

and New York (2010). Our recently 

released educational videos will also 

be on view. The ASH published “Blood 

Pressure and Your Health” patient 

information pamphlets are available 

here as well. 

Check it out!!—go to Times Square— 

42nd Street between 7th and 8th Avenues 

and look up at the CBS “Super 

Screen” and you will see the new ASH 

Public Service Announcement shown 

18 times a day. 

A & D Medical 


A&D Medical / LifeSource manufacturers 

blood pressure monitors and 

other home health care products for 

home and professional use. Models include 

automatic, manual, ambulatory, 

kiosk style and accessories including 

stethoscopes. 

A&D Medical is a division of A&D 

Engineering, and is ISO 13485:2003 

certified. Since 1977, A&D Medical 

has manufactured and distributed a 

full line of advanced electronic blood 

pressure monitoring equipment and 

health care products for home and 

professional use. The company has 

established itself as a leader in home 

health monitoring technology through 

the development and introduction 

of a variety of unique products. 

A&D’s LifeSource® blood pressure 

monitor line has garnered numerous 

industry awards. Recent product 

introductions include: the LifeSource® 

digital thermometers, personal scales, 

stethoscopes, and Ambulatory Blood 

Pressure Monitors. 

Ajinomoto USA, Inc. 


Since 1909, Ajinomoto Co., a leader 

in the development of pharmaceutical 

quality amino acids and distributor 

of products that offer a holistic, 

side-effect free solution to today’s top 

health concerns of weight management, 

sleep quality improvement and 

healthy blood pressure management. 

These products are Capsiate Natura®, 

a patented, side effect-free dietary 

supplement with natural capsinoids 

shown to boost the body’s metabolism; 

Glysom, a safe, effective and 

scientifically-proven amino acid-based 

solution for deeper, sounder and 

more satisfying sleep, and Natura 

Guard BP, a milk protein-derived 

nutraceutical to help maintain healthy 

blood pressure levels already within 

the normal range. 

For more information, visit 

www.capsiatenatura.com, 

www.glysom.com and 

www.naturaguardbp.com 

AtCor Medical, Inc. (USA) 


AtCor Medical developed and markets 

SphygmoCor® systems, the global gold 

standard in noninvasive assessment 

of central blood pressure and arterial 

stiffness. Featured in over 600 published 

studies, SphygmoCor systems 

are used worldwide in leading medical 

centers, physicians’ offices, in research 

and in pharmaceutical clinical trials. 



Daiichi Sankyo, Inc. (DSI), headquartered 

in Parsippany, NJ, is the 

U. S. subsidiary of Daiichi Sankyo 

Co., Ltd., a global pharmaceutical 

company. DSI was formed in 2006 

from the integration of two leading 

pharmaceutical companies, Sankyo 

Pharma, Inc. and Daiichi Pharmaceutical 

Corporation. Its team of nearly 

3,000 U.S. employees is dedicated to 

the creation and supply of innovative 

pharmaceutical products to address 

the diversified, unmet medical needs 

of patients. DSI concentrates in the 

therapy areas of hypertension, thrombosis, 

dyslipidemia, diabetes and 

acute coronary syndrome. Clinical 

development and regulatory activities 

are headquartered at Daiichi Sankyo 

Pharma Development in Edison, NJ. 

Visit www.dsi.com. 

David Lerner Associates 


Financial Investments at David Lerner 

Associates 

We believe gambling and investing are 

not the same. 

We believe the stock market should make 

for interesting dinner conversation but 

should not be a matter of financial life 

or death. 

We believe we have an obligation to 

guide our investors in directions we feel 

will help them achieve their financial 

objectives. 

We believe investors should not be chasing 

financial rainbows. 

We do not run with the herd. We pursue 

these fundamental investment principles 

regardless of market conditions. 

While offering a full range of investments, 

we feature those that we believe 

are based on real value and regularly pay 

dividends or interest. 

Elsevier 


ELSEVIER, a premier worldwide health 

science publishing company, is proud 

to publish Journal of the AMERICAN 

SOCIETY OF HYPERTENSION, the 

official journal of the American Society of 

Hypertension. Please stop by our booth 

to view the latest issue of the journal. 

Forest Pharmaceuticals, Inc. 


Forest Pharmaceuticals, Inc welcomes 

you to New York! We invite you to visit 

our exhibit. Please visit our website at 

www.forestpharm.com 

Community Partner of the ASH 

Hypertension Community Outreach 


HoMedics 


Since HoMedics was founded in 1987, 

they have become the #1 name in health 

and wellness with an extensive line of 

products that allow you to take a proactive 

role in managing your health. 

HoMedics blood pressure monitors are 

clinically proven accurate and offer a 

wide range of innovative features and 

technologies that make monitoring your 

blood pressure at home easier than ever. 

Select arm and wrist models offer Voice 

Assist® Talking Function, Supersize 

Digits®, Risk Category Index, Easy One 

Button Operation, Dual User Memory 

and 2 cuffs to fit most arm sizes. 




International Society on 

Hypertension in Blacks, Inc. (ISHIB) 


Founded in 1986, ISHIB is a non-profit 

organization of healthcare professions 

and leaders in cardiovascular disease 

and related disorders. Our mission is to 

improve the health and life expectancy of 

ethnic minorities and eliminate racial and 

ethnic health disparities in cardiovascular 

disease through professional and public 

education, targeted clinical research, and 

facilitation of the delivery of higher quality 

cardiovascular health care. We host 

an annual conference, membership and 

other programs. 

Lippincott, Williams & Wilkins, a 

Wolters Kluwer Health Company 


Lippincott Williams & Wilkins, Wolters 

Kluwer Health Company, is the proud 

publisher of Hypertension, Journal of 

the American Heart Association, and 

the Journal of Hypertension, Official 

Journal of the International Society of 

Hypertension and the European Society 

of Hypertension. We offer a full range 

of specialized books, journals, and electronic 

media. Visit us today! 

Mortara Instrument 


Mortara Instrument is proud to offer its 

Ambulo 2400 ambulatory blood pressure 

(ABPM) technology at the American 

Society of Hypertension’s 2011 Annual 

Scientific Meeting and Exposition. Designed 

and made in the USA, the Ambulo 

2400 system allows clinicians, researchers 

and other health professionals to better 

assess a patient’s blood pressure fluctuations 

throughout the 24-hour circadian 

rhythm. 

For over 25 years, Mortara Instrument 

has distinguished itself in the field of 

non-invasive cardiology by providing 

ECG, Holter and stress systems to customers 

worldwide. We are excited to be 

adding thorough blood pressure assessment 

tools to our portfolio of products. 



NKF offers the nephrology community 

the latest science through clinical 

practice guidelines, free kidney screening 

programs held around the world, and 

educational materials for patients and 

professionals. Learn more about the 

soon-to-be published guidelines, including: 

KDIGO’s Acute Kidney Injury and 

the Update on CKD and Diabetes by 

KDOQI. Please visit the booth to signup 

to review KDIGO’s Clinical Practice 

Guideline on Blood Pressure in CKD. 

Novartis Pharmaceuticals 

Corporation 

Booth Number: 1100, 1004 

Novartis Pharmaceuticals is dedicated to 

discovering, developing, manufacturing 

and marketing prescription drugs that 

help meet our customers’ medical needs 

and improve their quality of life. Please 

visit the Novartis exhibit where our sales 

representatives will be available to discuss 

our products. 




Omron Healthcare 


Omron Healthcare, Inc., is the leading 

manufacturer and distributor of blood 

pressure monitors for home use. Omron 

Healthcare markets clinically proven 

products that provide accurate health 

information to consumers and physicians 

and support position lifestyle changes and 

health improvement. 




SunTech Medical, Inc. 


For over twenty years, SunTech Medical 

has been the preeminent supplier of 

clinical grade blood pressure monitoring 

products and technologies. SunTech is the 

world’s foremost manufacturer of ambulatory 

blood pressure monitors, including 

the Oscar 2 ABPM system, now available 

with Pediatric ABPM Interpretation 

function, which automatically generates 

guidelines specific to analyzing the 

24-hour blood pressure data of pediatric 

patients. Additionally, SunTech offers solutions 

for in-office BP measurement with 

the SunTech 247, the first clinical grade 

automated blood pressure device to offer 

a manual back-up mode, as well as a complete 

line of blood pressure cuffs. Please 

visit our booth for more information. 

Takeda Pharmaceuticals North 

America, Inc. 


Based in Deerfield, IL. Takeda Pharmaceuticals 

North America, Inc. and Takeda 

Global Research & Development Center, 

Inc. market oral diabetes, insomnia, rheumatology 

and gastroenterology treatments 

and seek to bring innovative products to 

patients through a pipeline that includes 

compounds in development for diabetes, 

cardiovascular disease, gastroenterology 

and neurology. www.tpna.com. 



Wiley-Blackwell is the international 

scientific, technical, medical and scholarly 

publishing business of John Wiley & Sons, 

with strengths in every major academic 

and professional field and partnerships 

with many of the world’s leading societies. 

Wiley-Blackwell publishes over 1,400 

peer-reviewed journals as well as 1,500+ 

new books annually in print and online, 

as well as databases, major reference 

works and laboratory protocols. For more 

information, please visit 

www.wileyblackwell.com or 

http://onlinelibrary.wiley.com/ 

WomenHeart 


WomenHeart was founded by three 

women who had heart attacks while in 

their 40s. In addition to being faced with 

many obstacles, including misdiagnosis 

and social isolation, they were each 

amazed how little information about 

or services for women with heart 

disease were available and how the issue 

seemed invisible within the women’s 

health community. But in March 1999 

everything changed. 

156

2011 ASH Innovations Theater 

Rhinelander Gallery – 2nd Floor 

Saturday, May 21, 2011 • 6:30 PM to 7:30 PM 

Daiichi Sankyo, Inc. presents, 

The Growing Need for Combination Antihypertensive Therapy 

“The Innovations Theater content and the views expressed 

therein are those of the presenting corporate entity and not of 

the American Society of Hypertension, Inc. The content is not 

part of the ASH Annual Scientific Meeting as approved by the 

“Annual Scientific Program Committee.” 

Sunday, May 22, 2011 • 12:00 PM to 1:00 PM 

Takeda Pharmaceuticals, North American, Inc. presents, 

A Clinical Update in Hypertension. 





“Annual Scientific Program Committee.” 

Sunday, May 22, 2011 • 5:30 PM to 6:30 PM 

Novartis Pharmaceuticals Corporation Presentation 





Annual Scientific Program Committee.” 

157

2011 ASH Exhibitors 

ASH Hypertension Resource Pavilion • America’s Hall I – 3rd Floor 

American Society of Hypertension Community Outreach 

Contact: Gilda Caputo-Hansen 

148 Madison Ave. 5th Floor 


Phone: 212-696-9099 

Fax: 212-696-0711 

Email: gcaputo@ash-us.org 

Website: www.ash-us.org 


Controlling your blood pressure is a check away! 

Get your blood pressure checked today at our Outreach 

Booth!! 

In 2011, we are proud to continue with our Fourth Annual 

Hypertension Community Outreach Program in the Greater 

New York City area, Northern New Jersey, and Long Island, 

NY. View videos and photos of all of our past Outreach 

Programs from New Orleans (2008), San Francisco (2009), and 

New York (2010). Our recently released educational videos will 

also be on view. The ASH published “Blood Pressure and Your 

Health” patient information pamphlets are available here as 

well. 

Check it out!!—go to Times Square—42nd Street between 

7th and 8th Avenues and look up at the CBS “Super Screen” 

and you will see the new ASH Public Service Announcement 

shown 18 times a day. 

158

2011 ASH Exhibitors continued 

A & D Medical 

Contact: Amit Ghia 

1756 Automation Parkway 

San Jose, CA 95131 

Phone: 408-263-5333 

Fax: 408-263-0119 

E-mail: aghia@andmedical.com 

Website: www.andmedical.com 


A&D Medical / LifeSource manufacturers blood pressure 

monitors and other home health care products for home 

and professional use. Models include automatic, manual, 

ambulatory, kiosk style and accessories including stethoscopes. 

A&D Medical is a division of A&D Engineering, and is 

ISO 13485:2003 certified. Since 1977, A&D Medical has 

manufactured and distributed a full line of advanced 

electronic blood pressure monitoring equipment and health 

care products for home and professional use. The company 

has established itself as a leader in home health monitoring 

technology through the development and introduction of a 

variety of unique products. A&D’s LifeSource® blood pressure 

monitor line has garnered numerous industry awards. 

Recent product introductions include: the LifeSource® digital 

thermometers, personal scales, stethoscopes, and Ambulatory 

Blood Pressure Monitors. 

Ajinomoto USA, Inc. 

Contact: Junichi Tashiro 

400 Kelby Street 

Fort Lee, NJ 07024 

Phone: 201-292-3244 

Fax: 201-346-5639 

Email: tashiroj@ajiusa.com 


Since 1909, Ajinomoto Co., a leader in the development 

of pharmaceutical quality amino acids and distributor of 

products that offer a holistic, side-effect free solution to today’s 

top health concerns of weight management, sleep quality 

improvement and healthy blood pressure management. These 

products are Capsiate Natura®, a patented, side effect-free 

dietary supplement with natural capsinoids shown to boost the 

body’s metabolism; Glysom, a safe, effective and scientificallyproven 

amino acid-based solution for deeper, sounder and 

more satisfying sleep, and Natura Guard BP, a milk proteinderived 

nutraceutical to help maintain healthy blood pressure 

levels already within the normal range. 

For more information, visit www.capsiatenatura.com, 

www.glysom.com and www.naturaguardbp.com 

159


AtCor Medical, Inc. (USA) 

Contact: Beth Boyer 

One Pierce Place, Suite 225W 

Itasca, IL 60143 

Phone: 630-228-8871 

Fax: 630-228-8872 

Email: info@atcormedical.com 

Website: www.atcormedical.com 


AtCor Medical developed and markets SphygmoCor® systems, 

the global gold standard in noninvasive assessment of central 

blood pressure and arterial stiffness. Featured in over 600 

published studies, SphygmoCor systems are used worldwide in 

leading medical centers, physicians’ offices, in research and in 

pharmaceutical clinical trials. 


Contact: Ann Marie Bermudez 

2 Hilton Court 

Parsippany, NJ 07054 

Phone: 973-944-2600 

Fax: 973-944-2891 

Email: abermudez@dsi.com 

Website: www.dsi.com 


Daiichi Sankyo, Inc. (DSI), headquartered in Parsippany, NJ, 

is the U. S. subsidiary of Daiichi Sankyo Co., Ltd., a global 

pharmaceutical company. DSI was formed in 2006 from the 

integration of two leading pharmaceutical companies, Sankyo 

Pharma, Inc. and Daiichi Pharmaceutical Corporation. 

Its team of nearly 3,000 U.S. employees is dedicated to the 

creation and supply of innovative pharmaceutical products to 

address the diversified, unmet medical needs of patients. DSI 

concentrates in the therapy areas of hypertension, thrombosis, 

dyslipidemia, diabetes and acute coronary syndrome. Clinical 

development and regulatory activities are headquartered at 

Daiichi Sankyo Pharma Development in Edison, NJ. Visit 

www.dsi.com. 

160


David Lerner Associates 

Contact: James Faillace 

568 Yamato Road 3rd Floor 

Boca Raton FL 33431 

Phone: 561-226-4500 

Fax: 561-226-4598 

Email: jon.jarow@davidlerner.com 


Financial Investments at David Lerner Associates 

We believe gambling and investing are not the same. 

We believe the stock market should make for interesting 

dinner conversation but should not be a matter of financial life 

or death. 

We believe we have an obligation to guide our investors 

in directions we feel will help them achieve their financial 

objectives. 

We believe investors should not be chasing financial rainbows. 

We do not run with the herd. We pursue these fundamental 

investment principles regardless of market conditions. 

While offering a full range of investments, we feature those that 

we believe are based on real value and regularly pay dividends 

or interest. 

Elsevier 

Contact: 

Jeffrey Francis 

Elsevier, Inc. 

1600 JFK Blvd. Suite 1800 

Philadelphia, PA 19103 

Phone: 215-239-3491 

Fax: 215-239-3494 

Email: j.francis@elsevier.com 

Website: www.elsevierhealth.com 


ELSEVIER, a premier worldwide health science publishing 

company, is proud to publish Journal of the American Society 

of Hypertension, the official journal of the American Society of 

Hypertension. Please stop by our booth to view the latest issue 

of the journal. 

161


Forest Pharmaceuticals, Inc. 

Contact: info@forestpharm.com 

13600 Shoreline Drive 

St. Louis, MO 63045 

Phone: 800-678-1605 

Fax: 314-493-7450 

Email: info@forestpharm.com 

Website: www.forestpharm.com 


Forest Pharmaceuticals, Inc welcomes you to New York! We 

invite you to visit our exhibit. Please visit our website at 

www.forestpharm.com 

Community Partner of the ASH Hypertension Community 

Outreach Program 

HoMedics 

Contact: 

Anthony Vigliotti 

3000 Pontiac Trail 

Commerce Township, MI 48390 

Phone: 248-863-3000 

Fax: 248-863-3103 

Email: anthony.vigliotti@homedics.com 

Website: www.HoMedics.com 


Since HoMedics was founded in 1987, they have become the #1 

name in health and wellness with an extensive line of products 

that allow you to take a proactive role in managing your health. 

HoMedics blood pressure monitors are clinically proven 

accurate and offer a wide range of innovative features and 

technologies that make monitoring your blood pressure at 

home easier than ever. 

Select arm and wrist models offer Voice Assist® Talking 

Function, Supersize Digits®, Risk Category Index, Easy One 

Button Operation, Dual User Memory and 2 cuffs to fit most 

arm sizes. 



162


International Society on Hypertension in Blacks, Inc. (ISHIB) 

Contact: Terry E. Jackson 

2111 Wilson Boulevard, Suite 700 

Arlington, VA. 22201 

Phone: 703-351-5023 

Fax: 703-351-9292 

Email: terry-jackson@ishib.org 

Website: www.ishib.org 


Founded in 1986, ISHIB is a non-profit organization of 

healthcare professions and leaders in cardiovascular disease 

and related disorders. Our mission is to improve the health 

and life expectancy of ethnic minorities and eliminate racial 

and ethnic health disparities in cardiovascular disease through 

professional and public education, targeted clinical research, 

and facilitation of the delivery of higher quality cardiovascular 

health care. We host an annual conference, membership and 

other programs. 

Lippincott, Williams & Wilkins, a Wolters Kluwer Health 

Company 

Contact: Jeff Thompson (PSG) 

16522 Hunters Green Parkway 

Hagerstown, MD 21740 U.S.A. 

Phone: 1-800-638-3030 (North America) 

+44 (0) 20 7981 0525 (Europe) 

1-301-223-2300 (Rest of World) 

Fax: 1-301-223-2400 (North America) 

+44 (0) 20 7981 0535 (Europe) 

1-301-223-2400 (Rest of World) 

Email: Jeff.Thompson@wolterskluwer.com or 

customerservice@lww.com 

Website: www.lww.com 


Lippincott Williams & Wilkins, Wolters Kluwer Health 

Company, is the proud publisher of Hypertension, Journal 

of the American Heart Association, and the Journal of 

Hypertension, Official Journal of the International Society of 

Hypertension and the European Society of Hypertension. We 

offer a full range of specialized books, journals, and electronic 

media. Visit us today! 

163


Mortara Instrument 

Contact: Cynthia Muise 

7865 N. 86th Street 

Milwaukee, WI 53224 

Phone: 414-354-1600 x7738 

Fax: 414-354-4760 

Email: Cynthia.muise@mortara.com 


Mortara Instrument is proud to offer its Ambulo 2400 

ambulatory blood pressure (ABPM) technology at the 

American Society of Hypertension’s 2011 Annual Scientific 

Meeting and Exposition. Designed and made in the USA, the 

Ambulo 2400 system allows clinicians, researchers and other 

health professionals to better assess a patient’s blood pressure 

fluctuations throughout the 24-hour circadian rhythm. 

For over 25 years, Mortara Instrument has distinguished itself 

in the field of non-invasive cardiology by providing ECG, 

Holter and stress systems to customers worldwide. We are 

excited to be adding thorough blood pressure assessment tools 

to our portfolio of products. 


Contact: David Rexroad 

30 East 33rd Street 


Phone: 212-889-2210 

Fax: 212-889-2310 

Email: davidr@kidney.org 

Website: www.kidney.org 


NKF offers the nephrology community the latest science 

through clinical practice guidelines, free kidney screening 

programs held around the world, and educational materials for 

patients and professionals. Learn more about the soon-to-be 

published guidelines, including: KDIGO’s Acute Kidney Injury 

and the Update on CKD and Diabetes by KDOQI. Please 

visit the booth to sign-up to review KDIGO’s Clinical Practice 

Guideline on Blood Pressure in CKD. 

164



Contact: Becca Baileys 

One Health Plaza 

East Hanover, NJ 07936 

Phone: 862-778-8300 

Email: rebecca.baileys@novartis.com 

Website: www.novartis.com 

Booth Number: 1100, 1004 

Novartis Pharmaceuticals is dedicated to discovering, 

developing, manufacturing and marketing prescription drugs 

that help meet our customers’ medical needs and improve their 

quality of life. Please visit the Novartis exhibit where our sales 

representatives will be available to discuss our products. 



Omron Healthcare 

Contact: Dan Aske 

1200 Lakeside Drive 

Bannockburn, IL 60015 

Phone: 847-680-6200 

Fax: 847-680-6269 

Email: info@omron.com 


Omron Healthcare, Inc., is the leading manufacturer and 

distributor of blood pressure monitors for home use. Omron 

Healthcare markets clinically proven products that provide 

accurate health information to consumers and physicians and 

support position lifestyle changes and health improvement. 



165


SunTech Medical, Inc. 

Contact: Rod Thomson 

507 Airport Blvd.., Suite 117 

Morrisville, NC 27560 

Phone: +1 919 654 2300 x 355 

Fax: +1 919 654 2301 

Email: sales @suntechmed.com 

Website: www.SunTechMed.com 


For over twenty years, SunTech Medical has been the 

preeminent supplier of clinical grade blood pressure 

monitoring products and technologies. SunTech is the 

world’s foremost manufacturer of ambulatory blood pressure 

monitors, including the Oscar 2 ABPM system, now available 

with Pediatric ABPM Interpretation function, which 

automatically generates guidelines specific to analyzing the 

24-hour blood pressure data of pediatric patients. Additionally, 

SunTech offers solutions for in-office BP measurement with the 

SunTech 247, the first clinical grade automated blood pressure 

device to offer a manual back-up mode, as well as a complete 

line of blood pressure cuffs. Please visit our booth for more 

information. 


Contact: One Takeda Parkway 

Deerfield, Il 60015 

Phone: 224-554-6500 

Website: www.tpna.com 


Based in Deerfield, IL. Takeda Pharmaceuticals North 

America, Inc. and Takeda Global Research & Development 

Center, Inc. market oral diabetes, insomnia, rheumatology 

and gastroenterology treatments and seek to bring innovative 

products to patients through a pipeline that includes 

compounds in development for diabetes, cardiovascular 

disease, gastroenterology and neurology. www.tpna.com. 

166



Contact: 350 Main Street 

Malden, MA 02148 

Phone: 781-388-8250 

Fax: 781-338-8250 

Website: www.wiley.com 


Wiley-Blackwell is the international scientific, technical, 

medical and scholarly publishing business of John Wiley & 

Sons, with strengths in every major academic and professional 

field and partnerships with many of the world’s leading 

societies. Wiley-Blackwell publishes over 1,400 peer-reviewed 

journals as well as 1,500+ new books annually in print and 

online, as well as databases, major reference works and 

laboratory protocols. For more information, please visit 

www.wileyblackwell.com or http://onlinelibrary.wiley.com/ 

WomenHeart 

Contact: Mary McGowan, COO 

818 18th Street NW 

Washington DC 20006 

Phone: 202-464-8735 

Email: mmcgowan@womenheart.org 

Website: www.womenheart.org 


WomenHeart was founded by three women who had heart 

attacks while in their 40s. In addition to being faced with many 

obstacles, including misdiagnosis and social isolation, they 

were each amazed how little information about or services for 

women with heart disease were available and how the issue 

seemed invisible within the women’s health community. But in 

March 1999 everything changed. 

167

Author Index 

A 

Abad, María, 133 

Abaunza, Ricardo, 102 

Abbey, Susan, 136 

Abdallah, Rany T., 101 

Abdellatifi, Ibrahim L., 142 

Abecasis, Goncalo R., 79 

Abraham, Nader G., 66, 122 

Abramson, Beth, 136 

Acelajado, Maria Czarina, 88, 108, 

138 

Acelajado, Maria Czarina M., 120 

Acelajado‐Valdenor, Ma Czarlota 

M., 120 

Achouba, Assya, 92, 127 

Adamczyk, Maciej, 142 

Adams, Kenneth F., 106 

Adams, Robert J., 100, 102, 134 

Adler, G., 97 

Agarwal, Rajiv, 60, 145 

Agarwal, Vikram, 66, 93, 117 

Agarwal, Vikram V., 87, 117 

Aggelis, A., 66, 91, 124 

Agnoletti, Davide, 112, 126, 128 

Aguilar, Francisco, 101 

Ajzen, Sérgio Aron, 102 

Albarran, Olga Gonzalez, 99 

Alcon, Jose, 101 

Alebiosu, Olutayo Christopher, 97 

Alessi, Sheila M., 136 

Almenar, Luis, 116 

Almiroudi, M., 92, 96, 102, 122, 

124, 126 

Alonso, Ana, 91, 98 

Alonso, Ignacio, 114, 129 

Altun, Bulent, 97, 121 

Alvarez, Carlos, 98 

Alvarez, Carmen, 139 

Alvarez, Julio, 101 

Ambalavanan, Namasivayam, 118, 

144 

Ambrosio, Giuseppe, 91 

Amdur, Richard, 96, 105 

Amin, M. Yousri K., 142 

Ammary, Ibtissam, 141 

Anastasopoulos, I., 128 

Andrews, L. M., 133, 140 

Andrikou, E., 122, 126 

Andrikou, I., 92, 102, 122 

Angelini, Luca, 120 

Antonino, Cassi, 137 

Anunciato, Iara F., 143 

Anunciato, Iara Felício, 132 

Aonuma, Takanori, 117 

Appel, Lawrence J., 82, 145 

Aragiannis, D., 102 

Aranda, Pedro, 101, 102 

Arbique, Debbie, 59 

Arici, Mustafa, 97 

Arinsoy, Turgay, 121 

Armando, Ines, 47, 97, 123 

Arnett, Donna K., 145 

Aronne, Luigi, 123 

Artinian, Nancy, 45, 145 

Asche, Stephen E., 89 

Ascione, Frank, 87 

Asico, Laureano, 97 

Asico, Laureano D., 47 

Aslam, S., 91 

Asmar, Ali, 78 

Assia, Ehud, 103 

Ates, Kenan, 121 

Atkinson, Hal, 61 

Atluri, Tej K., 117 

Aucott, Lorna, 137 

August, Phyllis, 43, 145 

Aviv, Abraham, 76, 145 

Axon, R. Neal, 105, 130 

Ayala, Carma, 129 

Ayala, Diana E., 60, 97, 98, 99, 108, 

110, 111, 114, 121, 129, 131 

Azar, Silvia H., 123 

B 

Baba, Yoshichika, 121 

Babazadeh, Simon, 98 

Baber, Nigel, 95 

Bachman, David L., 134 

Bae, Jong‐Hoa, 116 

Baek, InYoung, 130 

Bagrov, Alexei Y., 142, 143 

Bailey, M., 97 

Bajaj, Jennifer, 90 

Baker, Brian, 136 

Baker, William L., 109 

Bakhtar, Omid, 93 

Bakris, George, 67, 78, 99 

Bakris, George L., 44, 50, 58, 68, 75, 

76, 78, 112, 140, 145 

Bakris, G. L., 115 

Balbarini, Alberto, 116, 126 

Baldo, Manuela S., 87 

Baldwin, William, 100 

Balish, Marshal, 136 

Ballesteros, Maria Jose, 95 

Baltatzi, Maria, 111 

Bancroft, T. J., 140 

Bandyopadhyay, Dipankar, 110 

Banegas, Jose R., 93, 123, 134 

Baraniuk, Sarah, 60 

Baranova, Elena I., 87 

Barbatelli, Paolo, 133 

Barbetseas, I., 61 

Barbosa, Loide, 96 

Bard, Robert L., 65, 129 

Barros, Jesús, 129 

Baschiera, Fabio, 130 

Basile, Jan, 98, 130 

Basile, Jan N., 49, 50, 64, 145 

Bastien, Carl, 127 

Bastos, Jose Mesquita, 129, 134 

Basu, Sanjib, 47, 113 

Batisky, Donald L., 40, 51, 145 

Batson, Bryan, 139 

Baur, Dorothee M., 95 

Bavisotto, Susan Harris, 140 

Baylis, Chris, 100 

Bayorh, Mohamed A., 107 

Bellavia, Diego, 116 

Bellner, Lars, 122 

Belyaeva, Olga D., 87 

Ben‐Dov, Iddo Z., 93 

Benedict, Patrick E., 141 

Benetos, Georgios N., 119 

Berenson, Abbey B., 95, 102 

Berenson, Gerald S., 93, 94, 127 

168

Author Index 

Berezina, Aelita V., 87 

Berkovich, Olga O., 87 

Berktas, Mehmet, 108 

Bernard, Gutin, 47 

Bernheim, Jacques, 131 

Bernstein, Ira, 142 

Berrios, Ronaldo Sevilla, 110 

Bertoquini, Susana, 129 

Bertoquini, Susana P., 137 

Bhabhe, Aditya S., 123, 132 

Bhaheetharan, Sujan, 110 

Bhandari, Simran, 67 

Bhandari, Simran K., 108 

Bianchini, Elisabetta, 91, 127 

Biggi, Almerina, 91 

Bisognano, John, 67 

Bisognano, John D., 40, 49, 67, 126, 

145 

Blacher, Jacques, 99, 112, 126, 128 

Black, Henry R., 40, 81, 145 

Bloch, Michael J., 50, 145 

Blom, Kimberly C., 136 

Blue, Amanda E., 101 

Blumenthal, James A., 131 

Boan, Andrea D., 102, 134 

Boateng, Frank K., 139 

Bobrie, Guillaume, 108 

Bochud, Murielle, 79 

Boden, William E., 44 

Boerrigter, Guido, 91 

Bolin, Paul, 124 

Bolondi, Luigi, 95 

Bolshakova, Olga O., 87 

Bolton, Charlotte, 128 

Bonartseva, Garina A., 108 

Bonartsev, Anton P., 108 

Borghi, Claudio, 93 

Bosi, Matteo, 130, 137 

Bougatsa, Vaia, 111 

Bowden, Charles, 78 

Boyaci, Bulent, 108 

Bracho, Mayela J., 87 

Brady, Tammy M., 101 

Brands, Michael W., 40, 72, 145 

Brashear, R. Jeffrey, 142 

Braucht, Drew, 101 

Braun‐Dullaeus, Rudiger C., 139 

Braun, Lynne T., 45, 145 

Bravo, Emmanuel, 50, 145 

Briasoulis, Alex, 93, 117 

Briasoulis, Alexandros, 87, 117 

Bridges, William, 102 

Brinson, Stephanie, 140 

Brook, Robert D., 65, 129 

Brosolo, Gabriele, 136 

Brough, Elizabeth, 90, 115 

Brown, Angela L., 49, 50, 146 

Brown, Michael D., 136, 138, 144 

Brown, Morris, 112 

Brown, Nancy J., 40, 146 

Brunel, Patrick, 130 

Bruno, Rosa Maria, 127 

Brzezinski, W. Adam, 130 

Bueno, Isabel, 129 

Buglioni, Alessia, 107 

Buren, Peter Van, 60 

Burnett, John C., 91, 116 

Burnett, Jr., John C., 47 

Burnett, Richard T., 129 

Burney, Basil, 99 

Burri, Philippe, 143 

Bursztyn, Michael, 93 

Bushinksy, David A., 146 

Bushinsky, David, 107 

Bushinsky, David A., 70 

Bustamante, Eduardo E., 138 

Buysman, E. K., 140 

Byun, Young‐Sup, 118, 119, 120 

C 

Cafazzo, Joseph, 132 

Caglar, Sali, 97 

Cai, Jingjing, 112 

Cain, Van, 118 

Calabrò, Raffaele, 123 

Calara, Federico, 67 

Calara, Federico B., 108 

Calderon, Berniza, 91 

Calderón, Berniza, 99 

Calhoun, David A., 88, 108, 138 

Callejas, Pedro A., 97, 131 

Calmon, Gustavo E., 87 

Calvo, Sara, 91 

Campbell, Norman R.C., 54, 146 

Campbell, Patrick T., 109, 136 

Campese, Vito M., 88 

Campoy, Jose, 98 

Camsari, Taner, 121 

Cañas, Juan, 129 

Cannone, Valentina, 47, 91 

Cano, Marta, 91, 99 

Cao, C., 115 

Cao, Charlie, 112 

Capobianco, Frine, 88 

Carlberg, Bo, 93 

Carnevale, Daniela, 134, 135 

Carrasco, Marta, 91, 99 

Carreño, Agustin, 95 

Carretero, Oscar A., 20, 76, 146 

Carter, Barry L., 45, 49, 146 

Carugo, S., 130 

Cassi, Antonino, 130 

Castillo, Zenaida, 127 

Castiñeira, Maria C., 99, 121 

Castresana, Elena, 91 

Cataliotti, Alessandro, 22, 47, 76, 91, 

116, 146 

Catena, Cristiana, 59, 88, 136 

Caulfield, Mark, 78 

Caulfield, Mark J., 79 

Celis, Susana I., 127 

Cerezo, Cesar, 67, 93, 96 

Chacko, Billy G., 117 

Chakravarti, Aravinda, 78, 79 

Chamarthi, B., 97 

Charney, Alan, 130 

Chasman, Daniel I., 79 

Chavanu, Kathleen J., 114, 115 

Chayan, Luisa, 60, 114, 129 

Chazova, I. E., 143 

Chazova, Irina E., 112 

Cheh, Christopher Newton, 79 

Cheng, Dunlei, 94 

Chen, W., 113 

Chen, Wei, 93, 94, 122 

169

Author Index 

Chen, Yiu‐Fai, 103, 118, 126, 144 

Cheruvu, Bharadwaj, 122 

Cheung, D. G., 113 

Childers, W. Kurtis, 47 

Chlapoutakis, G., 126 

Cho, Eun‐Joo, 88 

Choi, Kyu‐Young, 88 

Cho, Jin‐Man, 111, 116 

Chow, Josephine X., 87 

Christensen, Niels Juel, 78 

Christiano, Cindy, 124 

Chrysant, Steven G., 109, 111 

Chung, Wook‐Jin, 118, 119, 120 

Chung, Yeonseung, 132 

Cicero, Arrigo, 93 

Cifelli, Giuseppe, 134, 135 

Cinteza, Mircea, 143 

Cirillo, Chiara, 123 

Civitarese, Louis, 141 

Clark, Rebecca I., 127 

Clark, Sarah, 87 

Clar, Xavier, 105 

Clyburn, Benjamin, 130 

Cockcroft, John R., 46, 95, 128, 138, 

146 

Coelho, Eduardo B., 143 

Cohen, Debbie L., 127 

Cohn, Jay N., 51, 116, 144, 146 

Cohn, Lisa, 87 

Colaco, Clinton, 107 

Colby, Chris, 89 

Coloma, Ramon, 129 

Colussi, Gian Luca, 59 

Colussi, GianLuca, 59, 88, 136 

Comisky, Lauren, 123 

Concilio, Claudia, 123 

Connell, Barry, 92 

Corlan, Alexandru, 143 

Cornelissen‐Guillaume, Germaine 

G., 137 

Cosentino, Eugenio Roberto, 93 

Cosentino, Francesco, 91 

Couch, Sarah C., 106 

Coulson, James M., 138 

Craft, Chanda, 102 

Credendino, Maria, 123 

Crespo, Juan J., 97, 98, 121, 131 

Crippa, Giuseppe, 130, 137 

Croghan, Carry, 129 

Crowley, Steven D., 40, 146 

Cuevas, Santiago, 97 

Cui, Rong, 112 

Cushman, W. C., 115 

Cushman, William C., 54, 62, 78, 

112, 146 

D 

d’Addato, Sergio, 93 

D’Agostino, Ralph B., 96 

Dahlström, John K. F., 93 

Daley, Matt F., 106 

Damasceno, Albertino, 96 

Daniels, Stephen R., 47, 106, 146 

Daoud, Yahya, 94 

Darabont, Roxana O., 143 

Dart, Richard A., 135 

DasMahapatra, Pronabesh, 93, 94 

Dastani, H. B., 140 

Davidson, Michael H., 44, 146 

Davis, Barry R., 60 

Day, Wesley, 78 

De Angulo, Guillermo A., 100 

Dean, Lacy, 124 

Debenham, Ellen, 100 

Deedwania, P., 113 

Deghedi, Akram A., 142 

de la Cruz, Jose Juan, 101, 102 

de la Cruz, Juan J., 93, 123, 133, 134 

de la Sierra, Alejandro, 102, 105, 

123, 133, 134 

de la Sierra, Alex, 101 

De la Torre, Nuria, 47, 91, 92, 98 

Delgado‐Leon, Antonio J., 127 

de Lis, Jesus Perez, 99 

Del Tío, Rocío, 129 

Derici, Ulver, 97 

De Rosa, Maria Leonarda, 113 

Desai, Tejas, 122, 124 

DeSouza, Christopher A., 92 

Dessì-Fulgheri, Paolo, 120 

Dessì‐Fulgheri, Paolo, 107, 133 

Destounis, Antonios, 134 

Destounis, Antonis, 105 

DeVries, Andrea, 122 

Dhaun, N., 97, 121 

Diaz, Edgar A., 132 

Diaz, Keith M., 136, 144 

Díaz, María T., 129 

Di Bello, Vitantonio, 116, 126 

Dimitriadis, K., 66, 91, 92, 124, 126, 

128 

Diogo, Domingos, 96 

Dionne, Janis M., 87 

Dixon, John, 139 

Djordjevic, Dragan, 120 

Dobrokhod, Anna S., 133 

Dochee, Jennifer D., 107 

Does, Alec V., 90 

Dolan, Lawrence M., 106 

Dolz, Luis Martínez, 116 

Dominguez, Maria J., 114, 129 

Dominguez‐Sardiña, Manuel, 98, 

111, 121, 131 

Dongre, Neelesh, 94, 112 

Dong, Yanbin, 47 

Dormi, Ada, 93 

Doumas, Michael, 94, 96, 136 

Dourliou, Vasiliki, 111 

Drawz, Paul E., 60 

Dresser, George K., 141 

Dresser, G. K., 89 

Dubiel, Robert, 114, 115 

Dudenbostel, Tanja, 88, 108, 138 

Duh, Mei Sheng, 110, 131, 133 

Duprez, Daniel, 73, 109, 116, 130, 

146 

Duprez, Daniel A., 144 

Dvonch, J. Timothy, 65 

Dworkin, Lance D., 56, 146 

E 

Eatman, Danita, 107 

Ecder, Tevfik, 121 

Eckeli, Alan L., 143 

Egan, Brent, 105, 110, 130, 134 

Egan, Brent M., 40, 49, 134, 140, 147 

170

Author Index 

Eguchi, Kazuo, 110, 132 

Ehret, Georg, 78 

Ehret, Georg B., 79 

Einhorn, Paula T., 49, 147 

Eiroa, Peregrina, 97, 131 

Eisenberg, Debra F., 122 

Eleftheriadou, I., 122 

Eliseyeva, Marietta, 117 

Elliott, Paul, 79 

Elliott, William J., 47, 50, 61, 73, 113, 

140, 147 

Ennis, Riley C., 122 

Entcheva, Miglena, 93, 94 

Epstein, Benjamin J., 115 

Epstein, Michael J., 133 

Epstein, Murray, 24, 70, 76, 77, 147 

Erbay, Bulent, 97 

Erdem, Yunus, 97 

Escano, Crisanto, 97 

Esis, Carlos E., 87 

Esler, Murray D., 77, 138, 147 

Espinosa, Emma, 133 

Esposito, A., 130 

Eto, Masahiko, 117 

Eto, Tanenao, 114 

Eunsil, Yim, 100 

Evans, Gregory, 61 

Evora, Paulo R. B., 143 

Exuzides, Alex, 89 

F 

Fabregate, Martin, 47, 91, 92, 98, 110 

Fabregate, Rosa, 47, 91, 92, 98, 110 

Faillace, Robert T., 140 

Faita, Francesco, 91, 127 

Falck, John R., 66 

Falkner, Bonita, 40, 147 

Falvey, Heather, 110, 131 

Familoni, Oluranti, 97 

Fang, Christy, 122 

Fang, Jing, 136 

Fares, Maria Luisa, 130 

Farooqi, Sadaf, 58, 147 

Faselis, Charles, 94, 96, 105, 136 

Fawzy, Abdelmoneim A., 142 

Feagan, B. G., 89 

Feagan, Brian G., 141 

Feairheller, Deboarh L., 144 

Feairheller, Deborah L., 136, 138 

Fedecostante, Massimiliano, 133 

Fedorova, Olga V., 142, 143 

Fedorov, Sergiy V., 92 

Fedrizzi, Stefania, 88 

Feibel, Hedy, 123 

Feig, Daniel I., 66, 106, 147 

Feig, Denice, 132 

Feldman, R. D., 89 

Feldman, Ross, 54, 147 

Feldman, Ross D., 141 

Ferdinand, Keith, 105, 109, 130 

Ferdinand, Keith C., 44, 62, 110, 113, 

114, 147 

Ference, Brain, 107 

Ference, Brian A., 93 

Fernandes, Regina M. R., 143 

Fernandez, Angelica, 47, 91, 98, 110 

Fernandez, Camilo, 93, 94, 127 

Fernandez, Jose Carlos, 101, 102 

Fernandez, Jose R., 60, 97, 99, 108, 

110, 111, 114, 121, 129, 131 

Fernandez, Olga, 98 

Fernandez, Rafael, 109 

Fernandez, Victor, 109, 111 

Ferrario, Carlos M., 89 

Ferreras, Amelia, 121 

Ferrero, David, 133 

Ferrero‐Martinez, Ana Isabel, 120 

Ferriolli, Eduardo, 132, 143 

Ferris, Maria, 122 

Figueiredo, José Nuno, 134 

Filatova, Elena A., 108 

Filho, Sebastião R., 123 

Fiorentini, Lucia, 137 

Fiquet, Béatrice, 140 

Fivush, Barbara A., 101 

Flack, John, 107, 141 

Flack, John M., 62, 93, 114, 147 

Fleg, Jerome L., 90 

Flessas, D., 66, 126 

Fletcher, Ross, 94, 136 

Fletcher, Ross D., 96, 105 

Florea, Natalia, 116 

Flori, Serena, 95 

Flynn, Joseph, 101 

Flynn, Joseph T., 40, 58, 101, 106, 

147 

Fogari, Roberto, 87, 88 

Fogg, Louis, 138 

Foiato, Tariane F., 87 

Fontao, Maria J., 60, 99, 110, 111, 

114, 121, 129, 131 

Forker, Alan, 139 

Forrest, Brian, 89, 140 

Fortunati, Marco, 120 

Fox, Caroline S., 117 

Fragasso, Gabriele, 116 

Franchi, Eliana, 107 

Francillon, Alain, 140 

Franklin, Stanley S., 46, 147 

Fraser, William D., 137 

Frassetto, Lynda A., 98 

Frazer, Lauren C., 123 

Frech‐Tamas, Feride, 133 

Freed, Gary, 87 

Freitas, Joao, 135, 138 

Frishman, William H., 64, 147 

Froehlich, James B., 49, 147 

Fromer, Leonard M., 50, 147 

Frome, Wayne L., 135 

Fujii, Kenji, 130 

Fujimoto, Tetsuya, 99 

Fu, Qi, 142 

G 

Gaciong, Zbigniew, 138 

Gaida, Susan, 93, 94 

Galbreath, M. Melyn, 142 

Galgo, Alberto, 98 

Gaman, Iryna O., 119 

Ganotakis, Emmanuel S., 100 

Garcia‐Donaire, Jose A., 67, 96 

García‐Ortiz, Luis, 133 

Garg, Suchita, 133 

Garoufalis, Stefanos H., 119 

Garrett, Andrew T., 95 

Garvin, Jeffrey L., 80, 147 

171

Author Index 

Gassman, Jennifer, 115 

Gavish, Dov, 124 

Gavras, Haralambos, 52, 148 

Gavrilov, I. Y., 143 

Gemignani, Vincenzo, 91, 127 

Georgiadis, Ioannis V., 119 

Georgiopoulos, Georgios E., 119 

Germino, F. W., 131 

Germino, F. Wilford, 49, 148 

Germino, Megan M., 131 

Ghannad, Emmanuel, 92, 127 

Ghiadoni, Lorenzo, 91, 127 

Giakoumis, M., 122, 126 

Gialernios, T., 94 

Giannini, Elena, 133 

Gibstein, Raz, 103 

Gijon, Teresa, 105 

Giles, Thomas D., 47, 127, 140, 148 

Giovas, Periklis, 106 

Giralt, Patricio, 95 

Girerd, Xavier, 140 

Glasser, Stephen P., 108 

Go, Alan S., 81 

Goddard, J., 121 

Godleski, John J., 132 

Golan, Eliezer, 131 

Goldberg, Ruthie, 131 

Gomara, Sonia M., 98, 99 

Gómez, Manuel, 133 

Gong, Kaizheng, 118, 126, 144 

Gongora, Maria C., 122 

Gonzalez‐Albarran, Olga, 91 

Gonzalez, Alicex C., 87 

Gonzalez, Olga, 98 

Gonzalez, Santiago Cuevas, 47 

Gonzalez, Waddy, 110 

Gopalakrishnan, Kathirvel, 137 

Gorostidi, Manuel, 101, 102, 105, 

123, 134 

Gradman, Alan H., 54, 110, 131, 148 

Graeme, Katelyn, 101 

Graff, Alan, 114, 115 

Granato, Chiara, 123 

Grandits, Gregory A., 144 

Granger, Joey P., 43, 77, 148 

Grant, Joshua, 93, 94 

Greco, Barbara A., 139 

Green, Kelley R., 140 

Greenway, Frank L., 137 

Greiner, Jared J., 92 

Grennberg, George, 103 

Grima, Esther Zorio, 116 

Grim, Clarence E., 107, 142 

Grimm, Jr., Richard H., 57 

Grimm, Richard H., 148 

Grosman, Ehud, 124 

Grossman, Ehud, 103 

Guedj, Dominique, 92, 127 

Guenoun, Maxime, 92, 127 

Guerra, Federico, 107, 120, 133 

Guerri, Asuncion, 47, 98, 110 

Gunawardhana, Lhanoo, 100 

Guo, Yuan, 53, 148 

Gupta, Alok K., 137 

Gutierrez, G., 95 

H 

Hadker, Nandini, 133 

Hage, Fadi, 118, 126 

Hage, Fadi G., 103 

Hailpern, Susan M., 101 

Halberg, Franz, 132 

Halfon, Sherin, 107 

Hall, Jennifer, 116 

Hall, John E., 43, 59, 148 

Halpern, Michael, 141 

Hamad, Mazen, 89 

Hames, Melanie, 124 

Hamilton, Bruce, 61 

Handler, Joel, 40, 90, 131, 140, 148 

Hansen, Kimberley J., 117 

Hans, Nidhi, 66, 117 

Haque, Tahir, 92, 110 

Harats, Dror, 124 

Harb, Mohamed A., 142 

Harder, David, 57, 148 

Harrison, David G., 57, 72, 76, 122, 

148 

Harris, Raymond C., 65, 148 

Hartmann, Camila, 87 

Hasanoglu, Enver, 97 

Hasegawa, Kenichi, 59 

Hatzitolios, Apostolos I., 111 

Hatzopoulos, Anastasios, 111 

Haun, Daniel W., 91 

Hayakawa, Manabu, 118 

Hebert, Christopher, 94 

Hedquist, Lowell, 93, 107 

Heilbraun, Jeffrey, 124 

Hermida, Ramon C., 60, 65, 97, 98, 

99, 108, 110, 111, 114, 121, 129, 

131 

Hernaiz, Susana, 99 

Heublein, Denise M., 91 

Heyrman, Reinilde, 109, 111 

Hill, Joseph A., 76, 148 

Hinderliter, Alan L., 131 

Hollenberg, Norman K., 76, 148 

Holmstedt, Christine A., 102 

Hongyo, Kazuhiro, 121 

Hopkins, P., 97 

Hoshide, Satoshi, 102, 110, 132 

Ho, Timothy, 131 

Houston Miller, Nancy, 40, 45, 150 

Howard, Barbara V., 90 

Hoyem, Ruby, 138 

Hsueh, Willa, 138 

Hsu, Stephen C., 142 

Htun, Wah Wah, 127 

Htyte, Nay, 110 

Huang, I.‐Zu, 107 

Huang, Zhijun, 112 

Hughes, Suzanne, 45, 148 

Hull, Pamela, 118 

Hunt, Barbara, 100 

Huntley, Brenda K., 91 

Husaini, Baqar, 118 

Hwang, Shih‐Jen, 117 

Hygia, Investigadores Proyecto, 97, 

98, 99, 111, 121, 131 

I 

Iaria, Pierre, 126 

Ibrahim, Mediha, 127 

Ichiki, Tomoko, 47 

IIonze, Onyedika John, 126 

172

Author Index 

Ikeda, Yasuhiro, 116 

Imamura, Takuro, 96 

Inrig, Jula K., 60, 121, 122 

Ioannidis, Antonios, 100, 115 

Irvine, Jane, 132, 136 

Ishikawa, Joji, 126, 132 

Ishikawa, Shizukiyo, 110, 126 

Ishizaka, Nobukazu, 59 

Ito, Sadayoshi, 67 

Iwakura, Yoshitugu, 67 

Izzo, Joseph, 109, 111 

Izzo, Joseph L., 111, 128 

Izzo, Jr., Joseph L., 61, 114, 148 

J 

Jackson, Sharron M., 101 

Jaffe, Marc G., 61 

Jaimes, Edgar A., 52, 113, 114, 148 

Jamerson, Kenneth, 90, 115 

Jamerson, Kenneth A., 62, 149 

Jang, Sung‐Won, 88 

Jarvis, Sara S., 142 

Jason, Yap, 122 

Jatte, Fernanda, 132 

Jauch, Edward C., 102 

Javier, Angelo Dave C., 120 

Jin, Eun‐Sun, 111, 116 

Joe, Bina, 137 

Johannsen, Darcy, 137 

Johnson, Andrew D., 79 

Johnson, Julie A., 42, 115, 149 

Johnson, Mary A., 101 

Johnson, Richard J., 66, 100, 149 

Johnson, Toby, 78, 79 

Johnson, William D., 137 

Jones, John E., 122, 123 

Jones, Ronald, 105 

Jose, Pedro A., 47, 51, 97, 122, 123, 

149 

Joshi, Nomita, 102 

Josse, Robert, 61 

Joyner, JaNae, 89, 139, 140, 141 

Juncos, Luis, 52 

Juncos, Luis I., 149 

Jurgens, Julie A., 122 

K 

Kaciroti, Niko, 65 

Kaeser, Martha A., 91 

Kagan, Alexander, 123 

Kahan, Jonathan, 107 

Kajii, Eiji, 117 

Kakinoki, Shigeo, 99 

Kalantar‐Zadeh, Kamyar, 108 

Kales, Stefanos N., 95 

Kallikazaros, I., 92 

Kalpatthi, Ram V., 101 

Kamal, Khalid M., 141 

Kambona, Joseph, 141 

Kamide, Kei, 95, 121 

Kamran, Haroon, 127, 128 

Kanda, Kouichi, 99 

Kanter, Michael, 131 

Kantola, Ilkka M., 114 

Karan, Shaila, 111, 114, 128 

Karatan, Oktay, 97 

Kario, Kazuomi, 96, 102, 110, 118, 

126, 132 

Karpanou, Eva, 61, 94, 135 

Karpettas, Nikolaos, 134 

Karpettas, Nikos, 105 

Karpov, Yuri A., 112 

Kartalis, Athanasios N., 119 

Kasiakogias, A., 92, 96, 124, 128 

Kato, Johji, 114 

Kavey, Rae‐Ellen W., 58, 149 

Kawai, Tatsuo, 121 

Kawakami, Tomoko, 122 

Kayaba, Kazunori, 126 

Keenan, Nora L., 129, 136 

Kefala, A., 124 

Kerby, Tessa J., 89 

Kereiakes, Dean J., 109, 111 

Kershaw, David, 87 

Kerwin, Todd, 116 

Kettner, Norman W., 91 

Kevorkov, Amayak, 117 

Khan, Bobby V., 92, 110 

Khan, Shahnaz, 141 

Kharbanda, Elyse O., 106 

Kheirbek, Raya, 94, 136 

Kheirbek, Rhea, 136 

Kheterpal, Sachin, 141 

Khosla, Shikha, 136 

Khoury, Philip R., 106 

Kimball, Thomas R., 106 

Kim, Catherine, 60, 121, 122 

Kim, Chong‐Jin, 111, 116 

Kim, Dong‐Bin, 88 

Kim, DongHyun, 66 

Kim, Jae‐Hyung, 88 

Kimura, Joe, 131 

Kintis, K., 92, 96, 102, 126 

Kirkineska, Lambrini, 111 

Kirpalani, Ashok L., 123, 132 

Kirpalani, Dilip A., 123, 132 

Kitamura, Kazuo, 96, 114 

Kita, Toshihiro, 114 

Kitzman, Dalane, 107 

Kizilirmak, Pinar, 108 

Kluth, D. C., 97 

Kobayashi, Takeshi, 99 

Kobayashi, Tatsuya, 130 

Kohan, Donald E., 80, 149 

Kokkinos, Peter, 94, 96, 136 

Kollias, Anastasios, 105, 106 

Kordalis, A., 96, 102, 122, 124, 128 

Koren‐Morag, Nira, 103 

Kostic, Svetlana, 116, 120 

Koulousios, Konstantinos, 111 

Kountz, David S., 82, 149 

Krakoff, Lawrence R., 47, 63, 149 

Kretzschmar, Jan, 136, 138, 144 

Kroner, Beverly, 90 

Krum, Henry, 67, 149 

Kudo, Masataka, 67 

Kudyakov, Rustam, 94 

Ku, Elaine, 88 

Kumada, Maki, 117 

Kumarasamy, Sivarajan, 137 

Kumar, Sanjay, 119 

Kupfer, S., 115 

Kupfer, Stuart, 78, 112 

Kuritzky, Louis, 49, 149 

Kuroki, Kazuo, 118 

Kurtz, Theodore W., 42, 149 

173

Author Index 

Kushner, Robert F., 40, 149 

Kuznetsov, N. S., 143 

Kwiatkowski, Janet L., 100 

Kwon, Beom‐June, 88 

Kyvelou, S., 66 

Kyvelou, Stella Maria, 61, 94, 135 

L 

Labarthe, Darwin, 137 

Lackland, Daniel, 89, 110, 130 

Lackland, Daniel T., 62, 100, 102, 

134, 149 

Lafeuille, Marie‐Hélène, 110, 131 

Laghi, Luca, 93 

Lai, Hsiao, 124 

Lainscak, Mitja, 107 

Lai, Wen‐Ter, 94 

Lakatta, Edward G., 46, 142, 143, 

149 

Laken, Marilyn, 130 

LaMarca, Babbette, 72, 149 

Lambert, Gavin W., 138 

Lamoureux, Denise P., 132 

Lancioni, Letizia, 133 

Lande, Marc B., 51, 149 

Landini, Linda, 132 

Landry, Daniel L., 139 

Lanza, Gaetano A., 91 

Latrella, Margaret, 140 

Latsios, G., 124, 128 

Lavange, L., 65 

Lawrence, Joy, 132 

Lawson, Andrew B., 134 

Lazarevic, Gordana, 120 

Lazar, Jason, 119, 127, 128 

Lazich, Ivana, 99 

Laz, Tabassum H., 95, 102 

Lazzari, Pierangelo, 87, 88 

Lebreiro, Ana, 135 

Ledezma, Mateo Levine, 89 

Lee, James, 109, 111 

Lee, John S., 132 

Lee, Jong Y., 123, 132 

Lee, Mary S., 132 

Lee, Sang‐Hak, 119 

Lee‐Son, Kathy K. Y., 87 

Lefebvre, Patrick, 110, 131 

Leiba, Adi, 95 

Leibovitz, Eyal, 124 

Leighton, Harmony, 116 

Leitão, Maria Fátima, 135 

Lembo, Giuseppe, 134, 135 

Leone, Aurelio, 95, 132 

Leoni, Simona, 95 

Leon‐Muñoz, Luz, 95 

Levine, Benjamin D., 142 

Levine, Robert, 118 

Levin, Linda, 106 

Levy, Bernard I., 99 

Levy, Daniel, 61, 78, 79, 96, 117, 150 

Levy, Pavel J., 117 

Levy, Phillip, 107, 141 

Levy, Phillip D., 93 

Lewin, Andrew, 115 

Lex, Lora, 133 

Liakos, M., 94 

Lian, Jean, 122 

Lieber, Ari, 126, 128 

Lieber, Ari L., 99 

Li, Hewang, 123 

Lijnen, Paul J., 135 

Li, Li, 122 

Lillestol, Michael, 98 

Lima, Jr., Emilton, 87 

Lima, Leandra Gonçalves, 132 

Lima, Nereida K. C., 143 

Lima, Nereida K. Costa, 132 

Limdi, Nita A., 42 

Limor, Rona, 100 

Lindholm, Lars‐Hjalmar, 93 

Lindi, Nita A., 150 

Lioni, L., 66, 122 

Lioudaki, Eirini, 100 

Li, Peng, 118, 126, 144 

Littlejohn, Thomas, 109, 111 

Littman, Stephen, 127 

Liu, Chunyu, 117 

Liu, In Lu, 67 

Liu, Tianh, 150 

Liu, Tianhu, 53 

Li, Wei, 114, 115 

Lloyd, Eric, 78 

Lobo, Romulo R., 143 

Logan, Alexander G., 132 

Loide, Barbosa, 137 

Lo, Joan C., 106 

Long, Laura, 141 

Long, Mark S., 132 

Lopez‐Garcia, Esther, 95 

Lorenzo, Sonia, 99, 131 

Lovic, Dragan, 120 

Lowenstein, Charles J., 59, 150 

Lucas, Caridad Turpin, 88, 109, 129 

Lucas, Stephanie, 90 

Lu, Chunzeng, 116, 126 

Luepke, Erik, 88, 109, 129 

Lu, Fei, 116, 126 

Luo, Jianfang, 53, 150 

Luo, Jiangming, 135 

Luo, Yingjin, 123 

Lurbe, Empar, 101 

Luther, James M., 59, 150 

Lu, Yee, 88 

Lyass, Asya, 96 

Lyn, Deborah, 107 

Lyutikova, L. N., 143 

M 

Maa, Jen‐Fue, 96, 115, 138 

Macdonald, Helen M., 137 

MacDonald, Patricia, 100 

MacDonald, Thomas, 112 

Macedo, Espiga, 138 

Machida, Maiko, 99 

Maciel, Maria Julia, 135 

MacIntyre, I., 121 

Maciosek, Michael V., 89 

Madede, T., 96 

Madruga, Felipe, 105 

Magarik, Jordan A., 102 

Magid, David J., 106 

Magness, Ronald, 142 

Mahina, Tatiana K., 108 

Mahon, Jeffrey L., 141 

Mahon, J. L., 89 

Maisaidi, M., 130 

174

Author Index 

Makani, Harikrishna, 107, 110 

Mancia, G., 130 

Mancia, Giuseppe, 75, 150 

Mancinelli, Lucia, 107, 120 

Manning, Alexis, 138 

Mann, Samuel J., 49, 111, 150 

Manolis, Athanasios, 136 

Manolis, Athanasios J., 75, 150 

Maraj, Ilir, 127 

Marasi, Gianluigi, 87, 88 

Marek, George, 100 

Margolis, Karen, 61 

Margolis, Karen L., 89, 106 

Marin, Elena, 92, 98 

Mark, Allyn L., 77, 80, 150 

Marquez, David X., 138 

Marquis, A., 65 

Martell, Nieves, 133 

Martinez, Cristina, 91, 92, 98 

Martínez, María M., 129 

Martinez, Marie F., 89 

Martinez, Santos J., 88 

Martin, Fernando L., 116 

Martins, Helia, 135 

Marzilli, Mario, 116, 126 

Mascio, Giada, 134, 135 

Masharani, Umesh, 98 

Masica, Andrew, 94 

Masuo, Kazuko, 138 

Matei, Ana Maria, 91, 99 

Materson, Barry J., 71, 150 

Mathur, Vandana, 107 

Matsell, Douglas G., 87 

Matsuda, Hirohisa, 59 

Matsumura, Yasuo, 59 

Mattingly, Phillip G., 142 

Mattson, David L., 72, 150 

Mavimbe, C., 96 

Mavrogeni, Helen, 100 

McCoy, Connie E., 106 

McCrory, Mark A., 103 

McDonnell, Barry J., 128 

McEniery, Carmel M., 95, 128 

McInnes, Gordon, 112 

McIsaac, Warren, 132 

McKie, Paul M., 47 

McManus, Chris, 105 

McManus, Richard J., 63, 150 

McRae, Steven, 100 

Medvegy, Mihaly, 134 

Meier, Rhonda L., 142 

Meijide, Luis, 98 

Melander, Olle, 143 

Melino, Michael, 109, 111 

Mellen, Philip, 139 

Mendelowitz, David, 142 

Merchant, Nadya, 92, 110 

Merenich, John, 81, 150 

Mesas, Arthur E., 95 

Mesirov, Claire, 140 

Messerli, Franz, 66 

Messerli, Franz H., 64, 65, 87, 93, 

107, 110, 117, 150 

Mestek, Michael L., 92 

Mete, Mihriye, 90 

Meyer, Peter M., 47, 113 

Michaelides, A., 91 

Miguel, Robinson, 142 

Mijalkovic, Dragan, 116 

Mikhailidis, Dimitri P., 100 

Miliou, A., 124 

Miskulin, Dana, 115 

Mitsnefes, Mark, 106 

Moffatt, Steven M., 133 

Mohammad, Saklayen, 122 

Mohyeldin, Yousri A., 142 

Mojon, Artemio, 60, 97, 98, 99, 108, 

110, 114, 121, 129, 131 

Molitch, Mark E., 74, 150 

Moñivas, Vanesa, 96 

Monsalvo, M. L., 140 

Monteiro, Agostinho, 138 

Moore, Michael, 89 

Moore, Michael A., 89 

Mora, Carmen, 95 

Moreira, Nadia, 135 

Moreno, Carlos, 91 

Moreno, Jennifer, 127 

Moriguti, Julio C., 143 

Moriguti, Júlio Cesar, 132 

Morimoto, Ryo, 67 

Morishita, Masako, 65 

Morita, Kiyoshi, 122 

Mori, Tatsuhiko, 59 

Morris, Ken, 140 

Morris, Martha Clare, 138 

Moschouris, Panagiotis M., 119 

Mota, Victoria, 129 

Mounier‐Vehier, Claire, 92, 127 

Mousa, Tarek M., 116 

Moya, Ana, 97, 98, 99, 121 

Mpafakis, I., 92, 102, 126 

Mpekiari, Eleni, 99 

Mugellini, Amedeo, 87, 88 

Muiesan, Maria Lorenza, 91 

Munnery, Iain, 128 

Munnery, Margaret M., 128 

Munroe, Patricia, 78 

Munroe, Patricia B., 79 

Munshi, Mohamed, 127 

Myers, Martin, 136 

Myshkina, Vera L., 108 

N 

Nadim, Mitra, 67 

Nadkarni, Girish, 117 

Nadkarni, Girish N., 93, 117 

Nakamura, Yoshikazu, 117 

Naqvi, Syed U., 117 

Narkiewicz, Krzysztof, 75, 150 

Nasothimiou, Efthimia G., 134 

Nasser, Samar A., 93 

Nastac, Iulian, 128 

Natale, Francesco, 123 

Nautiyal, Amit, 119 

Navar, L. Gabriel, 52, 77, 151 

Navarro‐Ibáñez, Vicente, 90 

Naveen, Saxena, 102 

Nelson, S. A. E., 89 

Nelson, Sigrid A., 141 

Nesbitt, Shawna D., 62, 151 

Neumann, Claas L., 133 

Neutel, Joel M., 54, 138, 151 

Newton‐Cheh, Christopher, 78 

Nguyen, Phuong‐son, 132 

175

Author Index 

Nicholas, Joyce S., 134 

Nicholas, Susanne B., 47, 151 

Nichols, Wilmer W., 115 

Nieto, Javier, 95 

Nobre, Fernando, 143 

Nomura, Akikazu, 99 

Norsk, Peter, 78 

Notario, Patricia M., 123 

Novack, Victor, 103 

Nov, Ori, 103 

Nuñez, Ana Galdamez, 88, 129 

Nylen, Eric, 136 

O 

Obasare, Edinrin Rae, 127 

O’Brien, Eoin, 56, 151 

O’Connor, Patrick, 61 

O’Connor, Patrick J., 89, 106 

O’Donnell, Jennifer, 141 

Odusan, Olatunde, 97 

Oefelein, Michael, 139 

Ogedegbe, Gbenga, 45, 49, 63, 90, 

151 

Ogihara, Toshio, 138 

Ogunsemi, Olawale, 97 

Ogura, Toshihiko, 130 

Ohishi, Mitsuru, 95, 121 

Okada, Yoshiyuki, 142 

Okafor, H., 118 

Okayama, Masanobu, 117 

Okerson, Ted, 139 

Oliva, Raymond, 99 

Oliveras, Anna, 133 

Onishi, Miyuki, 95, 121 

Ono, Yoshikiyo, 67 

Onuigbo, Nwamaka, 128 

Oparil, Suzanne, 53, 65, 78, 88, 103, 

105, 109, 111, 118, 126, 138, 144, 

151 

Orak, John K., 101 

Oron, Yoram, 100 

Orynchak, Mariya A., 116, 119 

Osmond, Peter J., 111, 128 

Otero, Alfonso, 97, 111, 121, 131 

Owen, E. L., 97 

P 

Palaciao, Ryan, 116 

Palermo, Lisa, 61 

Paletas, Konstantinos, 99 

Pandey, Kailash N., 117 

Panjabi, Sumeet, 89, 141 

Pan, Nan, 135 

Pannu, Varinderpal, 100 

Panza, Julio A., 65, 151 

Papadakis, John A., 100 

Papademetriou, V., 91, 92, 124 

Papademetriou, Vasilios, 71, 94, 96, 

105, 136, 151 

Papagiannis, Nikolaos V., 119 

Papaioannou, T., 102 

Papapostolou, Vasileios, 132 

Papst, Cheraz Cherif, 98, 112, 139 

Paran, Esther, 103 

Parati, Gianfranco, 63 

Paredes‐Galan, Emilio, 120 

Parikh, Neal S., 111 

Parikh, Samip J., 47 

Parisé, Hélène, 110, 131 

Park, Chang‐Bum, 111, 116 

Parker, Emily D., 106 

Parker, Karen, 124 

Park, Jae Hong, 119 

Park, Jeong‐Euy, 94 

Park, Jinhee, 122, 133 

Patel, Rinkesh, 127 

Patel, Seema, 116 

Pavlidis, Athinodoros, 111 

Pavlyuk, Evhenia A., 133 

Pearson, Thomas A., 44, 151 

Pedrinelli, Roberto, 116 

Pego, Guilherme Augusto 

Mariano, 135 

Pego, João Bernardo, 135 

Peixoto, Aldo J., 60, 73, 151 

Pelazza, Bruno B., 123 

Pemba, Senga, 141 

Pencina, Michael, 96 

Perez de Lis, Jesus, 111 

Pérez, Javier, 129 

Pérez, Miguel Palencia, 116 

Perkins, Nancy, 136 

Peroz, Julie, 99, 126, 128 

Persson, Mats, 93 

Peterson, Jessica A., 100 

Petry, Nancy M., 136 

Phillips, Robert A., 40, 61, 126, 151 

Pickering, Thomas, 90 

Pierce, Caleb, 103 

Piñeiro, Luis, 121 

Pinol, Ramon, 142 

Pisoni, Roberto, 88, 108, 138 

Pi‐Sunyer, F. Xavier, 58, 151 

Pittaras, Andreas, 136 

Pitt, Bertram, 71, 107, 151 

Plavnik, Frida Liane, 102 

Podjarny, Eduardo, 131 

Pogue, Velvie A., 74, 151 

Pollock, David M., 51, 151 

Pollock, Norman K., 47 

Polonia, Jorge, 96, 129, 134 

Polonia, Jorge J., 137 

Popov, E. G., 143 

Potapova, Galina N., 143 

Poulakis, M., 124, 126 

Pousa, Lorenzo, 99, 111 

Pratt, Howard J., 151 

Pratt, J. Howard, 59 

Pressler, Susan, 90, 115 

Primak, Galina F., 133 

Priore, Emanuela Lo, 123 

Pritchard, Sheila L., 87 

Protogerou, Athanase D., 126 

Providência, Luis Augusto, 135 

Pruden, James, 140 

Pruette, Cozumel S., 101 

Pstay, Bruce M., 79 

Punzi, Henry A., 64, 96, 115, 152 

Purakal, John, 141 

Puri, Nitin, 66, 122 

Purkayastha, Das, 109, 113, 114 

Pyun, Wook Bum, 119 

Pyun, Wook‐Bum, 118, 120 

Q 

Quéré, Stéphane, 92, 127, 140 

R 

176

Author Index 

Rabelink, Ton J., 93 

Raheja, Prafull, 59 

Rahman, Mahboob, 60 

Rahman, Mahbubur, 95, 102 

Rahman, Syed T., 110 

Raij, Leopoldo, 52, 152 

Rajagopalan, Sanjay, 65 

Rajagopal, Desikan, 92 

Rajpal, Minesh, 111, 128 

Rakugi, Hiromi, 95, 121, 138 

Ramamurthy, Priyanka, 133 

Ram, C. Venkata S., 40, 73, 152 

Rana, Hamza, 117 

Ranieri, Alessandro, 123 

Rantamaula, Laura, 114 

Rapoport, Jayson, 123 

Rarra, Vagia, 134 

Rasgon, Scott, 67 

Rasgon, Scott A., 89, 108 

Rash, Carla J., 136 

Ratner, Robert E., 90 

Ravussin, Eric, 137 

Rebelo, Irene, 138 

Rechtman, Ehud, 103 

Reddy, Maithri, 90 

Reddy, Podduturu S., 90 

Reddy, Sushma, 90 

Reid, David M., 137 

Rekovets, Oksana L., 133 

Reyes, Andres, 92, 98 

Rey, Jose Manuel Del, 98 

Reynolds, Kristi, 131, 140 

Rezzani, Rita, 122 

Rho, Tae‐Ho, 88 

Rice, Kenneth, 78 

Rice, Kenneth M., 79 

Rich, Steven, 116 

Rieken, Eike M., 133 

Rim, Se‐Joong, 118, 119, 120 

Rios, Maria T., 98, 111 

Ríos, María T., 129 

Rippe, James, 82, 152 

Roberts, A., 115 

Roberts, Andrew, 78, 112 

Rocchini, Albert, 87 

Rodriguez, Arantxa, 47, 91, 92, 98, 

110 

Rodriguez‐Artalejo, Fernando, 95 

Rodríguez‐Artalejo, Fernando, 120 

Rodriguez‐Pascual, Carlos, 120 

Rogelio, Gregorio G., 139 

Roig‐Espert, Belén, 90 

Rojas, Jose M., 127 

Rollins-Hairston, Aisha, 107 

Roman, Mary J., 90 

Romero, Jorge, 107, 110 

Rosa, César S., 123 

Rosenthal, Talma, 100, 105, 152 

Rosman, Yosi, 103 

Rossi, Filippo, 137 

Rothwell, Peter M., 56 

Rousos, D., 124, 128 

Roussias, Leonidas, 106 

Roussias, Leonidas G., 134 

Routledge, Faye S., 131 

Rudich, Assaf, 103 

Rughani, Govind, 102 

Ruilope, Luis M., 60, 67, 70, 93, 96, 

105, 123, 133, 134, 152 

Ruilope, Luis Maria, 101, 102 

Ruiz, Santiago Garcia, 88, 109 

Russell, Holly Ann, 123 

Russell, Marie, 90 

Russo, Andrea, 136 

Russo, Kristen M., 123 

Russo, Maria Giovanna, 123 

Ryabikina, G. V., 143 

Ryan, Michael J., 23, 76, 152 

Ryu, Sung‐Kee, 118, 119, 120 

S 

Saban‐Ruiz, Jose, 47, 91, 92, 98, 110 

Sabharwal, Manpreet S., 93, 117 

Saelens, Brian E., 106 

Saez, Ana Osa, 116 

Safar, Michel E., 99, 112, 126, 128 

Sakata, Koji, 96 

Salciccioli, Louis, 127, 128 

Saldaña, Manuel Aguilera, 88, 129 

Saleh, Tarek M., 92 

Salgado, Jose L., 99, 131 

Salvi, Paolo, 128 

Samad, Zahid, 118 

Sampson, U., 118 

Samuel, Rita, 109 

Sanada, Hironobo, 123 

Sanchez, Luis, 67 

Sanchez, Olivia, 91, 98, 110 

Sander, Gary E., 127 

Sandu, Oana, 128 

Sangaralingham, S. Jeson, 47 

Sansone, Torry Mark, 140 

Santos, Jose Nobre, 134 

Santos, Rosa M., 138 

Sanz, Antonio Salvador, 116 

Sarafidis, Pantelis A., 99 

Sarda, Sujata P., 133 

Sarigianni, Maria, 99 

Sarmento, Priscilla Lopes, 102 

Sarzani, Riccardo, 107, 120, 133 

Sas, David J., 101 

Satoh, Fumitoshi, 67 

Saul, Sara, 116 

Saul, Sara M., 144 

Saunders, Elijah, 40, 152 

Sauter, Kathleen, 140 

Sautin, Yuri Y., 100 

Savopoulos, Christos, 111 

Schiffrin, Ernesto L., 72, 152 

Schmidlin, Olga, 98 

Schmieder, Roland E., 67, 152 

Schneider, Edward, 88 

Schneider, Stephanie C., 90 

Schoenthaler, Antoinette, 45, 152 

Schreiner, Susan, 90 

Schulz, Egbert G., 133 

Schwartz, Ann, 61 

Schwartz, Faina, 117 

Schwartz, Joseph, 90 

Schwartzman, Michal L., 66 

Scisney‐Matlock, Margaret, 90, 115 

Scott, Graham A., 141 

Sebastian, Anthony, 98 

Sechi, Leonardo A., 59, 88, 136 

Secombes, Karen R., 137 

177

Author Index 

Segev, Shlomo, 103 

Segura, Julian, 67, 93, 96, 101, 102, 

105, 123, 134 

Segura, Julián, 133 

Selassie, Anbesaw, 130 

Sen, Amanda, 90, 115 

Seo, Hye‐Sun, 118, 120 

Serdengecti, Kamil, 121 

Seredyuk, Nestor M., 92, 119 

Seredyuk, Vitaliy N., 92 

Sergakova, L. M., 143 

Serio, Ilaria, 95 

Severin, Thomas, 98, 139 

Seyoum, Berhane, 107 

Sgourakis, Panagiotis D., 119 

Shaftman, Stephanie, 110 

Shah, Arpit, 110 

Shahawy, Mahfouz El, 93, 94 

Shah, Hardik K., 123, 132 

Shah, Niren K., 115 

Shanks, Amy M., 141 

Shapiro, Joseph I., 142 

Sharabi, Yehonatan, 103 

Sharma, Abhishek, 128 

Shatat, Ibrahim F., 101 

Shea, J., 113 

Sheremeta, Oleg M., 119 

Sheriff, Helen, 136 

Sherrill, Beth, 141 

Sherwood, Andrew, 131 

Sherwood, Nancy E., 106 

Shibata, Shigeki, 142 

Shi, Jiaxiao, 67 

Shi, Jiaxiao M., 108 

Shilova, Victoria Y., 142 

Shimada, Kazuyuki, 102, 110, 118, 

132 

Shimaoka, Izumi, 121 

Shimizu, Motohiro, 110 

Shin, Hwashin H., 129 

Shin, Sung‐Hee, 118, 120 

Shi, Victor, 101 

Shlyakhto, Evgeny V., 87 

Shojaee, Ali, 96, 115, 138 

Shoval, Ishay, 123 

Shrabi, Yonatan, 124 

Shull, Cyndi, 141 

Shustov, Sergey B., 139 

Sica, D., 115 

Sica, Domenic, 67, 78, 112 

Sica, Domenic A., 40, 67, 70, 152 

Siciliano, Alessandro, 123 

Silva, Jose A., 96, 137 

Silverman, Angela, 90 

Sim, John, 67 

Sim, John J., 108 

Simmons, Debra, 61, 89 

Simonyi, Gabor, 134 

Simpson, William G., 137 

Sinaiko, Alan R., 106 

Sindel, Sukru, 97 

Sineiro, Elvira, 99, 121 

Sion‐Vrdy, Netta, 103 

Sirenko, Yuriy M., 133 

Siu, Kin Lung, 122 

Skoumas, I., 135 

Skrypnyk, Nadiya V., 119 

Slama, Gerard, 99 

Smith, Albert V., 79 

Smith, Jr., Sidney, 81 

Smith, Rick, 88 

Smith, Ronald D., 89 

Smith, Steven M., 115 

Smith, William, 139 

Smyrnioudis, Nikolaos E., 119 

Soboleva, Galina M., 108 

Sodhi, Komal, 66 

Sohn, Il‐Suk, 111, 116 

Solari, D., 130 

Solar‐Yohay, Susan, 101 

Soldatos, N., 96 

Sole, Ricardo M. Cabrera, 88, 109, 

129 

Soriano, Joaquin Rueda, 116 

Sorrentino, Matthew, 40, 152 

Sos, Thomas A., 56, 152 

Sousa, Alexandra, 135 

Sowers, James R., 74, 153 

SperlHillen, JoAnn M., 89 

Sridharan, Kanaka, 113, 114 

Srikakarlapudi, Sirisha, 111, 128 

Srinivasan, Sathanur R., 94 

Staffileno, Beth A., 138 

Stagni, Barbara, 95 

Stallmann-Jorgensen, Inger, 47 

Stasiv, Yuri, 107 

Stauffer, Brian L., 92 

Stefanadi, E., 66 

Stefanadis, C., 61, 66, 91, 92, 94, 96, 

102, 122, 124, 126, 128, 135 

Steigerwalt, Susan, 90, 115 

Stergiou, George S., 105, 106, 134 

Sterling, Kevin A., 127 

Stern, Naftali, 100 

Steven, Bendel D., 109 

Stevens, Lesley A., 68, 153 

Strano, Talita R., 87 

Strimike, Carolyn, 140 

Struthers, Allan D., 66, 153 

Sturgeon, Kathleen M., 136, 138, 144 

Stylianou, Mario, 90 

Suárez, Carmen, 133 

Suleymanlar, Gultekin, 121 

Sun, B., 97 

Sun, Fengzhu, 117 

Svetkey, Laura P., 49, 153 

Symonides, Bartosz, 138 

Syros, George, 93 

Syrseloudis, D., 92, 102, 124, 128 

Szalai, Alexander J., 103 

Szendro, Gabriel, 103 

T 

Tabassome, Simon, 92, 127 

Taddei, Stefano, 91 

Takahashi, Toru, 122 

Takechi, Shigeru, 99 

Takeya, Yasushi, 95, 121 

Taler, Sandra J., 73, 153 

Tamarit‐García, Juan José, 90 

Tangney, Christy, 138 

Tao, Jun, 128 

Tao, Ting, 53, 153 

Tasic, Ivan, 116, 120 

Tatara, Yuji, 95, 121 

178

Author Index 

Tatsis, I., 92, 124 

Taylor, Addison A., 47, 64, 153 

Taylor‐Zapata, Perdita, 101 

Teixeira, Tiago, 134 

Tejera, Eduardo, 138 

Tello, Susana, 47, 91, 92, 98, 110 

Terrone, Deborah, 140 

Tewksbury, Duane A., 135 

Thangaratnavel, Revathy, 127 

Thies, Frank, 137 

Thomopoulos, C., 92, 96, 122, 128 

Thopy, Amanda, 106 

Thrun, Jan‐Marc Schmidt, 133 

Tiawana, Simrandeep K., 89 

Tiktin, Margaret, 61 

Tisler, Andras, 132 

Titze, Jens, 77, 80, 153 

Tobe, Sheldon W., 54, 136, 153 

Tobin, Jonathan, 90 

Tomiyama, Hirofumi, 130 

Tong, Xin, 129 

Tonne, Jason M., 116 

Topouchian, Jirar, 128 

Torrente‐Carballido, Marta, 120 

Torro, Isabel, 101 

Toto, Robert, 60, 121 

Toto, Robert D., 74, 82, 122 

Touyz, Rhian M., 43, 65, 153 

Townsend, Raymond R., 46, 127, 

139, 153 

Tsapas, Apostolos, 99 

Tsiachris, D., 92, 124, 128 

Tsioufis, C., 66, 91, 92, 96, 102, 122, 

124, 126, 128 

Tsioufis, Costas, 96 

Tsounis, Dimitrios, 100, 115 

Turgan, Cetin, 97 

Turk, Aquilla S., 102 

Tutor, Elena, 91, 98 

Tyszkiewicz, Jerzy T., 138 

Tzamouranis, Dimitrios, 134 

Tzamouranis, Dimitris, 105 

Tziomalos, Konstantinos, 111 

U 

Uehara, Ritei, 117 

Ugalde, Arturo, 98 

Umans, Jason G., 90 

Underwood, P., 97 

Urbina, Elaine M., 106 

Uribarri, Jaime, 128 

Utas, Cengiz, 121 

V 

Vakalyuk, Igor P., 92, 116 

Vakalyuk, Iryna I., 116, 119 

Van Buren, Peter N., 121, 122 

Vandervoort, Margaret K., 141 

Vandervoort, M. K., 89 

van Duijn, Cornelia M., 79 

van Duin, Cornelia, 78 

Vanella, Luca, 66, 122 

VanGundy, Tiffany B., 142 

van Pelt, Jos F., 135 

Vansomphone, Southida S., 140 

Varis, Juha, 114 

Vasan, Ramachandran S., 117 

Vasan, R. S., 96 

Vaschilko, Alla S., 133 

Vassalotti, Joseph A., 68, 153 

Vecchione, Carmine, 134 

Veerabhadrappa, Praveen, 136, 138, 

144 

Velhas, Moncho, 129 

Venner-Jones, Kinda, 127 

Veronesi, Maddalena, 93 

Verri‐Junior, Waldiceu A., 143 

Vette, Alan, 129 

Victor, Ronald G., 40, 67, 153 

Vigdorchik, Alexey V., 112 

Vigil, Luis, 133 

Vilches‐Moraga, Arturo, 120 

Villafruela, Juanjo, 91 

Villar, Van Anthony M., 122, 123 

Vinereanu, Dragos, 143 

Vinita, Srivastava, 102 

Vittinghoff, Eric, 61 

Vives, Miguel Angel Arnau, 116 

Vongpatanasin, Wanpen, 59, 142 

Vrentzos, George E., 100 

Vyssoulis, Gregory, 61, 94, 135 

W 

Wagner, C., 110 

Wagner, C. Shaun, 130, 134 

Wang, Guijing, 137 

Wang, Hongyu, 53, 153 

Wang, Jackson, 94 

Wang, Si‐Tien, 133 

Wang, Zhijun, 59 

Ward, Rachel, 124 

Watkins, Shannon B., 144 

Waverczak, William F., 96, 115, 138 

Webb, David J., 65, 153 

Webb, D. J., 97, 121 

Webb, R. Clinton, 43, 153 

Weber, M. A., 115 

Weber, Michael, 78 

Weber, Michael A., 40, 112, 153 

Weder, Alan B., 42, 73, 141, 154 

Weil, Brian R., 92 

Weinberger, Myron H., 47, 154 

Weir, Matthew R., 74, 90, 96, 115, 

154 

Wei, Robert, 133 

Weitzman, Richard, 98, 113, 114 

Welch, Robert, 141 

Welch, W. Pete, 101 

Wells, Ann M., 90 

Wever‐Pinzon, Omar, 107 

Whalen, J. J., 113 

Whaley‐Connell, Adam, 68, 154 

Whelton, Andrew, 66, 100, 154 

White, W. B., 65, 115 

White, William B., 56, 58, 63, 75, 78, 

109, 112, 136, 154 

Wilbur, JoEllen, 138 

Wilcox, C., 91 

Wilkinson, Ian B., 46, 95, 128, 154 

Williams, Bryan, 56, 61, 74, 154 

Williams, Eric, 141 

Williams, G., 97 

Williams, Gordon H., 40, 154 

Williams, J., 97 

Williams‐Johnson, Jean, 141 

Williamson, Sheara, 136 

Williamson, Sheara M., 144 

179

Author Index 

Williamson, Sheara T., 138 

Williams, Ron, 129 

Wilson, Peter F., 154 

Wilson, Peter W. F., 44, 96 

Winborne, Courtland, 124 

Winkler, Amber, 141 

Wohlgemuth, William K., 131 

Wolak, Talya, 103 

Wolf, Philip A., 96 

Wong, Cindy J., 141 

Wong, C. J., 89 

Wong, Nathan D., 44, 154 

Wood, Adrian D., 137 

Wright, Richard F., 109 

Wymer, David, 100 

X 

Xavier, Ana C., 100 

Xing, Dongqi, 103, 118, 126, 144 

Y 

Yadao, Anthony, 139 

Yakovlev, Sergey A., 108 

Yamamoto‐Hanasaki, Hiroko, 121 

Yamashina, Akira, 130 

Yang, Qiong, 117 

Yang, Wenya, 101 

Yang, Yu, 47, 123 

Yang, Zhen, 128 

Yano, Yuichiro, 96, 102, 118 

Yan, Shi Du, 135 

Yatsyshyn, Natalya G., 97 

Yatsyshyn, Roman I., 97 

Yokota, Naoto, 114 

Yoon, Esther, 87 

Yoo, Sandra A., 90 

Young, Joseph D., 61 

Youn, Ho‐Joong, 88 

Younis, Firas, 100 

Yuan, Hong, 112 

Yu‐Isenberg, Kristina, 110 

Z 

Zacker, Christopher, 141 

Zager, Philip, 115 

Zajicek, Anne, 101 

Zamadio, Stacy, 142 

Zand, Martin S., 60, 154 

Zazulina, Antonina Y., 112 

Zeniodi, Maria‐Helen, 100 

Zhang, J., 140 

Zhang, Jack, 112, 139 

Zhang, Jie, 141 

Zhang, Shiling, 107 

Zhang, Wei, 103, 118 

Zhang, Yanrong, 47, 97 

Zhang, Yi, 112, 126, 128 

Zhang, Ying, 101 

Zhao, Yumin, 105, 130 

Zhong, Wei, 144 

Zhu, Haidong, 47 

Zoppi, Annalisa, 87, 88 

Zou, Guang Y., 141 

Zou, G. Y., 89 

180

Hilton New York Floor Plans 

Second Floor 

181


Thrid Floor 

182


Fourth Floor Concourse 

183

Notes 

184

Tekamlo (aliskiren and amlodipine) tablets 

Initial U.S. Approval: 2010 

BRIEF SUMMARY: Please see package insert for full prescribing information. 

WARNING: AVOID USE IN PREGNANCY 

When pregnancy is detected, discontinue Tekamlo as soon as possible. Drugs 

that act directly on the renin-angiotensin-aldosterone system can cause injury 

and even death to the developing fetus. [See Warnings and Precautions (5.1) 

and Use in Specific Populations (8.1)]. 

1 INDICATIONS AND USAGE 

Tekamlo is indicated for the treatment of hypertension, alone or with other antihypertensive 

agents. 

Initial Therapy 

Use Tekamlo as initial therapy in patients who are likely to need multiple drugs 

to achieve their blood pressure goals. 

Base the choice of Tekamlo as initial therapy on an assessment of potential benefits 

and risks. 

Add-On Therapy 

Switch a patient whose blood pressure is not adequately controlled with aliskiren 

alone or amlodipine besylate (or another dihydropyridine calcium channel 

blocker) to combination therapy with Tekamlo. 

Replacement Therapy 

Tekamlo may be substituted for its titrated components. 

Patients with moderate or severe hypertension are at a relatively high risk for 

cardiovascular events (such as strokes, heart attacks, and heart failure), kidney 

failure, and vision problems, so prompt treatment is clinically relevant. Individualize 

the decision to use a combination as initial therapy by weighing factors 

such as baseline blood pressure, the target goal, and the incremental likelihood 

of achieving goal with a combination compared to monotherapy. Individual 

blood pressure goals may vary based upon the patient’s risk. 

Data from the high-dose multifactorial study [see Clinical Studies (14) in the full 

prescribing information] provide estimates of the probability of reaching a target 

blood pressure with Tekamlo compared to aliskiren or amlodipine monotherapy. 

The figures below provide estimates of the likelihood of achieving systolic or 

diastolic blood pressure control with Tekamlo 300 mg/10 mg, based upon baseline 

systolic or diastolic blood pressure. The curve of each treatment group was 

estimated by logistic regression modeling. The estimated likelihood at the right 

tail of each curve is less reliable because of a small number of subjects with 

high baseline blood pressures. 

Figure 1: Probability of Achieving Systolic Blood Pressure (SBP)

Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP)

25% (systolic) and 27% (diastolic) [see Dosage and Administration (2) and 

Clinical Studies (14) in the full prescribing information]. 

4 CONTRAINDICATIONS 

None. 

5 WARNINGS AND PRECAUTIONS 

5.1 Fetal/Neonatal Morbidity and Mortality 

The use of drugs that act directly on the renin-angiotensin-aldosterone system 

during pregnancy can cause fetal and neonatal morbidity and death. No animal 

studies were conducted with Tekamlo; however, decreased fetal birth weight was 

observed in animal studies with aliskiren and intrauterine deaths were observed 

in animal studies with amlodipine. Tekamlo can cause fetal harm when administered 

to a pregnant woman. When pregnancy is detected, discontinue Tekamlo as 

soon as possible. If Tekamlo is used during pregnancy, or if a patient becomes 

pregnant while taking this drug, apprise the patient of the potential hazard to the 

fetus [see Use in Specific Populations (8.1)]. 

5.2 Head and Neck Angioedema 

Aliskiren 

Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been 

reported in patients treated with aliskiren and has necessitated hospitalization 

and intubation. This may occur at any time during treatment and has occurred 

in patients with and without a history of angioedema with ACE inhibitors or 

angiotensin receptor antagonists. If angioedema involves the throat, tongue, 

glottis or larynx, or if the patient has a history of upper respiratory surgery, airway 

obstruction may occur and be fatal. Patients who experience these effects, 

even without respiratory distress, require prolonged observation, since treatment 

with antihistamines and corticosteroids may not be sufficient to prevent 

respiratory involvement. Prompt administration of subcutaneous epinephrine 

solution 1:1000 (0.3 to 0.5 ml) and measures to ensure a patent airway may be 

necessary. 

Discontinue Tekamlo immediately in patients who develop angioedema and do 

not readminister. 

5.3 Hypotension 

An excessive fall in blood pressure (hypotension) was rarely seen (0.2%) in 

patients with uncomplicated hypertension treated with Tekamlo in controlled 

trials. 

In patients with an activated renin-angiotensin-aldosterone system, such as volumeand/or 

salt-depleted patients receiving high doses of diuretics, symptomatic 

hypotension may occur in patients receiving renin-angiotensin-aldosterone 

system (RAAS) blockers. Correct these conditions prior to administration of 

Tekamlo, or start the treatment under close medical supervision. 

If an excessive fall in blood pressure occurs with Tekamlo, place the patient in 

the supine position and, if necessary, give an intravenous infusion of normal 

saline. A transient hypotensive response is not a contraindication to further 

treatment, which usually can be continued without difficulty once the blood 

pressure has stabilized. 

5.4 Risk of Myocardial Infarction or Increased Angina 

Rarely, initiation or change to the dose of a calcium channel blocker has resulted 

in the development of documented increased frequency, duration or severity 

of angina or acute myocardial infarction, particularly in patients with severe 

obstructive coronary artery disease. The mechanism of this effect has not been 

elucidated. 

5.5 Impaired Renal Function 

Tekamlo 

Clinical trials with Tekamlo in hypertension excluded patients with severe renal 

impairment. 

Aliskiren 

Clinical trials of aliskiren in hypertension excluded patients with severe renal 

dysfunction (creatinine 1.7 mg/dL for women and 2.0 mg/dL for men and/or 

estimated GFR

should be exercised when administering Tekamlo to patients with severe hepatic 

impairment. 

5.7 Patients with Congestive Heart Failure 

Amlodipine besylate 

Amlodipine (5-10 mg per day) has been studied in a placebo-controlled trial of 

1153 patients with NYHA Class III or IV heart failure on stable doses of ACE 

inhibitor, digoxin, and diuretics. Follow-up was at least 6 months, with a mean of 

about 14 months. There was no overall adverse effect on survival or cardiac 

morbidity (as defined by life-threatening arrhythmia, acute myocardial infarction, 

or hospitalization for worsened heart failure). Amlodipine has been compared to 

placebo in four 8-12 week studies of patients with NYHA Class II/III heart failure, 

involving a total of 697 patients. In these studies, there was no evidence of 

worsened heart failure based on measures of exercise tolerance, NYHA classification, 

symptoms, or left ventricular ejection fraction. 

5.8 Renal Artery Stenosis 

No data are available on the use of Tekamlo or aliskiren in patients with unilateral 

or bilateral renal artery stenosis or stenosis of the artery to a solitary kidney. 

However, in studies of ACE inhibitors in hypertensive patients with unilateral or 

bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen 

have been reported. 

5.9 Cyclosporine or Itraconazole 

Aliskiren 

When aliskiren was given with cyclosporine or itraconazole, the blood concentrations 

of aliskiren were significantly increased. Avoid concomitant use of 

aliskiren with cyclosporine or itraconazole [see Drug Interactions (7)]. 

6 ADVERSE REACTIONS 

6.1 Clinical Studies Experience 

The following serious adverse reactions are discussed in greater detail in other 

sections of the label: 

• Risk of fetal/neonatal morbidity and mortality [see Warnings and Precautions 

(5.1)] 

• Head and neck angioedema [see Warnings and Precautions (5.2)] 

• Hypotension [see Warnings and Precautions (5.3)] 

Because clinical trials are conducted under widely varying conditions, adverse 

reaction rates observed in the clinical trials of a drug cannot be directly compared 

to rates in clinical trials of another drug and may not reflect the rates 

observed in practice. 

Tekamlo 

Tekamlo has been evaluated for safety in more than 2800 patients, including 372 

patients for 1 year or longer. 

In a placebo-controlled study, there were 51% males, 62% Caucasians, 20% 

Blacks, 18% Hispanics, and 17% who were over 65 years of age. In this study, 

the overall incidence of adverse events on therapy with Tekamlo was similar to 

the individual components. Discontinuation of therapy due to a clinical adverse 

event in this study occurred in 1.7% of patients treated with Tekamlo (2.2% in 

the highest dose group) versus 1.5% of patients given placebo. 

Peripheral edema is a known, dose-dependent adverse effect of amlodipine. The 

incidence of peripheral edema for Tekamlo in short-term double-blind placebocontrolled 

studies was lower than or equal to that of the corresponding amlodipine 

doses. 

The adverse event in a placebo-controlled trial that occurred in at least 2% of 

patients treated with Tekamlo and at a higher incidence than placebo was peripheral 

edema (6.2% versus 1.0%). The incidence rate of peripheral edema at high 

dose was 8.9%. 

In a long-term safety trial, the safety profile of adverse events was similar to that 

seen in the short-term controlled trials. 

Aliskiren 

Aliskiren has been evaluated for safety in 6460 patients, including 1740 treated 

for longer than 6 months, and 1250 for longer than 1 year. In placebo-controlled 

clinical trials, discontinuation of therapy because of a clinical adverse event, 

including uncontrolled hypertension, occurred in 2.2% of patients treated with 

aliskiren versus 3.5% of patients given placebo.

Two cases of angioedema with respiratory symptoms were reported with 

aliskiren use in the clinical studies. Two other cases of periorbital edema without 

respiratory symptoms were reported as possible angioedema and resulted in 

discontinuation. The rate of these angioedema cases in the completed studies 

was 0.06%. 

In addition, 26 other cases of edema involving the face, hands, or whole body 

were reported with aliskiren use, including 4 leading to discontinuation. 

In the placebo-controlled studies, however, the incidence of edema involving the 

face, hands, or whole body was 0.4% with aliskiren compared with 0.5% with 

placebo. In a long-term active-controlled study with aliskiren and HCTZ arms, 

the incidence of edema involving the face, hands, or whole body was 0.4% in 

both treatment arms. 

Aliskiren produces dose-related gastrointestinal (GI) adverse reactions. Diarrhea 

was reported by 2.3% of patients at 300 mg, compared to 1.2% in placebo 

patients. In women and the elderly (age ≥65) increases in diarrhea rates were 

evident starting at a dose of 150 mg daily, with rates for these subgroups at 

150 mg similar to those seen at 300 mg for men or younger patients (all rates 

about 2%). Other GI symptoms included abdominal pain, dyspepsia, and gastro - 

esophageal reflux, although increased rates for abdominal pain and dyspepsia 

were distinguished from placebo only at 600 mg daily. Diarrhea and other 

GI symptoms were typically mild and rarely led to discontinuation. 

Aliskiren was associated with a slight increase in cough in the placebo-controlled 

studies (1.1% for any aliskiren use versus 0.6% for placebo). In active-controlled 

trials with ACE inhibitor (ramipril, lisinopril) arms, the rates of cough for the 

aliskiren arms were about one-third to one-half the rates in the ACE inhibitor arms. 

Other adverse reactions with increased rates for aliskiren compared to placebo 

included rash (1% versus 0.3%), elevated uric acid (0.4% versus 0.1%), gout 

(0.2% versus 0.1%), and renal stones (0.2% versus 0%). 

Single episodes of tonic-clonic seizures with loss of consciousness were 

reported in two patients treated with aliskiren in the clinical trials. One patient 

had predisposing causes for seizures and had a negative electroencephalogram 

(EEG) and cerebral imaging following the seizures; for the other patient, EEG and 

imaging results were not reported. Aliskiren was discontinued and there was no 

rechallenge in either case. 

No clinically meaningful changes in vital signs or in ECG (including QTc interval) 

were observed in patients treated with aliskiren. 


Amlodipine (Norvasc ® ) has been evaluated for safety in more than 11,000 

patients in U.S. and foreign clinical trials. Other adverse events that have been 

reported 0.1% of patients in controlled clinical trials or under conditions 

of open trials or marketing experience where a causal relationship is 

uncertain were: 

Cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrillation), 

brady cardia, chest pain, peripheral ischemia, syncope, postural hypo - 

tension, vasculitis 

Central and Peripheral Nervous System: neuropathy peripheral, paresthesia, 

tremor, vertigo 

Gastrointestinal: anorexia, constipation, dyspepsia,** dysphagia, diarrhea, flatulence, 

pancreatitis, vomiting, gingival hyperplasia 

General: allergic reaction, asthenia,** back pain, hot flushes, malaise, pain, rigors, 

weight gain, weight decrease 

Musculoskeletal System: arthralgia, arthrosis, muscle cramps,** myalgia 

Psychiatric: sexual dysfunction (male** and female), insomnia, nervousness, 

depression, abnormal dreams, anxiety, depersonalization 

Respiratory System: dyspnea, epistaxis 

Skin and Appendages: angioedema, erythema multiforme, pruritus,** rash,** 

rash erythem atous, rash maculopapular 

**These events occurred in less than 1% in placebo-controlled trials, but the 

incidence of these side effects was between 1% and 2% in all multiple dose studies. 

Special Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus 

Urinary System: micturition frequency, micturition disorder, nocturia

Autonomic Nervous System: dry mouth, sweating increased 

Metabolic and Nutritional: hyperglycemia, thirst 

Hemopoietic: leukopenia, purpura, thrombocytopenia 

Other events reported with amlodipine at a frequency of ≤0.1% of patients 

include: cardiac failure, pulse irregularity, extrasystoles, skin discoloration, 

urticaria, skin dryness, alopecia, dermatitis, muscle weakness, twitching, ataxia, 

hypertonia, migraine, cold and clammy skin, apathy, agitation, amnesia, gastritis, 

increased appetite, loose stools, rhinitis, dysuria, polyuria, parosmia, taste 

perversion, abnormal visual accommodation, and xerophthalmia. Other reactions 

occurred sporadically and cannot be distinguished from medications or concurrent 

disease states such as myocardial infarction and angina. 

6.2 Clinical Laboratory Test Abnormalities 

RBC count, hemoglobin and hematocrit: Small mean changes from baseline 

were seen in RBC count, hemoglobin and hematocrit in patients treated with 

both Tekamlo and aliskiren monotherapy. This effect is also seen with other 

agents acting on the renin angiotensin system. In aliskiren monotherapy trials 

these decreases led to slight increases in rates of anemia compared to placebo 

(0.1% for any aliskiren use, 0.3% for aliskiren 600 mg daily, vs. 0% for 

placebo). No patients discontinued due to anemia. 

Blood Urea Nitrogen (BUN)/Creatinine: Elevations in BUN (>40 mg/dL) and creat - 

inine (>2.0 mg/dL) in patients treated with Tekamlo were 5.5 mEq/L were infrequent in 

patients with essential hypertension treated with both Tekamlo and aliskiren 

monotherapy (0.9% compared to 0.6% with placebo). However, when aliskiren 

was used in combination with an angiotensin-converting enzyme inhibitor (ACEI) 

in a diabetic population, increases in serum potassium were more frequent 

(5.5%). Monitor electrolytes and renal function in this population. 

6.3 Post-marketing Experience 

The following adverse reactions have been identified during postapproval use of 

either aliskiren or amlodipine. Because these reactions are reported voluntarily 

from a population of uncertain size, it is not always possible to estimate their 

frequency or establish a causal relationship to drug exposure: 

Hypersensitivity: angioedema requiring airway management and hospitalization 

Aliskiren: Peripheral edema, blood creatinine increased 

Amlodipine: The following postmarketing event has been reported infrequently 

where a causal relationship is uncertain: gynecomastia. In postmarketing experience, 

jaundice and hepatic enzyme elevations (mostly consistent with cholestasis 

or hepatitis), in some cases severe enough to require hospitalization, have 

been reported in association with use of amlodipine. 

7 DRUG INTERACTIONS 

No drug interaction studies have been conducted with Tekamlo and other drugs, 

although studies with the individual aliskiren and amlodipine besylate components 

are described below. 

Aliskiren 

Cyclosporine: Avoid co-administration of cyclosporine with aliskiren. 

Itraconazole: Avoid co-administration of itraconazole with aliskiren. 

[See Clinical Pharmacology (12.3) in the full prescribing information.] 


In clinical trials, amlodipine has been safely administered with thiazide diuretics, 

beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, 

sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory 

drugs, antibiotics, and oral hypoglycemic drugs. 

Cimetidine: Co-administration of amlodipine with cimetidine did not alter the 

pharmacokinetics of amlodipine. 

Grapefruit juice: Co-administration of 240 mL of grapefruit juice with a single 

oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect 

on the pharmacokinetics of amlodipine. 

Maalox ® (antacid): Co-administration of the antacid Maalox with a single dose of 

amlodipine had no significant effect on the pharmacokinetics of amlodipine. 

Sildenafil: A single 100 mg dose of sildenafil in subjects with essential hyper - 

tension had no effect on the pharmacokinetic parameters of amlodipine. When

amlodipine and sildenafil were used in combination, each agent independently 

exerted its own blood pressure lowering effect. 

Atorvastatin: Co-administration of multiple 10 mg doses of amlodipine with 80 mg 

of atorvastatin resulted in no significant change in the steady-state pharmaco - 

kinetic param eters of atorvastatin. 

Digoxin: Co-administration of amlodipine with digoxin did not change serum 

digoxin levels or digoxin renal clearance in normal volunteers. 

Ethanol (alcohol): Single and multiple 10 mg doses of amlodipine had no significant 

effect on the pharmacokinetics of ethanol. 

Warfarin: Co-administration of amlodipine with warfarin did not change the 

warfarin prothrombin response time. 

8 USE IN SPECIFIC POPULATIONS 

8.1 Pregnancy 

Pregnancy Category D [See Warnings and Precautions Section] 

The use of drugs that act directly on the renin-angiotensin-aldosterone system 

during the second and third trimesters of pregnancy can cause fetal and neo - 

natal morbidity and death. In addition, first trimester use of ACE inhibitors has 

been associated with birth defects in retrospective data. No animal studies were 

conducted with Tekamlo; however, decreased fetal birth weight was observed in 

animal studies with aliskiren and intrauterine deaths were observed in animal 

studies with amlodipine. Tekamlo can cause fetal harm when administered to a 

pregnant woman. When pregnancy is detected, discontinue Tekamlo as soon as 

possible. If Tekamlo is used during pregnancy, or if the patient becomes pregnant 

while taking this drug, the patient should be apprised of the potential hazard 

to the fetus. 

Human Data and Clinical Considerations 

Maternal hypertension is associated with increased risks for preterm delivery, 

intrauterine growth restriction, placental abruption, preeclampsia, and perinatal 

mortality. Appropriate management of maternal hypertension during pregnancy 

is important to optimize outcomes for both mother and fetus. Renin inhibitors 

(like aliskiren), angiotensin II receptor antagonists and angiotensin converting 

enzyme (ACE) inhibitors exert similar effects on the renin-angiotensin-aldosterone 

system. Based on several dozen published cases, ACE inhibitor use during the 

second and third trimesters of pregnancy is associated with fetal and neonatal 

injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or 

irreversible renal failure, and death. Decreased fetal renal function may result in 

oligohydramnios and associated with fetal limb contractures, craniofacial deformation, 

and hypoplastic lung development. Prematurity, intrauterine growth 

retardation, and patent ductus arteriosus have been reported in women using 

these drugs, but it is not clear whether these occurrences were due to drug 

exposure. Limited data are conflicting about whether first trimester use of ACE 

inhibitors is associated with an increased risk of birth defects, but the drugs’ 

mechanism of action raises a theoretical concern. 

When pregnancy occurs in a patient using Tekamlo, the physician should discontinue 

Tekamlo treatment as soon as possible. Inform the patient about potential 

risks to the fetus based on the time of gestational exposure to Tekamlo (first 

trimester only or later). If exposure occurs beyond the first trimester, perform an 

ultrasound examination. 

In rare cases when another antihypertensive agent cannot be used to treat the 

pregnant patient, serial ultrasound examinations should be used to assess the 

intraamniotic environment. Routine fetal testing with non-stress tests, biophysical 

profiles, and/or contraction stress tests may be appropriate based on gestational 

age and standards of care in the community. If oligohydramnios occurs in 

these situations, individualized decisions about continuing or discontinuing 

Tekamlo treatment and about pregnancy management should be made by the 

patient and her physicians. Patients and physicians should be aware that oligohydramnios 

may not appear until after the fetus has sustained irreversible injury. 

Infants exposed to Tekamlo in-utero should be closely observed for hypotension, 

oliguria, and hyperkalemia. If oliguria occurs, these infants may require blood 

pressure and renal perfusion support. Exchange transfusion or dialysis may be 

required to reverse hypotension and/or support decreased renal function.

Animal Data 

No reproductive toxicity studies have been conducted with the combination of 

aliskiren and amlodipine besylate. However, these studies have been conducted 

for aliskiren and amlodipine besylate alone. 

Aliskiren 

In developmental toxicity studies, pregnant rats and rabbits received oral 

aliskiren hemifumarate during organogenesis at doses up to 20 and 7 times 

the maximum recommended human dose (MRHD) based on body surface 

area (mg/m 2 ), respectively, in rats and rabbits. (Actual animal doses were up 

to 600 mg/kg/day in rats and up to 100 mg/kg/day in rabbits.) No teratogenicity 

was observed; however, fetal birth weight was decreased in rabbits at 

doses 3.2 times the MRHD based on body surface area (mg/m 2 ). Aliskiren 

was present in placentas, amniotic fluid and fetuses of pregnant rabbits. 

Amlodipine 

In developmental toxicity studies, pregnant rats and rabbits received oral 

amlodipine maleate during organogenesis at doses approximately 10 and 20 

times the maximum recommended human dose (MRHD) based on body surface 

area (mg/m 2 ), respectively, in rats and rabbits. (Actual animal doses 

were up to 10 mg/kg/day.) No evidence of teratogenicity or other embryo fetal 

toxicity was observed. However, litter size was decreased approximately 50% 

and the num ber of intrauterine deaths was increased approximately 5-fold for 

rats receiving amlodipine maleate at doses approximately 10 times the MRHD 

based on body surface area (mg/m 2 ) for 14 days before mating and throughout 

mating and gestation. Amlodipine maleate has been shown to prolong 

both the gestation period and the duration of labor in rats at this dose. 

8.3 Nursing Mothers 

It is not known whether aliskiren or amlodipine is excreted in human milk. 

Both aliskiren and amlodipine are secreted in the milk of lactating rats. 

Because of the potential for serious adverse reactions in human milk-fed 

infants from Tekamlo, a decision should be made whether to discontinue 

nursing or discontinue Tekamlo, taking into account the importance of the 

drug to the mother. 

8.4 Pediatric Use 

Safety and effectiveness of Tekamlo in pediatric patients have not been 

established. 

8.5 Geriatric Use 

Tekamlo 

In the short-term controlled clinical trials of Tekamlo, 17% of patients treated 

with Tekamlo were ≥65 years. No overall differences in safety or effectiveness 

were observed between these subjects and younger subjects. Other reported 

clinical experience has not identified differences in responses between the 

elderly and younger patients, but greater sensitivity of some older individuals 

cannot be ruled out. 

Aliskiren 

Impact of aging on aliskiren pharmacokinetics has been assessed, when 

compared to young adults (18-40 years), aliskiren mean AUC and C max in 

elderly subjects (>65 years) are increased by 57% and 28%, respectively. 

However, differences in efficacy and safety between the elderly and younger 

populations were minor, indicating that differences in exposure due to age do 

not significantly alter the clinical effect of the drug. Therefore, no starting 

dose adjustment in geriatric population is required. 

Amlodipine 

Other reported clinical experience has not identified differences in responses 

between the elderly and younger patients. However, elderly patients have 

decreased clearance of amlodipine with a resulting increase of AUC of approx - 

imately 40-60%. In general dose selection for an elderly patient should be 

cautious, usually starting at the low end of the dosing range, reflecting the 

greater frequency of decreased hepatic, renal or cardiac function, and of concomitant 

disease or other drug therapy. 

10 OVERDOSAGE 

Aliskiren 

Limited data are available related to overdosage in humans. The most likely 

manifestation of overdosage would be hypotension. If symptomatic hypotension 

should occur, provide supportive treatment.


Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg 

and 100 mg amlodipine/kg in mice and rats, respectively, caused deaths. Single 

oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg 

or higher in dogs (11 or more times the maximum recommended human 

dose on a mg/m 2 basis) caused a marked peripheral vasodilation and 

hypotension. 

Overdosage might be expected to cause excessive peripheral vasodilation 

with marked hypotension and possibly a reflex tachycardia. In humans, 

experience with intentional overdosage of amlodipine is limited. Reports of 

intentional overdosage include a patient who ingested 250 mg and was 

asymptomatic and was not hospitalized; another (120 mg) was hospitalized, 

underwent gastric lavage and remained normotensive; the third (105 mg) was 

hospitalized and had hypotension (90/50 mmHg) which normalized following 

plasma expansion. A case of accidental drug overdose has been documented 

in a 19-month-old male who ingested 30 mg amlodipine (about 2 mg/kg). 

During the emergency room presentation, vital signs were stable with no evidence 

of hypotension, but a heart rate of 180 bpm. Ipecac was administered 

3.5 hours after ingestion and on subsequent observation (overnight) no 

sequelae were noted. 

If massive overdose should occur, active cardiac and respiratory monitoring 

should be instituted. Frequent blood pressure measurements are essential. 

Should hypotension occur, cardiovascular support including elevation of the 

extremities and the judicious administration of fluids should be initiated. If 

hypotension remains unresponsive to these conservative mea sures, administration 

of vasopressors (such as phenylephrine) should be considered with 

attention to circulating volume and urine output. Intravenous calcium gluco - 

nate may help to reverse the effects of calcium entry blockade. As amlodipine 

is highly protein bound, hemodialysis is not likely to be of benefit. 

Distributed by: 



T2011-52 

March 2011 

©Novartis

Get to know TEKAMLO 

at booth 1100 

Ask our sales representative how to 

obtain professional samples.* 

150/5 mg 300/5 mg 300/10 mg 

150/10 mg dose not shown. 

*Samples are not available at booth 1100. 

Please see brief summary of Prescribing Information, 

including Boxed WARNING, on adjacent pages. 

Tekamlo 

(aliskiren and amlodipine) tablets 

150/5mg • 150/10mg • 300/5mg • 300/10mg 


East Hanover, New Jersey 07936-1080 

© 2011 Novartis Printed in USA 4/11 TKT-1053803

2011 ASH Program Book - American Society of Hypertension

Create successful ePaper yourself

Delete template?

Save as template?